head,relation,tail
NCT03207529,has_title,Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) 
NCT03207529,has_status,COMPLETED
NCT03207529,has_phase,
NCT03207529,sponsored_by,M.D. Anderson Cancer Center
NCT03207529,tests,Alpelisib
Alpelisib,has_type,DRUG
NCT03207529,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT04403529,has_title,Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-nega
NCT04403529,has_status,UNKNOWN
NCT04403529,has_phase,
NCT04403529,sponsored_by,Fudan University
NCT04403529,tests,Traditional Chinese Medicine Formulation
Traditional Chinese Medicine Formulation,has_type,DRUG
NCT04403529,tests,Placebo Formulation
Placebo Formulation,has_type,DRUG
NCT06245889,has_title,A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage
NCT06245889,has_status,RECRUITING
NCT06245889,has_phase,
NCT06245889,sponsored_by,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06245889,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06245889,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06245889,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06245889,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT06245889,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06245889,tests,Olaparib
Olaparib,has_type,DRUG
NCT06245889,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03792529,has_title,Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in 
NCT03792529,has_status,UNKNOWN
NCT03792529,has_phase,
NCT03792529,sponsored_by,Peking University Cancer Hospital & Institute
NCT03792529,tests,detect gene mutations of ctDNA and ctRNA
detect gene mutations of ctDNA and ctRNA,has_type,OTHER
NCT03692689,has_title,Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Relapsed or Metastatic Triple Rec
NCT03692689,has_status,UNKNOWN
NCT03692689,has_phase,
NCT03692689,sponsored_by,Sinocelltech Ltd.
NCT03692689,tests,SCT200
SCT200,has_type,BIOLOGICAL
NCT01930292,has_title,A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 
NCT01930292,has_status,TERMINATED
NCT01930292,has_phase,
NCT01930292,sponsored_by,Debiopharm International SA
NCT01930292,tests,Part A: Debio 1143
Part A: Debio 1143,has_type,DRUG
NCT01930292,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01930292,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01930292,tests,Part B: Debio 1143
Part B: Debio 1143,has_type,DRUG
NCT02157792,has_title,"An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M662"
NCT02157792,has_status,COMPLETED
NCT02157792,has_phase,
NCT02157792,sponsored_by,"EMD Serono Research & Development Institute, Inc."
NCT02157792,tests,M6620
M6620,has_type,DRUG
NCT02157792,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02157792,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02157792,tests,Etoposide
Etoposide,has_type,DRUG
NCT02157792,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02157792,tests,Irinotecan
Irinotecan,has_type,DRUG
NCT04174391,has_title,Lifestyles for the Prevention of Relapses Among Women with Early Breast Cancer
NCT04174391,has_status,ACTIVE_NOT_RECRUITING
NCT04174391,has_phase,
NCT04174391,sponsored_by,University of Navarra
NCT04174391,tests,Mediterranean diet supplemented with extra-virgin olive oil
Mediterranean diet supplemented with extra-virgin olive oil,has_type,BEHAVIORAL
NCT04174391,tests,Low-fat diet
Low-fat diet,has_type,BEHAVIORAL
NCT06418594,has_title,Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metas
NCT06418594,has_status,RECRUITING
NCT06418594,has_phase,
NCT06418594,sponsored_by,Beijing 302 Hospital
NCT06418594,tests,Adebrelimab
Adebrelimab,has_type,DRUG
NCT06418594,tests,Apatinib
Apatinib,has_type,DRUG
NCT06418594,tests,Etoposide
Etoposide,has_type,DRUG
NCT02883062,has_title,"Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without At"
NCT02883062,has_status,COMPLETED
NCT02883062,has_phase,
NCT02883062,sponsored_by,National Cancer Institute (NCI)
NCT02883062,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02883062,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT02883062,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02883062,tests,Lumpectomy
Lumpectomy,has_type,PROCEDURE
NCT02883062,tests,Mastectomy
Mastectomy,has_type,PROCEDURE
NCT02883062,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05680662,has_title,"The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, M"
NCT05680662,has_status,UNKNOWN
NCT05680662,has_phase,
NCT05680662,sponsored_by,"Ministry of Health, Saudi Arabia"
NCT05680662,tests,"quercetin, EGCG, metformin , zinc"
"quercetin, EGCG, metformin , zinc",has_type,COMBINATION_PRODUCT
NCT05483491,has_title,"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-"
NCT05483491,has_status,RECRUITING
NCT05483491,has_phase,
NCT05483491,sponsored_by,Christian Hinrichs
NCT05483491,tests,KK-LC-1 TCR-T cells
KK-LC-1 TCR-T cells,has_type,BIOLOGICAL
NCT05483491,tests,Aldesleukin
Aldesleukin,has_type,DRUG
NCT06636591,has_title,"A Prospective, Open-label, Single-center, Pilot Study of Neoadjuvant Chemotherapy Combined With Immu"
NCT06636591,has_status,RECRUITING
NCT06636591,has_phase,
NCT06636591,sponsored_by,Fudan University
NCT06636591,tests,Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin,has_type,COMBINATION_PRODUCT
NCT06636591,tests,Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin,has_type,COMBINATION_PRODUCT
NCT05522491,has_title,"An Open-label, Single-arm, Single-center Exploratory Clinical Study of Olaparib in the Treatment of "
NCT05522491,has_status,UNKNOWN
NCT05522491,has_phase,
NCT05522491,sponsored_by,Hebei Medical University Fourth Hospital
NCT05522491,tests,Olaparib
Olaparib,has_type,DRUG
NCT02455791,has_title,Pilot Study for Identification of Breast Cancer Patients for Potential Avoidance of Surgery: Accurac
NCT02455791,has_status,ACTIVE_NOT_RECRUITING
NCT02455791,has_phase,
NCT02455791,sponsored_by,M.D. Anderson Cancer Center
NCT02455791,tests,Ultrasound-Guided Biopsy
Ultrasound-Guided Biopsy,has_type,PROCEDURE
NCT01186991,has_title,"A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety an"
NCT01186991,has_status,COMPLETED
NCT01186991,has_phase,
NCT01186991,sponsored_by,"Genentech, Inc."
NCT01186991,tests,Onartuzumab
Onartuzumab,has_type,DRUG
NCT01186991,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01186991,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01186991,tests,Bevacizumab Placebo
Bevacizumab Placebo,has_type,DRUG
NCT01186991,tests,Onartuzumab Placebo
Onartuzumab Placebo,has_type,DRUG
NCT03872791,has_title,"A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combina"
NCT03872791,has_status,COMPLETED
NCT03872791,has_phase,
NCT03872791,sponsored_by,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd"
NCT03872791,tests,KN046
KN046,has_type,BIOLOGICAL
NCT03872791,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02368691,has_title,"A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx"
NCT02368691,has_status,TERMINATED
NCT02368691,has_phase,
NCT02368691,sponsored_by,GTx
NCT02368691,tests,GTx-024
GTx-024,has_type,DRUG
NCT05134194,has_title,"A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician C"
NCT05134194,has_status,TERMINATED
NCT05134194,has_phase,
NCT05134194,sponsored_by,"Suzhou Suncadia Biopharmaceuticals Co., Ltd."
NCT05134194,tests,Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine
Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine,has_type,DRUG
NCT05134194,tests,Capecitabine/eribulin/gemcitabine/vinorelbine
Capecitabine/eribulin/gemcitabine/vinorelbine,has_type,DRUG
NCT02679040,has_title,Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadj
NCT02679040,has_status,UNKNOWN
NCT02679040,has_phase,
NCT02679040,sponsored_by,Institut Paoli-Calmettes
NCT02679040,tests,Immediate mammary reconstruction
Immediate mammary reconstruction,has_type,PROCEDURE
NCT02679040,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT02679040,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT05636644,has_title,Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an
NCT05636644,has_status,UNKNOWN
NCT05636644,has_phase,
NCT05636644,sponsored_by,Mei Zhang
NCT05636644,tests,Taxol
Taxol,has_type,DRUG
NCT04489940,has_title,"A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants Wit"
NCT04489940,has_status,TERMINATED
NCT04489940,has_phase,
NCT04489940,sponsored_by,"EMD Serono Research & Development Institute, Inc."
NCT04489940,tests,Bintrafusp alfa
Bintrafusp alfa,has_type,DRUG
NCT06976944,has_title,Randomized Phase II Study of Pembrolizumab + Paclitaxel +/- Bevacizumab in Patients With Recurrent T
NCT06976944,has_status,RECRUITING
NCT06976944,has_phase,
NCT06976944,sponsored_by,Yukinori Ozaki
NCT06976944,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06976944,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06976944,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT06229067,has_title,Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic Chemotherapy of Vinorelbin
NCT06229067,has_status,NOT_YET_RECRUITING
NCT06229067,has_phase,
NCT06229067,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06229067,tests,Adebrelimab
Adebrelimab,has_type,DRUG
NCT06229067,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT06229067,tests,Cyclophosphamide (tablet)
Cyclophosphamide (tablet),has_type,DRUG
NCT06229067,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03199040,has_title,A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvaluma
NCT03199040,has_status,TERMINATED
NCT03199040,has_phase,
NCT03199040,sponsored_by,Washington University School of Medicine
NCT03199040,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03199040,tests,Neoantigen DNA vaccine
Neoantigen DNA vaccine,has_type,BIOLOGICAL
NCT03199040,tests,TDS-IM system (Inchor Medical Systems)
TDS-IM system (Inchor Medical Systems),has_type,DEVICE
NCT03199040,tests,Peripheral blood draw
Peripheral blood draw,has_type,PROCEDURE
NCT02706392,has_title,Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Auto
NCT02706392,has_status,TERMINATED
NCT02706392,has_phase,
NCT02706392,sponsored_by,Fred Hutchinson Cancer Center
NCT02706392,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02706392,tests,ROR1 CAR-specific Autologous T-Lymphocytes
ROR1 CAR-specific Autologous T-Lymphocytes,has_type,BIOLOGICAL
NCT04282044,has_title,A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembroli
NCT04282044,has_status,RECRUITING
NCT04282044,has_phase,
NCT04282044,sponsored_by,BioEclipse Therapeutics
NCT04282044,tests,CRX100 suspension for infusion
CRX100 suspension for infusion,has_type,BIOLOGICAL
NCT04282044,tests,Fludarabine
Fludarabine,has_type,COMBINATION_PRODUCT
NCT04282044,tests,Cyclophosphamide
Cyclophosphamide,has_type,COMBINATION_PRODUCT
NCT04149444,has_title,A Phase 2 Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
NCT04149444,has_status,WITHDRAWN
NCT04149444,has_phase,
NCT04149444,sponsored_by,AHS Cancer Control Alberta
NCT04149444,tests,Trifluridine/Tipiracil
Trifluridine/Tipiracil,has_type,DRUG
NCT05846789,has_title,A Pragmatic Phase II Trial of SOC Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER
NCT05846789,has_status,RECRUITING
NCT05846789,has_phase,
NCT05846789,sponsored_by,Kathy Miller
NCT05846789,tests,SOC Chemotherapy
SOC Chemotherapy,has_type,DRUG
NCT05846789,tests,Tocilizumab
Tocilizumab,has_type,DRUG
NCT06371989,has_title,Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders 
NCT06371989,has_status,COMPLETED
NCT06371989,has_phase,
NCT06371989,sponsored_by,Hospital Universitario 12 de Octubre
NCT06371989,tests,Image guided vacuum assisted biopsy
Image guided vacuum assisted biopsy,has_type,PROCEDURE
NCT01167192,has_title,Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Bre
NCT01167192,has_status,TERMINATED
NCT01167192,has_phase,
NCT01167192,sponsored_by,Washington University School of Medicine
NCT01167192,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01167192,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01167192,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT01167192,tests,Mastectomy (recommended but not mandatory)
Mastectomy (recommended but not mandatory),has_type,PROCEDURE
NCT06171789,has_title,A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
NCT06171789,has_status,RECRUITING
NCT06171789,has_phase,
NCT06171789,sponsored_by,Genmab
NCT06171789,tests,GEN1107
GEN1107,has_type,DRUG
NCT04947189,has_title,"4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating th"
NCT04947189,has_status,RECRUITING
NCT04947189,has_phase,
NCT04947189,sponsored_by,"St Vincent's Hospital, Sydney"
NCT04947189,tests,Seviteronel-D (Seivteronel in combination with dexamethasone)
Seviteronel-D (Seivteronel in combination with dexamethasone),has_type,DRUG
NCT04947189,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04081389,has_title,Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemothera
NCT04081389,has_status,COMPLETED
NCT04081389,has_phase,
NCT04081389,sponsored_by,Roswell Park Cancer Institute
NCT04081389,tests,Celecoxib
Celecoxib,has_type,DRUG
NCT04081389,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04081389,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04081389,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT04081389,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04081389,tests,Recombinant Interferon Alfa-2b
Recombinant Interferon Alfa-2b,has_type,BIOLOGICAL
NCT04081389,tests,Rintatolimod
Rintatolimod,has_type,DRUG
NCT04905329,has_title,Defendor Special: A Multicenter Prospective Observational Post-registration Study of Combined Chemot
NCT04905329,has_status,UNKNOWN
NCT04905329,has_phase,
NCT04905329,sponsored_by,Moscow Clinical Scientific Center
NCT04905329,tests,Empegfilgrastim
Empegfilgrastim,has_type,DRUG
NCT02587689,has_title,Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
NCT02587689,has_status,UNKNOWN
NCT02587689,has_phase,
NCT02587689,sponsored_by,"PersonGen BioTherapeutics (Suzhou) Co., Ltd."
NCT02587689,tests,anti-MUC1 CAR T Cells
anti-MUC1 CAR T Cells,has_type,BIOLOGICAL
NCT01520389,has_title,A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
NCT01520389,has_status,COMPLETED
NCT01520389,has_phase,
NCT01520389,sponsored_by,Merrimack Pharmaceuticals
NCT01520389,tests,MM-151
MM-151,has_type,DRUG
NCT01520389,tests,MM-151 + irinotecan
MM-151 + irinotecan,has_type,DRUG
NCT05712889,has_title,"An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor"
NCT05712889,has_status,COMPLETED
NCT05712889,has_phase,
NCT05712889,sponsored_by,"Vincerx Pharma, Inc."
NCT05712889,tests,VIP236 (Q3W)
VIP236 (Q3W),has_type,DRUG
NCT05712889,tests,VIP236 (Q2W)
VIP236 (Q2W),has_type,DRUG
NCT06084689,has_title,Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
NCT06084689,has_status,NOT_YET_RECRUITING
NCT06084689,has_phase,
NCT06084689,sponsored_by,Institut Bergonié
NCT06084689,tests,Ezabenlimab + BI907828
Ezabenlimab + BI907828,has_type,DRUG
NCT02445391,has_title,A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patie
NCT02445391,has_status,ACTIVE_NOT_RECRUITING
NCT02445391,has_phase,
NCT02445391,sponsored_by,ECOG-ACRIN Cancer Research Group
NCT02445391,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02445391,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02445391,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02187991,has_title,"A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With P"
NCT02187991,has_status,COMPLETED
NCT02187991,has_phase,
NCT02187991,sponsored_by,US Oncology Research
NCT02187991,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02187991,tests,Alisertib
Alisertib,has_type,DRUG
NCT03473691,has_title,Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Ad
NCT03473691,has_status,WITHDRAWN
NCT03473691,has_phase,
NCT03473691,sponsored_by,University of Virginia
NCT03473691,tests,Glembatumumab Vedotin
Glembatumumab Vedotin,has_type,DRUG
NCT05064280,has_title,"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Oth"
NCT05064280,has_status,RECRUITING
NCT05064280,has_phase,
NCT05064280,sponsored_by,M.D. Anderson Cancer Center
NCT05064280,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05064280,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT05706129,has_title,"A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging"
NCT05706129,has_status,RECRUITING
NCT05706129,has_phase,
NCT05706129,sponsored_by,Debiopharm International SA
NCT05706129,tests,[68Ga]Ga-DPI-4452
[68Ga]Ga-DPI-4452,has_type,DRUG
NCT05706129,tests,[177Lu]Lu-DPI-4452
[177Lu]Lu-DPI-4452,has_type,DRUG
NCT04561362,has_title,"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Pat"
NCT04561362,has_status,RECRUITING
NCT04561362,has_phase,
NCT04561362,sponsored_by,BicycleTx Limited
NCT04561362,tests,BT8009
BT8009,has_type,DRUG
NCT04561362,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03075462,has_title,"An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib "
NCT03075462,has_status,COMPLETED
NCT03075462,has_phase,
NCT03075462,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT03075462,tests,Fluzoparib
Fluzoparib,has_type,DRUG
NCT03075462,tests,Apatinib
Apatinib,has_type,DRUG
NCT01846091,has_title,Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Gene
NCT01846091,has_status,COMPLETED
NCT01846091,has_phase,
NCT01846091,sponsored_by,Mayo Clinic
NCT01846091,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01846091,tests,Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter,has_type,BIOLOGICAL
NCT05076760,has_title,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Ther
NCT05076760,has_status,RECRUITING
NCT05076760,has_phase,
NCT05076760,sponsored_by,"Memgen, Inc."
NCT05076760,tests,MEM-288 Intratumoral Injection
MEM-288 Intratumoral Injection,has_type,BIOLOGICAL
NCT05076760,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT05076760,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04434560,has_title,A Phase II Trial of Surgery and Stereotactic Radiosurgery With Neoadjuvant Nivolumab and Ipilimumab 
NCT04434560,has_status,TERMINATED
NCT04434560,has_phase,
NCT04434560,sponsored_by,"Sarah Sammons, MD"
NCT04434560,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04434560,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT05806060,has_title,Precise Treatment for BLIS Subtype of Triple-negative Breast Cancer in the First-line Treatment of L
NCT05806060,has_status,RECRUITING
NCT05806060,has_phase,
NCT05806060,sponsored_by,Fudan University
NCT05806060,tests,"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine"
"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",has_type,DRUG
NCT05806060,tests,"nab-paclitaxel, with maintenance of capecitabine"
"nab-paclitaxel, with maintenance of capecitabine",has_type,DRUG
NCT05806060,tests,Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1
Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1,has_type,DRUG
NCT05806060,tests,VEGFR and TPC
VEGFR and TPC,has_type,DRUG
NCT00827567,has_title,A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer
NCT00827567,has_status,TERMINATED
NCT00827567,has_phase,
NCT00827567,sponsored_by,Milton S. Hershey Medical Center
NCT00827567,tests,RAD 001
RAD 001,has_type,DRUG
NCT06324240,has_title,Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor
NCT06324240,has_status,NOT_YET_RECRUITING
NCT06324240,has_phase,
NCT06324240,sponsored_by,Emory University
NCT06324240,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT06324240,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06324240,tests,Vaccine Therapy
Vaccine Therapy,has_type,BIOLOGICAL
NCT03435640,has_title,"A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combin"
NCT03435640,has_status,TERMINATED
NCT03435640,has_phase,
NCT03435640,sponsored_by,Nektar Therapeutics
NCT03435640,tests,NKTR-262
NKTR-262,has_type,DRUG
NCT03435640,tests,bempegaldesleukin
bempegaldesleukin,has_type,DRUG
NCT03435640,tests,nivolumab
nivolumab,has_type,DRUG
NCT04464967,has_title,"A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Viv"
NCT04464967,has_status,WITHDRAWN
NCT04464967,has_phase,
NCT04464967,sponsored_by,"NKGen Biotech, Inc."
NCT04464967,tests,SNK01
SNK01,has_type,BIOLOGICAL
NCT04464967,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04464967,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT06690840,has_title,"A Phase II Study of Atezolizumab, Vinorelbine and Weekly Cyclophosphamide as T-cell Activators in Fi"
NCT06690840,has_status,NOT_YET_RECRUITING
NCT06690840,has_phase,
NCT06690840,sponsored_by,European Institute of Oncology
NCT06690840,tests,Atezolizumab in combination with Cyclophosphamide and Vinorelbine
Atezolizumab in combination with Cyclophosphamide and Vinorelbine,has_type,DRUG
NCT03750240,has_title,Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
NCT03750240,has_status,TERMINATED
NCT03750240,has_phase,
NCT03750240,sponsored_by,NYU Langone Health
NCT03750240,tests,Sodium (Na) Magnetic Resonance Imaging (MRI)
Sodium (Na) Magnetic Resonance Imaging (MRI),has_type,DIAGNOSTIC_TEST
NCT03750240,tests,Dynamic Contrast- Enhanced (DCE) MRI
Dynamic Contrast- Enhanced (DCE) MRI,has_type,DIAGNOSTIC_TEST
NCT01836640,has_title,Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patie
NCT01836640,has_status,TERMINATED
NCT01836640,has_phase,
NCT01836640,sponsored_by,Dartmouth-Hitchcock Medical Center
NCT04907344,has_title,"A Multicenter, Open, Randomized Controlled Study of Camrelizumab+ Nab-paclitaxel + Carboplatin Versu"
NCT04907344,has_status,UNKNOWN
NCT04907344,has_phase,
NCT04907344,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT04907344,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT04907344,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04907344,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00528567,has_title,"An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in ""Triple Ne"
NCT00528567,has_status,COMPLETED
NCT00528567,has_phase,
NCT00528567,sponsored_by,Hoffmann-La Roche
NCT00528567,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00528567,tests,Standard adjuvant chemotherapy
Standard adjuvant chemotherapy,has_type,DRUG
NCT03168880,has_title,A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly 
NCT03168880,has_status,ACTIVE_NOT_RECRUITING
NCT03168880,has_phase,
NCT03168880,sponsored_by,Tata Memorial Hospital
NCT03168880,tests,Paclitaxel + Carboplatin
Paclitaxel + Carboplatin,has_type,DRUG
NCT03168880,tests,Paclitaxel only
Paclitaxel only,has_type,DRUG
NCT04664829,has_title,Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in I
NCT04664829,has_status,RECRUITING
NCT04664829,has_phase,
NCT04664829,sponsored_by,"National Cancer Centre, Singapore"
NCT04664829,tests,Bexarotene
Bexarotene,has_type,DRUG
NCT04664829,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05629429,has_title,Olaparib Maintenance Therapy in Patients With Metastatic Breast Cancer Following DNA-damaging Based 
NCT05629429,has_status,RECRUITING
NCT05629429,has_phase,
NCT05629429,sponsored_by,National Taiwan University Hospital
NCT05629429,tests,Olaparib
Olaparib,has_type,DRUG
NCT05629429,tests,Chemotherapy drug
Chemotherapy drug,has_type,DRUG
NCT05928780,has_title,A Molecular Pathway-based Umbrella Trial for First-line Precision Therapy With TROP2 in Patients Wit
NCT05928780,has_status,NOT_YET_RECRUITING
NCT05928780,has_phase,
NCT05928780,sponsored_by,Fudan University
NCT05928780,tests,A1:SG with SHR3680
A1:SG with SHR3680,has_type,DRUG
NCT05928780,tests,A2:SG
A2:SG,has_type,DRUG
NCT05928780,tests,B1:SG with SHR1210
B1:SG with SHR1210,has_type,DRUG
NCT05928780,tests,B2:SG
B2:SG,has_type,DRUG
NCT05928780,tests,C1:SG with SHR3162
C1:SG with SHR3162,has_type,DRUG
NCT05928780,tests,C2:SG
C2:SG,has_type,DRUG
NCT05928780,tests,D1:SG with VEGFRI
D1:SG with VEGFRI,has_type,DRUG
NCT05928780,tests,D2:SG
D2:SG,has_type,DRUG
NCT02244580,has_title,"Evaluation of the MammaTyperTM Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Pat"
NCT02244580,has_status,COMPLETED
NCT02244580,has_phase,
NCT02244580,sponsored_by,BioNTech Diagnostics GmbH
NCT02244580,tests,MammaTyper™
MammaTyper™,has_type,DEVICE
NCT06022029,has_title,A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Co
NCT06022029,has_status,RECRUITING
NCT06022029,has_phase,
NCT06022029,sponsored_by,"OncoNano Medicine, Inc."
NCT06022029,tests,ONM-501
ONM-501,has_type,DRUG
NCT06022029,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT03109080,has_title,"A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced"
NCT03109080,has_status,COMPLETED
NCT03109080,has_phase,
NCT03109080,sponsored_by,Institut Curie
NCT03109080,tests,Olaparib
Olaparib,has_type,DRUG
NCT03109080,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT02620280,has_title,Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer
NCT02620280,has_status,COMPLETED
NCT02620280,has_phase,
NCT02620280,sponsored_by,Fondazione Michelangelo
NCT02620280,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02620280,tests,Abraxane
Abraxane,has_type,DRUG
NCT02620280,tests,MPDL3280A
MPDL3280A,has_type,DRUG
NCT02620280,tests,Surgery
Surgery,has_type,PROCEDURE
NCT02620280,tests,Anthra
Anthra,has_type,DRUG
NCT05209529,has_title,Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast Cancer
NCT05209529,has_status,WITHDRAWN
NCT05209529,has_phase,
NCT05209529,sponsored_by,European Organisation for Research and Treatment of Cancer - EORTC
NCT05209529,tests,olaparib
olaparib,has_type,DRUG
NCT05209529,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT02041429,has_title,Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Neg
NCT02041429,has_status,COMPLETED
NCT02041429,has_phase,
NCT02041429,sponsored_by,Dana-Farber Cancer Institute
NCT02041429,tests,Ruxolitinib
Ruxolitinib,has_type,DRUG
NCT02041429,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02807844,has_title,"A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With A"
NCT02807844,has_status,COMPLETED
NCT02807844,has_phase,
NCT02807844,sponsored_by,Novartis Pharmaceuticals
NCT02807844,tests,MCS110
MCS110,has_type,DRUG
NCT02807844,tests,PDR001
PDR001,has_type,DRUG
NCT06081244,has_title,NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sa
NCT06081244,has_status,RECRUITING
NCT06081244,has_phase,
NCT06081244,sponsored_by,West German Study Group
NCT06081244,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT06081244,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03366844,has_title,Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Can
NCT03366844,has_status,ACTIVE_NOT_RECRUITING
NCT03366844,has_phase,
NCT03366844,sponsored_by,Stephen Shiao
NCT03366844,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03366844,tests,RT Boost
RT Boost,has_type,RADIATION
NCT05341492,has_title,"A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR/B7H3 CAR-T"
NCT05341492,has_status,RECRUITING
NCT05341492,has_phase,
NCT05341492,sponsored_by,Second Affiliated Hospital of Guangzhou Medical University
NCT05341492,tests,EGFR/B7H3 CAR-T
EGFR/B7H3 CAR-T,has_type,BIOLOGICAL
NCT06568692,has_title,"A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Bre"
NCT06568692,has_status,RECRUITING
NCT06568692,has_phase,
NCT06568692,sponsored_by,Processa Pharmaceuticals
NCT06568692,tests,PCS6422 and capecitabine
PCS6422 and capecitabine,has_type,DRUG
NCT06568692,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03256344,has_title,A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Tripl
NCT03256344,has_status,COMPLETED
NCT03256344,has_phase,
NCT03256344,sponsored_by,Amgen
NCT03256344,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,BIOLOGICAL
NCT03256344,tests,Atezolizumab
Atezolizumab,has_type,BIOLOGICAL
NCT05059444,has_title,ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444,has_status,RECRUITING
NCT05059444,has_phase,
NCT05059444,sponsored_by,"Guardant Health, Inc."
NCT05059444,tests,Guardant Reveal
Guardant Reveal,has_type,DIAGNOSTIC_TEST
NCT03671044,has_title,"A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety o"
NCT03671044,has_status,RECRUITING
NCT03671044,has_phase,
NCT03671044,sponsored_by,Jina Pharmaceuticals Inc.
NCT03671044,tests,Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
Nanosomal Docetaxel Lipid Suspension (75 mg/m2),has_type,DRUG
NCT03671044,tests,Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
Nanosomal Docetaxel Lipid Suspension (100 mg/m2),has_type,DRUG
NCT03671044,tests,Taxotere® (100 mg/m2)
Taxotere® (100 mg/m2),has_type,DRUG
NCT06224244,has_title,A Prospective Phase II Trial of an Accelerated Hypofractionated Radiotherapy Schedule With Risk-adap
NCT06224244,has_status,RECRUITING
NCT06224244,has_phase,
NCT06224244,sponsored_by,Regina Elena Cancer Institute
NCT06224244,tests,Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost
Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost,has_type,RADIATION
NCT06224244,tests,Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost
Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost,has_type,RADIATION
NCT02003092,has_title,"A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Meta"
NCT02003092,has_status,TERMINATED
NCT02003092,has_phase,
NCT02003092,sponsored_by,"Rexahn Pharmaceuticals, Inc."
NCT02003092,tests,RX-5902
RX-5902,has_type,DRUG
NCT04807192,has_title,CMP-001 in Combination with Pre-Operative Stereotactic Body Radiation Therapy in Patients with Early
NCT04807192,has_status,ACTIVE_NOT_RECRUITING
NCT04807192,has_phase,
NCT04807192,sponsored_by,Centre Hospitalier Universitaire Vaudois
NCT04807192,tests,stereotactic body radiotherapy
stereotactic body radiotherapy,has_type,RADIATION
NCT04807192,tests,CMP-001
CMP-001,has_type,DRUG
NCT02854644,has_title,Study of the Anti-tumoral Immune Response T Cells Cluster of Differentiation 4 (TCD4): Proof of the 
NCT02854644,has_status,COMPLETED
NCT02854644,has_phase,
NCT02854644,sponsored_by,Centre Hospitalier Universitaire de Besancon
NCT02854644,tests,additional blood sample
additional blood sample,has_type,OTHER
NCT05852691,has_title,"A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-P"
NCT05852691,has_status,ACTIVE_NOT_RECRUITING
NCT05852691,has_phase,
NCT05852691,sponsored_by,Hoffmann-La Roche
NCT05852691,tests,Tobemstomig
Tobemstomig,has_type,DRUG
NCT05852691,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05852691,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT02719691,has_title,A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibi
NCT02719691,has_status,COMPLETED
NCT02719691,has_phase,
NCT02719691,sponsored_by,"University of Colorado, Denver"
NCT02719691,tests,Alisertib
Alisertib,has_type,DRUG
NCT02719691,tests,MLN0128
MLN0128,has_type,DRUG
NCT01928394,has_title,"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subj"
NCT01928394,has_status,COMPLETED
NCT01928394,has_phase,
NCT01928394,sponsored_by,Bristol-Myers Squibb
NCT01928394,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT01928394,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT01928394,tests,Cobimetinib
Cobimetinib,has_type,DRUG
NCT00542191,has_title,Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
NCT00542191,has_status,TERMINATED
NCT00542191,has_phase,
NCT00542191,sponsored_by,Leo W. Jenkins Cancer Center
NCT00542191,tests,Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin,has_type,DRUG
NCT00542191,tests,Definitive Surgery
Definitive Surgery,has_type,PROCEDURE
NCT00542191,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT05208762,has_title,A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762,has_status,RECRUITING
NCT05208762,has_phase,
NCT05208762,sponsored_by,"Seagen, a wholly owned subsidiary of Pfizer"
NCT05208762,tests,PF-08046054
PF-08046054,has_type,DRUG
NCT05208762,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT02425891,has_title,"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody)"
NCT02425891,has_status,COMPLETED
NCT02425891,has_phase,
NCT02425891,sponsored_by,Hoffmann-La Roche
NCT02425891,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
NCT02425891,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT02425891,tests,Placebo
Placebo,has_type,DRUG
NCT05491694,has_title,To Evaluate the Efficacy and Safety of Toripalimab Combined With Chemotherapy (Epirubicin + Cyclopho
NCT05491694,has_status,UNKNOWN
NCT05491694,has_phase,
NCT05491694,sponsored_by,The First Affiliated Hospital with Nanjing Medical University
NCT05491694,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT05491694,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05491694,tests,High Intensity Focused Ultrasoun
High Intensity Focused Ultrasoun,has_type,PROCEDURE
NCT05491694,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05491694,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05491694,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02393794,has_title,Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Can
NCT02393794,has_status,UNKNOWN
NCT02393794,has_phase,
NCT02393794,sponsored_by,Priyanka Sharma
NCT02393794,tests,Romidepsin
Romidepsin,has_type,DRUG
NCT02393794,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02393794,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT06154291,has_title,"Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investi"
NCT06154291,has_status,RECRUITING
NCT06154291,has_phase,
NCT06154291,sponsored_by,Xenothera SAS
NCT06154291,tests,XON7
XON7,has_type,DRUG
NCT03316794,has_title,An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
NCT03316794,has_status,TERMINATED
NCT03316794,has_phase,
NCT03316794,sponsored_by,AbbVie
NCT03316794,tests,SC-005
SC-005,has_type,DRUG
NCT03318562,has_title,A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and H
NCT03318562,has_status,TERMINATED
NCT03318562,has_phase,
NCT03318562,sponsored_by,Effector Therapeutics
NCT03318562,tests,eFT508
eFT508,has_type,DRUG
NCT05181462,has_title,A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination with Gemcitab
NCT05181462,has_status,ACTIVE_NOT_RECRUITING
NCT05181462,has_phase,
NCT05181462,sponsored_by,Cantargia AB
NCT05181462,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05181462,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05181462,tests,Nadunolimab
Nadunolimab,has_type,DRUG
NCT03289962,has_title,"A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a"
NCT03289962,has_status,COMPLETED
NCT03289962,has_phase,
NCT03289962,sponsored_by,"Genentech, Inc."
NCT03289962,tests,Autogene cevumeran
Autogene cevumeran,has_type,DRUG
NCT03289962,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03849469,has_title,A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and 
NCT03849469,has_status,COMPLETED
NCT03849469,has_phase,
NCT03849469,sponsored_by,"Xencor, Inc."
NCT03849469,tests,XmAb®22841
XmAb®22841,has_type,BIOLOGICAL
NCT03849469,tests,Pembrolizumab (Keytruda®)
Pembrolizumab (Keytruda®),has_type,BIOLOGICAL
NCT06448169,has_title,Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast 
NCT06448169,has_status,NOT_YET_RECRUITING
NCT06448169,has_phase,
NCT06448169,sponsored_by,Shandong University
NCT06448169,tests,PD-1 inhibitor
PD-1 inhibitor,has_type,DRUG
NCT02670668,has_title,Single Centre，Exploratory，Parallel and Retrospective Study to Analysis the Mutation and Expression o
NCT02670668,has_status,UNKNOWN
NCT02670668,has_phase,
NCT02670668,sponsored_by,Fudan University
NCT02670668,tests,Mutation analysis
Mutation analysis,has_type,OTHER
NCT06246968,has_title,Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Met
NCT06246968,has_status,RECRUITING
NCT06246968,has_phase,
NCT06246968,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT06246968,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06246968,tests,Cryoablation
Cryoablation,has_type,DEVICE
NCT05318469,has_title,A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Balstilimab 
NCT05318469,has_status,RECRUITING
NCT05318469,has_phase,
NCT05318469,sponsored_by,Yuan Yuan
NCT05318469,tests,Ivermectin
Ivermectin,has_type,DRUG
NCT05318469,tests,Balstilmab
Balstilmab,has_type,DRUG
NCT05318469,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04906369,has_title,Optimizing Treatment of Metastatic Breast Cancer Through Real-Time Disease Monitoring
NCT04906369,has_status,SUSPENDED
NCT04906369,has_phase,
NCT04906369,sponsored_by,Mayo Clinic
NCT04906369,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04789668,has_title,Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases
NCT04789668,has_status,COMPLETED
NCT04789668,has_phase,
NCT04789668,sponsored_by,M.D. Anderson Cancer Center
NCT04789668,tests,Bintrafusp Alfa
Bintrafusp Alfa,has_type,DRUG
NCT04789668,tests,Pimasertib
Pimasertib,has_type,DRUG
NCT04789668,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT04626440,has_title,Comprehensive Precision Medicine Research on the Heterogeneity of Taiwanese Breast Cancer Patients b
NCT04626440,has_status,RECRUITING
NCT04626440,has_phase,
NCT04626440,sponsored_by,vghtpe user
NCT04626440,tests,Diagnostic stage or the Clinical outcome
Diagnostic stage or the Clinical outcome,has_type,PROCEDURE
NCT05537740,has_title,"First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmac"
NCT05537740,has_status,RECRUITING
NCT05537740,has_phase,
NCT05537740,sponsored_by,Bayer
NCT05537740,tests,BAY3375968
BAY3375968,has_type,DRUG
NCT05537740,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06441240,has_title,Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuva
NCT06441240,has_status,RECRUITING
NCT06441240,has_phase,
NCT06441240,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06441240,tests,MRI
MRI,has_type,DIAGNOSTIC_TEST
NCT04434040,has_title,A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Tripl
NCT04434040,has_status,ACTIVE_NOT_RECRUITING
NCT04434040,has_phase,
NCT04434040,sponsored_by,Dana-Farber Cancer Institute
NCT04434040,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04434040,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT05420467,has_title,"A Prospective, Open-label, Non-inferiority Study to Evaluate Injectable Albumin-bound Paclitaxel Ver"
NCT05420467,has_status,RECRUITING
NCT05420467,has_phase,
NCT05420467,sponsored_by,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
NCT05420467,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05420467,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05420467,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05420467,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT05420467,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT05420467,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05420467,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05420467,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05420467,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05420467,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05420467,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT05420467,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03606967,has_title,Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoanti
NCT03606967,has_status,RECRUITING
NCT03606967,has_phase,
NCT03606967,sponsored_by,National Cancer Institute (NCI)
NCT03606967,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT03606967,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT03606967,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03606967,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT03606967,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT03606967,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT03606967,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03606967,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03606967,tests,Personalized Synthetic Long Peptide Vaccine
Personalized Synthetic Long Peptide Vaccine,has_type,BIOLOGICAL
NCT03606967,tests,Poly ICLC
Poly ICLC,has_type,DRUG
NCT03606967,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,BIOLOGICAL
NCT03606967,tests,Tremelimumab
Tremelimumab,has_type,BIOLOGICAL
NCT01745367,has_title,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Study Comparing Tivozanib Hydrochloride in C"
NCT01745367,has_status,TERMINATED
NCT01745367,has_phase,
NCT01745367,sponsored_by,"AVEO Pharmaceuticals, Inc."
NCT01745367,tests,Tivozanib Hydrochloride
Tivozanib Hydrochloride,has_type,DRUG
NCT01745367,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01745367,tests,Placebo
Placebo,has_type,DRUG
NCT04890340,has_title,An International Multicenter Blind Comparative Controlled in Vitro Study of the Liquid Biopsy Test S
NCT04890340,has_status,UNKNOWN
NCT04890340,has_phase,
NCT04890340,sponsored_by,ARNA Genomics US Inc.
NCT04890340,tests,ARNA Breast
ARNA Breast,has_type,DIAGNOSTIC_TEST
NCT02307240,has_title,"Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Or"
NCT02307240,has_status,COMPLETED
NCT02307240,has_phase,
NCT02307240,sponsored_by,"Curis, Inc."
NCT02307240,tests,CUDC-907
CUDC-907,has_type,DRUG
NCT06975644,has_title,A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Effica
NCT06975644,has_status,NOT_YET_RECRUITING
NCT06975644,has_phase,
NCT06975644,sponsored_by,Zhejiang Provincial People's Hospital
NCT06975644,tests,"nab-paclitaxel, carboplatin, and bemotuzumab"
"nab-paclitaxel, carboplatin, and bemotuzumab",has_type,DRUG
NCT06975644,tests,"epirubicin, cyclophosphamide, and bemotuzumab"
"epirubicin, cyclophosphamide, and bemotuzumab",has_type,DRUG
NCT06849492,has_title,"An Open, Multicenter Study on the Treatment of Recurrent and Metastatic Triple-negative Breast Cance"
NCT06849492,has_status,NOT_YET_RECRUITING
NCT06849492,has_phase,
NCT06849492,sponsored_by,Fudan University
NCT06849492,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT06849492,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06849492,tests,SKB264
SKB264,has_type,DRUG
NCT06849492,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT05438329,has_title,"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Phar"
NCT05438329,has_status,RECRUITING
NCT05438329,has_phase,
NCT05438329,sponsored_by,DualityBio Inc.
NCT05438329,tests,DB-1305/BNT325
DB-1305/BNT325,has_type,DRUG
NCT05438329,tests,Pembrolizumab
Pembrolizumab,has_type,COMBINATION_PRODUCT
NCT05438329,tests,BNT327
BNT327,has_type,DRUG
NCT00918892,has_title,Assessment of Candidate Protein Expression in Human Breast Cancer Specimens
NCT00918892,has_status,COMPLETED
NCT00918892,has_phase,
NCT00918892,sponsored_by,Case Comprehensive Cancer Center
NCT00918892,tests,gene expression analysis
gene expression analysis,has_type,GENETIC
NCT00918892,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,OTHER
NCT00918892,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT03292172,has_title,"Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and C"
NCT03292172,has_status,TERMINATED
NCT03292172,has_phase,
NCT03292172,sponsored_by,Hoffmann-La Roche
NCT03292172,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03292172,tests,RO6870810
RO6870810,has_type,DRUG
NCT04770272,has_title,An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono A
NCT04770272,has_status,COMPLETED
NCT04770272,has_phase,
NCT04770272,sponsored_by,Palleos Healthcare GmbH
NCT04770272,tests,Atezolizumab 840 MG in 14 ML Injection
Atezolizumab 840 MG in 14 ML Injection,has_type,DRUG
NCT04770272,tests,Atezolizumab 1200 MG in 20 ML Injection
Atezolizumab 1200 MG in 20 ML Injection,has_type,DRUG
NCT04770272,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04770272,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04770272,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04770272,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04770272,tests,Biopsy Arm A
Biopsy Arm A,has_type,PROCEDURE
NCT04770272,tests,Biopsy Arm B
Biopsy Arm B,has_type,PROCEDURE
NCT04770272,tests,Surgery
Surgery,has_type,PROCEDURE
NCT05194072,has_title,A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
NCT05194072,has_status,TERMINATED
NCT05194072,has_phase,
NCT05194072,sponsored_by,"Seagen, a wholly owned subsidiary of Pfizer"
NCT05194072,tests,Felmetatug Vedotin
Felmetatug Vedotin,has_type,DRUG
NCT05194072,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02635672,has_title,"An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preli"
NCT02635672,has_status,COMPLETED
NCT02635672,has_phase,
NCT02635672,sponsored_by,"Vincerx Pharma, Inc."
NCT02635672,tests,VIP152 (BAY 1251152)
VIP152 (BAY 1251152),has_type,DRUG
NCT02635672,tests,VIP152 (BAY 1251152) 30 mg
VIP152 (BAY 1251152) 30 mg,has_type,DRUG
NCT02635672,tests,Keytruda
Keytruda,has_type,DRUG
NCT02635672,tests,VIP152 (BAY 1251152) 15 mg
VIP152 (BAY 1251152) 15 mg,has_type,DRUG
NCT04664972,has_title,Comparing TP (Docetaxel + Cisplatin) and TAC (Docetaxel + Doxorubicin + Cyclophosphamide) in Neoadju
NCT04664972,has_status,COMPLETED
NCT04664972,has_phase,
NCT04664972,sponsored_by,Henan Cancer Hospital
NCT04664972,tests,Docetaxel +doxorubicin+ cyclophosphamide
Docetaxel +doxorubicin+ cyclophosphamide,has_type,DRUG
NCT04664972,tests,Docetaxel +Cisplatin
Docetaxel +Cisplatin,has_type,DRUG
NCT06910072,has_title,Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoa
NCT06910072,has_status,NOT_YET_RECRUITING
NCT06910072,has_phase,
NCT06910072,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06910072,tests,paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab,has_type,DRUG
NCT04216472,has_title,"A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory "
NCT04216472,has_status,ACTIVE_NOT_RECRUITING
NCT04216472,has_phase,
NCT04216472,sponsored_by,M.D. Anderson Cancer Center
NCT04216472,tests,Alpelisib
Alpelisib,has_type,DRUG
NCT04216472,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02499367,has_title,Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-
NCT02499367,has_status,ACTIVE_NOT_RECRUITING
NCT02499367,has_phase,
NCT02499367,sponsored_by,The Netherlands Cancer Institute
NCT02499367,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02499367,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT02499367,tests,Low dose doxorubicin
Low dose doxorubicin,has_type,DRUG
NCT02499367,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02499367,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03945604,has_title,"A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Comb"
NCT03945604,has_status,COMPLETED
NCT03945604,has_phase,
NCT03945604,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT03945604,tests,SHR-1210 + Apatinib +Fluzoparib
SHR-1210 + Apatinib +Fluzoparib,has_type,DRUG
NCT06403904,has_title,Assessing Clinical Features and Outcome of Breast Cancer in PALB2
NCT06403904,has_status,RECRUITING
NCT06403904,has_phase,
NCT06403904,sponsored_by,Azienda Ospedaliero-Universitaria di Modena
NCT04249167,has_title,Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC)
NCT04249167,has_status,WITHDRAWN
NCT04249167,has_phase,
NCT04249167,sponsored_by,Mayo Clinic
NCT04249167,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04249167,tests,Cryosurgery
Cryosurgery,has_type,PROCEDURE
NCT04249167,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05111067,has_title,Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity
NCT05111067,has_status,COMPLETED
NCT05111067,has_phase,
NCT05111067,sponsored_by,Nova Scotia Health Authority
NCT05111067,tests,DNA and whole transcriptome mRNA sequencing
DNA and whole transcriptome mRNA sequencing,has_type,GENETIC
NCT03207867,has_title,"A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Sele"
NCT03207867,has_status,TERMINATED
NCT03207867,has_phase,
NCT03207867,sponsored_by,Novartis Pharmaceuticals
NCT03207867,tests,NIR178
NIR178,has_type,DRUG
NCT03207867,tests,PDR001
PDR001,has_type,DRUG
NCT03644589,has_title,A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Adva
NCT03644589,has_status,WITHDRAWN
NCT03644589,has_phase,
NCT03644589,sponsored_by,University of Washington
NCT03644589,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03644589,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02530489,has_title,"Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibit"
NCT02530489,has_status,COMPLETED
NCT02530489,has_phase,
NCT02530489,sponsored_by,M.D. Anderson Cancer Center
NCT02530489,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02530489,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06157892,has_title,A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in
NCT06157892,has_status,RECRUITING
NCT06157892,has_phase,
NCT06157892,sponsored_by,"Seagen, a wholly owned subsidiary of Pfizer"
NCT06157892,tests,disitamab vedotin
disitamab vedotin,has_type,DRUG
NCT06157892,tests,tucatinib
tucatinib,has_type,DRUG
NCT03122444,has_title,A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untr
NCT03122444,has_status,COMPLETED
NCT03122444,has_phase,
NCT03122444,sponsored_by,The University of Texas Health Science Center at San Antonio
NCT03122444,tests,Imipramine
Imipramine,has_type,DRUG
NCT02125344,has_title,"A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) "
NCT02125344,has_status,COMPLETED
NCT02125344,has_phase,
NCT02125344,sponsored_by,GBG Forschungs GmbH
NCT02125344,tests,non-pegylated liposomal doxorubicin
non-pegylated liposomal doxorubicin,has_type,DRUG
NCT02125344,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02125344,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02125344,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02125344,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02125344,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT02125344,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02125344,tests,Ferric carboxymaltose
Ferric carboxymaltose,has_type,DRUG
NCT03197389,has_title,"Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation an"
NCT03197389,has_status,COMPLETED
NCT03197389,has_phase,
NCT03197389,sponsored_by,Universitaire Ziekenhuizen KU Leuven
NCT03197389,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04395989,has_title,An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Meta
NCT04395989,has_status,ACTIVE_NOT_RECRUITING
NCT04395989,has_phase,
NCT04395989,sponsored_by,Fudan University
NCT04395989,tests,A1: Pyrotinib with nab-paclitaxel
A1: Pyrotinib with nab-paclitaxel,has_type,DRUG
NCT04395989,tests,A2: nab-paclitaxel
A2: nab-paclitaxel,has_type,DRUG
NCT04395989,tests,B1: everolimus with nab-paclitaxel
B1: everolimus with nab-paclitaxel,has_type,DRUG
NCT04395989,tests,B2: nab-paclitaxel
B2: nab-paclitaxel,has_type,DRUG
NCT04395989,tests,C1: PD-1 with nab-paclitaxel and famitinib
C1: PD-1 with nab-paclitaxel and famitinib,has_type,DRUG
NCT04395989,tests,C2: nab-paclitaxel
C2: nab-paclitaxel,has_type,DRUG
NCT04395989,tests,"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine"
"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",has_type,DRUG
NCT04395989,tests,"D2: nab-paclitaxel, with maintenance of capecitabine"
"D2: nab-paclitaxel, with maintenance of capecitabine",has_type,DRUG
NCT04395989,tests,E1: everolimus with nab-paclitaxel
E1: everolimus with nab-paclitaxel,has_type,DRUG
NCT04395989,tests,E2: nab-paclitaxel
E2: nab-paclitaxel,has_type,DRUG
NCT03367689,has_title,A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Ho
NCT03367689,has_status,TERMINATED
NCT03367689,has_phase,
NCT03367689,sponsored_by,MedSIR
NCT03367689,tests,Olaparib
Olaparib,has_type,DRUG
NCT04095689,has_title,Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patie
NCT04095689,has_status,SUSPENDED
NCT04095689,has_phase,
NCT04095689,sponsored_by,The Methodist Hospital Research Institute
NCT04095689,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04095689,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04095689,tests,IL-12 gene therapy
IL-12 gene therapy,has_type,DRUG
NCT02657889,has_title,Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With A
NCT02657889,has_status,COMPLETED
NCT02657889,has_phase,
NCT02657889,sponsored_by,"Tesaro, Inc."
NCT02657889,tests,niraparib
niraparib,has_type,DRUG
NCT02657889,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT04510129,has_title,Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies
NCT04510129,has_status,RECRUITING
NCT04510129,has_phase,
NCT04510129,sponsored_by,"Cofactor Genomics, Inc."
NCT04510129,tests,OncoPrism™ assay
OncoPrism™ assay,has_type,DIAGNOSTIC_TEST
NCT05544929,has_title,"A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembro"
NCT05544929,has_status,RECRUITING
NCT05544929,has_phase,
NCT05544929,sponsored_by,Novartis Pharmaceuticals
NCT05544929,tests,KFA115
KFA115,has_type,DRUG
NCT05544929,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT04032080,has_title,Pilot Clinical Trial of Treatment With LY3023414 and Prexasertib to Inhibit Homologous Recombination
NCT04032080,has_status,COMPLETED
NCT04032080,has_phase,
NCT04032080,sponsored_by,Baylor Research Institute
NCT04032080,tests,Drug 1: LY3023414
Drug 1: LY3023414,has_type,COMBINATION_PRODUCT
NCT06125080,has_title,The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Tri
NCT06125080,has_status,RECRUITING
NCT06125080,has_phase,
NCT06125080,sponsored_by,Huihua Xiong
NCT06125080,tests,Utidelone
Utidelone,has_type,DRUG
NCT06125080,tests,Tirelizumab
Tirelizumab,has_type,DRUG
NCT06125080,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT06635980,has_title,A Randomized Phase II Trial of Hypofractionated Radiotherapy for Non-Metastatic Breast Cancer Before
NCT06635980,has_status,RECRUITING
NCT06635980,has_phase,
NCT06635980,sponsored_by,Mayo Clinic
NCT06635980,tests,Biopsy of Breast
Biopsy of Breast,has_type,PROCEDURE
NCT06635980,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06635980,tests,Breast Surgery
Breast Surgery,has_type,PROCEDURE
NCT06635980,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT06635980,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT06635980,tests,Contrast Enhanced Digital Mammography
Contrast Enhanced Digital Mammography,has_type,PROCEDURE
NCT06635980,tests,Hypofractionated Radiation Therapy
Hypofractionated Radiation Therapy,has_type,RADIATION
NCT06635980,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT06635980,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT06635980,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT06635980,tests,Tissue Collection
Tissue Collection,has_type,PROCEDURE
NCT06635980,tests,Ultrasound Imaging
Ultrasound Imaging,has_type,PROCEDURE
NCT06954480,has_title,"An Open-label Randomised, Phase II Trial of Datopotamab Deruxtecan Plus Durvalumab Versus Datopotama"
NCT06954480,has_status,NOT_YET_RECRUITING
NCT06954480,has_phase,
NCT06954480,sponsored_by,Queen Mary University of London
NCT06954480,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
NCT06954480,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT05645380,has_title,Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT05645380,has_status,RECRUITING
NCT05645380,has_phase,
NCT05645380,sponsored_by,University of Kansas Medical Center
NCT05645380,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05645380,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05645380,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05645380,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05645380,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05552001,has_title,"ISIdE: Open Label, Multicentric, Single-arm Phase IIIB Trial to Evaluate the Safety and Efficacy of "
NCT05552001,has_status,RECRUITING
NCT05552001,has_phase,
NCT05552001,sponsored_by,UNICANCER
NCT05552001,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT02488967,has_title,A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followe
NCT02488967,has_status,ACTIVE_NOT_RECRUITING
NCT02488967,has_phase,
NCT02488967,sponsored_by,NRG Oncology
NCT02488967,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02488967,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02488967,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT02488967,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02488967,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06926868,has_title,"A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986"
NCT06926868,has_status,NOT_YET_RECRUITING
NCT06926868,has_phase,
NCT06926868,sponsored_by,Bristol-Myers Squibb
NCT06926868,tests,Iza-bren
Iza-bren,has_type,DRUG
NCT06926868,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06926868,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06926868,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06926868,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06926868,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03332368,has_title,Clinical Study on Prevention and Treatment of Recurrent and Metastasis of Triple Negative Breast Can
NCT03332368,has_status,UNKNOWN
NCT03332368,has_phase,
NCT03332368,sponsored_by,Sheng Liu
NCT03332368,tests,Traditional Chinese medicine
Traditional Chinese medicine,has_type,OTHER
NCT06099769,has_title,"A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSI"
NCT06099769,has_status,RECRUITING
NCT06099769,has_phase,
NCT06099769,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT06099769,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT06099769,tests,Mifepristone
Mifepristone,has_type,DRUG
NCT06099769,tests,TPC
TPC,has_type,DRUG
NCT02993068,has_title,Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
NCT02993068,has_status,SUSPENDED
NCT02993068,has_phase,
NCT02993068,sponsored_by,M.D. Anderson Cancer Center
NCT02993068,tests,Educational Intervention
Educational Intervention,has_type,OTHER
NCT02993068,tests,Genetic Counseling
Genetic Counseling,has_type,OTHER
NCT02993068,tests,Genetic Counseling
Genetic Counseling,has_type,OTHER
NCT02993068,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02993068,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04368468,has_title,Study of the Modifications of the Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Tri
NCT04368468,has_status,COMPLETED
NCT04368468,has_phase,
NCT04368468,sponsored_by,Institut Claudius Regaud
NCT04368468,tests,biomarker evolution
biomarker evolution,has_type,OTHER
NCT05953168,has_title,"An Open-label, Single-arm Phase II Trial of First-line Treatment With Trastuzumab Deruxtecan for Pat"
NCT05953168,has_status,NOT_YET_RECRUITING
NCT05953168,has_phase,
NCT05953168,sponsored_by,Fudan University
NCT05953168,tests,Trastuzumab Deruxtecan
Trastuzumab Deruxtecan,has_type,DRUG
NCT05893368,has_title,New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast 
NCT05893368,has_status,UNKNOWN
NCT05893368,has_phase,
NCT05893368,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05893368,tests,Sharing all key aspects associated with the quality of life in a single digital environment
Sharing all key aspects associated with the quality of life in a single digital environment,has_type,OTHER
NCT02630368,has_title,A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Adv
NCT02630368,has_status,UNKNOWN
NCT02630368,has_phase,
NCT02630368,sponsored_by,Institut Bergonié
NCT02630368,tests,Cyclophosphamide and JX-594 dose escalation
Cyclophosphamide and JX-594 dose escalation,has_type,DRUG
NCT02630368,tests,Cyclophosphamide and JX-594
Cyclophosphamide and JX-594,has_type,DRUG
NCT02630368,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02630368,tests,Avelumab and JX-594 and Cyclophosphamide
Avelumab and JX-594 and Cyclophosphamide,has_type,DRUG
NCT04755868,has_title,A Randomized Phase II Clinical Trial of Talazoparib Maintenance Therapy in Triple-negative Breast Ca
NCT04755868,has_status,UNKNOWN
NCT04755868,has_phase,
NCT04755868,sponsored_by,Yonsei University
NCT04755868,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04755868,tests,Placebo
Placebo,has_type,DRUG
NCT00912444,has_title,"A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docet"
NCT00912444,has_status,TERMINATED
NCT00912444,has_phase,
NCT00912444,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT00912444,tests,"Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide"
"Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide",has_type,DRUG
NCT00912444,tests,"Docetaxel, cyclophosphamide"
"Docetaxel, cyclophosphamide",has_type,DRUG
NCT04445844,has_title,IRENE Study: Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Ne
NCT04445844,has_status,ACTIVE_NOT_RECRUITING
NCT04445844,has_phase,
NCT04445844,sponsored_by,"Mridula George, MD"
NCT04445844,tests,Pelareorep
Pelareorep,has_type,BIOLOGICAL
NCT04445844,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT04445844,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04445844,tests,Retifanlimab
Retifanlimab,has_type,BIOLOGICAL
NCT06631092,has_title,"An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 as add-on to First-line Neoadjuv"
NCT06631092,has_status,RECRUITING
NCT06631092,has_phase,
NCT06631092,sponsored_by,NEC Bio B.V
NCT06631092,tests,Oral DNA Vaccine
Oral DNA Vaccine,has_type,BIOLOGICAL
NCT01910844,has_title,
NCT01910844,has_status,TERMINATED
NCT01910844,has_phase,
NCT01910844,sponsored_by,Centre Jean Perrin
NCT01910844,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01910844,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01461044,has_title,"An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER"
NCT01461044,has_status,COMPLETED
NCT01461044,has_phase,
NCT01461044,sponsored_by,Hoffmann-La Roche
NCT06562192,has_title,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Prelimin"
NCT06562192,has_status,RECRUITING
NCT06562192,has_phase,
NCT06562192,sponsored_by,Novartis Pharmaceuticals
NCT06562192,tests,[68Ga]Ga-NNS309
[68Ga]Ga-NNS309,has_type,DRUG
NCT06562192,tests,[177Lu]Lu-NNS309
[177Lu]Lu-NNS309,has_type,DRUG
NCT07040644,has_title,"A Multi-center, Open-label, Randomized, Phase II Trial of Sacituzumab Govitecan Plus Toripalimab Ver"
NCT07040644,has_status,NOT_YET_RECRUITING
NCT07040644,has_phase,
NCT07040644,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07040644,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
NCT07040644,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT07040644,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05081492,has_title,"A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimer"
NCT05081492,has_status,ACTIVE_NOT_RECRUITING
NCT05081492,has_phase,
NCT05081492,sponsored_by,City of Hope Medical Center
NCT05081492,tests,Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody,has_type,BIOLOGICAL
NCT04517292,has_title,"A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus Gemcitabine Plus "
NCT04517292,has_status,UNKNOWN
NCT04517292,has_phase,
NCT04517292,sponsored_by,Fudan University
NCT04517292,tests,"Eribulin,cisplatin"
"Eribulin,cisplatin",has_type,DRUG
NCT04517292,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
NCT05464082,has_title,"Towards Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of "
NCT05464082,has_status,RECRUITING
NCT05464082,has_phase,
NCT05464082,sponsored_by,University of Utah
NCT05464082,tests,Functional Precision Oncology
Functional Precision Oncology,has_type,OTHER
NCT02819882,has_title,A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Can
NCT02819882,has_status,RECRUITING
NCT02819882,has_phase,
NCT02819882,sponsored_by,Spanish Breast Cancer Research Group
NCT02819882,tests,No intervention
No intervention,has_type,OTHER
NCT01434420,has_title,Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
NCT01434420,has_status,UNKNOWN
NCT01434420,has_phase,
NCT01434420,sponsored_by,Institut Paoli-Calmettes
NCT01434420,tests,BRCA1 BRCA2 PTEN PALB2 mutation
BRCA1 BRCA2 PTEN PALB2 mutation,has_type,GENETIC
NCT04118062,has_title,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication To
NCT04118062,has_status,ACTIVE_NOT_RECRUITING
NCT04118062,has_phase,
NCT04118062,sponsored_by,Institut Curie
NCT04118062,tests,Questionnaires
Questionnaires,has_type,BEHAVIORAL
NCT04118062,tests,Semi-structured individual interviews
Semi-structured individual interviews,has_type,BEHAVIORAL
NCT04118062,tests,Focus Group
Focus Group,has_type,OTHER
NCT04118062,tests,DELPHI Consensus Method
DELPHI Consensus Method,has_type,OTHER
NCT06534762,has_title,Efficacy and Safety of Milaberon in Combination With Standard Therapy in Advanced Solid Tumors: an O
NCT06534762,has_status,RECRUITING
NCT06534762,has_phase,
NCT06534762,sponsored_by,Zhejiang Provincial People's Hospital
NCT06534762,tests,Mirabegron
Mirabegron,has_type,BIOLOGICAL
NCT04734262,has_title,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravat"
NCT04734262,has_status,ACTIVE_NOT_RECRUITING
NCT04734262,has_phase,
NCT04734262,sponsored_by,Fudan University
NCT04734262,tests,Sitravatinib
Sitravatinib,has_type,DRUG
NCT04734262,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT04734262,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02365662,has_title,A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated L
NCT02365662,has_status,TERMINATED
NCT02365662,has_phase,
NCT02365662,sponsored_by,AbbVie
NCT02365662,tests,ABBV-221
ABBV-221,has_type,DRUG
NCT06259162,has_title,The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and 
NCT06259162,has_status,RECRUITING
NCT06259162,has_phase,
NCT06259162,sponsored_by,Samsung Medical Center
NCT06259162,tests,LAG-3 expression / immune checkpoint protein expression
LAG-3 expression / immune checkpoint protein expression,has_type,PROCEDURE
NCT01693562,has_title,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects"
NCT01693562,has_status,COMPLETED
NCT01693562,has_phase,
NCT01693562,sponsored_by,MedImmune LLC
NCT01693562,tests,MEDI4736
MEDI4736,has_type,DRUG
NCT02071862,has_title,"Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, a"
NCT02071862,has_status,COMPLETED
NCT02071862,has_phase,
NCT02071862,sponsored_by,"Calithera Biosciences, Inc"
NCT02071862,tests,CB-839
CB-839,has_type,DRUG
NCT02071862,tests,Pac-CB
Pac-CB,has_type,DRUG
NCT02071862,tests,CBE
CBE,has_type,DRUG
NCT02071862,tests,CB-Erl
CB-Erl,has_type,DRUG
NCT02071862,tests,CBD
CBD,has_type,DRUG
NCT02071862,tests,CB-Cabo
CB-Cabo,has_type,DRUG
NCT05769491,has_title,Investigation of Patterns in Clinical Trial Experiences by Patients Participating in Triple Negative
NCT05769491,has_status,NOT_YET_RECRUITING
NCT05769491,has_phase,
NCT05769491,sponsored_by,Power Life Sciences Inc.
NCT04362462,has_title,Genomic/Molecular Profiling of Residual Disease After Neoadjuvant Chemotherapy in Hispanic/ Latino W
NCT04362462,has_status,UNKNOWN
NCT04362462,has_phase,
NCT04362462,sponsored_by,"Texas Tech University Health Sciences Center, El Paso"
NCT01307891,has_title,"An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Inject"
NCT01307891,has_status,COMPLETED
NCT01307891,has_phase,
NCT01307891,sponsored_by,University of Alabama at Birmingham
NCT01307891,tests,Abraxane alone
Abraxane alone,has_type,DRUG
NCT01307891,tests,Abraxane + Tigatuzumab
Abraxane + Tigatuzumab,has_type,DRUG
NCT04706962,has_title,"A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid"
NCT04706962,has_status,ACTIVE_NOT_RECRUITING
NCT04706962,has_phase,
NCT04706962,sponsored_by,Theratechnologies
NCT04706962,tests,TH1902
TH1902,has_type,DRUG
NCT03808662,has_title,Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of R
NCT03808662,has_status,ACTIVE_NOT_RECRUITING
NCT03808662,has_phase,
NCT03808662,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT03808662,tests,Sterotactic Body Radiotherapy/SBRT
Sterotactic Body Radiotherapy/SBRT,has_type,RADIATION
NCT03808662,tests,Standard of care
Standard of care,has_type,DRUG
NCT01232062,has_title,Study of High-dose Chemotherapy Combined With Adoptive Cellular Therapy With Dentritic and Cytokine-
NCT01232062,has_status,COMPLETED
NCT01232062,has_phase,
NCT01232062,sponsored_by,Peking University Cancer Hospital & Institute
NCT02624973,has_title,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
NCT02624973,has_status,ACTIVE_NOT_RECRUITING
NCT02624973,has_phase,
NCT02624973,sponsored_by,Haukeland University Hospital
NCT02624973,tests,Neoadjuvant tamoxifen + goserelin (premenopausal women)
Neoadjuvant tamoxifen + goserelin (premenopausal women),has_type,DRUG
NCT02624973,tests,Neoadjuvant letrozole (postmenopausal women)
Neoadjuvant letrozole (postmenopausal women),has_type,DRUG
NCT02624973,tests,Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone),has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel + cyclophosphamide
Neoadjuvant docetaxel + cyclophosphamide,has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel
Neoadjuvant docetaxel,has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel + trastuzumab + pertuzumab
Neoadjuvant docetaxel + trastuzumab + pertuzumab,has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab
Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab,has_type,DRUG
NCT02624973,tests,Neoadjuvant olaparib
Neoadjuvant olaparib,has_type,DRUG
NCT02624973,tests,Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone),has_type,DRUG
NCT02624973,tests,Breast conserving surgery or mastectomy + SNB/axillary dissection
Breast conserving surgery or mastectomy + SNB/axillary dissection,has_type,PROCEDURE
NCT02624973,tests,Postoperative radiotherapy breast/chest wall + regional lymph nodes
Postoperative radiotherapy breast/chest wall + regional lymph nodes,has_type,RADIATION
NCT02624973,tests,Adjuvant trastuzumab
Adjuvant trastuzumab,has_type,DRUG
NCT02624973,tests,Adjuvant letrozole (postmenopausal women)
Adjuvant letrozole (postmenopausal women),has_type,DRUG
NCT02624973,tests,Adjuvant tamoxifen + goserelin (premenopausal women)
Adjuvant tamoxifen + goserelin (premenopausal women),has_type,DRUG
NCT02624973,tests,Adjuvant palbociclib (if palbociclib given neoadjuvant)
Adjuvant palbociclib (if palbociclib given neoadjuvant),has_type,DRUG
NCT02624973,tests,Adjuvant Epirubicin+ Cyclophosphamide
Adjuvant Epirubicin+ Cyclophosphamide,has_type,DRUG
NCT03739931,has_title,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsu"
NCT03739931,has_status,ACTIVE_NOT_RECRUITING
NCT03739931,has_phase,
NCT03739931,sponsored_by,"ModernaTX, Inc."
NCT03739931,tests,mRNA-2752
mRNA-2752,has_type,BIOLOGICAL
NCT03739931,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT07017673,has_title,Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Sta
NCT07017673,has_status,NOT_YET_RECRUITING
NCT07017673,has_phase,
NCT07017673,sponsored_by,Cedars-Sinai Medical Center
NCT07017673,tests,Ivonescimab
Ivonescimab,has_type,DRUG
NCT07017673,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT07017673,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06735131,has_title,"A Prospective, Multicenter Clinical Trial Exploring the Optimal Combination Strategies of Radiothera"
NCT06735131,has_status,RECRUITING
NCT06735131,has_phase,
NCT06735131,sponsored_by,Sun Yat-sen University
NCT06735131,tests,"radiotherapy 5 Gy × 5 fractions, once a day"
"radiotherapy 5 Gy × 5 fractions, once a day",has_type,RADIATION
NCT06735131,tests,"radiotherapy 8 Gy × 5 fractions, once a day"
"radiotherapy 8 Gy × 5 fractions, once a day",has_type,RADIATION
NCT06735131,tests,"radiotherapy 8 Gy × 3 fractions, once every other day"
"radiotherapy 8 Gy × 3 fractions, once every other day",has_type,RADIATION
NCT06735131,tests,"radiotherapy 10 Gy× 3 fractions, once every other day"
"radiotherapy 10 Gy× 3 fractions, once every other day",has_type,RADIATION
NCT06735131,tests,"radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)"
"radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)",has_type,RADIATION
NCT06735131,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT06735131,tests,chemotherapy regimen selected by the investigator
chemotherapy regimen selected by the investigator,has_type,DRUG
NCT05460273,has_title,"Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advan"
NCT05460273,has_status,ACTIVE_NOT_RECRUITING
NCT05460273,has_phase,
NCT05460273,sponsored_by,AstraZeneca
NCT05460273,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
NCT06358573,has_title,Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-nega
NCT06358573,has_status,RECRUITING
NCT06358573,has_phase,
NCT06358573,sponsored_by,Swiss Group for Clinical Cancer Research
NCT06358573,tests,INT230-6
INT230-6,has_type,DRUG
NCT06358573,tests,neoadjuvant immuno-chemotherapy
neoadjuvant immuno-chemotherapy,has_type,OTHER
NCT04373031,has_title,Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembroli
NCT04373031,has_status,ACTIVE_NOT_RECRUITING
NCT04373031,has_phase,
NCT04373031,sponsored_by,Providence Health & Services
NCT04373031,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04373031,tests,IRX 2
IRX 2,has_type,DRUG
NCT02338531,has_title,Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531,has_status,WITHDRAWN
NCT02338531,has_phase,
NCT02338531,sponsored_by,Jules Bordet Institute
NCT02338531,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT02338531,tests,Breast cancer surgery
Breast cancer surgery,has_type,PROCEDURE
NCT02260531,has_title,A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients 
NCT02260531,has_status,COMPLETED
NCT02260531,has_phase,
NCT02260531,sponsored_by,Dana-Farber Cancer Institute
NCT02260531,tests,Cabozantinib
Cabozantinib,has_type,DRUG
NCT02260531,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05086731,has_title,THRIVE Smart - Leveraging Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Brea
NCT05086731,has_status,COMPLETED
NCT05086731,has_phase,
NCT05086731,sponsored_by,Emory University
NCT05086731,tests,Best Practice
Best Practice,has_type,OTHER
NCT05086731,tests,Informational Intervention
Informational Intervention,has_type,OTHER
NCT05086731,tests,Medical Device Usage and Evaluation
Medical Device Usage and Evaluation,has_type,OTHER
NCT05086731,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT05086731,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT01750073,has_title,A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Ca
NCT01750073,has_status,ACTIVE_NOT_RECRUITING
NCT01750073,has_phase,
NCT01750073,sponsored_by,University of Nebraska
NCT01750073,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01750073,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT01750073,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01750073,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01750073,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT01750073,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT01750073,tests,Trastuzumab
Trastuzumab,has_type,BIOLOGICAL
NCT04725331,has_title,A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pemb
NCT04725331,has_status,RECRUITING
NCT04725331,has_phase,
NCT04725331,sponsored_by,Transgene
NCT04725331,tests,BT-001
BT-001,has_type,BIOLOGICAL
NCT04725331,tests,Pembrolizumab [KEYTRUDA®]
Pembrolizumab [KEYTRUDA®],has_type,DRUG
NCT02365831,has_title,Evaluation of Medical Treatments in MBC HER2 Negative Patients in Italy - Observational Study
NCT02365831,has_status,UNKNOWN
NCT02365831,has_phase,
NCT02365831,sponsored_by,Consorzio Oncotech
NCT02365831,tests,Observation of treatment management
Observation of treatment management,has_type,OTHER
NCT02993094,has_title,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative
NCT02993094,has_status,TERMINATED
NCT02993094,has_phase,
NCT02993094,sponsored_by,Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT02993094,tests,Ixazomib
Ixazomib,has_type,DRUG
NCT02993094,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06691594,has_title,"Prospective, Single-arm, Phase II Study of Stereotactic Radiotherapy Combined with PD-1 Monoclonal A"
NCT06691594,has_status,NOT_YET_RECRUITING
NCT06691594,has_phase,
NCT06691594,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06691594,tests,neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy,has_type,RADIATION
NCT02599194,has_title,An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy
NCT02599194,has_status,COMPLETED
NCT02599194,has_phase,
NCT02599194,sponsored_by,Andrei Iagaru
NCT02599194,tests,18F-FSPG
18F-FSPG,has_type,DRUG
NCT02599194,tests,18F-FDG
18F-FDG,has_type,DRUG
NCT03564691,has_title,"A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With"
NCT03564691,has_status,ACTIVE_NOT_RECRUITING
NCT03564691,has_phase,
NCT03564691,sponsored_by,Merck Sharp & Dohme LLC
NCT03564691,tests,MK-4830
MK-4830,has_type,DRUG
NCT03564691,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03564691,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03564691,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT03564691,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT03564691,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03564691,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03564691,tests,MK-4830A
MK-4830A,has_type,BIOLOGICAL
NCT05000294,has_title,Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT05000294,has_status,RECRUITING
NCT05000294,has_phase,
NCT05000294,sponsored_by,University of Florida
NCT05000294,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT05000294,tests,Tivozanib
Tivozanib,has_type,DRUG
NCT05422794,has_title,A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Meta
NCT05422794,has_status,RECRUITING
NCT05422794,has_phase,
NCT05422794,sponsored_by,National Cancer Institute (NCI)
NCT05422794,tests,BET Bromodomain Inhibitor ZEN-3694
BET Bromodomain Inhibitor ZEN-3694,has_type,DRUG
NCT05422794,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT05422794,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05422794,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05422794,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05422794,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05422794,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03328494,has_title,"A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibit"
NCT03328494,has_status,COMPLETED
NCT03328494,has_phase,
NCT03328494,sponsored_by,Boston Pharmaceuticals
NCT03328494,tests,BOS172722
BOS172722,has_type,DRUG
NCT03328494,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05983094,has_title,Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
NCT05983094,has_status,NOT_YET_RECRUITING
NCT05983094,has_phase,
NCT05983094,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT05983094,tests,Utidelone
Utidelone,has_type,DRUG
NCT05983094,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05983094,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05983094,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05983094,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT04750382,has_title,A Single-armed Multicenter Phase Ib / II Study of HX008 (a Recombinant Humanized Anti-PD-1 Monoclona
NCT04750382,has_status,UNKNOWN
NCT04750382,has_phase,
NCT04750382,sponsored_by,Taizhou Hanzhong biomedical co. LTD
NCT04750382,tests,HX008+Cisplatin+Gemcitabine
HX008+Cisplatin+Gemcitabine,has_type,DRUG
NCT06700382,has_title,A Cohort Study of Different Methods of Adjuvant Capecitabine Regimens in Patients With Non-PCR After
NCT06700382,has_status,RECRUITING
NCT06700382,has_phase,
NCT06700382,sponsored_by,Shu Wang
NCT06700382,tests,capecitabine
capecitabine,has_type,DRUG
NCT05492682,has_title,A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab 
NCT05492682,has_status,RECRUITING
NCT05492682,has_phase,
NCT05492682,sponsored_by,Valo Therapeutics Oy
NCT05492682,tests,PeptiCRAd-1
PeptiCRAd-1,has_type,DRUG
NCT05492682,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05492682,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03621982,has_title,"A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerabilit"
NCT03621982,has_status,TERMINATED
NCT03621982,has_phase,
NCT03621982,sponsored_by,ADC Therapeutics S.A.
NCT03621982,tests,ADCT-301
ADCT-301,has_type,DRUG
NCT03621982,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05076682,has_title,Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682,has_status,UNKNOWN
NCT05076682,has_phase,
NCT05076682,sponsored_by,Fudan University
NCT05076682,tests,Choline
Choline,has_type,DRUG
NCT05076682,tests,anti-PD-1 antibody and chemotherapy
anti-PD-1 antibody and chemotherapy,has_type,DRUG
NCT05076682,tests,Sodium Cromoglicate
Sodium Cromoglicate,has_type,DRUG
NCT05076682,tests,Efavirenz
Efavirenz,has_type,DRUG
NCT03970382,has_title,"A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-e"
NCT03970382,has_status,SUSPENDED
NCT03970382,has_phase,
NCT03970382,sponsored_by,"PACT Pharma, Inc."
NCT03970382,tests,NeoTCR-P1 adoptive cell therapy
NeoTCR-P1 adoptive cell therapy,has_type,BIOLOGICAL
NCT03970382,tests,nivolumab
nivolumab,has_type,BIOLOGICAL
NCT03970382,tests,IL-2
IL-2,has_type,BIOLOGICAL
NCT02227082,has_title,Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph 
NCT02227082,has_status,COMPLETED
NCT02227082,has_phase,
NCT02227082,sponsored_by,The Netherlands Cancer Institute
NCT02227082,tests,radiotherapy
radiotherapy,has_type,RADIATION
NCT02227082,tests,olaparib
olaparib,has_type,DRUG
NCT03243331,has_title,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NCT03243331,has_status,COMPLETED
NCT03243331,has_phase,
NCT03243331,sponsored_by,Kathy Miller
NCT03243331,tests,Gedatolisib
Gedatolisib,has_type,DRUG
NCT03243331,tests,PTK7-ADC
PTK7-ADC,has_type,DRUG
NCT03576131,has_title,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN10"
NCT03576131,has_status,TERMINATED
NCT03576131,has_phase,
NCT03576131,sponsored_by,Genmab
NCT03576131,tests,GEN1029 (HexaBody®-DR5/DR5)
GEN1029 (HexaBody®-DR5/DR5),has_type,BIOLOGICAL
NCT05627960,has_title,FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancie
NCT05627960,has_status,RECRUITING
NCT05627960,has_phase,
NCT05627960,sponsored_by,A&G Pharmaceutical Inc.
NCT05627960,tests,AG-01 Compound
AG-01 Compound,has_type,DRUG
NCT02929576,has_title,"A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Comb"
NCT02929576,has_status,WITHDRAWN
NCT02929576,has_phase,
NCT02929576,sponsored_by,Pfizer
NCT02929576,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02929576,tests,Placebo
Placebo,has_type,DRUG
NCT02929576,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06938373,has_title,Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Canc
NCT06938373,has_status,RECRUITING
NCT06938373,has_phase,
NCT06938373,sponsored_by,Xiangya Hospital of Central South University
NCT06235931,has_title,"Prospective, Single-arm, Single-center Clinical Study of Darcilil Combined With AI Combined With Pyr"
NCT06235931,has_status,RECRUITING
NCT06235931,has_phase,
NCT06235931,sponsored_by,Second Affiliated Hospital of Soochow University
NCT06235931,tests,Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib
Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib,has_type,DRUG
NCT06649331,has_title,"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label,"
NCT06649331,has_status,RECRUITING
NCT06649331,has_phase,
NCT06649331,sponsored_by,Fudan University
NCT06649331,tests,SHR-A1811
SHR-A1811,has_type,DRUG
NCT06649331,tests,SHR-A1921
SHR-A1921,has_type,DRUG
NCT06649331,tests,SHR-A2009
SHR-A2009,has_type,DRUG
NCT06649331,tests,SHR-A2102
SHR-A2102,has_type,DRUG
NCT03992131,has_title,"SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacoki"
NCT03992131,has_status,TERMINATED
NCT03992131,has_phase,
NCT03992131,sponsored_by,pharmaand GmbH
NCT03992131,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT03992131,tests,Lucitanib
Lucitanib,has_type,DRUG
NCT03992131,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT03241173,has_title,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination Wit"
NCT03241173,has_status,COMPLETED
NCT03241173,has_phase,
NCT03241173,sponsored_by,Incyte Biosciences International Sàrl
NCT03241173,tests,INCAGN01949
INCAGN01949,has_type,DRUG
NCT03241173,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03241173,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT04556773,has_title,"A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Sa"
NCT04556773,has_status,ACTIVE_NOT_RECRUITING
NCT04556773,has_phase,
NCT04556773,sponsored_by,AstraZeneca
NCT04556773,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
NCT04556773,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04556773,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04556773,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT04556773,tests,Anastrozole
Anastrozole,has_type,DRUG
NCT04556773,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04556773,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06305962,has_title,"Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single "
NCT06305962,has_status,RECRUITING
NCT06305962,has_phase,
NCT06305962,sponsored_by,"Radiopharm Theranostics, Ltd"
NCT06305962,tests,177Lu-RAD204
177Lu-RAD204,has_type,DRUG
NCT02536794,has_title,A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Treme
NCT02536794,has_status,COMPLETED
NCT02536794,has_phase,
NCT02536794,sponsored_by,Northwestern University
NCT02536794,tests,Anti-B7H1 Monoclonal Antibody MEDI4736
Anti-B7H1 Monoclonal Antibody MEDI4736,has_type,BIOLOGICAL
NCT02536794,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02536794,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02536794,tests,Tremelimumab
Tremelimumab,has_type,BIOLOGICAL
NCT04293094,has_title,"A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety,"
NCT04293094,has_status,COMPLETED
NCT04293094,has_phase,
NCT04293094,sponsored_by,"Volastra Therapeutics, Inc."
NCT04293094,tests,AMG 650
AMG 650,has_type,DRUG
NCT04548960,has_title,Molecular Profiles Associated With Resistance Development in Cancer Patients. Prospective Explorator
NCT04548960,has_status,UNKNOWN
NCT04548960,has_phase,
NCT04548960,sponsored_by,Oncodesign SA
NCT04548960,tests,cancer patients
cancer patients,has_type,OTHER
NCT03170960,has_title,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With A
NCT03170960,has_status,UNKNOWN
NCT03170960,has_phase,
NCT03170960,sponsored_by,Exelixis
NCT03170960,tests,cabozantinib
cabozantinib,has_type,DRUG
NCT03170960,tests,atezolizumab
atezolizumab,has_type,DRUG
NCT03170960,tests,cabozantinib
cabozantinib,has_type,DRUG
NCT03170960,tests,cabozantinib
cabozantinib,has_type,DRUG
NCT04437160,has_title,"A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Adjuvant"
NCT04437160,has_status,RECRUITING
NCT04437160,has_phase,
NCT04437160,sponsored_by,Chinese Academy of Medical Sciences
NCT04437160,tests,Epirubicin or Pirarubicin
Epirubicin or Pirarubicin,has_type,DRUG
NCT04437160,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04178460,has_title,"A Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical "
NCT04178460,has_status,TERMINATED
NCT04178460,has_phase,
NCT04178460,sponsored_by,"Zai Lab (Shanghai) Co., Ltd."
NCT04178460,tests,Niraparib combined with MGD013
Niraparib combined with MGD013,has_type,DRUG
NCT05020860,has_title,A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemi
NCT05020860,has_status,RECRUITING
NCT05020860,has_phase,
NCT05020860,sponsored_by,Baylor Breast Care Center
NCT05020860,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05020860,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05020860,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05020860,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT05020860,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05020860,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05020860,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05020860,tests,Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Pertuzumab/Trastuzumab/Hyaluronidase-zzxf,has_type,DRUG
NCT03356860,has_title,A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting fo
NCT03356860,has_status,COMPLETED
NCT03356860,has_phase,
NCT03356860,sponsored_by,Grand Hôpital de Charleroi
NCT03356860,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03356860,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03356860,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03356860,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03362060,has_title,A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pemb
NCT03362060,has_status,ACTIVE_NOT_RECRUITING
NCT03362060,has_phase,
NCT03362060,sponsored_by,Massachusetts General Hospital
NCT03362060,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03362060,tests,PVX-410
PVX-410,has_type,BIOLOGICAL
NCT02681562,has_title,"A Phase II, Open Label, Controlled Study of Olaparib in Locally Advanced ER, PgR and HER2 Negative ("
NCT02681562,has_status,UNKNOWN
NCT02681562,has_phase,
NCT02681562,sponsored_by,Istituti Ospitalieri di Cremona
NCT02681562,tests,olaparib
olaparib,has_type,DRUG
NCT02708680,has_title,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Wi"
NCT02708680,has_status,COMPLETED
NCT02708680,has_phase,
NCT02708680,sponsored_by,Syndax Pharmaceuticals
NCT02708680,tests,Entinostat
Entinostat,has_type,DRUG
NCT02708680,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02708680,tests,Placebo
Placebo,has_type,DRUG
NCT06880029,has_title,Circadian Rhythm Impact on Triple Negative Breast Cancer Response to Neoadjuvant Immunotherapy - a F
NCT06880029,has_status,RECRUITING
NCT06880029,has_phase,
NCT06880029,sponsored_by,"Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E."
NCT06880029,tests,Morning pembrolizumab infusions
Morning pembrolizumab infusions,has_type,OTHER
NCT07007780,has_title,"Multicenter, Phase II Clinical Study of Lutikizumab in Neoadjuvant Treatment of Early-Stage TNBC"
NCT07007780,has_status,NOT_YET_RECRUITING
NCT07007780,has_phase,
NCT07007780,sponsored_by,Xijing Hospital
NCT07007780,tests,Lutikizumab monotherapy
Lutikizumab monotherapy,has_type,DRUG
NCT03101280,has_title,A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With
NCT03101280,has_status,COMPLETED
NCT03101280,has_phase,
NCT03101280,sponsored_by,Hoffmann-La Roche
NCT03101280,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03101280,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT02435680,has_title,A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple N
NCT02435680,has_status,COMPLETED
NCT02435680,has_phase,
NCT02435680,sponsored_by,Novartis Pharmaceuticals
NCT02435680,tests,MCS110
MCS110,has_type,DRUG
NCT02435680,tests,carboplatin
carboplatin,has_type,DRUG
NCT02435680,tests,gemcitabine
gemcitabine,has_type,DRUG
NCT01426880,has_title,A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Tri
NCT01426880,has_status,COMPLETED
NCT01426880,has_phase,
NCT01426880,sponsored_by,GBG Forschungs GmbH
NCT01426880,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01426880,tests,background treatment
background treatment,has_type,DRUG
NCT05763992,has_title,Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FA
NCT05763992,has_status,RECRUITING
NCT05763992,has_phase,
NCT05763992,sponsored_by,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
NCT05763992,tests,"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)"
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",has_type,DIETARY_SUPPLEMENT
NCT06369831,has_title,Evaluating the Diagnostic Performance of Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Po
NCT06369831,has_status,RECRUITING
NCT06369831,has_phase,
NCT06369831,sponsored_by,ABSCINT NV/SA
NCT06369831,tests,68Ga-NOTA-ABSCINT-HER2 PET/CT
68Ga-NOTA-ABSCINT-HER2 PET/CT,has_type,DIAGNOSTIC_TEST
NCT02659631,has_title,A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WI
NCT02659631,has_status,TERMINATED
NCT02659631,has_phase,
NCT02659631,sponsored_by,Pfizer
NCT02659631,tests,PF-06671008
PF-06671008,has_type,DRUG
NCT02659631,tests,PF-06671008
PF-06671008,has_type,DRUG
NCT05809895,has_title,"AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy"
NCT05809895,has_status,WITHDRAWN
NCT05809895,has_phase,
NCT05809895,sponsored_by,Novartis Pharmaceuticals
NCT05809895,tests,Ociperlimab
Ociperlimab,has_type,DRUG
NCT05809895,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT05809895,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05809895,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05809895,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05809895,tests,Placebo
Placebo,has_type,DRUG
NCT05809895,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05809895,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT00789581,has_title,Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Pacl
NCT00789581,has_status,COMPLETED
NCT00789581,has_phase,
NCT00789581,sponsored_by,"SCRI Development Innovations, LLC"
NCT00789581,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT00789581,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00789581,tests,Ixabepilone (Ixempra)
Ixabepilone (Ixempra),has_type,DRUG
NCT00789581,tests,Paclitaxel (Taxol)
Paclitaxel (Taxol),has_type,DRUG
NCT03580395,has_title,Efficacy and Safety of Apatinib Added to Docetaxel and Cisplatin Neoadjuvant Therapy for Patients Wi
NCT03580395,has_status,UNKNOWN
NCT03580395,has_phase,
NCT03580395,sponsored_by,Hebei Medical University Fourth Hospital
NCT03580395,tests,Apatinib
Apatinib,has_type,DRUG
NCT03580395,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT03580395,tests,cisplatin
cisplatin,has_type,DRUG
NCT06682195,has_title,Neoadjuvant Chemotherapy Combined With Toripalimab for Triple-negative Breast Cancer : a Prospective
NCT06682195,has_status,RECRUITING
NCT06682195,has_phase,
NCT06682195,sponsored_by,First Affiliated Hospital of Zhejiang University
NCT06682195,tests,Neoadjuvant chemotherapy combined with Toripalimab
Neoadjuvant chemotherapy combined with Toripalimab,has_type,DRUG
NCT05088395,has_title,Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
NCT05088395,has_status,RECRUITING
NCT05088395,has_phase,
NCT05088395,sponsored_by,Institut Curie
NCT05088395,tests,Blood sample
Blood sample,has_type,OTHER
NCT05088395,tests,Biopsy
Biopsy,has_type,OTHER
NCT03709446,has_title,A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancer
NCT03709446,has_status,ACTIVE_NOT_RECRUITING
NCT03709446,has_phase,
NCT03709446,sponsored_by,Joseph Sparano
NCT03709446,tests,Leflunomide
Leflunomide,has_type,DRUG
NCT02890069,has_title,"Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynami"
NCT02890069,has_status,COMPLETED
NCT02890069,has_phase,
NCT02890069,sponsored_by,Novartis Pharmaceuticals
NCT02890069,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT02890069,tests,LCL161
LCL161,has_type,DRUG
NCT02890069,tests,Everolimus
Everolimus,has_type,DRUG
NCT02890069,tests,Panobinostat
Panobinostat,has_type,DRUG
NCT02890069,tests,QBM076
QBM076,has_type,DRUG
NCT02890069,tests,HDM201
HDM201,has_type,DRUG
NCT04274946,has_title,The Comparative Analysis of Multimodal Markers to Identify Sentinel Lymph Node in Breast Cancer
NCT04274946,has_status,UNKNOWN
NCT04274946,has_phase,
NCT04274946,sponsored_by,Bulent Ecevit University
NCT04274946,tests,Sentinel lymph node biopsy
Sentinel lymph node biopsy,has_type,PROCEDURE
NCT03970967,has_title,A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatmen
NCT03970967,has_status,TERMINATED
NCT03970967,has_phase,
NCT03970967,sponsored_by,Alpha Tau Medical LTD.
NCT03970967,tests,Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT),has_type,DEVICE
NCT04331067,has_title,Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in P
NCT04331067,has_status,ACTIVE_NOT_RECRUITING
NCT04331067,has_phase,
NCT04331067,sponsored_by,Washington University School of Medicine
NCT04331067,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04331067,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04331067,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT04331067,tests,Cabiralizumab
Cabiralizumab,has_type,BIOLOGICAL
NCT04331067,tests,Tumor biopsy
Tumor biopsy,has_type,PROCEDURE
NCT04331067,tests,Bone marrow
Bone marrow,has_type,PROCEDURE
NCT04331067,tests,Blood draw
Blood draw,has_type,PROCEDURE
NCT03752723,has_title,"A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics a"
NCT03752723,has_status,COMPLETED
NCT03752723,has_phase,
NCT03752723,sponsored_by,"Genexine, Inc."
NCT03752723,tests,GX-I7
GX-I7,has_type,DRUG
NCT03752723,tests,Pembrolizumab(KEYTRUDA®)
Pembrolizumab(KEYTRUDA®),has_type,DRUG
NCT03752723,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03544723,has_title,"A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Im"
NCT03544723,has_status,UNKNOWN
NCT03544723,has_phase,
NCT03544723,sponsored_by,"MultiVir, Inc."
NCT03544723,tests,Ad-p53
Ad-p53,has_type,DRUG
NCT05303038,has_title,A Phase II Clinical Study of Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metasta
NCT05303038,has_status,UNKNOWN
NCT05303038,has_phase,
NCT05303038,sponsored_by,Fudan University
NCT05303038,tests,Cryoablation Combined with Tirelizumab and Bevacizumab
Cryoablation Combined with Tirelizumab and Bevacizumab,has_type,COMBINATION_PRODUCT
NCT02595138,has_title,
NCT02595138,has_status,UNKNOWN
NCT02595138,has_phase,
NCT02595138,sponsored_by,Chinese Academy of Medical Sciences
NCT02595138,tests,Zoledronic acid
Zoledronic acid,has_type,DRUG
NCT02041338,has_title,Phase 2 Randomized Study of Different Neoadjuvant Regimens in Subtypes of Breast Cancer
NCT02041338,has_status,UNKNOWN
NCT02041338,has_phase,
NCT02041338,sponsored_by,Chinese Academy of Medical Sciences
NCT02041338,tests,Paclitaxel and carboplatin
Paclitaxel and carboplatin,has_type,DRUG
NCT02041338,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02041338,tests,Epirubicin and Paclitaxel
Epirubicin and Paclitaxel,has_type,DRUG
NCT05582538,has_title,Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralase
NCT05582538,has_status,RECRUITING
NCT05582538,has_phase,
NCT05582538,sponsored_by,IFOM ETS - The AIRC Institute of Molecular Oncology
NCT05582538,tests,Ceralasertib
Ceralasertib,has_type,DRUG
NCT05582538,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT05582538,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03634150,has_title,"A Phase 1b, Open-Label, Dose-Confirmation Study Evaluating the Safety, and Clinical Effects of Intra"
NCT03634150,has_status,WITHDRAWN
NCT03634150,has_phase,
NCT03634150,sponsored_by,Immune System Key Ltd
NCT03634150,tests,"Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties."
"Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.",has_type,BIOLOGICAL
NCT03775850,has_title,A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A
NCT03775850,has_status,COMPLETED
NCT03775850,has_phase,
NCT03775850,sponsored_by,"Evelo Biosciences, Inc."
NCT03775850,tests,EDP1503
EDP1503,has_type,BIOLOGICAL
NCT03775850,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05520723,has_title,"Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tole"
NCT05520723,has_status,ACTIVE_NOT_RECRUITING
NCT05520723,has_phase,
NCT05520723,sponsored_by,MedSIR
NCT05520723,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT05520723,tests,Loperamide
Loperamide,has_type,DRUG
NCT05520723,tests,Granulocyte Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor,has_type,DRUG
NCT07046923,has_title,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of L"
NCT07046923,has_status,NOT_YET_RECRUITING
NCT07046923,has_phase,
NCT07046923,sponsored_by,Eli Lilly and Company
NCT07046923,tests,LY4175408
LY4175408,has_type,DRUG
NCT02419495,has_title,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard C
NCT02419495,has_status,TERMINATED
NCT02419495,has_phase,
NCT02419495,sponsored_by,M.D. Anderson Cancer Center
NCT02419495,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02419495,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02419495,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02419495,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02419495,tests,Eribulin
Eribulin,has_type,DRUG
NCT02419495,tests,Fluorouracil
Fluorouracil,has_type,DRUG
NCT02419495,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT02419495,tests,Irinotecan Hydrochloride
Irinotecan Hydrochloride,has_type,DRUG
NCT02419495,tests,Leucovorin Calcium
Leucovorin Calcium,has_type,DRUG
NCT02419495,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT02419495,tests,Olaparib
Olaparib,has_type,DRUG
NCT02419495,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT02419495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02419495,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02419495,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT02419495,tests,Selinexor
Selinexor,has_type,DRUG
NCT02419495,tests,Topotecan
Topotecan,has_type,DRUG
NCT06405295,has_title,A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
NCT06405295,has_status,ENROLLING_BY_INVITATION
NCT06405295,has_phase,
NCT06405295,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06405295,tests,no intervention
no intervention,has_type,OTHER
NCT02788981,has_title,"A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclita"
NCT02788981,has_status,ACTIVE_NOT_RECRUITING
NCT02788981,has_phase,
NCT02788981,sponsored_by,University of Chicago
NCT02788981,tests,Mifepristone
Mifepristone,has_type,DRUG
NCT02788981,tests,Placebo
Placebo,has_type,OTHER
NCT02788981,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04131881,has_title,The Consistency of Drug Sensitivity in Vitro and Neoadjuvant Chemotherapy Results in Vivo for Early 
NCT04131881,has_status,COMPLETED
NCT04131881,has_phase,
NCT04131881,sponsored_by,Peking University People's Hospital
NCT05541367,has_title,Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
NCT05541367,has_status,RECRUITING
NCT05541367,has_phase,
NCT05541367,sponsored_by,Tongji Hospital
NCT06027268,has_title,"ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Adv"
NCT06027268,has_status,RECRUITING
NCT06027268,has_phase,
NCT06027268,sponsored_by,Wake Forest University Health Sciences
NCT06027268,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT06027268,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06027268,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06027268,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06274268,has_title,Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments. Prospective Co
NCT06274268,has_status,RECRUITING
NCT06274268,has_phase,
NCT06274268,sponsored_by,Centre Hospitalier Metropole Savoie
NCT06274268,tests,Sarcopenia diagnostic test
Sarcopenia diagnostic test,has_type,DIAGNOSTIC_TEST
NCT06347068,has_title,Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containi
NCT06347068,has_status,RECRUITING
NCT06347068,has_phase,
NCT06347068,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT06347068,tests,iC9-CAR.B7-H3 T Cell Therapy
iC9-CAR.B7-H3 T Cell Therapy,has_type,BIOLOGICAL
NCT06347068,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT06347068,tests,fludarabine
fludarabine,has_type,DRUG
NCT05154201,has_title,"A Multicenter, Open-label, Phase I Clinical Study: A Dose-finding and Dose Expansion Study to Evalua"
NCT05154201,has_status,COMPLETED
NCT05154201,has_phase,
NCT05154201,sponsored_by,"Orinove, Inc."
NCT05154201,tests,ORIN1001
ORIN1001,has_type,DRUG
NCT04585750,has_title,"A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Phar"
NCT04585750,has_status,RECRUITING
NCT04585750,has_phase,
NCT04585750,sponsored_by,"PMV Pharmaceuticals, Inc"
NCT04585750,tests,rezatapopt
rezatapopt,has_type,DRUG
NCT04585750,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT04291950,has_title,Epigenetics of Triple-Negative Breast Cancer in Overweight and Obese Hispanic and Non-Hispanic White
NCT04291950,has_status,WITHDRAWN
NCT04291950,has_phase,
NCT04291950,sponsored_by,University of Arizona
NCT04291950,tests,Needle core biopsy
Needle core biopsy,has_type,PROCEDURE
NCT05973864,has_title,A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for 
NCT05973864,has_status,RECRUITING
NCT05973864,has_phase,
NCT05973864,sponsored_by,UNICANCER
NCT05973864,tests,Pembrolizumab injection
Pembrolizumab injection,has_type,DRUG
NCT05973864,tests,Capecitabine tablets
Capecitabine tablets,has_type,DRUG
NCT05973864,tests,Local radiotherapy
Local radiotherapy,has_type,RADIATION
NCT03667612,has_title,Endogenous Mechanisms of Inactivation of the Endothelium Tumor
NCT03667612,has_status,UNKNOWN
NCT03667612,has_phase,
NCT03667612,sponsored_by,Centre Oscar Lambret
NCT04502680,has_title,"A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Mainten"
NCT04502680,has_status,UNKNOWN
NCT04502680,has_phase,
NCT04502680,sponsored_by,The First Affiliated Hospital with Nanjing Medical University
NCT04502680,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT01208480,has_title,"A Phase II Trial of Neoadjuvant Bevacizumab, Docetaxel and Carboplatin for Triple Negative Breast Ca"
NCT01208480,has_status,COMPLETED
NCT01208480,has_phase,
NCT01208480,sponsored_by,Severance Hospital
NCT01208480,tests,"Avastin, docetaxel, carboplatin"
"Avastin, docetaxel, carboplatin",has_type,DRUG
NCT04758780,has_title,"Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab"
NCT04758780,has_status,UNKNOWN
NCT04758780,has_phase,
NCT04758780,sponsored_by,Institut Cancerologie de l'Ouest
NCT04758780,tests,89Zr-TLX250 PET/CT
89Zr-TLX250 PET/CT,has_type,DRUG
NCT01928680,has_title,Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Trip
NCT01928680,has_status,UNKNOWN
NCT01928680,has_phase,
NCT01928680,sponsored_by,Chinese Academy of Medical Sciences
NCT01928680,tests,Cisplatin/Capecitabine
Cisplatin/Capecitabine,has_type,DRUG
NCT06268327,has_title,Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Pati
NCT06268327,has_status,NOT_YET_RECRUITING
NCT06268327,has_phase,
NCT06268327,sponsored_by,Assiut University
NCT06268327,tests,Cisplatin injection and gemcitabine
Cisplatin injection and gemcitabine,has_type,DRUG
NCT06268327,tests,Capecitabine tablets
Capecitabine tablets,has_type,DRUG
NCT01805076,has_title,"Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Brea"
NCT01805076,has_status,ACTIVE_NOT_RECRUITING
NCT01805076,has_phase,
NCT01805076,sponsored_by,Alliance for Clinical Trials in Oncology
NCT01805076,tests,Breast surgery
Breast surgery,has_type,PROCEDURE
NCT01805076,tests,Magnetic resonance imaging
Magnetic resonance imaging,has_type,PROCEDURE
NCT01805076,tests,Mammography
Mammography,has_type,PROCEDURE
NCT06774027,has_title,ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negat
NCT06774027,has_status,NOT_YET_RECRUITING
NCT06774027,has_phase,
NCT06774027,sponsored_by,"University of California, San Francisco"
NCT06774027,tests,Specimen collection
Specimen collection,has_type,PROCEDURE
NCT06774027,tests,Non-Investigational Antibody-Drug Conjugates (ADC)
Non-Investigational Antibody-Drug Conjugates (ADC),has_type,DRUG
NCT06774027,tests,Medical Record Review
Medical Record Review,has_type,OTHER
NCT00777673,has_title,Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclopho
NCT00777673,has_status,UNKNOWN
NCT00777673,has_phase,
NCT00777673,sponsored_by,University of Tennessee Cancer Institute
NCT00777673,tests,"Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim"
"Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim",has_type,DRUG
NCT02154776,has_title,A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treat
NCT02154776,has_status,COMPLETED
NCT02154776,has_phase,
NCT02154776,sponsored_by,Novartis Pharmaceuticals
NCT02154776,tests,LEE011
LEE011,has_type,DRUG
NCT02154776,tests,Buparlisib
Buparlisib,has_type,DRUG
NCT02154776,tests,Letrozole
Letrozole,has_type,DRUG
NCT02593227,has_title,A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Va
NCT02593227,has_status,COMPLETED
NCT02593227,has_phase,
NCT02593227,sponsored_by,"Marker Therapeutics, Inc."
NCT02593227,tests,Low dose FRα vaccine
Low dose FRα vaccine,has_type,BIOLOGICAL
NCT02593227,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02593227,tests,High dose FRα vaccine
High dose FRα vaccine,has_type,BIOLOGICAL
NCT00532727,has_title,Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patient
NCT00532727,has_status,UNKNOWN
NCT00532727,has_phase,
NCT00532727,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT00532727,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00532727,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT03017573,has_title,Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Mol
NCT03017573,has_status,RECRUITING
NCT03017573,has_phase,
NCT03017573,sponsored_by,Institut Curie
NCT03017573,tests,Tumor biopsies / Tumor surgery
Tumor biopsies / Tumor surgery,has_type,PROCEDURE
NCT03017573,tests,Blood withdrawal
Blood withdrawal,has_type,PROCEDURE
NCT01740427,has_title,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LE"
NCT01740427,has_status,COMPLETED
NCT01740427,has_phase,
NCT01740427,sponsored_by,Pfizer
NCT01740427,tests,PD-0332991
PD-0332991,has_type,DRUG
NCT01740427,tests,Letrozole
Letrozole,has_type,DRUG
NCT01740427,tests,Placebo
Placebo,has_type,DRUG
NCT01740427,tests,Letrozole
Letrozole,has_type,DRUG
NCT03838367,has_title,A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metasta
NCT03838367,has_status,ACTIVE_NOT_RECRUITING
NCT03838367,has_phase,
NCT03838367,sponsored_by,"CytoDyn, Inc."
NCT03838367,tests,350 mg leronlimab
350 mg leronlimab,has_type,DRUG
NCT03838367,tests,525 mg leronlimab
525 mg leronlimab,has_type,DRUG
NCT03838367,tests,700 mg leronlimab
700 mg leronlimab,has_type,DRUG
NCT03838367,tests,AUC 5 Carboplatin
AUC 5 Carboplatin,has_type,DRUG
NCT03838367,tests,Maximum Tolerated Dose (MTD) of leronlimab
Maximum Tolerated Dose (MTD) of leronlimab,has_type,DRUG
NCT06212076,has_title,"A Phase I/II, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokineti"
NCT06212076,has_status,RECRUITING
NCT06212076,has_phase,
NCT06212076,sponsored_by,"Nanjing Immunophage Biotech Co., Ltd"
NCT06212076,tests,IPG1094
IPG1094,has_type,DRUG
NCT04802876,has_title,Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MR
NCT04802876,has_status,ACTIVE_NOT_RECRUITING
NCT04802876,has_phase,
NCT04802876,sponsored_by,SOLTI Breast Cancer Research Group
NCT04802876,tests,Spartalizumab
Spartalizumab,has_type,DRUG
NCT04802876,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT02689427,has_title,A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclita
NCT02689427,has_status,COMPLETED
NCT02689427,has_phase,
NCT02689427,sponsored_by,M.D. Anderson Cancer Center
NCT02689427,tests,Axillary Lymph Node Dissection
Axillary Lymph Node Dissection,has_type,PROCEDURE
NCT02689427,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02689427,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02689427,tests,Lymph Node Biopsy
Lymph Node Biopsy,has_type,PROCEDURE
NCT02689427,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02689427,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT03205176,has_title,"A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Prelim"
NCT03205176,has_status,COMPLETED
NCT03205176,has_phase,
NCT03205176,sponsored_by,AstraZeneca
NCT03205176,tests,AZD5153
AZD5153,has_type,DRUG
NCT03205176,tests,Olaparib
Olaparib,has_type,DRUG
NCT03010176,has_title,"Phase 1 Open-label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monothera"
NCT03010176,has_status,COMPLETED
NCT03010176,has_phase,
NCT03010176,sponsored_by,Merck Sharp & Dohme LLC
NCT03010176,tests,Ulevostinag
Ulevostinag,has_type,DRUG
NCT03010176,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05288127,has_title,Phase II Study to Assess the Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With
NCT05288127,has_status,RECRUITING
NCT05288127,has_phase,
NCT05288127,sponsored_by,University of Malaya
NCT05288127,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT05086692,has_title,"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered "
NCT05086692,has_status,RECRUITING
NCT05086692,has_phase,
NCT05086692,sponsored_by,"Medicenna Therapeutics, Inc."
NCT05086692,tests,MDNA11
MDNA11,has_type,DRUG
NCT05086692,tests,Pembrolizumab (KEYTRUDA®)
Pembrolizumab (KEYTRUDA®),has_type,DRUG
NCT05843292,has_title,Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-n
NCT05843292,has_status,NOT_YET_RECRUITING
NCT05843292,has_phase,
NCT05843292,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT05843292,tests,Taxane and Carboplatin
Taxane and Carboplatin,has_type,DRUG
NCT05843292,tests,Short-term Sintilimab
Short-term Sintilimab,has_type,DRUG
NCT05843292,tests,Surgery
Surgery,has_type,PROCEDURE
NCT06229392,has_title,A Phase I Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breas
NCT06229392,has_status,NOT_YET_RECRUITING
NCT06229392,has_phase,
NCT06229392,sponsored_by,Rush University Medical Center
NCT06229392,tests,Fluzone Quadrivalent
Fluzone Quadrivalent,has_type,BIOLOGICAL
NCT06140576,has_title,The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line 
NCT06140576,has_status,NOT_YET_RECRUITING
NCT06140576,has_phase,
NCT06140576,sponsored_by,Zhejiang Cancer Hospital
NCT06140576,tests,Sindilimab
Sindilimab,has_type,DRUG
NCT06140576,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06140576,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT03394027,has_title,A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial 
NCT03394027,has_status,COMPLETED
NCT03394027,has_phase,
NCT03394027,sponsored_by,National Cancer Institute (NCI)
NCT03394027,tests,ONC201
ONC201,has_type,DRUG
NCT01891227,has_title,Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastati
NCT01891227,has_status,COMPLETED
NCT01891227,has_phase,
NCT01891227,sponsored_by,Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT01891227,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT01891227,tests,Bendamustine
Bendamustine,has_type,DRUG
NCT04085276,has_title,"A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With N"
NCT04085276,has_status,ACTIVE_NOT_RECRUITING
NCT04085276,has_phase,
NCT04085276,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT04085276,tests,JS001
JS001,has_type,DRUG
NCT04085276,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04085276,tests,Placebo
Placebo,has_type,DRUG
NCT04085276,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03150576,has_title,"Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olapa"
NCT03150576,has_status,RECRUITING
NCT03150576,has_phase,
NCT03150576,sponsored_by,Cambridge University Hospitals NHS Foundation Trust
NCT03150576,tests,Olaparib
Olaparib,has_type,DRUG
NCT03150576,tests,Paclitaxel and Carboplatin
Paclitaxel and Carboplatin,has_type,DRUG
NCT02027376,has_title,"A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 (Sonidegib) in Combinati"
NCT02027376,has_status,COMPLETED
NCT02027376,has_phase,
NCT02027376,sponsored_by,Spanish Breast Cancer Research Group
NCT02027376,tests,LDE225
LDE225,has_type,DRUG
NCT02027376,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05390476,has_title,"Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,"
NCT05390476,has_status,UNKNOWN
NCT05390476,has_phase,
NCT05390476,sponsored_by,wang shusen
NCT05390476,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05390476,tests,Tucidinostat
Tucidinostat,has_type,DRUG
NCT06724263,has_title,"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Inje"
NCT06724263,has_status,NOT_YET_RECRUITING
NCT06724263,has_phase,
NCT06724263,sponsored_by,"Tasly Biopharmaceuticals Co., Ltd."
NCT06724263,tests,B1962
B1962,has_type,DRUG
NCT06402435,has_title,"A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Thera"
NCT06402435,has_status,RECRUITING
NCT06402435,has_phase,
NCT06402435,sponsored_by,Hubei Cancer Hospital
NCT06402435,tests,Lvonescimab (AK112)
Lvonescimab (AK112),has_type,DRUG
NCT02750358,has_title,Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Br
NCT02750358,has_status,ACTIVE_NOT_RECRUITING
NCT02750358,has_phase,
NCT02750358,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02750358,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02750358,tests,assessment
assessment,has_type,BEHAVIORAL
NCT05300958,has_title,"Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase I"
NCT05300958,has_status,RECRUITING
NCT05300958,has_phase,
NCT05300958,sponsored_by,Sun Yat-sen University
NCT05300958,tests,Deferoxamine Plus Chemotherapy
Deferoxamine Plus Chemotherapy,has_type,DRUG
NCT04481763,has_title,A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-
NCT04481763,has_status,RECRUITING
NCT04481763,has_phase,
NCT04481763,sponsored_by,Jiangxi Provincial Cancer Hospital
NCT04481763,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT04481763,tests,radiotherapy
radiotherapy,has_type,RADIATION
NCT04494958,has_title,Phase IB Clinical Trial of Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer Wit
NCT04494958,has_status,COMPLETED
NCT04494958,has_phase,
NCT04494958,sponsored_by,Fundacion Oncosur
NCT04494958,tests,"Combination, Palbociclib + Binimetinib"
"Combination, Palbociclib + Binimetinib",has_type,DRUG
NCT03067935,has_title,
NCT03067935,has_status,NO_LONGER_AVAILABLE
NCT03067935,has_phase,
NCT03067935,sponsored_by,Celldex Therapeutics
NCT03067935,tests,glembatumumab vedotin
glembatumumab vedotin,has_type,DRUG
NCT01127763,has_title,Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer
NCT01127763,has_status,COMPLETED
NCT01127763,has_phase,
NCT01127763,sponsored_by,NYU Langone Health
NCT01127763,tests,RAD001
RAD001,has_type,DRUG
NCT01127763,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02521363,has_title,Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Earl
NCT02521363,has_status,COMPLETED
NCT02521363,has_phase,
NCT02521363,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02521363,tests,KIBUR MICRODEVICE
KIBUR MICRODEVICE,has_type,DEVICE
NCT02521363,tests,anthracycline and taxane based chemotherapy
anthracycline and taxane based chemotherapy,has_type,DRUG
NCT03197935,has_title,A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Anti
NCT03197935,has_status,COMPLETED
NCT03197935,has_phase,
NCT03197935,sponsored_by,Hoffmann-La Roche
NCT03197935,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
NCT03197935,tests,Placebo
Placebo,has_type,DRUG
NCT03197935,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03197935,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT03197935,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03197935,tests,Filgrastim
Filgrastim,has_type,DRUG
NCT03197935,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT02207335,has_title,A Multicenter Randomized Phase Ⅲ Clinical Trial of Gemcitabine in Combination With Capecitabine Vers
NCT02207335,has_status,UNKNOWN
NCT02207335,has_phase,
NCT02207335,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT02207335,tests,Gemcitabine，Capecitabine
Gemcitabine，Capecitabine,has_type,DRUG
NCT02207335,tests,"Gemcitabine, Carboplatin"
"Gemcitabine, Carboplatin",has_type,DRUG
NCT02432963,has_title,A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
NCT02432963,has_status,ACTIVE_NOT_RECRUITING
NCT02432963,has_phase,
NCT02432963,sponsored_by,City of Hope Medical Center
NCT02432963,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02432963,tests,Modified Vaccinia Virus Ankara Vaccine Expressing p53
Modified Vaccinia Virus Ankara Vaccine Expressing p53,has_type,BIOLOGICAL
NCT02432963,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06313463,has_title,"A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety "
NCT06313463,has_status,RECRUITING
NCT06313463,has_phase,
NCT06313463,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06313463,tests,Carrellizumab + Capecitabine
Carrellizumab + Capecitabine,has_type,DRUG
NCT06313463,tests,Placebo + Capecitabine
Placebo + Capecitabine,has_type,DRUG
NCT04577963,has_title,"An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination W"
NCT04577963,has_status,TERMINATED
NCT04577963,has_phase,
NCT04577963,sponsored_by,Hutchmed
NCT04577963,tests,Fruquintinib
Fruquintinib,has_type,DRUG
NCT04577963,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT06817525,has_title,Nab-P+Cb+PD1 Inhibitor Combined/not Combined with Bevacizumab Neoadjuvant Therapy for Early TNBC: a 
NCT06817525,has_status,RECRUITING
NCT06817525,has_phase,
NCT06817525,sponsored_by,Henan Cancer Hospital
NCT06817525,tests,6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1),has_type,DRUG
NCT06817525,tests,"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)"
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)",has_type,DRUG
NCT06817525,tests,6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1),has_type,DRUG
NCT06817525,tests,"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)"
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)",has_type,DRUG
NCT06418139,has_title,Etude de l'Effet de l'Horaire de Perfusion de l'immunothérapie Sur la réponse et la toxicité Des Tra
NCT06418139,has_status,NOT_YET_RECRUITING
NCT06418139,has_phase,
NCT06418139,sponsored_by,Assistance Publique - Hôpitaux de Paris
NCT06418139,tests,No intervention
No intervention,has_type,OTHER
NCT05402722,has_title,A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Trip
NCT05402722,has_status,UNKNOWN
NCT05402722,has_phase,
NCT05402722,sponsored_by,Beijing 302 Hospital
NCT05402722,tests,Eribulin
Eribulin,has_type,DRUG
NCT05402722,tests,anti-PD-1 antibody
anti-PD-1 antibody,has_type,DRUG
NCT06692725,has_title,De-escalation of Neoadjuvant Chemotherapy Regimens (Taxane Plus Carboplatin Versus Taxane Plus Carbo
NCT06692725,has_status,RECRUITING
NCT06692725,has_phase,
NCT06692725,sponsored_by,Peking University People's Hospital
NCT03544125,has_title,A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer
NCT03544125,has_status,COMPLETED
NCT03544125,has_phase,
NCT03544125,sponsored_by,OHSU Knight Cancer Institute
NCT03544125,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT03544125,tests,Olaparib
Olaparib,has_type,DRUG
NCT05453825,has_title,"A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With "
NCT05453825,has_status,UNKNOWN
NCT05453825,has_phase,
NCT05453825,sponsored_by,"OncXerna Theraputics, Inc."
NCT05453825,tests,navicixizumab+paclitaxel
navicixizumab+paclitaxel,has_type,BIOLOGICAL
NCT05453825,tests,navicixizumab+irinotecan
navicixizumab+irinotecan,has_type,BIOLOGICAL
NCT05453825,tests,navicixizumab monotherapy
navicixizumab monotherapy,has_type,BIOLOGICAL
NCT02352025,has_title,A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.
NCT02352025,has_status,COMPLETED
NCT02352025,has_phase,
NCT02352025,sponsored_by,The University of Texas Health Science Center at San Antonio
NCT02352025,tests,S-equol
S-equol,has_type,DRUG
NCT05238922,has_title,"A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Antica"
NCT05238922,has_status,RECRUITING
NCT05238922,has_phase,
NCT05238922,sponsored_by,Incyte Corporation
NCT05238922,tests,INCB0123667
INCB0123667,has_type,DRUG
NCT05238922,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT05238922,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05238922,tests,Olaparib
Olaparib,has_type,DRUG
NCT05238922,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05238922,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT05238922,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT06497322,has_title,Effectiveness of High-intensity Interval Training During Neoadjuvant Immunochemotherapy on Complete 
NCT06497322,has_status,NOT_YET_RECRUITING
NCT06497322,has_phase,
NCT06497322,sponsored_by,University Hospital of Cologne
NCT06497322,tests,Exercise intervention - High intensity interval training on a cycle-ergometer
Exercise intervention - High intensity interval training on a cycle-ergometer,has_type,OTHER
NCT06449222,has_title,"A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and "
NCT06449222,has_status,RECRUITING
NCT06449222,has_phase,
NCT06449222,sponsored_by,BioNTech SE
NCT06449222,tests,BNT327 Dose Level 1 (DL1)
BNT327 Dose Level 1 (DL1),has_type,DRUG
NCT06449222,tests,BNT327 Dose Level 1 (DL2)
BNT327 Dose Level 1 (DL2),has_type,DRUG
NCT06449222,tests,Nab-placlitaxel
Nab-placlitaxel,has_type,DRUG
NCT06449222,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06449222,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06449222,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06449222,tests,Eribulin
Eribulin,has_type,DRUG
NCT06449222,tests,BNT327 Optimized Dose
BNT327 Optimized Dose,has_type,DRUG
NCT06449222,tests,BNT327 Equivalent Q3W Dose
BNT327 Equivalent Q3W Dose,has_type,DRUG
NCT01560663,has_title,Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II 
NCT01560663,has_status,ACTIVE_NOT_RECRUITING
NCT01560663,has_phase,
NCT01560663,sponsored_by,Miguel Martín Jiménez
NCT01560663,tests,Docetaxel- Carboplatin
Docetaxel- Carboplatin,has_type,DRUG
NCT03978663,has_title,Evaluating the Use of Stereotactic Radiation Therapy Prior to Neoadjuvant Chemotherapy for High-risk
NCT03978663,has_status,ACTIVE_NOT_RECRUITING
NCT03978663,has_phase,
NCT03978663,sponsored_by,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT03978663,tests,Neoadjuvant radiotherapy
Neoadjuvant radiotherapy,has_type,RADIATION
NCT03280563,has_title,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety"
NCT03280563,has_status,COMPLETED
NCT03280563,has_phase,
NCT03280563,sponsored_by,Hoffmann-La Roche
NCT03280563,tests,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody"
"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody",has_type,DRUG
NCT03280563,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT03280563,tests,Entinostat
Entinostat,has_type,DRUG
NCT03280563,tests,Exemestane
Exemestane,has_type,DRUG
NCT03280563,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT03280563,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03280563,tests,Tamoxifen
Tamoxifen,has_type,DRUG
NCT03280563,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT06646263,has_title,Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
NCT06646263,has_status,ENROLLING_BY_INVITATION
NCT06646263,has_phase,
NCT06646263,sponsored_by,Institute of Applied Biosciences
NCT05388435,has_title,"A Phase 1/2, Open-Label, Multicenter, Dose-Finding Study of SKL27969 to Evaluate Safety, Tolerabilit"
NCT05388435,has_status,TERMINATED
NCT05388435,has_phase,
NCT05388435,sponsored_by,"SK Life Science, Inc."
NCT05388435,tests,SKL27969
SKL27969,has_type,DRUG
NCT05230186,has_title,A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Target
NCT05230186,has_status,UNKNOWN
NCT05230186,has_phase,
NCT05230186,sponsored_by,"TScan Therapeutics, Inc."
NCT05230186,tests,Tumor Biopsy
Tumor Biopsy,has_type,PROCEDURE
NCT01377363,has_title,Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
NCT01377363,has_status,COMPLETED
NCT01377363,has_phase,
NCT01377363,sponsored_by,Spanish Breast Cancer Research Group
NCT01287624,has_title,"A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gem"
NCT01287624,has_status,COMPLETED
NCT01287624,has_phase,
NCT01287624,sponsored_by,Fudan University
NCT01287624,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
NCT01287624,tests,"Gemcitabine, Paclitaxel"
"Gemcitabine, Paclitaxel",has_type,DRUG
NCT07064018,has_title,"Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies"
NCT07064018,has_status,RECRUITING
NCT07064018,has_phase,
NCT07064018,sponsored_by,"University of California, Irvine"
NCT07064018,tests,Spedox-6
Spedox-6,has_type,DRUG
NCT07064018,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT07064018,tests,Filgrastim
Filgrastim,has_type,DRUG
NCT05057013,has_title,"A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Ant"
NCT05057013,has_status,RECRUITING
NCT05057013,has_phase,
NCT05057013,sponsored_by,Cancer Research UK
NCT05057013,tests,HMBD-001
HMBD-001,has_type,DRUG
NCT05057013,tests,HMBD-001 and enzalutamide
HMBD-001 and enzalutamide,has_type,DRUG
NCT05340413,has_title,Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negat
NCT05340413,has_status,UNKNOWN
NCT05340413,has_phase,
NCT05340413,sponsored_by,SOLTI Breast Cancer Research Group
NCT05340413,tests,Olaparib
Olaparib,has_type,DRUG
NCT06261918,has_title,Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanc
NCT06261918,has_status,RECRUITING
NCT06261918,has_phase,
NCT06261918,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06261918,tests,Influence of metabolic syndrome on the achievement of pathological complete response
Influence of metabolic syndrome on the achievement of pathological complete response,has_type,PROCEDURE
NCT01445418,has_title,A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Ca
NCT01445418,has_status,COMPLETED
NCT01445418,has_phase,
NCT01445418,sponsored_by,National Cancer Institute (NCI)
NCT01445418,tests,AZ2281 + Carboplatin
AZ2281 + Carboplatin,has_type,DRUG
NCT04159818,has_title,Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Bre
NCT04159818,has_status,RECRUITING
NCT04159818,has_phase,
NCT04159818,sponsored_by,The Netherlands Cancer Institute
NCT04159818,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04159818,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04159818,tests,Low dose doxorubicin
Low dose doxorubicin,has_type,DRUG
NCT04188119,has_title,A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negat
NCT04188119,has_status,UNKNOWN
NCT04188119,has_phase,
NCT04188119,sponsored_by,The Christie NHS Foundation Trust
NCT04188119,tests,Avelumab
Avelumab,has_type,DRUG
NCT04188119,tests,Aspirin
Aspirin,has_type,DRUG
NCT04188119,tests,Lansoprazole
Lansoprazole,has_type,DRUG
NCT04250818,has_title,Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients C
NCT04250818,has_status,SUSPENDED
NCT04250818,has_phase,
NCT04250818,sponsored_by,"Texas Tech University Health Sciences Center, El Paso"
NCT02162719,has_title,"A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibit"
NCT02162719,has_status,COMPLETED
NCT02162719,has_phase,
NCT02162719,sponsored_by,"Genentech, Inc."
NCT02162719,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT02162719,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02162719,tests,Placebo
Placebo,has_type,DRUG
NCT04408118,has_title,Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combinatio
NCT04408118,has_status,COMPLETED
NCT04408118,has_phase,
NCT04408118,sponsored_by,MedSIR
NCT04408118,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04408118,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04408118,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01939418,has_title,A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negativ
NCT01939418,has_status,TERMINATED
NCT01939418,has_phase,
NCT01939418,sponsored_by,"National Cancer Center, Korea"
NCT01939418,tests,RAD001
RAD001,has_type,DRUG
NCT01939418,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01939418,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04418219,has_title,A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Com
NCT04418219,has_status,WITHDRAWN
NCT04418219,has_phase,
NCT04418219,sponsored_by,Thomas Jefferson University
NCT04418219,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04418219,tests,Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM
Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM,has_type,BIOLOGICAL
NCT04418219,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04418219,tests,Recombinant Interferon Alpha 2b-like Protein
Recombinant Interferon Alpha 2b-like Protein,has_type,BIOLOGICAL
NCT04418219,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04418219,tests,Quality of Life Assessment
Quality of Life Assessment,has_type,OTHER
NCT05750719,has_title,Impact of BRCA Mutation Status on Outcome and Response to Neoadjuvant Chemotherapy (NACT) in Triple-
NCT05750719,has_status,COMPLETED
NCT05750719,has_phase,
NCT05750719,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05750719,tests,BRCA1/2 genetic testing
BRCA1/2 genetic testing,has_type,GENETIC
NCT03289819,has_title,A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel 
NCT03289819,has_status,COMPLETED
NCT03289819,has_phase,
NCT03289819,sponsored_by,Institut fuer Frauengesundheit
NCT03289819,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03289819,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03289819,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03289819,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06203119,has_title,Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
NCT06203119,has_status,RECRUITING
NCT06203119,has_phase,
NCT06203119,sponsored_by,Peking University Cancer Hospital & Institute
NCT01372579,has_title,Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer P
NCT01372579,has_status,UNKNOWN
NCT01372579,has_phase,
NCT01372579,sponsored_by,Northwestern University
NCT01372579,tests,eribulin mesylate
eribulin mesylate,has_type,DRUG
NCT01372579,tests,carboplatin
carboplatin,has_type,DRUG
NCT01372579,tests,biopsy
biopsy,has_type,PROCEDURE
NCT04134884,has_title,A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ H
NCT04134884,has_status,COMPLETED
NCT04134884,has_phase,
NCT04134884,sponsored_by,Kathy Miller
NCT04134884,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04134884,tests,ASTX727
ASTX727,has_type,DRUG
NCT04916002,has_title,"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With I"
NCT04916002,has_status,TERMINATED
NCT04916002,has_phase,
NCT04916002,sponsored_by,Regeneron Pharmaceuticals
NCT04916002,tests,vidutolimod
vidutolimod,has_type,DRUG
NCT04916002,tests,cemiplimab
cemiplimab,has_type,DRUG
NCT01094184,has_title,Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-Line Treatment of Pa
NCT01094184,has_status,COMPLETED
NCT01094184,has_phase,
NCT01094184,sponsored_by,Hoffmann-La Roche
NCT01094184,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01094184,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01094184,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06078384,has_title,Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With 
NCT06078384,has_status,RECRUITING
NCT06078384,has_phase,
NCT06078384,sponsored_by,UNICANCER
NCT06078384,tests,Pembrolizumab 25 mg/ml
Pembrolizumab 25 mg/ml,has_type,DRUG
NCT06078384,tests,Paclitaxel injection
Paclitaxel injection,has_type,DRUG
NCT06337084,has_title,Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patient
NCT06337084,has_status,RECRUITING
NCT06337084,has_phase,
NCT06337084,sponsored_by,Monopar Therapeutics
NCT06337084,tests,MNPR-101-DFO*-89Zr
MNPR-101-DFO*-89Zr,has_type,DRUG
NCT06337084,tests,PET/CT Diagnostic Imaging
PET/CT Diagnostic Imaging,has_type,DIAGNOSTIC_TEST
NCT05969184,has_title,Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Ad
NCT05969184,has_status,UNKNOWN
NCT05969184,has_phase,
NCT05969184,sponsored_by,Peking University Cancer Hospital & Institute
NCT05969184,tests,"CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)"
"CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)",has_type,DRUG
NCT01147484,has_title,"A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), a"
NCT01147484,has_status,COMPLETED
NCT01147484,has_phase,
NCT01147484,sponsored_by,NCIC Clinical Trials Group
NCT01147484,tests,Foretinib
Foretinib,has_type,DRUG
NCT03777579,has_title,"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of JS001 (Anti-PD-1 Antibody) in Comb"
NCT03777579,has_status,SUSPENDED
NCT03777579,has_phase,
NCT03777579,sponsored_by,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
NCT03777579,tests,JS001，an engineered anti-PD-1 antibody
JS001，an engineered anti-PD-1 antibody,has_type,DRUG
NCT03777579,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03777579,tests,Placebo
Placebo,has_type,DRUG
NCT04514484,has_title,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
NCT04514484,has_status,ACTIVE_NOT_RECRUITING
NCT04514484,has_phase,
NCT04514484,sponsored_by,National Cancer Institute (NCI)
NCT04514484,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04514484,tests,Cabozantinib S-malate
Cabozantinib S-malate,has_type,DRUG
NCT04514484,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT04514484,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT04514484,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT04260802,has_title,"A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of"
NCT04260802,has_status,RECRUITING
NCT04260802,has_phase,
NCT04260802,sponsored_by,"Ocellaris Pharma, Inc."
NCT04260802,tests,OC-001
OC-001,has_type,DRUG
NCT04260802,tests,Drug: OC-001 in Combination with Avelumab
Drug: OC-001 in Combination with Avelumab,has_type,DRUG
NCT02981303,has_title,"A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced "
NCT02981303,has_status,COMPLETED
NCT02981303,has_phase,
NCT02981303,sponsored_by,"HiberCell, Inc."
NCT02981303,tests,Imprime PGG
Imprime PGG,has_type,BIOLOGICAL
NCT02981303,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02850302,has_title,
NCT02850302,has_status,COMPLETED
NCT02850302,has_phase,
NCT02850302,sponsored_by,Centre Georges Francois Leclerc
NCT02850302,tests,PET with FDG
PET with FDG,has_type,OTHER
NCT02850302,tests,Tumor exome analysis
Tumor exome analysis,has_type,OTHER
NCT05741164,has_title,Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory M
NCT05741164,has_status,RECRUITING
NCT05741164,has_phase,
NCT05741164,sponsored_by,Roswell Park Cancer Institute
NCT05741164,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05741164,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05741164,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05741164,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05741164,tests,Propranolol
Propranolol,has_type,DRUG
NCT05741164,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT05296564,has_title,"A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene "
NCT05296564,has_status,RECRUITING
NCT05296564,has_phase,
NCT05296564,sponsored_by,Hadassah Medical Organization
NCT05296564,tests,CYCLOPHOSPHAMIDE and FLUDARABIN
CYCLOPHOSPHAMIDE and FLUDARABIN,has_type,DRUG
NCT05296564,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05296564,tests,HBI 0201-ESO TCRT
HBI 0201-ESO TCRT,has_type,BIOLOGICAL
NCT05296564,tests,Aldesleukin
Aldesleukin,has_type,DRUG
NCT04877821,has_title,An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combine
NCT04877821,has_status,RECRUITING
NCT04877821,has_phase,
NCT04877821,sponsored_by,Guangdong Provincial People's Hospital
NCT04877821,tests,Sintilimab
Sintilimab,has_type,DRUG
NCT04877821,tests,Anlotinib
Anlotinib,has_type,DRUG
NCT04877821,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT04877821,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04877821,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04877821,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01045421,has_title,"A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Non"
NCT01045421,has_status,COMPLETED
NCT01045421,has_phase,
NCT01045421,sponsored_by,"Millennium Pharmaceuticals, Inc."
NCT01045421,tests,MLN8237 (Alisertib)
MLN8237 (Alisertib),has_type,DRUG
NCT05227664,has_title,A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untrea
NCT05227664,has_status,RECRUITING
NCT05227664,has_phase,
NCT05227664,sponsored_by,Akeso
NCT05227664,tests,AK117
AK117,has_type,DRUG
NCT05227664,tests,AK112
AK112,has_type,DRUG
NCT05227664,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT05227664,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT03815890,has_title,Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI 
NCT03815890,has_status,RECRUITING
NCT03815890,has_phase,
NCT03815890,sponsored_by,The Netherlands Cancer Institute
NCT03815890,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03815890,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT03815890,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT04461990,has_title,Clinical Study of Imaging Genomics Based on Machine Learning for Breast Cancer Molecular Typing and 
NCT04461990,has_status,UNKNOWN
NCT04461990,has_phase,
NCT04461990,sponsored_by,Fudan University
NCT04461990,tests,Multidisciplinary cooperative comprehensive treatment
Multidisciplinary cooperative comprehensive treatment,has_type,PROCEDURE
NCT05461690,has_title,Phase II Study of Niraparib Single Agent in Metastatic Triple Negative Breast Cancer Patients With H
NCT05461690,has_status,UNKNOWN
NCT05461690,has_phase,
NCT05461690,sponsored_by,Zhejiang Cancer Hospital
NCT05461690,tests,Niraparib
Niraparib,has_type,DRUG
NCT04365790,has_title,"Investigation of Gene Mutations or Changes in Protein Expression,as Biomarkers With Prognostic/Predi"
NCT04365790,has_status,UNKNOWN
NCT04365790,has_phase,
NCT04365790,sponsored_by,Hellenic Cooperative Oncology Group
NCT05019690,has_title,Apatinib Mesylate Combined with Albumin-bound Paclitaxel for Second-line Treatment of Advanced Tripl
NCT05019690,has_status,RECRUITING
NCT05019690,has_phase,
NCT05019690,sponsored_by,Fujian Cancer Hospital
NCT05019690,tests,Apatinib Mesylate
Apatinib Mesylate,has_type,DRUG
NCT05019690,tests,Albumin-Bound Paclitaxel
Albumin-Bound Paclitaxel,has_type,DRUG
NCT06175390,has_title,"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial"
NCT06175390,has_status,RECRUITING
NCT06175390,has_phase,
NCT06175390,sponsored_by,Institut Curie
NCT06175390,tests,68Ga-FAPI-46 PET/CT
68Ga-FAPI-46 PET/CT,has_type,RADIATION
NCT06175390,tests,Tumor samples analysis
Tumor samples analysis,has_type,BIOLOGICAL
NCT06175390,tests,Blood samples analysis: Circulating Tumor DNA
Blood samples analysis: Circulating Tumor DNA,has_type,BIOLOGICAL
NCT04914390,has_title,"A Prospective, Open, Single-arm, Phase Ⅱ Clinical Study of Anlotinib Combined With Tislelizumab and "
NCT04914390,has_status,RECRUITING
NCT04914390,has_phase,
NCT04914390,sponsored_by,Sichuan Provincial People's Hospital
NCT04914390,tests,AT regimen
AT regimen,has_type,DRUG
NCT04914390,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT04914390,tests,Anlotinib
Anlotinib,has_type,DRUG
NCT03945721,has_title,A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Brea
NCT03945721,has_status,ACTIVE_NOT_RECRUITING
NCT03945721,has_phase,
NCT03945721,sponsored_by,Massachusetts General Hospital
NCT03945721,tests,Niraparib
Niraparib,has_type,DRUG
NCT03945721,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT06238921,has_title,Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Manage
NCT06238921,has_status,RECRUITING
NCT06238921,has_phase,
NCT06238921,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT06238921,tests,Stereotactic Radiation
Stereotactic Radiation,has_type,RADIATION
NCT06238921,tests,Zimberelimab
Zimberelimab,has_type,DRUG
NCT06238921,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT06150664,has_title,"A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in P"
NCT06150664,has_status,RECRUITING
NCT06150664,has_phase,
NCT06150664,sponsored_by,Compass Therapeutics
NCT06150664,tests,CTX-8371
CTX-8371,has_type,DRUG
NCT01234402,has_title,"An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirum"
NCT01234402,has_status,COMPLETED
NCT01234402,has_phase,
NCT01234402,sponsored_by,Eli Lilly and Company
NCT01234402,tests,Ramucirumab DP
Ramucirumab DP,has_type,BIOLOGICAL
NCT01234402,tests,IMC-18F1
IMC-18F1,has_type,BIOLOGICAL
NCT01234402,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT00203502,has_title,Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub
NCT00203502,has_status,COMPLETED
NCT00203502,has_phase,
NCT00203502,sponsored_by,University of Arkansas
NCT00203502,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00203502,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00203502,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01207102,has_title,"A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for ""Triple Negative"" (Demonst"
NCT01207102,has_status,TERMINATED
NCT01207102,has_phase,
NCT01207102,sponsored_by,Duke University
NCT01207102,tests,Abraxane
Abraxane,has_type,DRUG
NCT01207102,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06419621,has_title,"A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab"
NCT06419621,has_status,RECRUITING
NCT06419621,has_phase,
NCT06419621,sponsored_by,Biotheus Inc.
NCT06419621,tests,PM8002
PM8002,has_type,DRUG
NCT06419621,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT06419621,tests,Placebo
Placebo,has_type,DRUG
NCT06840821,has_title,"A Phase I/II, Multicenter, Open-label, Single-arm, Dose-escalation and Dose-expansion Study Evaluati"
NCT06840821,has_status,RECRUITING
NCT06840821,has_phase,
NCT06840821,sponsored_by,"Mainline Biosciences (Shanghai) Co., Ltd"
NCT06840821,tests,MB0151 for injection
MB0151 for injection,has_type,DRUG
NCT05949021,has_title,OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer
NCT05949021,has_status,RECRUITING
NCT05949021,has_phase,
NCT05949021,sponsored_by,"Mridula George, MD"
NCT05949021,tests,Combination of liposomal doxorubicin
Combination of liposomal doxorubicin,has_type,DRUG
NCT05935384,has_title,SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384,has_status,RECRUITING
NCT05935384,has_phase,
NCT05935384,sponsored_by,"Guardant Health, Inc."
NCT05935384,tests,Guardant360
Guardant360,has_type,DIAGNOSTIC_TEST
NCT06264921,has_title,"A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminar"
NCT06264921,has_status,ACTIVE_NOT_RECRUITING
NCT06264921,has_phase,
NCT06264921,sponsored_by,"NiKang Therapeutics, Inc."
NCT06264921,tests,NKT3447
NKT3447,has_type,DRUG
NCT00749502,has_title,A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies
NCT00749502,has_status,COMPLETED
NCT00749502,has_phase,
NCT00749502,sponsored_by,"Tesaro, Inc."
NCT00749502,tests,MK-4827
MK-4827,has_type,DRUG
NCT02124902,has_title,A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
NCT02124902,has_status,TERMINATED
NCT02124902,has_phase,
NCT02124902,sponsored_by,Washington University School of Medicine
NCT02124902,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02124902,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02124902,tests,FDG-PET/MR
FDG-PET/MR,has_type,PROCEDURE
NCT02876302,has_title,Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Neg
NCT02876302,has_status,ACTIVE_NOT_RECRUITING
NCT02876302,has_phase,
NCT02876302,sponsored_by,Dana-Farber Cancer Institute
NCT02876302,tests,Ruxolitinib
Ruxolitinib,has_type,DRUG
NCT02876302,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02876302,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02876302,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06833502,has_title,Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant
NCT06833502,has_status,RECRUITING
NCT06833502,has_phase,
NCT06833502,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT06833502,tests,CT Scan
CT Scan,has_type,OTHER
NCT05460702,has_title,Evaluation of the Relationship Between Stage I-II Breast Cancer Subtypes and Soluble Immune Checkpoi
NCT05460702,has_status,COMPLETED
NCT05460702,has_phase,
NCT05460702,sponsored_by,Istanbul Training and Research Hospital
NCT05460702,tests,Soluble immune checkpoints
Soluble immune checkpoints,has_type,DIAGNOSTIC_TEST
NCT03340402,has_title,Pilot Study of Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer
NCT03340402,has_status,WITHDRAWN
NCT03340402,has_phase,
NCT03340402,sponsored_by,Massachusetts General Hospital
NCT03340402,tests,Accelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation,has_type,RADIATION
NCT03340402,tests,AlignRT
AlignRT,has_type,DEVICE
NCT06014502,has_title,"A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerab"
NCT06014502,has_status,RECRUITING
NCT06014502,has_phase,
NCT06014502,sponsored_by,ImmunoGenesis
NCT06014502,tests,IMGS-001
IMGS-001,has_type,DRUG
NCT06533384,has_title,PARPi or Capecitabine Combined With PD-1 Inhibitors Was Selected Based on the Germline BRCA1/2 Mutat
NCT06533384,has_status,RECRUITING
NCT06533384,has_phase,
NCT06533384,sponsored_by,Guangdong Provincial People's Hospital
NCT06533384,tests,"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy."
"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.",has_type,DRUG
NCT06533384,tests,9 cycles of Camrelizumab as adjuvant therapy.
9 cycles of Camrelizumab as adjuvant therapy.,has_type,DRUG
NCT01662284,has_title,A Phase 1/2 Study of 124I-NM404 in Subjects With Advanced Solid Malignancies
NCT01662284,has_status,TERMINATED
NCT01662284,has_phase,
NCT01662284,sponsored_by,"University of Wisconsin, Madison"
NCT01662284,tests,124I-NM404
124I-NM404,has_type,DRUG
NCT04067102,has_title,Albumin Bound (Nab)-Paclitaxel Combined With Carboplatin Versus Paclitaxel Combined With Carboplatin
NCT04067102,has_status,WITHDRAWN
NCT04067102,has_phase,
NCT04067102,sponsored_by,Hebei Medical University Fourth Hospital
NCT04067102,tests,Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,has_type,DRUG
NCT04067102,tests,paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,has_type,DRUG
NCT06036121,has_title,A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
NCT06036121,has_status,RECRUITING
NCT06036121,has_phase,
NCT06036121,sponsored_by,Adcentrx Therapeutics
NCT06036121,tests,ADRX-0706
ADRX-0706,has_type,DRUG
NCT02936102,has_title,"A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combinati"
NCT02936102,has_status,TERMINATED
NCT02936102,has_phase,
NCT02936102,sponsored_by,Novartis Pharmaceuticals
NCT02936102,tests,FAZ053
FAZ053,has_type,DRUG
NCT02936102,tests,PDR001
PDR001,has_type,DRUG
NCT05770102,has_title,DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defin
NCT05770102,has_status,RECRUITING
NCT05770102,has_phase,
NCT05770102,sponsored_by,Cancer Research UK
NCT05770102,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04521621,has_title,A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab
NCT04521621,has_status,TERMINATED
NCT04521621,has_phase,
NCT04521621,sponsored_by,Merck Sharp & Dohme LLC
NCT04521621,tests,Gebasaxturev
Gebasaxturev,has_type,BIOLOGICAL
NCT04521621,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT00633464,has_title,Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen
NCT00633464,has_status,COMPLETED
NCT00633464,has_phase,
NCT00633464,sponsored_by,R-Pharm
NCT00633464,tests,ixabepilone
ixabepilone,has_type,DRUG
NCT00633464,tests,ixabepilone + cetuximab
ixabepilone + cetuximab,has_type,DRUG
NCT02402764,has_title,Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic
NCT02402764,has_status,COMPLETED
NCT02402764,has_phase,
NCT02402764,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02402764,tests,Selinexor
Selinexor,has_type,DRUG
NCT02950064,has_title,Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation
NCT02950064,has_status,UNKNOWN
NCT02950064,has_phase,
NCT02950064,sponsored_by,Placon Therapeutics
NCT02950064,tests,BTP-114
BTP-114,has_type,DRUG
NCT06976021,has_title,Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Rad
NCT06976021,has_status,NOT_YET_RECRUITING
NCT06976021,has_phase,
NCT06976021,sponsored_by,Maria Sklodowska-Curie National Research Institute of Oncology
NCT06976021,tests,Baseline 89-Zr Pembrolizumab Immuno PET-CT
Baseline 89-Zr Pembrolizumab Immuno PET-CT,has_type,DIAGNOSTIC_TEST
NCT06976021,tests,Proteomic assay
Proteomic assay,has_type,DIAGNOSTIC_TEST
NCT06976021,tests,Follow-up 89-Zr Pembrolizumab Immuno PET-CT
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,has_type,DIAGNOSTIC_TEST
NCT06257264,has_title,"A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tum"
NCT06257264,has_status,RECRUITING
NCT06257264,has_phase,
NCT06257264,sponsored_by,BeiGene
NCT06257264,tests,BG-68501
BG-68501,has_type,DRUG
NCT06257264,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT06257264,tests,BGB-43395
BGB-43395,has_type,DRUG
NCT05336721,has_title,"An Open Labelled, Multicenter-phase II Study of Chiauranib Combine With Capecitabine in Advanced Tri"
NCT05336721,has_status,TERMINATED
NCT05336721,has_phase,
NCT05336721,sponsored_by,"Chipscreen Biosciences, Ltd."
NCT05336721,tests,Chiauranib
Chiauranib,has_type,DRUG
NCT05336721,tests,capecitabine
capecitabine,has_type,DRUG
NCT05404321,has_title,Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate 
NCT05404321,has_status,RECRUITING
NCT05404321,has_phase,
NCT05404321,sponsored_by,Centre Francois Baclesse
NCT05404321,tests,Establishment of ex vivo breast cancer organoid models
Establishment of ex vivo breast cancer organoid models,has_type,OTHER
NCT05955521,has_title,Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Tre
NCT05955521,has_status,ACTIVE_NOT_RECRUITING
NCT05955521,has_phase,
NCT05955521,sponsored_by,Samsung Medical Center
NCT05955521,tests,exosome and ctDNA evaluation
exosome and ctDNA evaluation,has_type,PROCEDURE
NCT00546364,has_title,IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or C
NCT00546364,has_status,TERMINATED
NCT00546364,has_phase,
NCT00546364,sponsored_by,R-Pharm
NCT00546364,tests,"Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2"
"Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2",has_type,DRUG
NCT00546364,tests,"Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2"
"Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2",has_type,DRUG
NCT00546364,tests,"Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2"
"Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2",has_type,DRUG
NCT06279364,has_title,"A Randomized, Open-Label, Multicenter Phase 3 Study of SKB264 Versus Investigator's Choice Chemother"
NCT06279364,has_status,RECRUITING
NCT06279364,has_phase,
NCT06279364,sponsored_by,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
NCT06279364,tests,SKB264
SKB264,has_type,DRUG
NCT06279364,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06279364,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06279364,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06279364,tests,Eribulin
Eribulin,has_type,DRUG
NCT06279364,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04292821,has_title,Performance Study of BIOPSY SCANNER LLTECH© Technology in the Immediate Diagnosis of Breast Cancer
NCT04292821,has_status,UNKNOWN
NCT04292821,has_phase,
NCT04292821,sponsored_by,Assistance Publique - Hôpitaux de Paris
NCT06681064,has_title,Breast Cancer Evolution During Neoadjuvant Systemic Therapy
NCT06681064,has_status,RECRUITING
NCT06681064,has_phase,
NCT06681064,sponsored_by,Royal Marsden NHS Foundation Trust
NCT03742102,has_title,"A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durval"
NCT03742102,has_status,ACTIVE_NOT_RECRUITING
NCT03742102,has_phase,
NCT03742102,sponsored_by,AstraZeneca
NCT03742102,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03742102,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT03742102,tests,Oleclumab
Oleclumab,has_type,DRUG
NCT03742102,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03742102,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
NCT03742102,tests,Datopotamab deruxtecan
Datopotamab deruxtecan,has_type,DRUG
NCT01015521,has_title,A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positi
NCT01015521,has_status,WITHDRAWN
NCT01015521,has_phase,
NCT01015521,sponsored_by,Tigris Pharmaceuticals
NCT01015521,tests,Aminoflavone Prodrug
Aminoflavone Prodrug,has_type,DRUG
NCT03414684,has_title,A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple
NCT03414684,has_status,ACTIVE_NOT_RECRUITING
NCT03414684,has_phase,
NCT03414684,sponsored_by,Dana-Farber Cancer Institute
NCT03414684,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03414684,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT01837602,has_title,Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Br
NCT01837602,has_status,COMPLETED
NCT01837602,has_phase,
NCT01837602,sponsored_by,University of Pennsylvania
NCT01837602,tests,cMet RNA CAR T cells
cMet RNA CAR T cells,has_type,BIOLOGICAL
NCT05447702,has_title,"A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuva"
NCT05447702,has_status,RECRUITING
NCT05447702,has_phase,
NCT05447702,sponsored_by,West China Hospital
NCT05447702,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT05447702,tests,Apatinib
Apatinib,has_type,DRUG
NCT05447702,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05447702,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05447702,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05677802,has_title,Examining the Feasibility of Implementing a Biobehavioral Stress Reduction Program in Triple Negativ
NCT05677802,has_status,RECRUITING
NCT05677802,has_phase,
NCT05677802,sponsored_by,Ohio State University Comprehensive Cancer Center
NCT05677802,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05677802,tests,Medical Chart Review
Medical Chart Review,has_type,OTHER
NCT05677802,tests,Stress Management Therapy
Stress Management Therapy,has_type,PROCEDURE
NCT05677802,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT06299202,has_title,Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and 
NCT06299202,has_status,RECRUITING
NCT06299202,has_phase,
NCT06299202,sponsored_by,Hospices Civils de Lyon
NCT06299202,tests,Diagnostic test
Diagnostic test,has_type,DIAGNOSTIC_TEST
NCT03125902,has_title,"A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P"
NCT03125902,has_status,COMPLETED
NCT03125902,has_phase,
NCT03125902,sponsored_by,Hoffmann-La Roche
NCT03125902,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
NCT03125902,tests,Atezolizumab Placebo
Atezolizumab Placebo,has_type,DRUG
NCT03125902,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06409221,has_title,VISION: Defining Biomarkers of Chemotherapy & Immunotherapy Response and Validation of the Breast Ca
NCT06409221,has_status,ENROLLING_BY_INVITATION
NCT06409221,has_phase,
NCT06409221,sponsored_by,Concr
NCT06409221,tests,"Non-interventional study, Observational only"
"Non-interventional study, Observational only",has_type,OTHER
NCT04592484,has_title,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Inject"
NCT04592484,has_status,COMPLETED
NCT04592484,has_phase,
NCT04592484,sponsored_by,Codiak BioSciences
NCT04592484,tests,CDK-002
CDK-002,has_type,BIOLOGICAL
NCT04549584,has_title,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
NCT04549584,has_status,TERMINATED
NCT04549584,has_phase,
NCT04549584,sponsored_by,Seoul National University Hospital
NCT04549584,tests,Vimentin/pan CK stain
Vimentin/pan CK stain,has_type,DIAGNOSTIC_TEST
NCT04927884,has_title,Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment 
NCT04927884,has_status,TERMINATED
NCT04927884,has_phase,
NCT04927884,sponsored_by,"ImmunityBio, Inc."
NCT04927884,tests,N-803
N-803,has_type,BIOLOGICAL
NCT04927884,tests,PD-L1 t-haNK
PD-L1 t-haNK,has_type,BIOLOGICAL
NCT04927884,tests,Sacituzumab Govitecan-Hziy
Sacituzumab Govitecan-Hziy,has_type,DRUG
NCT04927884,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05675579,has_title,A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemothera
NCT05675579,has_status,RECRUITING
NCT05675579,has_phase,
NCT05675579,sponsored_by,M.D. Anderson Cancer Center
NCT05675579,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT05675579,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06225284,has_title,A Randomized Phase II Study of Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopaus
NCT06225284,has_status,RECRUITING
NCT06225284,has_phase,
NCT06225284,sponsored_by,National Taiwan University Hospital
NCT06225284,tests,Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,has_type,DRUG
NCT00691379,has_title,Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati
NCT00691379,has_status,COMPLETED
NCT00691379,has_phase,
NCT00691379,sponsored_by,Hellenic Oncology Research Group
NCT00691379,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00691379,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00691379,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06112379,has_title,"A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durv"
NCT06112379,has_status,RECRUITING
NCT06112379,has_phase,
NCT06112379,sponsored_by,AstraZeneca
NCT06112379,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT06112379,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT06112379,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06112379,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT06112379,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT06112379,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06112379,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06112379,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06112379,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06112379,tests,Olaparib
Olaparib,has_type,DRUG
NCT03383679,has_title,A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recur
NCT03383679,has_status,COMPLETED
NCT03383679,has_phase,
NCT03383679,sponsored_by,UNICANCER
NCT03383679,tests,Darolutamide
Darolutamide,has_type,DRUG
NCT03383679,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03799679,has_title,Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in Combination With Cycl
NCT03799679,has_status,UNKNOWN
NCT03799679,has_phase,
NCT03799679,sponsored_by,Fudan University
NCT03799679,tests,Chemotherapeutic Agent
Chemotherapeutic Agent,has_type,DRUG
NCT01042379,has_title,I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And m
NCT01042379,has_status,RECRUITING
NCT01042379,has_phase,
NCT01042379,sponsored_by,QuantumLeap Healthcare Collaborative
NCT01042379,tests,Standard Therapy
Standard Therapy,has_type,DRUG
NCT01042379,tests,AMG 386 with or without Trastuzumab
AMG 386 with or without Trastuzumab,has_type,DRUG
NCT01042379,tests,AMG 479 (Ganitumab) plus Metformin
AMG 479 (Ganitumab) plus Metformin,has_type,DRUG
NCT01042379,tests,MK-2206 with or without Trastuzumab
MK-2206 with or without Trastuzumab,has_type,DRUG
NCT01042379,tests,AMG 386 and Trastuzumab
AMG 386 and Trastuzumab,has_type,DRUG
NCT01042379,tests,T-DM1 and Pertuzumab
T-DM1 and Pertuzumab,has_type,DRUG
NCT01042379,tests,Pertuzumab and Trastuzumab
Pertuzumab and Trastuzumab,has_type,DRUG
NCT01042379,tests,Ganetespib
Ganetespib,has_type,DRUG
NCT01042379,tests,ABT-888
ABT-888,has_type,DRUG
NCT01042379,tests,Neratinib
Neratinib,has_type,DRUG
NCT01042379,tests,PLX3397
PLX3397,has_type,DRUG
NCT01042379,tests,Pembrolizumab - 4 cycle
Pembrolizumab - 4 cycle,has_type,DRUG
NCT01042379,tests,Talazoparib plus Irinotecan
Talazoparib plus Irinotecan,has_type,DRUG
NCT01042379,tests,Patritumab and Trastuzumab
Patritumab and Trastuzumab,has_type,DRUG
NCT01042379,tests,Pembrolizumab - 8 cycle
Pembrolizumab - 8 cycle,has_type,DRUG
NCT01042379,tests,SGN-LIV1A
SGN-LIV1A,has_type,DRUG
NCT01042379,tests,Durvalumab plus Olaparib
Durvalumab plus Olaparib,has_type,DRUG
NCT01042379,tests,SD-101 + Pembrolizumab
SD-101 + Pembrolizumab,has_type,DRUG
NCT01042379,tests,Tucatinib plus trastuzumab and pertuzumab
Tucatinib plus trastuzumab and pertuzumab,has_type,DRUG
NCT01042379,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT01042379,tests,Cemiplimab plus REGN3767
Cemiplimab plus REGN3767,has_type,DRUG
NCT01042379,tests,Trilaciclib with or without trastuzumab + pertuzumab
Trilaciclib with or without trastuzumab + pertuzumab,has_type,DRUG
NCT01042379,tests,SYD985 ([vic-]trastuzumab duocarmazine)
SYD985 ([vic-]trastuzumab duocarmazine),has_type,DRUG
NCT01042379,tests,Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,has_type,DRUG
NCT01042379,tests,Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,has_type,DRUG
NCT01042379,tests,Amcenestrant
Amcenestrant,has_type,DRUG
NCT01042379,tests,Amcenestrant + Abemaciclib
Amcenestrant + Abemaciclib,has_type,DRUG
NCT01042379,tests,Amcenestrant + Letrozole
Amcenestrant + Letrozole,has_type,DRUG
NCT01042379,tests,ARX788
ARX788,has_type,DRUG
NCT01042379,tests,ARX788 + Cemiplimab
ARX788 + Cemiplimab,has_type,DRUG
NCT01042379,tests,VV1 + Cemiplimab
VV1 + Cemiplimab,has_type,DRUG
NCT01042379,tests,Datopotamab deruxtecan
Datopotamab deruxtecan,has_type,DRUG
NCT01042379,tests,Datopotamab deruxtecan + Durvalumab
Datopotamab deruxtecan + Durvalumab,has_type,DRUG
NCT01042379,tests,Zanidatamab
Zanidatamab,has_type,DRUG
NCT01042379,tests,Lasofoxifene
Lasofoxifene,has_type,DRUG
NCT01042379,tests,Z-endoxifen
Z-endoxifen,has_type,DRUG
NCT01042379,tests,ARV-471
ARV-471,has_type,DRUG
NCT01042379,tests,ARV-471 + Letrozole
ARV-471 + Letrozole,has_type,DRUG
NCT01042379,tests,ARV-471 + Abemaciclib
ARV-471 + Abemaciclib,has_type,DRUG
NCT01042379,tests,Endoxifen + Abemaciclib
Endoxifen + Abemaciclib,has_type,DRUG
NCT01042379,tests,Rilvegostomig + TDXd
Rilvegostomig + TDXd,has_type,DRUG
NCT01042379,tests,Dan222 + Niraparib
Dan222 + Niraparib,has_type,DRUG
NCT01042379,tests,Sarilumab + Cemiplimab + Paclitaxel
Sarilumab + Cemiplimab + Paclitaxel,has_type,DRUG
NCT02161679,has_title,Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Rela
NCT02161679,has_status,WITHDRAWN
NCT02161679,has_phase,
NCT02161679,sponsored_by,Gilead Sciences
NCT02161679,tests,IMMU-132 infusion is administered to participants in one arm for the study
IMMU-132 infusion is administered to participants in one arm for the study,has_type,DRUG
NCT02161679,tests,IMMU-132 plus Carboplatin infusion
IMMU-132 plus Carboplatin infusion,has_type,DRUG
NCT05451784,has_title,Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ Tumo
NCT05451784,has_status,RECRUITING
NCT05451784,has_phase,
NCT05451784,sponsored_by,Fundacio Clinic Barcelona
NCT05451784,tests,PD1+ TILs (NUMARZU-001) product infusion
PD1+ TILs (NUMARZU-001) product infusion,has_type,DRUG
NCT06238479,has_title,"A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participa"
NCT06238479,has_status,RECRUITING
NCT06238479,has_phase,
NCT06238479,sponsored_by,Eli Lilly and Company
NCT06238479,tests,LY4101174
LY4101174,has_type,DRUG
NCT04683679,has_title,Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Tri
NCT04683679,has_status,RECRUITING
NCT04683679,has_phase,
NCT04683679,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT04683679,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04683679,tests,Olaparib
Olaparib,has_type,DRUG
NCT04683679,tests,Radiation
Radiation,has_type,RADIATION
NCT04803084,has_title,Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment in Breast Cancer
NCT04803084,has_status,SUSPENDED
NCT04803084,has_phase,
NCT04803084,sponsored_by,Laura Kennedy
NCT04803084,tests,Tempus assay
Tempus assay,has_type,OTHER
NCT04803084,tests,Advanced pathology 1
Advanced pathology 1,has_type,OTHER
NCT04803084,tests,Advanced pathology 2
Advanced pathology 2,has_type,OTHER
NCT05252390,has_title,Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or En
NCT05252390,has_status,TERMINATED
NCT05252390,has_phase,
NCT05252390,sponsored_by,Nuvation Bio Inc.
NCT05252390,tests,NUV-868
NUV-868,has_type,DRUG
NCT05252390,tests,Olaparib
Olaparib,has_type,DRUG
NCT05252390,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT04980690,has_title,"A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Ad"
NCT04980690,has_status,RECRUITING
NCT04980690,has_phase,
NCT04980690,sponsored_by,"SUNHO（China）BioPharmaceutical CO., Ltd."
NCT04980690,tests,IBC0966
IBC0966,has_type,BIOLOGICAL
NCT02734290,has_title,"A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che"
NCT02734290,has_status,ACTIVE_NOT_RECRUITING
NCT02734290,has_phase,
NCT02734290,sponsored_by,Providence Health & Services
NCT02734290,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02734290,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02734290,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04925284,has_title,A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent an
NCT04925284,has_status,COMPLETED
NCT04925284,has_phase,
NCT04925284,sponsored_by,Exelixis
NCT04925284,tests,XB002
XB002,has_type,DRUG
NCT04925284,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04925284,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT06136884,has_title,"A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumor"
NCT06136884,has_status,RECRUITING
NCT06136884,has_phase,
NCT06136884,sponsored_by,A2A Pharmaceuticals Inc.
NCT06136884,tests,AO-252
AO-252,has_type,DRUG
NCT02900664,has_title,"Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynami"
NCT02900664,has_status,COMPLETED
NCT02900664,has_phase,
NCT02900664,sponsored_by,Novartis Pharmaceuticals
NCT02900664,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT02900664,tests,ACZ885
ACZ885,has_type,BIOLOGICAL
NCT02900664,tests,CJM112
CJM112,has_type,BIOLOGICAL
NCT02900664,tests,TMT212
TMT212,has_type,DRUG
NCT02900664,tests,EGF816
EGF816,has_type,DRUG
NCT06103864,has_title,"A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durva"
NCT06103864,has_status,RECRUITING
NCT06103864,has_phase,
NCT06103864,sponsored_by,AstraZeneca
NCT06103864,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT06103864,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT06103864,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06103864,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06103864,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06103864,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06103864,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04874064,has_title,Triple Negative Breast Cancer Markers in Liquid Biopsies Using Artificial Intelligence (TRICIA Study
NCT04874064,has_status,UNKNOWN
NCT04874064,has_phase,
NCT04874064,sponsored_by,Jewish General Hospital
NCT04874064,tests,Liquid Biopsy
Liquid Biopsy,has_type,OTHER
NCT06291064,has_title,TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of 
NCT06291064,has_status,NOT_YET_RECRUITING
NCT06291064,has_phase,
NCT06291064,sponsored_by,University of Chicago
NCT06291064,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06291064,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT06291064,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06291064,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06291064,tests,Breast Surgery
Breast Surgery,has_type,PROCEDURE
NCT06291064,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02945579,has_title,Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to
NCT02945579,has_status,RECRUITING
NCT02945579,has_phase,
NCT02945579,sponsored_by,M.D. Anderson Cancer Center
NCT02945579,tests,Undergo EBRT
Undergo EBRT,has_type,RADIATION
NCT02945579,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02945579,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT02945579,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT02945579,tests,Partial Breast Irradiation
Partial Breast Irradiation,has_type,RADIATION
NCT03457779,has_title,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative (TN) Breast Canc
NCT03457779,has_status,COMPLETED
NCT03457779,has_phase,
NCT03457779,sponsored_by,Baylor Research Institute
NCT03457779,tests,Glucose
Glucose,has_type,DIETARY_SUPPLEMENT
NCT04809779,has_title,PD-1 Inhibitor Sintilimab Concurrent With Epirubicin Cyclophosphamide and Nab-paclitaxel as Neoadjuv
NCT04809779,has_status,UNKNOWN
NCT04809779,has_phase,
NCT04809779,sponsored_by,"First Affiliated Hospital, Sun Yat-Sen University"
NCT04809779,tests,Sintilimab
Sintilimab,has_type,DRUG
NCT01250379,has_title,A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizu
NCT01250379,has_status,COMPLETED
NCT01250379,has_phase,
NCT01250379,sponsored_by,Hoffmann-La Roche
NCT01250379,tests,bevacizumab [Avastin]
bevacizumab [Avastin],has_type,DRUG
NCT01250379,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT06434064,has_title,"A Pilot, Single-Arm, Phase II Trial of Tamoxifen Plus Pegylated Liposomal Doxorubicin in Patients Wi"
NCT06434064,has_status,RECRUITING
NCT06434064,has_phase,
NCT06434064,sponsored_by,Roswell Park Cancer Institute
NCT06434064,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT06434064,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06434064,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT06434064,tests,Echocardiography
Echocardiography,has_type,PROCEDURE
NCT06434064,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT06434064,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
NCT06434064,tests,Tamoxifen
Tamoxifen,has_type,DRUG
NCT01779479,has_title,"Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus W"
NCT01779479,has_status,COMPLETED
NCT01779479,has_phase,
NCT01779479,sponsored_by,GBG Forschungs GmbH
NCT01779479,tests,Cabacitaxel
Cabacitaxel,has_type,DRUG
NCT01779479,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01071564,has_title,A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibit
NCT01071564,has_status,TERMINATED
NCT01071564,has_phase,
NCT01071564,sponsored_by,National Cancer Institute (NCI)
NCT01071564,tests,Gamma-Secretase Inhibitor RO4929097
Gamma-Secretase Inhibitor RO4929097,has_type,DRUG
NCT01071564,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01071564,tests,Pharmacogenomic Study
Pharmacogenomic Study,has_type,OTHER
NCT01071564,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01071564,tests,Vismodegib
Vismodegib,has_type,DRUG
NCT06991790,has_title,"A Prospective, Single-arm, Multicenter Phase II Clinical Study of Sacituzumab Govitecan in Combinati"
NCT06991790,has_status,RECRUITING
NCT06991790,has_phase,
NCT06991790,sponsored_by,Peking University Cancer Hospital & Institute
NCT06991790,tests,Sacituzumab Govitecan (SG)+Toripalimab
Sacituzumab Govitecan (SG)+Toripalimab,has_type,DRUG
NCT06220214,has_title,Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant 
NCT06220214,has_status,RECRUITING
NCT06220214,has_phase,
NCT06220214,sponsored_by,Alison Stopeck
NCT06220214,tests,CEDM
CEDM,has_type,DIAGNOSTIC_TEST
NCT06220214,tests,CEDBT
CEDBT,has_type,DIAGNOSTIC_TEST
NCT06220214,tests,Omnipaque 350mgI/mL Solution for Injection
Omnipaque 350mgI/mL Solution for Injection,has_type,DRUG
NCT02658214,has_title,A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati
NCT02658214,has_status,COMPLETED
NCT02658214,has_phase,
NCT02658214,sponsored_by,AstraZeneca
NCT02658214,tests,paclitaxel + carboplatin
paclitaxel + carboplatin,has_type,DRUG
NCT02658214,tests,carboplatin + etoposide
carboplatin + etoposide,has_type,DRUG
NCT02658214,tests,gemcitabine + carboplatin
gemcitabine + carboplatin,has_type,DRUG
NCT02658214,tests,nab-paclitaxel (paclitaxel-albumin) + carboplatin
nab-paclitaxel (paclitaxel-albumin) + carboplatin,has_type,DRUG
NCT02658214,tests,oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),has_type,DRUG
NCT02658214,tests,durvalumab
durvalumab,has_type,BIOLOGICAL
NCT02658214,tests,tremelimumab
tremelimumab,has_type,BIOLOGICAL
NCT02658214,tests,nab-paclitaxel (paclitaxel-albumin) + gemcitabine
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,has_type,DRUG
NCT02658214,tests,cisplatin + 5-fluorouracil (5FU)
cisplatin + 5-fluorouracil (5FU),has_type,DRUG
NCT02263495,has_title,"A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemci"
NCT02263495,has_status,COMPLETED
NCT02263495,has_phase,
NCT02263495,sponsored_by,Asan Medical Center
NCT02263495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02263495,tests,Eribulin
Eribulin,has_type,DRUG
NCT02263495,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04584255,has_title,A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BR
NCT04584255,has_status,ACTIVE_NOT_RECRUITING
NCT04584255,has_phase,
NCT04584255,sponsored_by,Dana-Farber Cancer Institute
NCT04584255,tests,Niraparib
Niraparib,has_type,DRUG
NCT04584255,tests,Dostarlimab
Dostarlimab,has_type,DRUG
NCT05546255,has_title,Phase II Clinical Study of Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent 
NCT05546255,has_status,UNKNOWN
NCT05546255,has_phase,
NCT05546255,sponsored_by,Chinese Academy of Medical Sciences
NCT05546255,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT05546255,tests,Lobaplatin
Lobaplatin,has_type,DRUG
NCT06618014,has_title,"A Single-Arm Phase II Trial of Neoadjuvant Toripalimab, Docetaxel, Plus Carboplatin in Patients With"
NCT06618014,has_status,COMPLETED
NCT06618014,has_phase,
NCT06618014,sponsored_by,Sun Yat-sen University
NCT06618014,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT06618014,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06618014,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT07046195,has_title,Clinical Study of the Optimal Combination Mode of Adjuvant Radiotherapy Combined With Immunotherapy 
NCT07046195,has_status,ACTIVE_NOT_RECRUITING
NCT07046195,has_phase,
NCT07046195,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT03761914,has_title,A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Sel
NCT03761914,has_status,COMPLETED
NCT03761914,has_phase,
NCT03761914,sponsored_by,Sellas Life Sciences Group
NCT03761914,tests,galinpepimut-S
galinpepimut-S,has_type,BIOLOGICAL
NCT03761914,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT03761914,tests,Montanide
Montanide,has_type,OTHER
NCT03761914,tests,GM-CSF
GM-CSF,has_type,BIOLOGICAL
NCT05495295,has_title,"An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibi"
NCT05495295,has_status,RECRUITING
NCT05495295,has_phase,
NCT05495295,sponsored_by,Phost'In Therapeutics
NCT05495295,tests,PhOx430
PhOx430,has_type,DRUG
NCT05495295,tests,PhOx430
PhOx430,has_type,DRUG
NCT03893955,has_title,"A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, an"
NCT03893955,has_status,ACTIVE_NOT_RECRUITING
NCT03893955,has_phase,
NCT03893955,sponsored_by,AbbVie
NCT03893955,tests,ABBV-927
ABBV-927,has_type,DRUG
NCT03893955,tests,ABBV-368
ABBV-368,has_type,DRUG
NCT03893955,tests,ABBV-181
ABBV-181,has_type,DRUG
NCT03893955,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03893955,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04690855,has_title,"A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy an"
NCT04690855,has_status,TERMINATED
NCT04690855,has_phase,
NCT04690855,sponsored_by,"Mylin A. Torres, MD"
NCT04690855,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04690855,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04690855,tests,Radiation
Radiation,has_type,RADIATION
NCT04582955,has_title,Chidamide Combined With Neoadjuvant Chemotherapy in Early Triple-negative Breast Cancer
NCT04582955,has_status,UNKNOWN
NCT04582955,has_phase,
NCT04582955,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT04582955,tests,Chidamide in combination with chemotherapy
Chidamide in combination with chemotherapy,has_type,DRUG
NCT02574455,has_title,"An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Ver"
NCT02574455,has_status,COMPLETED
NCT02574455,has_phase,
NCT02574455,sponsored_by,Gilead Sciences
NCT02574455,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT02574455,tests,Eribulin
Eribulin,has_type,DRUG
NCT02574455,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02574455,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02574455,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT02259114,has_title,"A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Termin"
NCT02259114,has_status,COMPLETED
NCT02259114,has_phase,
NCT02259114,sponsored_by,"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
NCT02259114,tests,Birabresib
Birabresib,has_type,DRUG
NCT02897050,has_title,Phase II Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With 
NCT02897050,has_status,SUSPENDED
NCT02897050,has_phase,
NCT02897050,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02897050,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02897050,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02897050,tests,Cyclophosphamide (tablet)
Cyclophosphamide (tablet),has_type,DRUG
NCT02897050,tests,Fluorouracil
Fluorouracil,has_type,DRUG
NCT02897050,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02897050,tests,Cyclophosphamide (injection)
Cyclophosphamide (injection),has_type,DRUG
NCT01619514,has_title,
NCT01619514,has_status,UNKNOWN
NCT01619514,has_phase,
NCT01619514,sponsored_by,"National University Hospital, Singapore"
NCT06135714,has_title,a Randomized Trial for OLIGo Metastases Breast cAncer With or Without Metastasis-dIrected Therapy
NCT06135714,has_status,RECRUITING
NCT06135714,has_phase,
NCT06135714,sponsored_by,Tokyo Medical and Dental University
NCT06135714,tests,Systemic therapy for 12 weeks after primary registration
Systemic therapy for 12 weeks after primary registration,has_type,DRUG
NCT06135714,tests,Radiation therapy (SBRT/conventional RT)
Radiation therapy (SBRT/conventional RT),has_type,PROCEDURE
NCT06135714,tests,Surgery
Surgery,has_type,PROCEDURE
NCT06135714,tests,Same systemic therapy after secondary registration
Same systemic therapy after secondary registration,has_type,DRUG
NCT06240195,has_title,Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With T
NCT06240195,has_status,RECRUITING
NCT06240195,has_phase,
NCT06240195,sponsored_by,Regina Elena Cancer Institute
NCT06240195,tests,data collection
data collection,has_type,OTHER
NCT02743910,has_title,"Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer"
NCT02743910,has_status,ACTIVE_NOT_RECRUITING
NCT02743910,has_phase,
NCT02743910,sponsored_by,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02743910,tests,ptDNA
ptDNA,has_type,OTHER
NCT02743910,tests,Tissue sample
Tissue sample,has_type,OTHER
NCT01698281,has_title,"A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Met"
NCT01698281,has_status,TERMINATED
NCT01698281,has_phase,
NCT01698281,sponsored_by,AEterna Zentaris
NCT01698281,tests,AEZS-108
AEZS-108,has_type,DRUG
NCT01698281,tests,SCCC
SCCC,has_type,DRUG
NCT01698281,tests,Dexamethasone
Dexamethasone,has_type,DRUG
NCT06084481,has_title,A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid 
NCT06084481,has_status,RECRUITING
NCT06084481,has_phase,
NCT06084481,sponsored_by,AbbVie
NCT06084481,tests,ABBV-400
ABBV-400,has_type,DRUG
NCT01612910,has_title,"A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive,"
NCT01612910,has_status,WITHDRAWN
NCT01612910,has_phase,
NCT01612910,sponsored_by,Barbara Ann Karmanos Cancer Institute
NCT01612910,tests,oral microencapsulated diindolylmethane
oral microencapsulated diindolylmethane,has_type,DRUG
NCT01612910,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT05730010,has_title,Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a 
NCT05730010,has_status,COMPLETED
NCT05730010,has_phase,
NCT05730010,sponsored_by,Indiana University
NCT04061408,has_title,A Phase II Pilot Study of Fractionated Stereotactic Radiotherapy(FSRT) in Breast Cancer Patients Wit
NCT04061408,has_status,UNKNOWN
NCT04061408,has_phase,
NCT04061408,sponsored_by,Fudan University
NCT04061408,tests,Fractionated stereotactic radiotherapy(FSRT)
Fractionated stereotactic radiotherapy(FSRT),has_type,RADIATION
NCT00972023,has_title,A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer
NCT00972023,has_status,TERMINATED
NCT00972023,has_phase,
NCT00972023,sponsored_by,Barbara Ann Karmanos Cancer Institute
NCT00972023,tests,DHEA
DHEA,has_type,DRUG
NCT00972023,tests,Surgical resection
Surgical resection,has_type,PROCEDURE
NCT02838823,has_title,"A Phase I,Open,Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of"
NCT02838823,has_status,COMPLETED
NCT02838823,has_phase,
NCT02838823,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT02838823,tests,humanized anti-PD-1 monoclonal antibody toripalimab
humanized anti-PD-1 monoclonal antibody toripalimab,has_type,BIOLOGICAL
NCT01969643,has_title,"A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in"
NCT01969643,has_status,COMPLETED
NCT01969643,has_phase,
NCT01969643,sponsored_by,Seagen Inc.
NCT01969643,tests,ladiratuzumab vedotin
ladiratuzumab vedotin,has_type,DRUG
NCT01969643,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02779855,has_title,A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple
NCT02779855,has_status,ACTIVE_NOT_RECRUITING
NCT02779855,has_phase,
NCT02779855,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02779855,tests,Talimogene laherparepvec
Talimogene laherparepvec,has_type,BIOLOGICAL
NCT02779855,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04052555,has_title,A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resist
NCT04052555,has_status,ACTIVE_NOT_RECRUITING
NCT04052555,has_phase,
NCT04052555,sponsored_by,National Cancer Institute (NCI)
NCT04052555,tests,Berzosertib
Berzosertib,has_type,DRUG
NCT04052555,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04052555,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT04052555,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04052555,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT05916755,has_title,Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors
NCT05916755,has_status,RECRUITING
NCT05916755,has_phase,
NCT05916755,sponsored_by,Vall d'Hebron Institute of Oncology
NCT05916755,tests,Whole Genome Sequencing
Whole Genome Sequencing,has_type,DIAGNOSTIC_TEST
NCT05916755,tests,RNA-Sequencing
RNA-Sequencing,has_type,DIAGNOSTIC_TEST
NCT05916755,tests,Microbiome analysis
Microbiome analysis,has_type,DIAGNOSTIC_TEST
NCT05916755,tests,ctDNA analysis
ctDNA analysis,has_type,DIAGNOSTIC_TEST
NCT05916755,tests,TCR-β repertoire sequencing
TCR-β repertoire sequencing,has_type,DIAGNOSTIC_TEST
NCT05916755,tests,PBMCs phenotyping
PBMCs phenotyping,has_type,DIAGNOSTIC_TEST
NCT05916755,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05916755,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT06422455,has_title,Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Age
NCT06422455,has_status,RECRUITING
NCT06422455,has_phase,
NCT06422455,sponsored_by,University of Southern California
NCT06422455,tests,Best Practice
Best Practice,has_type,OTHER
NCT06422455,tests,Educational Intervention
Educational Intervention,has_type,OTHER
NCT06422455,tests,Electronic Health Record Review
Electronic Health Record Review,has_type,OTHER
NCT06422455,tests,Genetic Counseling
Genetic Counseling,has_type,OTHER
NCT06422455,tests,Interview
Interview,has_type,OTHER
NCT06422455,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT02284581,has_title,"Evaluation of Medical Treatments (Chemotherapy, Hormonal Therapy and Biological Therapies) in Metast"
NCT02284581,has_status,RECRUITING
NCT02284581,has_phase,
NCT02284581,sponsored_by,Consorzio Oncotech
NCT03613181,has_title,"A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared With Physician's Best Choice"
NCT03613181,has_status,UNKNOWN
NCT03613181,has_phase,
NCT03613181,sponsored_by,Angiochem Inc
NCT03613181,tests,ANG1005
ANG1005,has_type,DRUG
NCT03613181,tests,Physician's Best Choice
Physician's Best Choice,has_type,DRUG
NCT03150810,has_title,"A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination "
NCT03150810,has_status,COMPLETED
NCT03150810,has_phase,
NCT03150810,sponsored_by,BeiGene
NCT03150810,tests,Pamiparib
Pamiparib,has_type,DRUG
NCT03150810,tests,Temozolomide
Temozolomide,has_type,DRUG
NCT00031681,has_title,A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part
NCT00031681,has_status,COMPLETED
NCT00031681,has_phase,
NCT00031681,sponsored_by,National Cancer Institute (NCI)
NCT00031681,tests,7-hydroxystaurosporine
7-hydroxystaurosporine,has_type,DRUG
NCT00031681,tests,irinotecan hydrochloride
irinotecan hydrochloride,has_type,DRUG
NCT00031681,tests,diagnostic laboratory biomarker analysis
diagnostic laboratory biomarker analysis,has_type,OTHER
NCT02575781,has_title,A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors
NCT02575781,has_status,COMPLETED
NCT02575781,has_phase,
NCT02575781,sponsored_by,Sanofi
NCT02575781,tests,SAR428926
SAR428926,has_type,DRUG
NCT01837095,has_title,"A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative "
NCT01837095,has_status,COMPLETED
NCT01837095,has_phase,
NCT01837095,sponsored_by,Polyphor Ltd.
NCT01837095,tests,POL6326
POL6326,has_type,DRUG
NCT02978495,has_title,Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE T
NCT02978495,has_status,COMPLETED
NCT02978495,has_phase,
NCT02978495,sponsored_by,Barretos Cancer Hospital
NCT02978495,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02978495,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02978495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02978495,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02322814,has_title,"A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobi"
NCT02322814,has_status,TERMINATED
NCT02322814,has_phase,
NCT02322814,sponsored_by,Hoffmann-La Roche
NCT02322814,tests,Cobimetinib
Cobimetinib,has_type,DRUG
NCT02322814,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02322814,tests,Placebo
Placebo,has_type,DRUG
NCT02322814,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02322814,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT00483223,has_title,A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evalua
NCT00483223,has_status,COMPLETED
NCT00483223,has_phase,
NCT00483223,sponsored_by,Massachusetts General Hospital
NCT00483223,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT00483223,tests,carboplatin
carboplatin,has_type,DRUG
NCT04068623,has_title,"PERCEPTION Trial Protocol: Comparison of Predictive and Prognostic Capacities of Neutrophil, Lymphoc"
NCT04068623,has_status,RECRUITING
NCT04068623,has_phase,
NCT04068623,sponsored_by,Centre Jean Perrin
NCT04068623,tests,Blood sample
Blood sample,has_type,OTHER
NCT01677455,has_title,An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Br
NCT01677455,has_status,COMPLETED
NCT01677455,has_phase,
NCT01677455,sponsored_by,Synta Pharmaceuticals Corp.
NCT01677455,tests,ganetespib
ganetespib,has_type,DRUG
NCT02802423,has_title,"A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety"
NCT02802423,has_status,NOT_YET_RECRUITING
NCT02802423,has_phase,
NCT02802423,sponsored_by,"BioLite, Inc."
NCT02802423,tests,BLEX 404 Oral Liquid
BLEX 404 Oral Liquid,has_type,DRUG
NCT01281150,has_title,A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Adva
NCT01281150,has_status,COMPLETED
NCT01281150,has_phase,
NCT01281150,sponsored_by,National Cancer Institute (NCI)
NCT01281150,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01281150,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01281150,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01281150,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01281150,tests,Veliparib
Veliparib,has_type,DRUG
NCT05816655,has_title,Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribocic
NCT05816655,has_status,RECRUITING
NCT05816655,has_phase,
NCT05816655,sponsored_by,Korea University Guro Hospital
NCT05816655,tests,Fulvestrant plus AI plus ribociclib
Fulvestrant plus AI plus ribociclib,has_type,DRUG
NCT05816655,tests,AI plus ribociclib
AI plus ribociclib,has_type,DRUG
NCT01194908,has_title,Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabin
NCT01194908,has_status,TERMINATED
NCT01194908,has_phase,
NCT01194908,sponsored_by,Emory University
NCT01194908,tests,"Decitabine, LBH589, Tamoxifen"
"Decitabine, LBH589, Tamoxifen",has_type,DRUG
NCT01391143,has_title,A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
NCT01391143,has_status,COMPLETED
NCT01391143,has_phase,
NCT01391143,sponsored_by,MacroGenics
NCT01391143,tests,MGA271
MGA271,has_type,BIOLOGICAL
NCT05698238,has_title,Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to
NCT05698238,has_status,NOT_YET_RECRUITING
NCT05698238,has_phase,
NCT05698238,sponsored_by,"Mabpro, a.s."
NCT05698238,tests,CA9hu-1
CA9hu-1,has_type,DRUG
NCT03154190,has_title,St. Judes-Stanford Comprehensive Support Initiative
NCT03154190,has_status,COMPLETED
NCT03154190,has_phase,
NCT03154190,sponsored_by,Stanford University
NCT03154190,tests,Best Practice
Best Practice,has_type,OTHER
NCT03154190,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03154190,tests,Supportive Care
Supportive Care,has_type,PROCEDURE
NCT03154190,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT03756090,has_title,A Randomized Study Evaluating the Safety and Effects of the Combination of Palbociclib With Epirubic
NCT03756090,has_status,UNKNOWN
NCT03756090,has_phase,
NCT03756090,sponsored_by,Zhejiang Cancer Hospital
NCT03756090,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT03756090,tests,Placebo oral capsule
Placebo oral capsule,has_type,DRUG
NCT03756090,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03756090,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03756090,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03861403,has_title,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab i
NCT03861403,has_status,TERMINATED
NCT03861403,has_phase,
NCT03861403,sponsored_by,"Leap Therapeutics, Inc."
NCT03861403,tests,TRX518
TRX518,has_type,DRUG
NCT03861403,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03861403,tests,Avelumab
Avelumab,has_type,DRUG
NCT04059003,has_title,Circulating Tumor Cell Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast C
NCT04059003,has_status,UNKNOWN
NCT04059003,has_phase,
NCT04059003,sponsored_by,Shengjing Hospital
NCT04059003,tests,Taxanes or/and anthracycline-based therapy
Taxanes or/and anthracycline-based therapy,has_type,DRUG
NCT00499603,has_title,Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FE
NCT00499603,has_status,UNKNOWN
NCT00499603,has_phase,
NCT00499603,sponsored_by,M.D. Anderson Cancer Center
NCT00499603,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00499603,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT00499603,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT00499603,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00499603,tests,RAD001
RAD001,has_type,DRUG
NCT05089643,has_title,"Anrotinib in Combination With Capecitabine in the Single-arm, Open Phase II Treatment of Relapsed or"
NCT05089643,has_status,UNKNOWN
NCT05089643,has_phase,
NCT05089643,sponsored_by,Chinese Academy of Medical Sciences
NCT05089643,tests,Anlotinib
Anlotinib,has_type,DRUG
NCT05089643,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03206203,has_title,A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Neg
NCT03206203,has_status,COMPLETED
NCT03206203,has_phase,
NCT03206203,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT03206203,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03206203,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03206203,tests,Laboratory Biomarker
Laboratory Biomarker,has_type,OTHER
NCT03206203,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03620643,has_title,"Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobula"
NCT03620643,has_status,ACTIVE_NOT_RECRUITING
NCT03620643,has_phase,
NCT03620643,sponsored_by,Royal Marsden NHS Foundation Trust
NCT03620643,tests,Crizotinib Oral Capsule [Xalkori]
Crizotinib Oral Capsule [Xalkori],has_type,DRUG
NCT03620643,tests,Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic],has_type,DRUG
NCT03291938,has_title,A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Sol
NCT03291938,has_status,COMPLETED
NCT03291938,has_phase,
NCT03291938,sponsored_by,M.D. Anderson Cancer Center
NCT03291938,tests,Oxidative Phosphorylation Inhibitor IACS-010759
Oxidative Phosphorylation Inhibitor IACS-010759,has_type,DRUG
NCT03291938,tests,Pharmacodynamic Study
Pharmacodynamic Study,has_type,OTHER
NCT03291938,tests,Pharmacokinetic Study
Pharmacokinetic Study,has_type,OTHER
NCT04031703,has_title,Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant 
NCT04031703,has_status,COMPLETED
NCT04031703,has_phase,
NCT04031703,sponsored_by,Fudan University
NCT04031703,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04031703,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04031703,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04031703,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04031703,tests,5-fluorouracil
5-fluorouracil,has_type,DRUG
NCT04031703,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05889390,has_title,"[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthe"
NCT05889390,has_status,ACTIVE_NOT_RECRUITING
NCT05889390,has_phase,
NCT05889390,sponsored_by,Semmelweis University
NCT05889390,tests,Oncotherm EHY-2030
Oncotherm EHY-2030,has_type,DEVICE
NCT05889390,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05889390,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05889390,tests,Cyclophosphamide/Doxorubicin
Cyclophosphamide/Doxorubicin,has_type,DRUG
NCT05889390,tests,Breast cancer removal surgery
Breast cancer removal surgery,has_type,PROCEDURE
NCT02834403,has_title,Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally
NCT02834403,has_status,COMPLETED
NCT02834403,has_phase,
NCT02834403,sponsored_by,The Methodist Hospital Research Institute
NCT02834403,tests,L-NMMA
L-NMMA,has_type,DRUG
NCT02834403,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02834403,tests,Amlodipine
Amlodipine,has_type,DRUG
NCT02834403,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT02834403,tests,Enteric-coated aspirin
Enteric-coated aspirin,has_type,DRUG
NCT07038369,has_title,"A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced S"
NCT07038369,has_status,NOT_YET_RECRUITING
NCT07038369,has_phase,
NCT07038369,sponsored_by,"Atavistik Bio, Inc"
NCT07038369,tests,ATV-1601
ATV-1601,has_type,DRUG
NCT07038369,tests,ATV-1601 + Fulvestrant
ATV-1601 + Fulvestrant,has_type,COMBINATION_PRODUCT
NCT02644369,has_title,Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
NCT02644369,has_status,ACTIVE_NOT_RECRUITING
NCT02644369,has_phase,
NCT02644369,sponsored_by,"University Health Network, Toronto"
NCT02644369,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT01617668,has_title,"A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or With"
NCT01617668,has_status,COMPLETED
NCT01617668,has_phase,
NCT01617668,sponsored_by,Novartis Pharmaceuticals
NCT01617668,tests,LCL161
LCL161,has_type,DRUG
NCT01617668,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT05742269,has_title,Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab to Monitor Immune Responses in Metastatic Trip
NCT05742269,has_status,RECRUITING
NCT05742269,has_phase,
NCT05742269,sponsored_by,Karolinska University Hospital
NCT05742269,tests,89Zr-atezolizumab PET/CT
89Zr-atezolizumab PET/CT,has_type,DIAGNOSTIC_TEST
NCT06335069,has_title,18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer - a Pilot Study.
NCT06335069,has_status,NOT_YET_RECRUITING
NCT06335069,has_phase,
NCT06335069,sponsored_by,Maastricht University Medical Center
NCT06335069,tests,68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI
68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI,has_type,DIAGNOSTIC_TEST
NCT03219268,has_title,"A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein B"
NCT03219268,has_status,COMPLETED
NCT03219268,has_phase,
NCT03219268,sponsored_by,MacroGenics
NCT03219268,tests,tebotelimab 1 mg
tebotelimab 1 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 3 mg
tebotelimab 3 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 10 mg
tebotelimab 10 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 30 mg
tebotelimab 30 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 120 mg
tebotelimab 120 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 300 mg
tebotelimab 300 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 400 mg
tebotelimab 400 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 600 mg
tebotelimab 600 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 800 mg
tebotelimab 800 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 1200 mg
tebotelimab 1200 mg,has_type,BIOLOGICAL
NCT03219268,tests,margetuximab
margetuximab,has_type,BIOLOGICAL
NCT01194869,has_title,Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclita
NCT01194869,has_status,TERMINATED
NCT01194869,has_phase,
NCT01194869,sponsored_by,Emory University
NCT01194869,tests,Sorafenib
Sorafenib,has_type,DRUG
NCT01194869,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01194869,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02977468,has_title,Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Ca
NCT02977468,has_status,RECRUITING
NCT02977468,has_phase,
NCT02977468,sponsored_by,Eileen Connolly
NCT02977468,tests,Merck 3475 Pembrolizumab
Merck 3475 Pembrolizumab,has_type,DRUG
NCT02977468,tests,Intraoperative radiation therapy (IORT)
Intraoperative radiation therapy (IORT),has_type,RADIATION
NCT01057069,has_title,Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breas
NCT01057069,has_status,ACTIVE_NOT_RECRUITING
NCT01057069,has_phase,
NCT01057069,sponsored_by,The Netherlands Cancer Institute
NCT01057069,tests,Carboplatin and Paclitaxel
Carboplatin and Paclitaxel,has_type,DRUG
NCT01057069,tests,"Doxorubicin, cyclophosphamide"
"Doxorubicin, cyclophosphamide",has_type,DRUG
NCT01057069,tests,"Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide"
"Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide",has_type,DRUG
NCT05929768,has_title,Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Nega
NCT05929768,has_status,RECRUITING
NCT05929768,has_phase,
NCT05929768,sponsored_by,SWOG Cancer Research Network
NCT05929768,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05929768,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05929768,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05929768,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05929768,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05929768,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05929768,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05929768,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT05929768,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT05929768,tests,Surgical Procedure
Surgical Procedure,has_type,PROCEDURE
NCT06931769,has_title,TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
NCT06931769,has_status,NOT_YET_RECRUITING
NCT06931769,has_phase,
NCT06931769,sponsored_by,The Netherlands Cancer Institute
NCT06465069,has_title,"A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants Wit"
NCT06465069,has_status,SUSPENDED
NCT06465069,has_phase,
NCT06465069,sponsored_by,Eli Lilly and Company
NCT06465069,tests,LY4052031
LY4052031,has_type,DRUG
NCT05099068,has_title,A Prospective Longitudinal Profiling Program of Cancer Patients With Sequential Tumor and Liquid Bio
NCT05099068,has_status,RECRUITING
NCT05099068,has_phase,
NCT05099068,sponsored_by,Centre Leon Berard
NCT05099068,tests,Blood and tumor samples
Blood and tumor samples,has_type,BIOLOGICAL
NCT02120469,has_title,Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cance
NCT02120469,has_status,COMPLETED
NCT02120469,has_phase,
NCT02120469,sponsored_by,City of Hope Medical Center
NCT02120469,tests,everolimus
everolimus,has_type,DRUG
NCT02120469,tests,eribulin mesylate
eribulin mesylate,has_type,DRUG
NCT02120469,tests,pharmacological study
pharmacological study,has_type,OTHER
NCT02120469,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02957968,has_title,T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast C
NCT02957968,has_status,ACTIVE_NOT_RECRUITING
NCT02957968,has_phase,
NCT02957968,sponsored_by,Virginia Commonwealth University
NCT02957968,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02957968,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02957968,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02957968,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02957968,tests,Decitabine
Decitabine,has_type,DRUG
NCT02957968,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03974204,has_title,Benefit of Analyzing Exosomes in the Cerebrospinal Fluid During the Medical Care of Breast Cancer Pa
NCT03974204,has_status,WITHDRAWN
NCT03974204,has_phase,
NCT03974204,sponsored_by,Centre Oscar Lambret
NCT03974204,tests,Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment
Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment,has_type,PROCEDURE
NCT03974204,tests,"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification"
"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification",has_type,PROCEDURE
NCT03974204,tests,"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment"
"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment",has_type,PROCEDURE
NCT03358004,has_title,"An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Tw"
NCT03358004,has_status,TERMINATED
NCT03358004,has_phase,
NCT03358004,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT03358004,tests,Vinorelbine Tartrate
Vinorelbine Tartrate,has_type,DRUG
NCT03358004,tests,Capecitabine 500 MG
Capecitabine 500 MG,has_type,DRUG
NCT02768701,has_title,Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Neg
NCT02768701,has_status,COMPLETED
NCT02768701,has_phase,
NCT02768701,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT02768701,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02768701,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02755272,has_title,A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in
NCT02755272,has_status,ACTIVE_NOT_RECRUITING
NCT02755272,has_phase,
NCT02755272,sponsored_by,Fox Chase Cancer Center
NCT02755272,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02755272,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02755272,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04265872,has_title,Pilot Clinical Trial of Treatment With Bortezomib to Inhibit Homologous Recombination (HR) Followed 
NCT04265872,has_status,RECRUITING
NCT04265872,has_phase,
NCT04265872,sponsored_by,Baylor Research Institute
NCT04265872,tests,Bortezomib
Bortezomib,has_type,DRUG
NCT06879704,has_title,"Quadrimodal Radiological Prediction (Ultrasound, Angiography/Mammography, Magnetic Rsonance Imaging,"
NCT06879704,has_status,NOT_YET_RECRUITING
NCT06879704,has_phase,
NCT06879704,sponsored_by,Centre Henri Becquerel
NCT06879704,tests,Imaging assessment
Imaging assessment,has_type,OTHER
NCT02513472,has_title,"An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribul"
NCT02513472,has_status,COMPLETED
NCT02513472,has_phase,
NCT02513472,sponsored_by,Eisai Inc.
NCT02513472,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT02513472,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT00608972,has_title,"A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metas"
NCT00608972,has_status,COMPLETED
NCT00608972,has_phase,
NCT00608972,sponsored_by,"Rutgers, The State University of New Jersey"
NCT00608972,tests,Doxil
Doxil,has_type,DRUG
NCT00608972,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00608972,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01421472,has_title,"A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer"
NCT01421472,has_status,COMPLETED
NCT01421472,has_phase,
NCT01421472,sponsored_by,Merrimack Pharmaceuticals
NCT01421472,tests,MM-121
MM-121,has_type,DRUG
NCT01421472,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05490472,has_title,"A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics,"
NCT05490472,has_status,RECRUITING
NCT05490472,has_phase,
NCT05490472,sponsored_by,"Jacobio Pharmaceuticals Co., Ltd."
NCT05490472,tests,JAB-2485 (Aurora A inhibitor)
JAB-2485 (Aurora A inhibitor),has_type,DRUG
NCT05490472,tests,JAB-2485 (Aurora A inhibitor)
JAB-2485 (Aurora A inhibitor),has_type,DRUG
NCT02595372,has_title,Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
NCT02595372,has_status,COMPLETED
NCT02595372,has_phase,
NCT02595372,sponsored_by,Kathy Miller
NCT02595372,tests,Omeprazole
Omeprazole,has_type,DRUG
NCT01045304,has_title,"Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibit"
NCT01045304,has_status,COMPLETED
NCT01045304,has_phase,
NCT01045304,sponsored_by,Sanofi
NCT01045304,tests,Iniparib
Iniparib,has_type,DRUG
NCT01045304,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01045304,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00894504,has_title,"A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast C"
NCT00894504,has_status,COMPLETED
NCT00894504,has_phase,
NCT00894504,sponsored_by,"SCRI Development Innovations, LLC"
NCT00894504,tests,Panitumumab
Panitumumab,has_type,DRUG
NCT00894504,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00894504,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06433804,has_title,Exploring the Clinicopathological Parameters of HER2 Low Breast Cancers
NCT06433804,has_status,COMPLETED
NCT06433804,has_phase,
NCT06433804,sponsored_by,Vardhman Mahavir Medical College And Safdarjung Hospital
NCT06433804,tests,HER2 IHC
HER2 IHC,has_type,DIAGNOSTIC_TEST
NCT03829501,has_title,"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and"
NCT03829501,has_status,TERMINATED
NCT03829501,has_phase,
NCT03829501,sponsored_by,Kymab Limited
NCT03829501,tests,Alomfilimab
Alomfilimab,has_type,DRUG
NCT03829501,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04762901,has_title,LCI-BRE-MTN-NIR-001: A Phase I Study of Niraparib in Combination With Standard Chemotherapy in Metas
NCT04762901,has_status,WITHDRAWN
NCT04762901,has_phase,
NCT04762901,sponsored_by,Wake Forest University Health Sciences
NCT04762901,tests,Niraparib
Niraparib,has_type,DRUG
NCT04762901,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04762901,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04762901,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04762901,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT04762901,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05581004,has_title,"A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokineti"
NCT05581004,has_status,RECRUITING
NCT05581004,has_phase,
NCT05581004,sponsored_by,"Genentech, Inc."
NCT05581004,tests,RO7502175
RO7502175,has_type,DRUG
NCT05581004,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT05581004,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04314401,has_title,Cancer Moonshot Biobank Research Protocol
NCT04314401,has_status,RECRUITING
NCT04314401,has_phase,
NCT04314401,sponsored_by,National Cancer Institute (NCI)
NCT04314401,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04314401,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT04314401,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT04314401,tests,Medical Chart Review
Medical Chart Review,has_type,OTHER
NCT04314401,tests,Paracentesis
Paracentesis,has_type,PROCEDURE
NCT04314401,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT04123704,has_title,"A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer"
NCT04123704,has_status,TERMINATED
NCT04123704,has_phase,
NCT04123704,sponsored_by,Xiang Zhang
NCT04123704,tests,Sitravatinib
Sitravatinib,has_type,DRUG
NCT04297267,has_title,"A Prospective, Single Arm, Multicenter, Phase II Trial of Gemcitabine Plus Cisplatin in the Treatmen"
NCT04297267,has_status,UNKNOWN
NCT04297267,has_phase,
NCT04297267,sponsored_by,Fudan University
NCT04297267,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04297267,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT06974604,has_title,Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HE
NCT06974604,has_status,NOT_YET_RECRUITING
NCT06974604,has_phase,
NCT06974604,sponsored_by,Brown University
NCT06974604,tests,Dexamethasone oral
Dexamethasone oral,has_type,DRUG
NCT02202746,has_title,"A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF"
NCT02202746,has_status,TERMINATED
NCT02202746,has_phase,
NCT02202746,sponsored_by,"Clovis Oncology, Inc."
NCT02202746,tests,Lucitanib
Lucitanib,has_type,DRUG
NCT04335669,has_title,A Translational Randomized Phase III Study Exploring the Effect of the Addition of Capecitabine to C
NCT04335669,has_status,RECRUITING
NCT04335669,has_phase,
NCT04335669,sponsored_by,Lund University Hospital
NCT04335669,tests,"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab"
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",has_type,DRUG
NCT04335669,tests,"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab"
"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",has_type,DRUG
NCT01276769,has_title,Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Trea
NCT01276769,has_status,UNKNOWN
NCT01276769,has_phase,
NCT01276769,sponsored_by,Chinese Academy of Medical Sciences
NCT01276769,tests,Paclitaxel plus carboplatin
Paclitaxel plus carboplatin,has_type,DRUG
NCT01276769,tests,Paclitaxel and epirubicin
Paclitaxel and epirubicin,has_type,DRUG
NCT06598046,has_title,"A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Trea"
NCT06598046,has_status,RECRUITING
NCT06598046,has_phase,
NCT06598046,sponsored_by,Henan Cancer Hospital
NCT06598046,tests,Utidelone and capecitabine
Utidelone and capecitabine,has_type,DRUG
NCT03303846,has_title,Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
NCT03303846,has_status,ACTIVE_NOT_RECRUITING
NCT03303846,has_phase,
NCT03303846,sponsored_by,City of Hope Medical Center
NCT03303846,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03303846,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT03303846,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT04504669,has_title,"A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Effica"
NCT04504669,has_status,COMPLETED
NCT04504669,has_phase,
NCT04504669,sponsored_by,AstraZeneca
NCT04504669,tests,AZD8701
AZD8701,has_type,DRUG
NCT04504669,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT04001569,has_title,Phase1b/2 Study of AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer
NCT04001569,has_status,UNKNOWN
NCT04001569,has_phase,
NCT04001569,sponsored_by,Seoul National University Bundang Hospital
NCT04001569,tests,AZD8186 in combination with paclitaxel
AZD8186 in combination with paclitaxel,has_type,DRUG
NCT04606472,has_title,"Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pre"
NCT04606472,has_status,RECRUITING
NCT04606472,has_phase,
NCT04606472,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT04606472,tests,SI-B003
SI-B003,has_type,DRUG
NCT02484404,has_title,Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination
NCT02484404,has_status,ACTIVE_NOT_RECRUITING
NCT02484404,has_phase,
NCT02484404,sponsored_by,National Cancer Institute (NCI)
NCT02484404,tests,Olaparib
Olaparib,has_type,DRUG
NCT02484404,tests,Cediranib
Cediranib,has_type,DRUG
NCT02484404,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03076372,has_title,"A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients W"
NCT03076372,has_status,UNKNOWN
NCT03076372,has_phase,
NCT03076372,sponsored_by,Merrimack Pharmaceuticals
NCT03076372,tests,MM-310
MM-310,has_type,DRUG
NCT06400472,has_title,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of L"
NCT06400472,has_status,RECRUITING
NCT06400472,has_phase,
NCT06400472,sponsored_by,Eli Lilly and Company
NCT06400472,tests,LY4170156
LY4170156,has_type,DRUG
NCT06400472,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT06400472,tests,carboplatin
carboplatin,has_type,DRUG
NCT03579472,has_title,A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TN
NCT03579472,has_status,TERMINATED
NCT03579472,has_phase,
NCT03579472,sponsored_by,M.D. Anderson Cancer Center
NCT03579472,tests,Bintrafusp Alfa
Bintrafusp Alfa,has_type,DRUG
NCT03579472,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT03997968,has_title,"A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell M"
NCT03997968,has_status,COMPLETED
NCT03997968,has_phase,
NCT03997968,sponsored_by,"Cyteir Therapeutics, Inc."
NCT03997968,tests,CYT-0851
CYT-0851,has_type,DRUG
NCT03997968,tests,CYT-0851 in combination with gemcitabine
CYT-0851 in combination with gemcitabine,has_type,DRUG
NCT03997968,tests,CYT-0851 in combination with capecitabine
CYT-0851 in combination with capecitabine,has_type,DRUG
NCT03997968,tests,CYT-0851 in combination with rituximab and bendamustine
CYT-0851 in combination with rituximab and bendamustine,has_type,DRUG
NCT04981119,has_title,An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell T
NCT04981119,has_status,RECRUITING
NCT04981119,has_phase,
NCT04981119,sponsored_by,A2 Biotherapeutics Inc.
NCT04981119,tests,Apheresis
Apheresis,has_type,OTHER
NCT04981119,tests,Next Generation Sequencing (NGS)
Next Generation Sequencing (NGS),has_type,DIAGNOSTIC_TEST
NCT04981119,tests,Long Range NGS HLA typing
Long Range NGS HLA typing,has_type,DIAGNOSTIC_TEST
NCT04722718,has_title,Efficacy and Safety of Neoadjuvant Therapy With Sintilimab and Apatinib Combined Chemotherapy in Tri
NCT04722718,has_status,UNKNOWN
NCT04722718,has_phase,
NCT04722718,sponsored_by,Jiuda Zhao
NCT04722718,tests,Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin,has_type,DRUG
NCT06768931,has_title,"A Multicenter, Randomized Controlled Phase II Clinical Study of Standard Neoadjuvant Therapy Combine"
NCT06768931,has_status,RECRUITING
NCT06768931,has_phase,
NCT06768931,sponsored_by,Sun Yat-sen University
NCT06768931,tests,Biolosion (oral probiotic compound preparation)
Biolosion (oral probiotic compound preparation),has_type,OTHER
NCT02637531,has_title,"A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokin"
NCT02637531,has_status,UNKNOWN
NCT02637531,has_phase,
NCT02637531,sponsored_by,"Infinity Pharmaceuticals, Inc."
NCT02637531,tests,IPI-549 (eganelisib)
IPI-549 (eganelisib),has_type,DRUG
NCT02637531,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03720431,has_title,"A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab"
NCT03720431,has_status,UNKNOWN
NCT03720431,has_phase,
NCT03720431,sponsored_by,PharmAbcine
NCT03720431,tests,TTAC-0001 and pembrolizumab combination
TTAC-0001 and pembrolizumab combination,has_type,DRUG
NCT06545331,has_title,A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects
NCT06545331,has_status,RECRUITING
NCT06545331,has_phase,
NCT06545331,sponsored_by,Exelixis
NCT06545331,tests,XB010
XB010,has_type,DRUG
NCT06545331,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05466760,has_title,"Use of PET/MR Radiomics to Evaluate the Clinical Phenotypes, Response Status of Neoadjuvant Chemothe"
NCT05466760,has_status,UNKNOWN
NCT05466760,has_phase,
NCT05466760,sponsored_by,"Taipei Veterans General Hospital, Taiwan"
NCT05466760,tests,PET/MR
PET/MR,has_type,RADIATION
NCT03875313,has_title,"A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in "
NCT03875313,has_status,TERMINATED
NCT03875313,has_phase,
NCT03875313,sponsored_by,"Calithera Biosciences, Inc"
NCT03875313,tests,CB-839
CB-839,has_type,DRUG
NCT03875313,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04025216,has_title,"A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chim"
NCT04025216,has_status,TERMINATED
NCT04025216,has_phase,
NCT04025216,sponsored_by,"Kite, A Gilead Company"
NCT04025216,tests,CART-TnMUC1
CART-TnMUC1,has_type,BIOLOGICAL
NCT04025216,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04025216,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT03393416,has_title,"A Single Center, Phase I Clinical Study to Evaluate the Safety of MASCT-I Combined With PD1 Antibody"
NCT03393416,has_status,UNKNOWN
NCT03393416,has_phase,
NCT03393416,sponsored_by,HRYZ Biotech Co.
NCT03393416,tests,MASCT-I
MASCT-I,has_type,BIOLOGICAL
NCT03393416,tests,PD1 antibody
PD1 antibody,has_type,DRUG
NCT04243616,has_title,Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )
NCT04243616,has_status,ACTIVE_NOT_RECRUITING
NCT04243616,has_phase,
NCT04243616,sponsored_by,Medical College of Wisconsin
NCT04243616,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT04243616,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04243616,tests,Carboplatin (not mandatory)
Carboplatin (not mandatory),has_type,DRUG
NCT04243616,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04243616,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04102618,has_title,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)
NCT04102618,has_status,TERMINATED
NCT04102618,has_phase,
NCT04102618,sponsored_by,Oncolytics Biotech
NCT04102618,tests,Pelareorep
Pelareorep,has_type,BIOLOGICAL
NCT04102618,tests,Letrozole
Letrozole,has_type,DRUG
NCT04102618,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04102618,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT01141530,has_title,Deep Sequencing of the Breast Cancer Transcriptome
NCT01141530,has_status,WITHDRAWN
NCT01141530,has_phase,
NCT01141530,sponsored_by,University of Arkansas
NCT01141530,tests,No intervention
No intervention,has_type,OTHER
NCT04699630,has_title,A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer
NCT04699630,has_status,COMPLETED
NCT04699630,has_phase,
NCT04699630,sponsored_by,"SCRI Development Innovations, LLC"
NCT04699630,tests,U3-1402
U3-1402,has_type,DRUG
NCT04039230,has_title,Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP 
NCT04039230,has_status,RECRUITING
NCT04039230,has_phase,
NCT04039230,sponsored_by,Massachusetts General Hospital
NCT04039230,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04039230,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT02616848,has_title,
NCT02616848,has_status,UNKNOWN
NCT02616848,has_phase,
NCT02616848,sponsored_by,Istituti Ospitalieri di Cremona
NCT02616848,tests,Everolimus
Everolimus,has_type,DRUG
NCT02616848,tests,Eribulin
Eribulin,has_type,DRUG
NCT06845319,has_title,Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients With Ca
NCT06845319,has_status,NOT_YET_RECRUITING
NCT06845319,has_phase,
NCT06845319,sponsored_by,Medical University of South Carolina
NCT06845319,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06845319,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06845319,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06195618,has_title,ESTUDIO CLÍNICO FASE I DE INMUNOTERAPIA CON VACUNAS SINTÉTICAS PERSONALIZADAS EN PACIENTES CON CÁNCE
NCT06195618,has_status,NOT_YET_RECRUITING
NCT06195618,has_phase,
NCT06195618,sponsored_by,Universidad Nacional de Colombia
NCT06195618,tests,Peptide (neoantigen) pulsed autologous Dendritic cell
Peptide (neoantigen) pulsed autologous Dendritic cell,has_type,BIOLOGICAL
NCT03733119,has_title,ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
NCT03733119,has_status,TERMINATED
NCT03733119,has_phase,
NCT03733119,sponsored_by,"University of Wisconsin, Madison"
NCT03733119,tests,Akt/ERK Inhibitor ONC201
Akt/ERK Inhibitor ONC201,has_type,DRUG
NCT03733119,tests,Methionine-Restricted Diet
Methionine-Restricted Diet,has_type,DIETARY_SUPPLEMENT
NCT06526819,has_title,"An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerabili"
NCT06526819,has_status,RECRUITING
NCT06526819,has_phase,
NCT06526819,sponsored_by,"Sumitomo Pharma America, Inc."
NCT06526819,tests,SMP3124LP
SMP3124LP,has_type,DRUG
NCT02819518,has_title,"A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo "
NCT02819518,has_status,COMPLETED
NCT02819518,has_phase,
NCT02819518,sponsored_by,Merck Sharp & Dohme LLC
NCT02819518,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02819518,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02819518,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02819518,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02819518,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02819518,tests,Normale Saline Solution
Normale Saline Solution,has_type,DRUG
NCT01351103,has_title,"A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent "
NCT01351103,has_status,COMPLETED
NCT01351103,has_phase,
NCT01351103,sponsored_by,Novartis Pharmaceuticals
NCT01351103,tests,LGK974
LGK974,has_type,DRUG
NCT01351103,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT05198843,has_title,Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative I
NCT05198843,has_status,TERMINATED
NCT05198843,has_phase,
NCT05198843,sponsored_by,National Cancer Institute (NCI)
NCT05198843,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT05198843,tests,Icosapent Ethyl
Icosapent Ethyl,has_type,DIETARY_SUPPLEMENT
NCT03002103,has_title,"An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®"
NCT03002103,has_status,SUSPENDED
NCT03002103,has_phase,
NCT03002103,sponsored_by,"SynCore Biotechnology Co., Ltd."
NCT03002103,tests,EndoTAG-1
EndoTAG-1,has_type,DRUG
NCT03002103,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03002103,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT02447003,has_title,A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B
NCT02447003,has_status,COMPLETED
NCT02447003,has_phase,
NCT02447003,sponsored_by,Merck Sharp & Dohme LLC
NCT02447003,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02276443,has_title,ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival
NCT02276443,has_status,RECRUITING
NCT02276443,has_phase,
NCT02276443,sponsored_by,M.D. Anderson Cancer Center
NCT02276443,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT02276443,tests,Immunotherapy
Immunotherapy,has_type,OTHER
NCT02276443,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02276443,tests,Lymph Node Biopsy
Lymph Node Biopsy,has_type,PROCEDURE
NCT02276443,tests,Ultrasonography
Ultrasonography,has_type,PROCEDURE
NCT01849250,has_title,A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Canc
NCT01849250,has_status,COMPLETED
NCT01849250,has_phase,
NCT01849250,sponsored_by,National Cancer Institute (NCI)
NCT01849250,tests,Docosahexaenoic Acid
Docosahexaenoic Acid,has_type,DRUG
NCT01849250,tests,Placebo
Placebo,has_type,OTHER
NCT03098550,has_title,Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum
NCT03098550,has_status,COMPLETED
NCT03098550,has_phase,
NCT03098550,sponsored_by,Bristol-Myers Squibb
NCT03098550,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03098550,tests,Daratumumab
Daratumumab,has_type,BIOLOGICAL
NCT05654623,has_title,"A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PART"
NCT05654623,has_status,ACTIVE_NOT_RECRUITING
NCT05654623,has_phase,
NCT05654623,sponsored_by,Pfizer
NCT05654623,tests,ARV-471
ARV-471,has_type,DRUG
NCT05654623,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04130750,has_title,Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug 
NCT04130750,has_status,UNKNOWN
NCT04130750,has_phase,
NCT04130750,sponsored_by,Peking University People's Hospital
NCT04130750,tests,treatment of drug screening
treatment of drug screening,has_type,COMBINATION_PRODUCT
NCT03301350,has_title,A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosp
NCT03301350,has_status,COMPLETED
NCT03301350,has_phase,
NCT03301350,sponsored_by,"University of Wisconsin, Madison"
NCT03301350,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03301350,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03301350,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT03301350,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03301350,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT03301350,tests,Filgrastim
Filgrastim,has_type,DRUG
NCT05445050,has_title,Development of Motion-Model Ultrasound Localization Microscopy to Support Breast Cancer Diagnosis an
NCT05445050,has_status,RECRUITING
NCT05445050,has_phase,
NCT05445050,sponsored_by,RWTH Aachen University
NCT05445050,tests,Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)
Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS),has_type,DIAGNOSTIC_TEST
NCT03243838,has_title,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative B
NCT03243838,has_status,COMPLETED
NCT03243838,has_phase,
NCT03243838,sponsored_by,Guangdong Provincial People's Hospital
NCT03243838,tests,Apatinib
Apatinib,has_type,DRUG
NCT02476955,has_title,An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects 
NCT02476955,has_status,TERMINATED
NCT02476955,has_phase,
NCT02476955,sponsored_by,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)"
NCT02476955,tests,ARQ 092 + carboplatin + paclitaxel (Closed)
ARQ 092 + carboplatin + paclitaxel (Closed),has_type,DRUG
NCT02476955,tests,ARQ 092 + paclitaxel (Closed)
ARQ 092 + paclitaxel (Closed),has_type,DRUG
NCT02476955,tests,ARQ 092 + anastrozole
ARQ 092 + anastrozole,has_type,DRUG
NCT07046455,has_title,Translational Research on the Construction of Trop-2 Targeted PET Probes and Their Application in Ad
NCT07046455,has_status,RECRUITING
NCT07046455,has_phase,
NCT07046455,sponsored_by,Peking University Cancer Hospital & Institute
NCT07046455,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
NCT06831955,has_title,The LESLIE Trial: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Systemic Therapy in Pati
NCT06831955,has_status,NOT_YET_RECRUITING
NCT06831955,has_phase,
NCT06831955,sponsored_by,Universitaire Ziekenhuizen KU Leuven
NCT06831955,tests,Exercise Therapy
Exercise Therapy,has_type,OTHER
NCT06831955,tests,Fasting-Mimicking Diet
Fasting-Mimicking Diet,has_type,DIETARY_SUPPLEMENT
NCT06831955,tests,SOC
SOC,has_type,DRUG
NCT05722795,has_title,Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer
NCT05722795,has_status,RECRUITING
NCT05722795,has_phase,
NCT05722795,sponsored_by,Vastra Gotaland Region
NCT05722795,tests,Imatinib 400 MG Oral Tablet
Imatinib 400 MG Oral Tablet,has_type,DRUG
NCT01957514,has_title,Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Tri
NCT01957514,has_status,TERMINATED
NCT01957514,has_phase,
NCT01957514,sponsored_by,University of Washington
NCT01957514,tests,Cytology Specimen Collection Procedure
Cytology Specimen Collection Procedure,has_type,OTHER
NCT01957514,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01957514,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT01957514,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT05694364,has_title,A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Adv
NCT05694364,has_status,ACTIVE_NOT_RECRUITING
NCT05694364,has_phase,
NCT05694364,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05694364,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05694364,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05694364,tests,PRGN-3007
PRGN-3007,has_type,BIOLOGICAL
NCT04508803,has_title,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer: a muLti-centEr Pha
NCT04508803,has_status,COMPLETED
NCT04508803,has_phase,
NCT04508803,sponsored_by,Fudan University
NCT04508803,tests,HX008，Niraparib
HX008，Niraparib,has_type,DRUG
NCT04508803,tests,HX008，Niraparib
HX008，Niraparib,has_type,DRUG
NCT04508803,tests,HX008，Niraparib，Trastuzumab
HX008，Niraparib，Trastuzumab,has_type,DRUG
NCT04508803,tests,HX008，Niraparib，Pyrrolitinib
HX008，Niraparib，Pyrrolitinib,has_type,DRUG
NCT04365803,has_title,Comparison Between Histological VABB and Histological Post-surgery in Patient With Complete Patholog
NCT04365803,has_status,UNKNOWN
NCT04365803,has_phase,
NCT04365803,sponsored_by,European Institute of Oncology
NCT04365803,tests,vacuum-assisted breast biopsy
vacuum-assisted breast biopsy,has_type,PROCEDURE
NCT02688803,has_title,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three
NCT02688803,has_status,COMPLETED
NCT02688803,has_phase,
NCT02688803,sponsored_by,Ottawa Hospital Research Institute
NCT02688803,tests,Dose dense AC-P
Dose dense AC-P,has_type,DRUG
NCT02688803,tests,Dose dense AC
Dose dense AC,has_type,DRUG
NCT02688803,tests,FEC-D
FEC-D,has_type,DRUG
NCT06309290,has_title,Prehabilitation Based on Resistance-exercise Training in Women With Breast Cancer Undergoing Neoadju
NCT06309290,has_status,RECRUITING
NCT06309290,has_phase,
NCT06309290,sponsored_by,Universidad de La Frontera
NCT06309290,tests,Prehabilitation with resistance-exercise training
Prehabilitation with resistance-exercise training,has_type,OTHER
NCT06309290,tests,Usual care program
Usual care program,has_type,OTHER
NCT02926690,has_title,"A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics"
NCT02926690,has_status,ACTIVE_NOT_RECRUITING
NCT02926690,has_phase,
NCT02926690,sponsored_by,"OncoTherapy Science, Inc."
NCT02926690,tests,OTS167PO
OTS167PO,has_type,DRUG
NCT01587703,has_title,"A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmaco"
NCT01587703,has_status,COMPLETED
NCT01587703,has_phase,
NCT01587703,sponsored_by,GlaxoSmithKline
NCT01587703,tests,GSK525762
GSK525762,has_type,DRUG
NCT04192903,has_title,Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
NCT04192903,has_status,UNKNOWN
NCT04192903,has_phase,
NCT04192903,sponsored_by,Fudan University
NCT04192903,tests,Chidamide combined with Cisplatin
Chidamide combined with Cisplatin,has_type,DRUG
NCT06612203,has_title,Phase Ib/II Study to Evaluate Safety and Preliminary Efficacy of the Wee1 Inhibitor Debio 0123 in Co
NCT06612203,has_status,RECRUITING
NCT06612203,has_phase,
NCT06612203,sponsored_by,MedSIR
NCT06612203,tests,Debio 0123 and Sacituzumab govitecan
Debio 0123 and Sacituzumab govitecan,has_type,DRUG
NCT02423603,has_title,"A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combi"
NCT02423603,has_status,COMPLETED
NCT02423603,has_phase,
NCT02423603,sponsored_by,Queen Mary University of London
NCT02423603,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02423603,tests,AZD5363
AZD5363,has_type,DRUG
NCT02423603,tests,Placebo
Placebo,has_type,DRUG
NCT05609903,has_title,Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr
NCT05609903,has_status,COMPLETED
NCT05609903,has_phase,
NCT05609903,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05609903,tests,Atezolizumab in combination with nab-paclitaxel
Atezolizumab in combination with nab-paclitaxel,has_type,DRUG
NCT05005403,has_title,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single"
NCT05005403,has_status,RECRUITING
NCT05005403,has_phase,
NCT05005403,sponsored_by,AbbVie
NCT05005403,tests,Azirkitug
Azirkitug,has_type,DRUG
NCT05005403,tests,Budigalimab
Budigalimab,has_type,DRUG
NCT05005403,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT06795503,has_title,Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
NCT06795503,has_status,NOT_YET_RECRUITING
NCT06795503,has_phase,
NCT06795503,sponsored_by,Fudan University
NCT06795503,tests,Docetaxel plus cyclophosphamide
Docetaxel plus cyclophosphamide,has_type,DRUG
NCT06795503,tests,"Epirubicin, cyclophosphamide plus paclitaxel"
"Epirubicin, cyclophosphamide plus paclitaxel",has_type,DRUG
NCT06385990,has_title,Clinical Study of the Efficacy and Safety of Utidelone (UTD1) Combined With Capecitabine as Adjuvant
NCT06385990,has_status,RECRUITING
NCT06385990,has_phase,
NCT06385990,sponsored_by,Hunan Cancer Hospital
NCT06385990,tests,UTD1
UTD1,has_type,DRUG
NCT07054190,has_title,"A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatmen"
NCT07054190,has_status,NOT_YET_RECRUITING
NCT07054190,has_phase,
NCT07054190,sponsored_by,Hoffmann-La Roche
NCT07054190,tests,Inavolisib
Inavolisib,has_type,DRUG
NCT07054190,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT07054190,tests,Letrozole
Letrozole,has_type,DRUG
NCT05132790,has_title,Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neo
NCT05132790,has_status,ACTIVE_NOT_RECRUITING
NCT05132790,has_phase,
NCT05132790,sponsored_by,Shengjing Hospital
NCT05132790,tests,SHR-1316 at a dose 20mg/kg q3w
SHR-1316 at a dose 20mg/kg q3w,has_type,DRUG
NCT05132790,tests,"SHR6390 at a dose of 150mg orally, daily"
"SHR6390 at a dose of 150mg orally, daily",has_type,DRUG
NCT05132790,tests,SBRT
SBRT,has_type,RADIATION
NCT04849364,has_title,"A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients "
NCT04849364,has_status,TERMINATED
NCT04849364,has_phase,
NCT04849364,sponsored_by,"Bryan Schneider, MD"
NCT04849364,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04849364,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04849364,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04849364,tests,Inavolisib
Inavolisib,has_type,DRUG
NCT05862064,has_title,"A Single-center, Randomized, Open-label, Phase III Study Comparing PD-1 Combined With Anthracycline/"
NCT05862064,has_status,RECRUITING
NCT05862064,has_phase,
NCT05862064,sponsored_by,Fudan University
NCT05862064,tests,"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab"
"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab",has_type,DRUG
NCT05862064,tests,"epirubicin,cyclophosphamide,paclitaxel"
"epirubicin,cyclophosphamide,paclitaxel",has_type,DRUG
NCT03997123,has_title,A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclita
NCT03997123,has_status,ACTIVE_NOT_RECRUITING
NCT03997123,has_phase,
NCT03997123,sponsored_by,AstraZeneca
NCT03997123,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT03997123,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03997123,tests,Placebo
Placebo,has_type,DRUG
NCT03650738,has_title,"A Prospective, One-arm Open Clinical Trial of Apatinib Combined With Albumin Paclitaxel and Carbopla"
NCT03650738,has_status,UNKNOWN
NCT03650738,has_phase,
NCT03650738,sponsored_by,The First Affiliated Hospital with Nanjing Medical University
NCT03650738,tests,Apatinib
Apatinib,has_type,DRUG
NCT05445908,has_title,A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanc
NCT05445908,has_status,UNKNOWN
NCT05445908,has_phase,
NCT05445908,sponsored_by,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
NCT05445908,tests,SKB264
SKB264,has_type,DRUG
NCT05445908,tests,KL-A167
KL-A167,has_type,DRUG
NCT03979508,has_title,"Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breas"
NCT03979508,has_status,RECRUITING
NCT03979508,has_phase,
NCT03979508,sponsored_by,Mayo Clinic
NCT03979508,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT03979508,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT03449108,has_title,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured 
NCT03449108,has_status,ACTIVE_NOT_RECRUITING
NCT03449108,has_phase,
NCT03449108,sponsored_by,M.D. Anderson Cancer Center
NCT03449108,tests,Aldesleukin
Aldesleukin,has_type,BIOLOGICAL
NCT03449108,tests,Autologous Tumor Infiltrating Lymphocytes LN-145
Autologous Tumor Infiltrating Lymphocytes LN-145,has_type,BIOLOGICAL
NCT03449108,tests,Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,has_type,BIOLOGICAL
NCT03449108,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03449108,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT03449108,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT03449108,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03449108,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03449108,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT06732323,has_title,"A Randomized, Open-label, Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy as Fir"
NCT06732323,has_status,NOT_YET_RECRUITING
NCT06732323,has_phase,
NCT06732323,sponsored_by,"Qilu Pharmaceutical Co., Ltd."
NCT06732323,tests,ESG401
ESG401,has_type,DRUG
NCT06732323,tests,Investigator's Choice Chemotherapy
Investigator's Choice Chemotherapy,has_type,DRUG
NCT06210438,has_title,SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases：a Prospec
NCT06210438,has_status,NOT_YET_RECRUITING
NCT06210438,has_phase,
NCT06210438,sponsored_by,Fudan University
NCT06210438,tests,SHR-A1921 + Bevacizumab
SHR-A1921 + Bevacizumab,has_type,DRUG
NCT00603408,has_title,Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Br
NCT00603408,has_status,TERMINATED
NCT00603408,has_phase,
NCT00603408,sponsored_by,Washington University School of Medicine
NCT00603408,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT00603408,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT00603408,tests,Mastectomy
Mastectomy,has_type,PROCEDURE
NCT07011823,has_title,Phase II Trial of Immunochemotherapy and Partial Breast Irradiation in Early TNBC With Immune-cold T
NCT07011823,has_status,NOT_YET_RECRUITING
NCT07011823,has_phase,
NCT07011823,sponsored_by,Gangnam Severance Hospital
NCT07011823,tests,Partial breast-irradiation
Partial breast-irradiation,has_type,RADIATION
NCT03390608,has_title,"Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Br"
NCT03390608,has_status,COMPLETED
NCT03390608,has_phase,
NCT03390608,sponsored_by,Karolinska Institutet
NCT03390608,tests,Endocrine therapy
Endocrine therapy,has_type,DRUG
NCT03390608,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT03390608,tests,Herceptin
Herceptin,has_type,DRUG
NCT03390608,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT03390608,tests,Type of breast cancer surgery
Type of breast cancer surgery,has_type,PROCEDURE
NCT03390608,tests,Age at diagnosis
Age at diagnosis,has_type,OTHER
NCT03390608,tests,Screen detected tumor
Screen detected tumor,has_type,OTHER
NCT03390608,tests,Menopausal status at diagnosis
Menopausal status at diagnosis,has_type,OTHER
NCT03390608,tests,Tumor size
Tumor size,has_type,OTHER
NCT03390608,tests,Estrogen receptor (ER) status
Estrogen receptor (ER) status,has_type,OTHER
NCT03390608,tests,Tumor grade
Tumor grade,has_type,OTHER
NCT03390608,tests,HER2-status
HER2-status,has_type,OTHER
NCT03390608,tests,Intrinsic subgroups of breast cancer
Intrinsic subgroups of breast cancer,has_type,OTHER
NCT03390608,tests,Nodal status
Nodal status,has_type,OTHER
NCT00733408,has_title,Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly 
NCT00733408,has_status,COMPLETED
NCT00733408,has_phase,
NCT00733408,sponsored_by,University of Washington
NCT00733408,tests,paclitaxel albumin-stabilized nanoparticle formulation
paclitaxel albumin-stabilized nanoparticle formulation,has_type,DRUG
NCT00733408,tests,bevacizumab
bevacizumab,has_type,BIOLOGICAL
NCT00733408,tests,erlotinib hydrochloride
erlotinib hydrochloride,has_type,DRUG
NCT04501523,has_title,"A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy A"
NCT04501523,has_status,RECRUITING
NCT04501523,has_phase,
NCT04501523,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04501523,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT04501523,tests,capecitabine
capecitabine,has_type,DRUG
NCT06833723,has_title,Construction and Validation of a Multi-omics Prediction Model to Assess Immunotherapy Efficacy in Pa
NCT06833723,has_status,ACTIVE_NOT_RECRUITING
NCT06833723,has_phase,
NCT06833723,sponsored_by,"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences"
NCT06833723,tests,Retrospective Data Collection and Analysis
Retrospective Data Collection and Analysis,has_type,OTHER
NCT01375023,has_title,Allogenic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total
NCT01375023,has_status,TERMINATED
NCT01375023,has_phase,
NCT01375023,sponsored_by,European Institute of Oncology
NCT01375023,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT01375023,tests,Anti-Thymocyte Globulin
Anti-Thymocyte Globulin,has_type,BIOLOGICAL
NCT03369223,has_title,A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced S
NCT03369223,has_status,COMPLETED
NCT03369223,has_phase,
NCT03369223,sponsored_by,Bristol-Myers Squibb
NCT03369223,tests,BMS-986249
BMS-986249,has_type,BIOLOGICAL
NCT03369223,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03369223,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT01738438,has_title,A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer
NCT01738438,has_status,COMPLETED
NCT01738438,has_phase,
NCT01738438,sponsored_by,Dana-Farber Cancer Institute
NCT01738438,tests,Cabozantinib
Cabozantinib,has_type,DRUG
NCT01333423,has_title,A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Co
NCT01333423,has_status,WITHDRAWN
NCT01333423,has_phase,
NCT01333423,sponsored_by,M.D. Anderson Cancer Center
NCT01333423,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
NCT01333423,tests,Seliciclib
Seliciclib,has_type,DRUG
NCT01889238,has_title,"A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTA"
NCT01889238,has_status,COMPLETED
NCT01889238,has_phase,
NCT01889238,sponsored_by,Pfizer
NCT01889238,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02370238,has_title,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Repar"
NCT02370238,has_status,COMPLETED
NCT02370238,has_phase,
NCT02370238,sponsored_by,Dompé Farmaceutici S.p.A
NCT02370238,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT02370238,tests,Reparixin
Reparixin,has_type,DRUG
NCT02370238,tests,placebo
placebo,has_type,DRUG
NCT04177108,has_title,"A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With A"
NCT04177108,has_status,COMPLETED
NCT04177108,has_phase,
NCT04177108,sponsored_by,Hoffmann-La Roche
NCT04177108,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04177108,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT04177108,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04177108,tests,Placebo for Atezolizumab
Placebo for Atezolizumab,has_type,DRUG
NCT04177108,tests,Placebo for Ipatasertib
Placebo for Ipatasertib,has_type,DRUG
NCT03577743,has_title,Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
NCT03577743,has_status,COMPLETED
NCT03577743,has_phase,
NCT03577743,sponsored_by,Assiut University
NCT03577743,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT02201381,has_title,"A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Meta"
NCT02201381,has_status,WITHDRAWN
NCT02201381,has_phase,
NCT02201381,sponsored_by,Health Clinics Limited
NCT02201381,tests,Metabolic treatment
Metabolic treatment,has_type,DRUG
NCT02762981,has_title,Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
NCT02762981,has_status,COMPLETED
NCT02762981,has_phase,
NCT02762981,sponsored_by,Corcept Therapeutics
NCT02762981,tests,Relacorilant with nab-paclitaxel
Relacorilant with nab-paclitaxel,has_type,DRUG
NCT04438681,has_title,INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relap
NCT04438681,has_status,RECRUITING
NCT04438681,has_phase,
NCT04438681,sponsored_by,Centre Jean Perrin
NCT06636981,has_title,All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Me
NCT06636981,has_status,RECRUITING
NCT06636981,has_phase,
NCT06636981,sponsored_by,Fudan University
NCT06636981,tests,Cohort2: ATRA+Toripalimab+TPC
Cohort2: ATRA+Toripalimab+TPC,has_type,DRUG
NCT06636981,tests,Cohort1: ATRA+Toripalimab+chemo
Cohort1: ATRA+Toripalimab+chemo,has_type,DRUG
NCT01467310,has_title,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
NCT01467310,has_status,COMPLETED
NCT01467310,has_phase,
NCT01467310,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT01467310,tests,GSK1120212
GSK1120212,has_type,DRUG
NCT02457910,has_title,"A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in P"
NCT02457910,has_status,TERMINATED
NCT02457910,has_phase,
NCT02457910,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT02457910,tests,Biomarker Analysis
Biomarker Analysis,has_type,OTHER
NCT02457910,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02457910,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02457910,tests,Taselisib
Taselisib,has_type,DRUG
NCT06532812,has_title,Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrol
NCT06532812,has_status,RECRUITING
NCT06532812,has_phase,
NCT06532812,sponsored_by,Essen Biotech
NCT06532812,tests,Tumor Infiltrating Lymphocytes (TIL)
Tumor Infiltrating Lymphocytes (TIL),has_type,BIOLOGICAL
NCT06532812,tests,Cyclophosphamid
Cyclophosphamid,has_type,DRUG
NCT06532812,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT06532812,tests,Interleukin-2
Interleukin-2,has_type,DRUG
NCT06532812,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT00754312,has_title,"A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in S"
NCT00754312,has_status,TERMINATED
NCT00754312,has_phase,
NCT00754312,sponsored_by,Syndax Pharmaceuticals
NCT00754312,tests,SNDX-275
SNDX-275,has_type,DRUG
NCT03822312,has_title,A Pilot Study of Digital Breast Tomosynthesis Guided Near-infrared Tomographic Optical Breast Imagin
NCT03822312,has_status,ACTIVE_NOT_RECRUITING
NCT03822312,has_phase,
NCT03822312,sponsored_by,Massachusetts General Hospital
NCT03822312,tests,DBT-TOBI
DBT-TOBI,has_type,DEVICE
NCT03822312,tests,MRI-TOBI
MRI-TOBI,has_type,DEVICE
NCT03483012,has_title,A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple
NCT03483012,has_status,ACTIVE_NOT_RECRUITING
NCT03483012,has_phase,
NCT03483012,sponsored_by,Dana-Farber Cancer Institute
NCT03483012,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03483012,tests,Stereotactic radiosurgery (SRS)
Stereotactic radiosurgery (SRS),has_type,PROCEDURE
NCT02554812,has_title,"A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODY"
NCT02554812,has_status,TERMINATED
NCT02554812,has_phase,
NCT02554812,sponsored_by,Pfizer
NCT02554812,tests,Avelumab
Avelumab,has_type,DRUG
NCT02554812,tests,Utomilumab
Utomilumab,has_type,DRUG
NCT02554812,tests,PF-04518600
PF-04518600,has_type,DRUG
NCT02554812,tests,PD 0360324
PD 0360324,has_type,DRUG
NCT02554812,tests,CMP-001
CMP-001,has_type,DRUG
NCT05300412,has_title,"The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer: a Cross-sectional, Obse"
NCT05300412,has_status,COMPLETED
NCT05300412,has_phase,
NCT05300412,sponsored_by,University Clinical Centre of Kosova
NCT05314114,has_title,Selective Omission of Axillary Surgery in Distinct Responders With Triple-negative and HER2-positive
NCT05314114,has_status,RECRUITING
NCT05314114,has_phase,
NCT05314114,sponsored_by,Peking University
NCT05314114,tests,No axillary surgery
No axillary surgery,has_type,PROCEDURE
NCT04596150,has_title,"A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine"
NCT04596150,has_status,COMPLETED
NCT04596150,has_phase,
NCT04596150,sponsored_by,CytomX Therapeutics
NCT04596150,tests,CX-2009
CX-2009,has_type,DRUG
NCT04596150,tests,CX-072
CX-072,has_type,DRUG
NCT02792114,has_title,A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Ant
NCT02792114,has_status,ACTIVE_NOT_RECRUITING
NCT02792114,has_phase,
NCT02792114,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02792114,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02792114,tests,Mesothelin-targeted T cells
Mesothelin-targeted T cells,has_type,BIOLOGICAL
NCT02792114,tests,AP1903
AP1903,has_type,DRUG
NCT05309655,has_title,The Cardiac Outcomes With Near-Complete Estrogen Deprivation (CROWN) Study
NCT05309655,has_status,RECRUITING
NCT05309655,has_phase,
NCT05309655,sponsored_by,Duke University
NCT05309655,tests,Adenosine Stress Cardiac Magnetic Resonance Imaging
Adenosine Stress Cardiac Magnetic Resonance Imaging,has_type,DRUG
NCT05309655,tests,Electrocardiogram
Electrocardiogram,has_type,DIAGNOSTIC_TEST
NCT05309655,tests,Computed Tomography Angiogram
Computed Tomography Angiogram,has_type,DIAGNOSTIC_TEST
NCT05309655,tests,Laboratory Testing
Laboratory Testing,has_type,OTHER
NCT05309655,tests,Quality of Life Survey
Quality of Life Survey,has_type,BEHAVIORAL
NCT04915755,has_title,A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo 
NCT04915755,has_status,ACTIVE_NOT_RECRUITING
NCT04915755,has_phase,
NCT04915755,sponsored_by,GlaxoSmithKline
NCT04915755,tests,Niraparib
Niraparib,has_type,DRUG
NCT04915755,tests,Placebo
Placebo,has_type,DRUG
NCT06889610,has_title,"A Single-center,Multi-cohort,Prospective Phase II Clinical Study of Multimodal Ablation Combined Wit"
NCT06889610,has_status,NOT_YET_RECRUITING
NCT06889610,has_phase,
NCT06889610,sponsored_by,Fudan University
NCT06889610,tests,MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer,has_type,DEVICE
NCT06889610,tests,MTT(Multimodal Tumor Thermal Therapy System)- Melanoma
MTT(Multimodal Tumor Thermal Therapy System)- Melanoma,has_type,DEVICE
NCT02427581,has_title,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long 
NCT02427581,has_status,WITHDRAWN
NCT02427581,has_phase,
NCT02427581,sponsored_by,Washington University School of Medicine
NCT02427581,tests,Personalized synthetic long peptide vaccine (Poly ICLC)
Personalized synthetic long peptide vaccine (Poly ICLC),has_type,BIOLOGICAL
NCT02427581,tests,Poly ICLC
Poly ICLC,has_type,DRUG
NCT05862610,has_title,"A Prospective, Randomized, Controlled Phase II Clinical Study of Trilaciclib Combined With Standard "
NCT05862610,has_status,NOT_YET_RECRUITING
NCT05862610,has_phase,
NCT05862610,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05862610,tests,Trilaciclib plus chemotherapy
Trilaciclib plus chemotherapy,has_type,DRUG
NCT05862610,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT04111510,has_title,A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Me
NCT04111510,has_status,COMPLETED
NCT04111510,has_phase,
NCT04111510,sponsored_by,Yale University
NCT04111510,tests,Tumor infiltrating lymphocytes (TIL) LN-145
Tumor infiltrating lymphocytes (TIL) LN-145,has_type,DRUG
NCT06407310,has_title,"Phase II Open-label, Single-arm Trial of Neoadjuvant Pembrolizumab With Carboplatin and Paclitaxel i"
NCT06407310,has_status,NOT_YET_RECRUITING
NCT06407310,has_phase,
NCT06407310,sponsored_by,Tel Aviv Medical Center
NCT06407310,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06407310,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06407310,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03126110,has_title,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination Wit"
NCT03126110,has_status,COMPLETED
NCT03126110,has_phase,
NCT03126110,sponsored_by,Incyte Biosciences International Sàrl
NCT03126110,tests,INCAGN01876
INCAGN01876,has_type,DRUG
NCT03126110,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03126110,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT05269381,has_title,A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizuma
NCT05269381,has_status,RECRUITING
NCT05269381,has_phase,
NCT05269381,sponsored_by,Mayo Clinic
NCT05269381,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05269381,tests,Neoantigen Peptide Vaccine
Neoantigen Peptide Vaccine,has_type,BIOLOGICAL
NCT05269381,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05269381,tests,Sargramostim
Sargramostim,has_type,BIOLOGICAL
NCT02348281,has_title,"A Prospective, Single Center, Phase II Study of Bicalutamide as A Treatment in Androgen Receptor (AR"
NCT02348281,has_status,TERMINATED
NCT02348281,has_phase,
NCT02348281,sponsored_by,Fudan University
NCT02348281,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT03917381,has_title,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN10"
NCT03917381,has_status,ACTIVE_NOT_RECRUITING
NCT03917381,has_phase,
NCT03917381,sponsored_by,Genmab
NCT03917381,tests,Acasunlimab
Acasunlimab,has_type,BIOLOGICAL
NCT03917381,tests,Acasunlimab in combination with docetaxel (in a single expansion cohort)
Acasunlimab in combination with docetaxel (in a single expansion cohort),has_type,BIOLOGICAL
NCT03917381,tests,Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),has_type,BIOLOGICAL
NCT03917381,tests,Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),has_type,BIOLOGICAL
NCT05910710,has_title,Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT05910710,has_status,RECRUITING
NCT05910710,has_phase,
NCT05910710,sponsored_by,Samsung Medical Center
NCT05910710,tests,"Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)"
"Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)",has_type,GENETIC
NCT02454010,has_title,"A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advan"
NCT02454010,has_status,COMPLETED
NCT02454010,has_phase,
NCT02454010,sponsored_by,"Fujifilm Pharmaceuticals U.S.A., Inc."
NCT02454010,tests,FF21101
FF21101,has_type,BIOLOGICAL
NCT04584112,has_title,"A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolum"
NCT04584112,has_status,COMPLETED
NCT04584112,has_phase,
NCT04584112,sponsored_by,Hoffmann-La Roche
NCT04584112,tests,Tiragolumab
Tiragolumab,has_type,DRUG
NCT04584112,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04584112,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04584112,tests,Tiragolumab
Tiragolumab,has_type,DRUG
NCT04584112,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04584112,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04584112,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04584112,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04584112,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04584112,tests,Granulocyte colony-stimulating factor (G-CSF)
Granulocyte colony-stimulating factor (G-CSF),has_type,DRUG
NCT04584112,tests,Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Granulocyte-macrophage colony-stimulating factor (GM-CSF),has_type,DRUG
NCT01031446,has_title,"A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer"
NCT01031446,has_status,COMPLETED
NCT01031446,has_phase,
NCT01031446,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT01031446,tests,cisplatin
cisplatin,has_type,DRUG
NCT01031446,tests,everolimus
everolimus,has_type,DRUG
NCT01031446,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01031446,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT03801369,has_title,"A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti"
NCT03801369,has_status,TERMINATED
NCT03801369,has_phase,
NCT03801369,sponsored_by,"Gordon Mills, MD, PhD"
NCT03801369,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03801369,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT03801369,tests,Ceralasertib
Ceralasertib,has_type,DRUG
NCT03801369,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT03801369,tests,Olaparib
Olaparib,has_type,DRUG
NCT03801369,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03801369,tests,Selumetinib
Selumetinib,has_type,DRUG
NCT03094169,has_title,"Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplasti"
NCT03094169,has_status,TERMINATED
NCT03094169,has_phase,
NCT03094169,sponsored_by,Formation Biologics
NCT03094169,tests,AVID100 IV
AVID100 IV,has_type,DRUG
NCT03901469,has_title,A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breas
NCT03901469,has_status,TERMINATED
NCT03901469,has_phase,
NCT03901469,sponsored_by,Zenith Epigenetics
NCT03901469,tests,ZEN003694
ZEN003694,has_type,DRUG
NCT03901469,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT01176669,has_title,A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Meta
NCT01176669,has_status,COMPLETED
NCT01176669,has_phase,
NCT01176669,sponsored_by,Fudan University
NCT01176669,tests,Apatinib
Apatinib,has_type,DRUG
NCT06617169,has_title,"Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177L"
NCT06617169,has_status,RECRUITING
NCT06617169,has_phase,
NCT06617169,sponsored_by,Monopar Therapeutics
NCT06617169,tests,MNPR-101-PCTA-177Lu
MNPR-101-PCTA-177Lu,has_type,DRUG
NCT06059469,has_title,"PRISMA: A Single-centre, Prospective Phase II Imaging Study Using PSMA-PET/CT to Assess the Expressi"
NCT06059469,has_status,RECRUITING
NCT06059469,has_phase,
NCT06059469,sponsored_by,Jules Bordet Institute
NCT06059469,tests,Ga-PSMA PET/CT
Ga-PSMA PET/CT,has_type,DIAGNOSTIC_TEST
NCT06700369,has_title,De-escalation of Neoadjuvant Chemotherapy Regimens (Taxanes Plus Carboplatin Versus Taxanes Only) Wi
NCT06700369,has_status,RECRUITING
NCT06700369,has_phase,
NCT06700369,sponsored_by,Shu Wang
NCT06281210,has_title,Non-inferiority Study in Patients With Complete Pathological Response After Neoadjuvant Chemotherapy
NCT06281210,has_status,RECRUITING
NCT06281210,has_phase,
NCT06281210,sponsored_by,European Institute of Oncology
NCT06281210,tests,Omission of surgical treatment
Omission of surgical treatment,has_type,PROCEDURE
NCT05082610,has_title,"A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy "
NCT05082610,has_status,ACTIVE_NOT_RECRUITING
NCT05082610,has_phase,
NCT05082610,sponsored_by,Hummingbird Bioscience
NCT05082610,tests,HMBD-002
HMBD-002,has_type,DRUG
NCT05082610,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06920810,has_title,Efficacy and Safety of Viscum Album in Patients With Triple-negative Breast Cancer Undergoing Immune
NCT06920810,has_status,RECRUITING
NCT06920810,has_phase,
NCT06920810,sponsored_by,Ilsan Cha hospital
NCT06920810,tests,viscum album
viscum album,has_type,DRUG
NCT05008510,has_title,Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Gov
NCT05008510,has_status,WITHDRAWN
NCT05008510,has_phase,
NCT05008510,sponsored_by,Veru Inc.
NCT05008510,tests,Sabizabulin
Sabizabulin,has_type,DRUG
NCT05008510,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT05008510,tests,Sabizabulin/Sacituzumab govitecan-hziy Combo
Sabizabulin/Sacituzumab govitecan-hziy Combo,has_type,DRUG
NCT00580112,has_title,"Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Can"
NCT00580112,has_status,COMPLETED
NCT00580112,has_phase,
NCT00580112,sponsored_by,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00580112,tests,Dexamethasone
Dexamethasone,has_type,DRUG
NCT00580112,tests,Trabectedin
Trabectedin,has_type,DRUG
NCT05276310,has_title,"An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability,"
NCT05276310,has_status,RECRUITING
NCT05276310,has_phase,
NCT05276310,sponsored_by,ImmuneOncia Therapeutics Inc.
NCT05276310,tests,IMC-002
IMC-002,has_type,BIOLOGICAL
NCT05872412,has_title,Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breas
NCT05872412,has_status,UNKNOWN
NCT05872412,has_phase,
NCT05872412,sponsored_by,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"
NCT05872412,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05872412,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05872412,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05872412,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05396612,has_title,Role of the Immune Environment in Response to Therapy in Breast Cancer
NCT05396612,has_status,RECRUITING
NCT05396612,has_phase,
NCT05396612,sponsored_by,Abramson Cancer Center at Penn Medicine
NCT05396612,tests,Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,has_type,OTHER
NCT01105312,has_title,Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic 
NCT01105312,has_status,COMPLETED
NCT01105312,has_phase,
NCT01105312,sponsored_by,Alliance for Clinical Trials in Oncology
NCT01105312,tests,letrozole
letrozole,has_type,DRUG
NCT01105312,tests,panobinostat
panobinostat,has_type,DRUG
NCT01105312,tests,RNA analysis
RNA analysis,has_type,GENETIC
NCT01105312,tests,microarray analysis
microarray analysis,has_type,GENETIC
NCT01105312,tests,reverse transcriptase-polymerase chain reaction
reverse transcriptase-polymerase chain reaction,has_type,GENETIC
NCT01105312,tests,enzyme-linked immunosorbent assay
enzyme-linked immunosorbent assay,has_type,OTHER
NCT01105312,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,OTHER
NCT01105312,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT06627712,has_title,Stereotactic Body Radiotherapy (SBRT) Combined With PD-1 Inhibitor and Chemotherapy in Early-stage T
NCT06627712,has_status,NOT_YET_RECRUITING
NCT06627712,has_phase,
NCT06627712,sponsored_by,West China Hospital
NCT06627712,tests,SBRT+PD-1 Inhibitor + Chemotherapy
SBRT+PD-1 Inhibitor + Chemotherapy,has_type,DRUG
NCT06627712,tests,PD-1 Inhibitor + Chemotherapy
PD-1 Inhibitor + Chemotherapy,has_type,DRUG
NCT06349512,has_title,68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Tripl
NCT06349512,has_status,RECRUITING
NCT06349512,has_phase,
NCT06349512,sponsored_by,Institut Curie
NCT06349512,tests,68Ga-FAPI-46 PET/CT imaging
68Ga-FAPI-46 PET/CT imaging,has_type,PROCEDURE
NCT03055312,has_title,"A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatmen"
NCT03055312,has_status,TERMINATED
NCT03055312,has_phase,
NCT03055312,sponsored_by,Sun Yat-sen University
NCT03055312,tests,TPC
TPC,has_type,DRUG
NCT03055312,tests,Bicalutamide 150 mg
Bicalutamide 150 mg,has_type,DRUG
NCT05390710,has_title,A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII S
NCT05390710,has_status,COMPLETED
NCT05390710,has_phase,
NCT05390710,sponsored_by,Laekna Limited
NCT05390710,tests,LAE005 + Afuresertib + Nab-Paclitaxel
LAE005 + Afuresertib + Nab-Paclitaxel,has_type,COMBINATION_PRODUCT
NCT05374512,has_title,"A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's C"
NCT05374512,has_status,ACTIVE_NOT_RECRUITING
NCT05374512,has_phase,
NCT05374512,sponsored_by,AstraZeneca
NCT05374512,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT05374512,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05374512,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05374512,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05374512,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05374512,tests,Eribulin mesylate
Eribulin mesylate,has_type,DRUG
NCT05918133,has_title,"A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, "
NCT05918133,has_status,ACTIVE_NOT_RECRUITING
NCT05918133,has_phase,
NCT05918133,sponsored_by,Biotheus Inc.
NCT05918133,tests,PM8002
PM8002,has_type,DRUG
NCT05918133,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT02393287,has_title,Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observ
NCT02393287,has_status,COMPLETED
NCT02393287,has_phase,
NCT02393287,sponsored_by,Institut Cancerologie de l'Ouest
NCT02393287,tests,Eribulin (ReProLine)
Eribulin (ReProLine),has_type,OTHER
NCT06224387,has_title,"A Multi-center, Open-label, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Ph"
NCT06224387,has_status,RECRUITING
NCT06224387,has_phase,
NCT06224387,sponsored_by,"CytosinLab Therapeutics Co., Ltd."
NCT06224387,tests,CTS2190 capsules
CTS2190 capsules,has_type,DRUG
NCT06238687,has_title,"A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy"
NCT06238687,has_status,RECRUITING
NCT06238687,has_phase,
NCT06238687,sponsored_by,"Tasly Pharmaceutical Group Co., Ltd"
NCT06238687,tests,STRO-002
STRO-002,has_type,BIOLOGICAL
NCT06577987,has_title,"A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-"
NCT06577987,has_status,RECRUITING
NCT06577987,has_phase,
NCT06577987,sponsored_by,Circle Pharma
NCT06577987,tests,CID-078 Monotherapy
CID-078 Monotherapy,has_type,DRUG
NCT05528133,has_title,Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Nega
NCT05528133,has_status,RECRUITING
NCT05528133,has_phase,
NCT05528133,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05528133,tests,Genomically Guided Radiation Therapy
Genomically Guided Radiation Therapy,has_type,RADIATION
NCT05528133,tests,Genomically Guided Radiation Therapy
Genomically Guided Radiation Therapy,has_type,RADIATION
NCT01953536,has_title,"A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide an"
NCT01953536,has_status,WITHDRAWN
NCT01953536,has_phase,
NCT01953536,sponsored_by,Endocyte
NCT01953536,tests,Vintafolide 2.5 mg
Vintafolide 2.5 mg,has_type,DRUG
NCT01953536,tests,Paclitaxel 80 mg/m^2
Paclitaxel 80 mg/m^2,has_type,DRUG
NCT01953536,tests,Etarfolatide
Etarfolatide,has_type,DRUG
NCT01953536,tests,Folic acid
Folic acid,has_type,DRUG
NCT01953536,tests,Premedication for Paclitaxel
Premedication for Paclitaxel,has_type,DRUG
NCT01498536,has_title,"Fit for the Fight: Effect of a Multidisciplinary Diet and Exercise Program on Body Weight, Quality o"
NCT01498536,has_status,COMPLETED
NCT01498536,has_phase,
NCT01498536,sponsored_by,West Virginia University
NCT01498536,tests,aerobic exercise
aerobic exercise,has_type,BEHAVIORAL
NCT06637306,has_title,"Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplati"
NCT06637306,has_status,RECRUITING
NCT06637306,has_phase,
NCT06637306,sponsored_by,Rima Patel
NCT06637306,tests,Dupilumab
Dupilumab,has_type,DRUG
NCT06637306,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06637306,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06637306,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05555706,has_title,A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel 
NCT05555706,has_status,COMPLETED
NCT05555706,has_phase,
NCT05555706,sponsored_by,"Shanghai Jiaolian Drug Research and Development Co., Ltd"
NCT05555706,tests,B013+Nab-Paclitaxel
B013+Nab-Paclitaxel,has_type,DRUG
NCT05180006,has_title,Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
NCT05180006,has_status,RECRUITING
NCT05180006,has_phase,
NCT05180006,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT05180006,tests,Atezolizumab Injection
Atezolizumab Injection,has_type,DRUG
NCT05180006,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05180006,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT05180006,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04799249,has_title,"A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or "
NCT04799249,has_status,COMPLETED
NCT04799249,has_phase,
NCT04799249,sponsored_by,"G1 Therapeutics, Inc."
NCT04799249,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT04799249,tests,Placebo
Placebo,has_type,DRUG
NCT04799249,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04799249,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05759949,has_title,"A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Ther"
NCT05759949,has_status,COMPLETED
NCT05759949,has_phase,
NCT05759949,sponsored_by,"Relay Therapeutics, Inc."
NCT05759949,tests,RLY-5836
RLY-5836,has_type,DRUG
NCT05759949,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT05759949,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT05759949,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT05759949,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT04879849,has_title,"An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activ"
NCT04879849,has_status,COMPLETED
NCT04879849,has_phase,
NCT04879849,sponsored_by,Takeda
NCT04879849,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04879849,tests,TAK-676
TAK-676,has_type,DRUG
NCT04879849,tests,Image-guided radiation therapy
Image-guided radiation therapy,has_type,RADIATION
NCT01618136,has_title,"An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as"
NCT01618136,has_status,COMPLETED
NCT01618136,has_phase,
NCT01618136,sponsored_by,Eisai Limited
NCT01618136,tests,E7449 alone
E7449 alone,has_type,DRUG
NCT01618136,tests,E7449 plus TMZ
E7449 plus TMZ,has_type,DRUG
NCT01618136,tests,E7449 plus carboplatin and paclitaxel
E7449 plus carboplatin and paclitaxel,has_type,DRUG
NCT05451849,has_title,A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expr
NCT05451849,has_status,ACTIVE_NOT_RECRUITING
NCT05451849,has_phase,
NCT05451849,sponsored_by,TCR2 Therapeutics
NCT05451849,tests,TC-510
TC-510,has_type,BIOLOGICAL
NCT05451849,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05451849,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02366949,has_title,"An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerabil"
NCT02366949,has_status,COMPLETED
NCT02366949,has_phase,
NCT02366949,sponsored_by,Bayer
NCT02366949,tests,BAY1217389
BAY1217389,has_type,DRUG
NCT02366949,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06404736,has_title,A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk TNBC Early-S
NCT06404736,has_status,NOT_YET_RECRUITING
NCT06404736,has_phase,
NCT06404736,sponsored_by,Fudan University
NCT06404736,tests,Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,has_type,DRUG
NCT06404736,tests,Albumin-bound paclitaxel
Albumin-bound paclitaxel,has_type,DRUG
NCT06404736,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06247449,has_title,MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Brea
NCT06247449,has_status,RECRUITING
NCT06247449,has_phase,
NCT06247449,sponsored_by,Sunnybrook Health Sciences Centre
NCT06247449,tests,Brain imaging
Brain imaging,has_type,DIAGNOSTIC_TEST
NCT06247449,tests,Analysis of circulating tumor DNA
Analysis of circulating tumor DNA,has_type,DIAGNOSTIC_TEST
NCT06247449,tests,Testing Morbidities Index
Testing Morbidities Index,has_type,BEHAVIORAL
NCT03742349,has_title,"A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunothe"
NCT03742349,has_status,TERMINATED
NCT03742349,has_phase,
NCT03742349,sponsored_by,Novartis Pharmaceuticals
NCT03742349,tests,spartalizumab
spartalizumab,has_type,BIOLOGICAL
NCT03742349,tests,LAG525
LAG525,has_type,BIOLOGICAL
NCT03742349,tests,NIR178
NIR178,has_type,DRUG
NCT03742349,tests,capmatinib
capmatinib,has_type,DRUG
NCT03742349,tests,MCS110
MCS110,has_type,BIOLOGICAL
NCT03742349,tests,canakinumab
canakinumab,has_type,BIOLOGICAL
NCT06992336,has_title,"A Phase II, Open-label, Randomized Trial to Compare Anlotinib and Immunotherapy and Capecitabine Ver"
NCT06992336,has_status,RECRUITING
NCT06992336,has_phase,
NCT06992336,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06992336,tests,"Anlotinib ,"
"Anlotinib ,",has_type,DRUG
NCT06992336,tests,Benmelstobart
Benmelstobart,has_type,DRUG
NCT06992336,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT01674842,has_title,A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative
NCT01674842,has_status,COMPLETED
NCT01674842,has_phase,
NCT01674842,sponsored_by,Dana-Farber Cancer Institute
NCT01674842,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT01674842,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04060342,has_title,"A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combinat"
NCT04060342,has_status,TERMINATED
NCT04060342,has_phase,
NCT04060342,sponsored_by,"GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc."
NCT04060342,tests,GB1275
GB1275,has_type,DRUG
NCT04060342,tests,nab-paclitaxel and gemcitabine
nab-paclitaxel and gemcitabine,has_type,DRUG
NCT04060342,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT03464942,has_title,A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereo
NCT03464942,has_status,COMPLETED
NCT03464942,has_phase,
NCT03464942,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT03464942,tests,SABR
SABR,has_type,RADIATION
NCT03464942,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT06349642,has_title,Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT06349642,has_status,RECRUITING
NCT06349642,has_phase,
NCT06349642,sponsored_by,Mayo Clinic
NCT06349642,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06349642,tests,Tissue Collection
Tissue Collection,has_type,PROCEDURE
NCT05383170,has_title,"A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evalua"
NCT05383170,has_status,COMPLETED
NCT05383170,has_phase,
NCT05383170,sponsored_by,Cytovation AS
NCT05383170,tests,CyPep-1
CyPep-1,has_type,DRUG
NCT05383170,tests,Pembrolizumab 25 MG/ML [KEYTRUDA®]
Pembrolizumab 25 MG/ML [KEYTRUDA®],has_type,DRUG
NCT04669899,has_title,Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor
NCT04669899,has_status,COMPLETED
NCT04669899,has_phase,
NCT04669899,sponsored_by,"Jounce Therapeutics, Inc."
NCT04669899,tests,JTX-8064
JTX-8064,has_type,DRUG
NCT04669899,tests,pimivalimab
pimivalimab,has_type,DRUG
NCT04452370,has_title,Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
NCT04452370,has_status,UNKNOWN
NCT04452370,has_phase,
NCT04452370,sponsored_by,Chinese Academy of Medical Sciences
NCT04452370,tests,oral etoposide + anlotinib
oral etoposide + anlotinib,has_type,DRUG
NCT02225470,has_title,An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female
NCT02225470,has_status,COMPLETED
NCT02225470,has_phase,
NCT02225470,sponsored_by,"Eisai Co., Ltd."
NCT02225470,tests,E7389 (Eribulin Mesylate)
E7389 (Eribulin Mesylate),has_type,DRUG
NCT02225470,tests,Vinorelbine injection
Vinorelbine injection,has_type,DRUG
NCT05097599,has_title,StrataPATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity
NCT05097599,has_status,TERMINATED
NCT05097599,has_phase,
NCT05097599,sponsored_by,Strata Oncology
NCT05097599,tests,lorlatinib
lorlatinib,has_type,DRUG
NCT05097599,tests,encorafenib + binimetinib
encorafenib + binimetinib,has_type,DRUG
NCT05097599,tests,talazoparib
talazoparib,has_type,DRUG
NCT05097599,tests,sacituzumab govitecan
sacituzumab govitecan,has_type,DRUG
NCT05097599,tests,axitinib
axitinib,has_type,DRUG
NCT05097599,tests,Fam-Trastuzumab Deruxtecan-Nxki
Fam-Trastuzumab Deruxtecan-Nxki,has_type,DRUG
NCT05097599,tests,enfortumab vedotin
enfortumab vedotin,has_type,DRUG
NCT02938442,has_title,A Combined Phase i/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51
NCT02938442,has_status,COMPLETED
NCT02938442,has_phase,
NCT02938442,sponsored_by,University of Arkansas
NCT02938442,tests,P10s-PADRE with MONTANIDE™ ISA 51 VG
P10s-PADRE with MONTANIDE™ ISA 51 VG,has_type,BIOLOGICAL
NCT02938442,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02938442,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02938442,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01910870,has_title,
NCT01910870,has_status,TERMINATED
NCT01910870,has_phase,
NCT01910870,sponsored_by,Centre Jean Perrin
NCT01910870,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01910870,tests,Metronomic Cyclophosphamide
Metronomic Cyclophosphamide,has_type,DRUG
NCT05810870,has_title,"Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive/HER2-negative, "
NCT05810870,has_status,RECRUITING
NCT05810870,has_phase,
NCT05810870,sponsored_by,MedSIR
NCT05810870,tests,MEN1611
MEN1611,has_type,DRUG
NCT05810870,tests,Eribulin
Eribulin,has_type,DRUG
NCT06977542,has_title,"A Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Ivonescimab Combined With Chemothe"
NCT06977542,has_status,NOT_YET_RECRUITING
NCT06977542,has_phase,
NCT06977542,sponsored_by,Fudan University
NCT06977542,tests,Ivonescimab
Ivonescimab,has_type,DRUG
NCT04159142,has_title,Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Tre
NCT04159142,has_status,UNKNOWN
NCT04159142,has_phase,
NCT04159142,sponsored_by,Hebei Medical University Fourth Hospital
NCT04159142,tests,Nab-paclitaxel + Carboplatin
Nab-paclitaxel + Carboplatin,has_type,DRUG
NCT04159142,tests,Nab-paclitaxel + Capecitabine
Nab-paclitaxel + Capecitabine,has_type,DRUG
NCT07054242,has_title,"A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembroli"
NCT07054242,has_status,NOT_YET_RECRUITING
NCT07054242,has_phase,
NCT07054242,sponsored_by,Yantai Yuhuangding Hospital
NCT07054242,tests,Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab,has_type,DRUG
NCT05958199,has_title,"A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to"
NCT05958199,has_status,SUSPENDED
NCT05958199,has_phase,
NCT05958199,sponsored_by,"NextPoint Therapeutics, Inc."
NCT05958199,tests,NPX267
NPX267,has_type,DRUG
NCT03499899,has_title,"A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With "
NCT03499899,has_status,COMPLETED
NCT03499899,has_phase,
NCT03499899,sponsored_by,Novartis Pharmaceuticals
NCT03499899,tests,LAG525
LAG525,has_type,DRUG
NCT03499899,tests,PDR001
PDR001,has_type,DRUG
NCT03499899,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04107142,has_title,A Phase I Dose-escalation Trial to Evaluate Haploidentical / Allogeneic Natural Killer Group 2D Liga
NCT04107142,has_status,UNKNOWN
NCT04107142,has_phase,
NCT04107142,sponsored_by,CytoMed Therapeutics Pte Ltd
NCT04107142,tests,Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell,has_type,BIOLOGICAL
NCT04892342,has_title,"An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I/II Study to Investigate t"
NCT04892342,has_status,RECRUITING
NCT04892342,has_phase,
NCT04892342,sponsored_by,"Shanghai Escugen Biotechnology Co., Ltd"
NCT04892342,tests,ESG401
ESG401,has_type,DRUG
NCT04296942,has_title,"A Phase 1b Trial of Sequential Combinations of BN-Brachyury, Entinostat, Ado-trastuzuamb Emtansine a"
NCT04296942,has_status,TERMINATED
NCT04296942,has_phase,
NCT04296942,sponsored_by,National Cancer Institute (NCI)
NCT04296942,tests,Brachyury-TRICOM
Brachyury-TRICOM,has_type,BIOLOGICAL
NCT04296942,tests,Entinostat
Entinostat,has_type,DRUG
NCT04296942,tests,M7824
M7824,has_type,BIOLOGICAL
NCT04296942,tests,Ado-trastuzumab emtansine
Ado-trastuzumab emtansine,has_type,BIOLOGICAL
NCT01097642,has_title,Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cet
NCT01097642,has_status,COMPLETED
NCT01097642,has_phase,
NCT01097642,sponsored_by,The Methodist Hospital Research Institute
NCT01097642,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT01097642,tests,Ixabepilone
Ixabepilone,has_type,DRUG
NCT01074970,has_title,PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER
NCT01074970,has_status,COMPLETED
NCT01074970,has_phase,
NCT01074970,sponsored_by,Hoosier Cancer Research Network
NCT01074970,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01074970,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT01074970,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03077776,has_title,Tracking Triple-negative Breast Cancer Evolution Through Therapy
NCT03077776,has_status,ACTIVE_NOT_RECRUITING
NCT03077776,has_phase,
NCT03077776,sponsored_by,UNICANCER
NCT03077776,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03077776,tests,Biopsy (optional)
Biopsy (optional),has_type,PROCEDURE
NCT03077776,tests,Biopsy (metastatic)
Biopsy (metastatic),has_type,PROCEDURE
NCT02732860,has_title,Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host
NCT02732860,has_status,RECRUITING
NCT02732860,has_phase,
NCT02732860,sponsored_by,"University Health Network, Toronto"
NCT02732860,tests,Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,has_type,OTHER
NCT02698176,has_title,"A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Ex"
NCT02698176,has_status,TERMINATED
NCT02698176,has_phase,
NCT02698176,sponsored_by,Merck Sharp & Dohme LLC
NCT02698176,tests,Birabresib
Birabresib,has_type,DRUG
NCT03596073,has_title,A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT03596073,has_status,TERMINATED
NCT03596073,has_phase,
NCT03596073,sponsored_by,Massachusetts General Hospital
NCT03596073,tests,Topical Calcipotriene Ointment
Topical Calcipotriene Ointment,has_type,DRUG
NCT03596073,tests,Topical Vaseline
Topical Vaseline,has_type,OTHER
NCT04142931,has_title,"A Pilot Study, Single-Center, Open-Label, Sequentional Immuno Apheresis Plasma Volume Escalation Coh"
NCT04142931,has_status,UNKNOWN
NCT04142931,has_phase,
NCT04142931,sponsored_by,Dr. Ronnie Shapira
NCT04142931,tests,ImmunicomAIAC
ImmunicomAIAC,has_type,COMBINATION_PRODUCT
NCT02448576,has_title,A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advance
NCT02448576,has_status,NOT_YET_RECRUITING
NCT02448576,has_phase,
NCT02448576,sponsored_by,wang shusen
NCT02448576,tests,prophylactic cranial irradiation
prophylactic cranial irradiation,has_type,RADIATION
NCT01732276,has_title,"Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer"
NCT01732276,has_status,UNKNOWN
NCT01732276,has_phase,
NCT01732276,sponsored_by,Jiangmen Central Hospital
NCT01732276,tests,gefitinib
gefitinib,has_type,DRUG
NCT03982173,has_title,A Phase II Whole Exome Sequencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-P
NCT03982173,has_status,WITHDRAWN
NCT03982173,has_phase,
NCT03982173,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT03982173,tests,Tremelimumab
Tremelimumab,has_type,DRUG
NCT03982173,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT06894173,has_title,EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed 
NCT06894173,has_status,RECRUITING
NCT06894173,has_phase,
NCT06894173,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06224673,has_title,Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2
NCT06224673,has_status,NOT_YET_RECRUITING
NCT06224673,has_phase,
NCT06224673,sponsored_by,"Laura Huppert, MD, BA"
NCT06224673,tests,ARX788
ARX788,has_type,DRUG
NCT06224673,tests,Computed Tomography (CT)
Computed Tomography (CT),has_type,PROCEDURE
NCT06224673,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06224673,tests,Amiloride
Amiloride,has_type,DRUG
NCT03911973,has_title,Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA
NCT03911973,has_status,ACTIVE_NOT_RECRUITING
NCT03911973,has_phase,
NCT03911973,sponsored_by,Kari Wisinski
NCT03911973,tests,Gedatolisib
Gedatolisib,has_type,DRUG
NCT03911973,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT03746431,has_title,A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Soli
NCT03746431,has_status,RECRUITING
NCT03746431,has_phase,
NCT03746431,sponsored_by,Fusion Pharmaceuticals Inc.
NCT03746431,tests,[111In]-FPI-1547 Injection
[111In]-FPI-1547 Injection,has_type,DRUG
NCT03746431,tests,[225Ac]-FPI-1434 Injection multi-dose
[225Ac]-FPI-1434 Injection multi-dose,has_type,DRUG
NCT03746431,tests,FPI-1175 Infusion
FPI-1175 Infusion,has_type,BIOLOGICAL
NCT03746431,tests,[225Ac]-FPI-1434 Injection single-dose
[225Ac]-FPI-1434 Injection single-dose,has_type,DRUG
NCT05888831,has_title,A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advance
NCT05888831,has_status,ACTIVE_NOT_RECRUITING
NCT05888831,has_phase,
NCT05888831,sponsored_by,Bristol-Myers Squibb
NCT05888831,tests,BMS-986449
BMS-986449,has_type,DRUG
NCT05888831,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT00817531,has_title,"A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple"
NCT00817531,has_status,TERMINATED
NCT00817531,has_phase,
NCT00817531,sponsored_by,Baylor Breast Care Center
NCT00817531,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT01984866,has_title,Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Rad
NCT01984866,has_status,TERMINATED
NCT01984866,has_phase,
NCT01984866,sponsored_by,Hospital General Universitario Gregorio Marañon
NCT01525966,has_title,Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Loca
NCT01525966,has_status,ACTIVE_NOT_RECRUITING
NCT01525966,has_phase,
NCT01525966,sponsored_by,City of Hope Medical Center
NCT01525966,tests,carboplatin
carboplatin,has_type,DRUG
NCT01525966,tests,paclitaxel albumin-stabilized nanoparticle formulation
paclitaxel albumin-stabilized nanoparticle formulation,has_type,DRUG
NCT01525966,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT04140526,has_title,"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pem"
NCT04140526,has_status,ACTIVE_NOT_RECRUITING
NCT04140526,has_phase,
NCT04140526,sponsored_by,"OncoC4, Inc."
NCT04140526,tests,ONC-392
ONC-392,has_type,DRUG
NCT04140526,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04140526,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04442126,has_title,A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patie
NCT04442126,has_status,TERMINATED
NCT04442126,has_phase,
NCT04442126,sponsored_by,Numab Therapeutics AG
NCT04442126,tests,NM21-1480
NM21-1480,has_type,BIOLOGICAL
NCT05255666,has_title,Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Neg
NCT05255666,has_status,WITHDRAWN
NCT05255666,has_phase,
NCT05255666,sponsored_by,Washington University School of Medicine
NCT05255666,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05255666,tests,Liposomal Irinotecan
Liposomal Irinotecan,has_type,DRUG
NCT03797326,has_title,"A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) i"
NCT03797326,has_status,COMPLETED
NCT03797326,has_phase,
NCT03797326,sponsored_by,Merck Sharp & Dohme LLC
NCT03797326,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03797326,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT03218826,has_title,A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mut
NCT03218826,has_status,ACTIVE_NOT_RECRUITING
NCT03218826,has_phase,
NCT03218826,sponsored_by,National Cancer Institute (NCI)
NCT03218826,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT03218826,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03218826,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT03218826,tests,PI3Kbeta Inhibitor AZD8186
PI3Kbeta Inhibitor AZD8186,has_type,DRUG
NCT01986426,has_title,"A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Mono"
NCT01986426,has_status,COMPLETED
NCT01986426,has_phase,
NCT01986426,sponsored_by,Lytix Biopharma AS
NCT01986426,tests,LTX-315 consecutive lesions
LTX-315 consecutive lesions,has_type,DRUG
NCT01986426,tests,LTX-315
LTX-315,has_type,DRUG
NCT01986426,tests,LTX-315 + ipilimumab
LTX-315 + ipilimumab,has_type,DRUG
NCT01986426,tests,LTX-315 + pembrolizumab
LTX-315 + pembrolizumab,has_type,DRUG
NCT04768426,has_title,Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Tri
NCT04768426,has_status,RECRUITING
NCT04768426,has_phase,
NCT04768426,sponsored_by,Stanford University
NCT04768426,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04443348,has_title,"P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADia"
NCT04443348,has_status,RECRUITING
NCT04443348,has_phase,
NCT04443348,sponsored_by,"Laura M. Spring, MD"
NCT04443348,tests,Radiation Therapy Boost
Radiation Therapy Boost,has_type,RADIATION
NCT04443348,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04443348,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04443348,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04443348,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04443348,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04443348,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03639948,has_title,Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast
NCT03639948,has_status,ACTIVE_NOT_RECRUITING
NCT03639948,has_phase,
NCT03639948,sponsored_by,University of Kansas Medical Center
NCT03639948,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03639948,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT03639948,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03639948,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT04985357,has_title,Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Dru
NCT04985357,has_status,WITHDRAWN
NCT04985357,has_phase,
NCT04985357,sponsored_by,Travera Inc
NCT03000257,has_title,"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combinat"
NCT03000257,has_status,COMPLETED
NCT03000257,has_phase,
NCT03000257,sponsored_by,AbbVie
NCT03000257,tests,Venetoclax
Venetoclax,has_type,DRUG
NCT03000257,tests,Rovalpituzumab Tesirine
Rovalpituzumab Tesirine,has_type,DRUG
NCT03000257,tests,ABBV-181
ABBV-181,has_type,DRUG
NCT02316457,has_title,First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID f
NCT02316457,has_status,COMPLETED
NCT02316457,has_phase,
NCT02316457,sponsored_by,BioNTech SE
NCT02316457,tests,IVAC_W_bre1_uID
IVAC_W_bre1_uID,has_type,BIOLOGICAL
NCT02316457,tests,IVAC_W_bre1_uID/IVAC_M_uID
IVAC_W_bre1_uID/IVAC_M_uID,has_type,BIOLOGICAL
NCT06249048,has_title,"A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokin"
NCT06249048,has_status,RECRUITING
NCT06249048,has_phase,
NCT06249048,sponsored_by,Strand Therapeutics Inc.
NCT06249048,tests,STX-001
STX-001,has_type,BIOLOGICAL
NCT06249048,tests,Keytruda®
Keytruda®,has_type,BIOLOGICAL
NCT01982448,has_title,A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Nega
NCT01982448,has_status,COMPLETED
NCT01982448,has_phase,
NCT01982448,sponsored_by,Dana-Farber Cancer Institute
NCT01982448,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01982448,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05097248,has_title,Camrelizumab Combined With Liposomal Doxorubicin and Losartan in the Treatment With Advanced or Loca
NCT05097248,has_status,UNKNOWN
NCT05097248,has_phase,
NCT05097248,sponsored_by,"Wuhan Union Hospital, China"
NCT05097248,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT05097248,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
NCT05097248,tests,Losartan
Losartan,has_type,DRUG
NCT06266026,has_title,"ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography. An International, M"
NCT06266026,has_status,RECRUITING
NCT06266026,has_phase,
NCT06266026,sponsored_by,ThermoMind Ltd.
NCT06266026,tests,ThermoBreast - AI-based evaluation of dynamic breast thermography imaging
ThermoBreast - AI-based evaluation of dynamic breast thermography imaging,has_type,DIAGNOSTIC_TEST
NCT05981326,has_title,Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer P
NCT05981326,has_status,RECRUITING
NCT05981326,has_phase,
NCT05981326,sponsored_by,Institut Cancerologie de l'Ouest
NCT05981326,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05981326,tests,Blood samples
Blood samples,has_type,PROCEDURE
NCT05981326,tests,Questionnaires
Questionnaires,has_type,BEHAVIORAL
NCT06678048,has_title,"A Single-Arm, Two Stage, Phase II Study of Arsenous Acid Combined With Palliative Chemotherapy for R"
NCT06678048,has_status,RECRUITING
NCT06678048,has_phase,
NCT06678048,sponsored_by,Sun Yat-sen University
NCT06678048,tests,Arsenous Acid plus Chemotherapy
Arsenous Acid plus Chemotherapy,has_type,DRUG
NCT03487666,has_title,OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy 
NCT03487666,has_status,COMPLETED
NCT03487666,has_phase,
NCT03487666,sponsored_by,Georgetown University
NCT03487666,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03487666,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05579366,has_title,Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
NCT05579366,has_status,RECRUITING
NCT05579366,has_phase,
NCT05579366,sponsored_by,Genmab
NCT05579366,tests,Rina-S
Rina-S,has_type,DRUG
NCT05579366,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05579366,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05579366,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03952325,has_title,"A Multicenter, Phase 2 Study of Tesetaxel Plus Three Different PD-(L)1 Inhibitors in Patients With T"
NCT03952325,has_status,TERMINATED
NCT03952325,has_phase,
NCT03952325,sponsored_by,"Odonate Therapeutics, Inc."
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT03952325,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03952325,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03952325,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT04224922,has_title,"A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and"
NCT04224922,has_status,COMPLETED
NCT04224922,has_phase,
NCT04224922,sponsored_by,AZ-VUB
NCT04224922,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04224922,tests,Carboplatinum
Carboplatinum,has_type,DRUG
NCT04224922,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04224922,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06657222,has_title,"A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerabi"
NCT06657222,has_status,RECRUITING
NCT06657222,has_phase,
NCT06657222,sponsored_by,Tubulis GmbH
NCT06657222,tests,TUB-030
TUB-030,has_type,DRUG
NCT01111825,has_title,A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Tri
NCT01111825,has_status,COMPLETED
NCT01111825,has_phase,
NCT01111825,sponsored_by,"Puma Biotechnology, Inc."
NCT01111825,tests,Temsirolimus
Temsirolimus,has_type,DRUG
NCT01111825,tests,Neratinib
Neratinib,has_type,DRUG
NCT01204125,has_title,"Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent a"
NCT01204125,has_status,COMPLETED
NCT01204125,has_phase,
NCT01204125,sponsored_by,Sanofi
NCT01204125,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01204125,tests,Iniparib (SAR2405550 -BSI-201)
Iniparib (SAR2405550 -BSI-201),has_type,DRUG
NCT04669522,has_title,How do Psychological Factors Interact With the Oncological Outcomes of Women With Triple-negative Br
NCT04669522,has_status,UNKNOWN
NCT04669522,has_phase,
NCT04669522,sponsored_by,Pius-Hospital Oldenburg
NCT04432857,has_title,An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients Wit
NCT04432857,has_status,ACTIVE_NOT_RECRUITING
NCT04432857,has_phase,
NCT04432857,sponsored_by,"Adlai Nortye Biopharma Co., Ltd."
NCT04432857,tests,AN0025
AN0025,has_type,DRUG
NCT04432857,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01695057,has_title,A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases
NCT01695057,has_status,WITHDRAWN
NCT01695057,has_phase,
NCT01695057,sponsored_by,University of Southern California
NCT01695057,tests,vorinostat
vorinostat,has_type,DRUG
NCT01695057,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT01695057,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02615457,has_title,
NCT02615457,has_status,RECRUITING
NCT02615457,has_phase,
NCT02615457,sponsored_by,Shandong University
NCT02615457,tests,Huaier Granule
Huaier Granule,has_type,DRUG
NCT04993625,has_title,Selective Avoidanve of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/T
NCT04993625,has_status,ACTIVE_NOT_RECRUITING
NCT04993625,has_phase,
NCT04993625,sponsored_by,Jeong Eon Lee
NCT04993625,tests,avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy
avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy,has_type,PROCEDURE
NCT06878625,has_title,"A Multicenter, Prospective, Cohort Study Evaluating the Efficacy of Trop-2 ADC Combination Therapy i"
NCT06878625,has_status,RECRUITING
NCT06878625,has_phase,
NCT06878625,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT06878625,tests,Sacituzumab Govitecan combined with Toripalimab
Sacituzumab Govitecan combined with Toripalimab,has_type,COMBINATION_PRODUCT
NCT06878625,tests,Sacituzumab govitecan combined with anti-angiogenesis
Sacituzumab govitecan combined with anti-angiogenesis,has_type,COMBINATION_PRODUCT
NCT03130439,has_title,"A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic"
NCT03130439,has_status,TERMINATED
NCT03130439,has_phase,
NCT03130439,sponsored_by,Dana-Farber Cancer Institute
NCT03130439,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT04301739,has_title,"A Randomized, Double-Blind, International Multi-Centre, Phase III Clinical Study to Evaluate Efficac"
NCT04301739,has_status,NOT_YET_RECRUITING
NCT04301739,has_phase,
NCT04301739,sponsored_by,Shanghai Henlius Biotech
NCT04301739,tests,HLX10
HLX10,has_type,DRUG
NCT04301739,tests,"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide"
"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide",has_type,DRUG
NCT04301739,tests,Placebo
Placebo,has_type,DRUG
NCT04226222,has_title,"Bringing Semi-quantitative PET-TDM FDG Data and Texture Analysis to Clinical, Histological and Immun"
NCT04226222,has_status,UNKNOWN
NCT04226222,has_phase,
NCT04226222,sponsored_by,Institut Cancerologie de l'Ouest
NCT04226222,tests,TEP-TDM FDG
TEP-TDM FDG,has_type,DIAGNOSTIC_TEST
NCT05783622,has_title,"An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Soli"
NCT05783622,has_status,RECRUITING
NCT05783622,has_phase,
NCT05783622,sponsored_by,Janux Therapeutics
NCT05783622,tests,JANX008
JANX008,has_type,DRUG
NCT05358639,has_title,A Phase I Trial of the Combination of Olaparib and Navitoclax in Women with High Grade Serous Epithe
NCT05358639,has_status,ACTIVE_NOT_RECRUITING
NCT05358639,has_phase,
NCT05358639,sponsored_by,Sunnybrook Health Sciences Centre
NCT05358639,tests,Olaparib tablet
Olaparib tablet,has_type,DRUG
NCT05358639,tests,Navitoclax
Navitoclax,has_type,DRUG
NCT05830539,has_title,"A Phase Ib/II, Open-label, Multicenter Clinical Study to Evaluate the Antitumor Activities, Safety, "
NCT05830539,has_status,COMPLETED
NCT05830539,has_phase,
NCT05830539,sponsored_by,"InxMed (Shanghai) Co., Ltd."
NCT05830539,tests,IN10018+PLD
IN10018+PLD,has_type,DRUG
NCT05830539,tests,IN10018+PLD+Toripalimab
IN10018+PLD+Toripalimab,has_type,DRUG
NCT00618657,has_title,"A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzuma"
NCT00618657,has_status,COMPLETED
NCT00618657,has_phase,
NCT00618657,sponsored_by,"University of California, Irvine"
NCT00618657,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00618657,tests,paclitaxel albumin-stabilized nanoparticle formulation
paclitaxel albumin-stabilized nanoparticle formulation,has_type,DRUG
NCT00618657,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT00618657,tests,trastuzumab
trastuzumab,has_type,DRUG
NCT00618657,tests,magnetic resonance imaging
magnetic resonance imaging,has_type,PROCEDURE
NCT00618657,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT02456857,has_title,"Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and"
NCT02456857,has_status,COMPLETED
NCT02456857,has_phase,
NCT02456857,sponsored_by,M.D. Anderson Cancer Center
NCT02456857,tests,Bevacizumab
Bevacizumab,has_type,BIOLOGICAL
NCT02456857,tests,Everolimus
Everolimus,has_type,DRUG
NCT02456857,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02456857,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
NCT06586957,has_title,"A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminar"
NCT06586957,has_status,RECRUITING
NCT06586957,has_phase,
NCT06586957,sponsored_by,"NiKang Therapeutics, Inc."
NCT06586957,tests,NKT3964
NKT3964,has_type,DRUG
NCT05088057,has_title,A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Camrelizumab Plus Chemotherapy as Neoadjuvant
NCT05088057,has_status,UNKNOWN
NCT05088057,has_phase,
NCT05088057,sponsored_by,Aiping Shi
NCT05088057,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT05088057,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05088057,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05088057,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01639248,has_title,A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Local
NCT01639248,has_status,COMPLETED
NCT01639248,has_phase,
NCT01639248,sponsored_by,"CASI Pharmaceuticals, Inc."
NCT01639248,tests,ENMD-2076
ENMD-2076,has_type,DRUG
NCT02555657,has_title,A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemothera
NCT02555657,has_status,COMPLETED
NCT02555657,has_phase,
NCT02555657,sponsored_by,Merck Sharp & Dohme LLC
NCT02555657,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT02555657,tests,capecitabine
capecitabine,has_type,DRUG
NCT02555657,tests,eribulin
eribulin,has_type,DRUG
NCT02555657,tests,gemcitabine
gemcitabine,has_type,DRUG
NCT02555657,tests,vinorelbine
vinorelbine,has_type,DRUG
NCT05978648,has_title,"A Prospective, Multi-cohort, Exploratory Phase II Study of Trilaciclib Combined With Standard Chemot"
NCT05978648,has_status,RECRUITING
NCT05978648,has_phase,
NCT05978648,sponsored_by,wang shusen
NCT05978648,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT05978648,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05978648,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05978648,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05978648,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05978648,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05978648,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05978648,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT02580448,has_title,"A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy"
NCT02580448,has_status,COMPLETED
NCT02580448,has_phase,
NCT02580448,sponsored_by,Innocrin Pharmaceutical
NCT02580448,tests,Seviteronel
Seviteronel,has_type,DRUG
NCT04152057,has_title,"A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin Paclitax"
NCT04152057,has_status,UNKNOWN
NCT04152057,has_phase,
NCT04152057,sponsored_by,West China Hospital
NCT04152057,tests,Pyrotinib Maleate Tablets
Pyrotinib Maleate Tablets,has_type,DRUG
NCT04152057,tests,Albumin Paclitaxel
Albumin Paclitaxel,has_type,DRUG
NCT04152057,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02685657,has_title,A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel
NCT02685657,has_status,UNKNOWN
NCT02685657,has_phase,
NCT02685657,sponsored_by,Russian Academy of Medical Sciences
NCT02685657,tests,Drug: Selumetinib
Drug: Selumetinib,has_type,DRUG
NCT02685657,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02685657,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02685657,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06802757,has_title,"A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus Pembrolizumab and Chemoth"
NCT06802757,has_status,RECRUITING
NCT06802757,has_phase,
NCT06802757,sponsored_by,Shandong Cancer Hospital and Institute
NCT06802757,tests,Posaconazole
Posaconazole,has_type,DRUG
NCT06802757,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06802757,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06802757,tests,Anthracycline
Anthracycline,has_type,DRUG
NCT06802757,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06802757,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03071757,has_title,"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacoki"
NCT03071757,has_status,COMPLETED
NCT03071757,has_phase,
NCT03071757,sponsored_by,AbbVie
NCT03071757,tests,ABBV-368
ABBV-368,has_type,DRUG
NCT03071757,tests,ABBV-181
ABBV-181,has_type,DRUG
NCT03863457,has_title,Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer
NCT03863457,has_status,RECRUITING
NCT03863457,has_phase,
NCT03863457,sponsored_by,Abramson Cancer Center at Penn Medicine
NCT03863457,tests,Fluoroglutamine [18F]F-GLN
Fluoroglutamine [18F]F-GLN,has_type,DRUG
NCT06399757,has_title,A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Ad
NCT06399757,has_status,RECRUITING
NCT06399757,has_phase,
NCT06399757,sponsored_by,Apollo Therapeutics Ltd
NCT06399757,tests,APL-5125
APL-5125,has_type,DRUG
NCT02489448,has_title,Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Na
NCT02489448,has_status,COMPLETED
NCT02489448,has_phase,
NCT02489448,sponsored_by,Yale University
NCT02489448,tests,MEDI4736
MEDI4736,has_type,DRUG
NCT06787339,has_title,"A Prospective, Single-arm,Clinical Trial Exploring the Efficacy and Safety of Chemotherapy De-escala"
NCT06787339,has_status,NOT_YET_RECRUITING
NCT06787339,has_phase,
NCT06787339,sponsored_by,Fudan University
NCT06787339,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04045522,has_title,A Multicenter Prospective Real-world Study on Bisphosphonates Targeting Triple-negative Breast Cance
NCT04045522,has_status,UNKNOWN
NCT04045522,has_phase,
NCT04045522,sponsored_by,Shengjing Hospital
NCT04045522,tests,Zoledronic Acid
Zoledronic Acid,has_type,DRUG
NCT03616886,has_title,A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Olecluma
NCT03616886,has_status,ACTIVE_NOT_RECRUITING
NCT03616886,has_phase,
NCT03616886,sponsored_by,Jules Bordet Institute
NCT03616886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03616886,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03616886,tests,MEDI4736
MEDI4736,has_type,DRUG
NCT03616886,tests,MEDI9447
MEDI9447,has_type,DRUG
NCT02222922,has_title,"A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT "
NCT02222922,has_status,COMPLETED
NCT02222922,has_phase,
NCT02222922,sponsored_by,Pfizer
NCT02222922,tests,PF-06647020 Q3W
PF-06647020 Q3W,has_type,DRUG
NCT02222922,tests,fluconazole
fluconazole,has_type,DRUG
NCT02222922,tests,PF-06647020 Q2W
PF-06647020 Q2W,has_type,DRUG
NCT02222922,tests,PF-06647020 combined with Avelumab
PF-06647020 combined with Avelumab,has_type,DRUG
NCT05957939,has_title,"Targeting Triple-negative Breast Cancer or ER-positive, PR Positive her2 Negative by Alkaline Glucos"
NCT05957939,has_status,UNKNOWN
NCT05957939,has_phase,
NCT05957939,sponsored_by,"Ministry of Health, Saudi Arabia"
NCT05957939,tests,Alkaline Glucosodiene Molecules
Alkaline Glucosodiene Molecules,has_type,DRUG
NCT02178722,has_title,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With IN"
NCT02178722,has_status,COMPLETED
NCT02178722,has_phase,
NCT02178722,sponsored_by,Incyte Corporation
NCT02178722,tests,MK-3475
MK-3475,has_type,DRUG
NCT02178722,tests,INCB024360
INCB024360,has_type,DRUG
NCT03546686,has_title,A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women 
NCT03546686,has_status,RECRUITING
NCT03546686,has_phase,
NCT03546686,sponsored_by,University of Texas Southwestern Medical Center
NCT03546686,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03546686,tests,Core Biopsy/Cryoablation
Core Biopsy/Cryoablation,has_type,PROCEDURE
NCT03546686,tests,Breast Surgery
Breast Surgery,has_type,PROCEDURE
NCT03546686,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT03546686,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT05842148,has_title,IRONY: lIfe afteR ONcoplastic surgerY
NCT05842148,has_status,RECRUITING
NCT05842148,has_phase,
NCT05842148,sponsored_by,Campus Bio-Medico University
NCT05842148,tests,Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.
Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.,has_type,OTHER
NCT05842148,tests,Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.
Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.,has_type,OTHER
NCT05842148,tests,"Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient."
"Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.",has_type,OTHER
NCT04176848,has_title,A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative B
NCT04176848,has_status,ACTIVE_NOT_RECRUITING
NCT04176848,has_phase,
NCT04176848,sponsored_by,Canadian Cancer Trials Group
NCT04176848,tests,CFI-400945
CFI-400945,has_type,DRUG
NCT04176848,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT02627430,has_title,A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Soli
NCT02627430,has_status,WITHDRAWN
NCT02627430,has_phase,
NCT02627430,sponsored_by,National Cancer Institute (NCI)
NCT02627430,tests,Hsp90 Inhibitor AT13387
Hsp90 Inhibitor AT13387,has_type,DRUG
NCT02627430,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02627430,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02627430,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT03310957,has_title,"Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Lin"
NCT03310957,has_status,COMPLETED
NCT03310957,has_phase,
NCT03310957,sponsored_by,Seagen Inc.
NCT03310957,tests,ladiratuzumab vedotin
ladiratuzumab vedotin,has_type,DRUG
NCT03310957,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02632448,has_title,A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY28800
NCT02632448,has_status,COMPLETED
NCT02632448,has_phase,
NCT02632448,sponsored_by,Esperas Pharma Inc.
NCT02632448,tests,LY2880070
LY2880070,has_type,DRUG
NCT02632448,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06337630,has_title,A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With
NCT06337630,has_status,RECRUITING
NCT06337630,has_phase,
NCT06337630,sponsored_by,Institut Curie
NCT06337630,tests,PLX038 + Tuvusertib
PLX038 + Tuvusertib,has_type,DRUG
NCT06878248,has_title,"A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, "
NCT06878248,has_status,RECRUITING
NCT06878248,has_phase,
NCT06878248,sponsored_by,"Calibr, a division of Scripps Research"
NCT06878248,tests,Two Component Product CLBR001 + ABBV-461
Two Component Product CLBR001 + ABBV-461,has_type,BIOLOGICAL
NCT05632848,has_title,The Efficacy and Safety of Chidamide Combined With Zimberelimab in the Treatment of Metastatic Tripl
NCT05632848,has_status,RECRUITING
NCT05632848,has_phase,
NCT05632848,sponsored_by,Sun Yat-sen University
NCT05632848,tests,Chidamide combined with Zimberelimab
Chidamide combined with Zimberelimab,has_type,DRUG
NCT03444025,has_title,Prospective Phase II Randomized Trial of Evaluating the Effect of Adding LHRH Analogue to the Neoadj
NCT03444025,has_status,UNKNOWN
NCT03444025,has_phase,
NCT03444025,sponsored_by,Kasr El Aini Hospital
NCT03444025,tests,Goserelin
Goserelin,has_type,DRUG
NCT02996825,has_title,A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Ge
NCT02996825,has_status,COMPLETED
NCT02996825,has_phase,
NCT02996825,sponsored_by,City of Hope Medical Center
NCT02996825,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02996825,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT02996825,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02996825,tests,Mirvetuximab Soravtansine
Mirvetuximab Soravtansine,has_type,BIOLOGICAL
NCT02996825,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02730130,has_title,A Multicenter Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in
NCT02730130,has_status,COMPLETED
NCT02730130,has_phase,
NCT02730130,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02730130,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02730130,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT01575522,has_title,A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer
NCT01575522,has_status,COMPLETED
NCT01575522,has_phase,
NCT01575522,sponsored_by,National Cancer Institute (NCI)
NCT01575522,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01575522,tests,Tivantinib
Tivantinib,has_type,DRUG
NCT01975831,has_title,"A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With"
NCT01975831,has_status,COMPLETED
NCT01975831,has_phase,
NCT01975831,sponsored_by,Ludwig Institute for Cancer Research
NCT01975831,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT01975831,tests,Tremelimumab
Tremelimumab,has_type,DRUG
NCT03589339,has_title,A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients wi
NCT03589339,has_status,RECRUITING
NCT03589339,has_phase,
NCT03589339,sponsored_by,Nanobiotix
NCT03589339,tests,NBTXR3
NBTXR3,has_type,DRUG
NCT03589339,tests,SABR
SABR,has_type,RADIATION
NCT03589339,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03589339,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06246786,has_title,A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Cyclosporin A on Triple Negat
NCT06246786,has_status,RECRUITING
NCT06246786,has_phase,
NCT06246786,sponsored_by,Virginia G. Kaklamani
NCT06246786,tests,Cyclosporin A
Cyclosporin A,has_type,DRUG
NCT02676986,has_title,Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone o
NCT02676986,has_status,COMPLETED
NCT02676986,has_phase,
NCT02676986,sponsored_by,Queen Mary University of London
NCT02676986,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02676986,tests,Exemestane
Exemestane,has_type,DRUG
NCT04803539,has_title,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Ch"
NCT04803539,has_status,RECRUITING
NCT04803539,has_phase,
NCT04803539,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04803539,tests,capecitabine
capecitabine,has_type,DRUG
NCT04803539,tests,capecitabine + camrelizumab + apatinib
capecitabine + camrelizumab + apatinib,has_type,DRUG
NCT05821686,has_title,Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast Cancer
NCT05821686,has_status,NOT_YET_RECRUITING
NCT05821686,has_phase,
NCT05821686,sponsored_by,Nova Scotia Health Authority
NCT05821686,tests,Human Interleukin-2 (IL-2) (Proleukin)
Human Interleukin-2 (IL-2) (Proleukin),has_type,DRUG
NCT05382286,has_title,"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment "
NCT05382286,has_status,ACTIVE_NOT_RECRUITING
NCT05382286,has_phase,
NCT05382286,sponsored_by,Gilead Sciences
NCT05382286,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT05382286,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05382286,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05382286,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT05382286,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05382286,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05774886,has_title,Pilot Study of an Implantable Microdevice to Evaluate Drug Responses in Situ in Early-stage Triple-n
NCT05774886,has_status,WITHDRAWN
NCT05774886,has_phase,
NCT05774886,sponsored_by,Dana-Farber Cancer Institute
NCT05774886,tests,Implantable Microdevice (IMD)
Implantable Microdevice (IMD),has_type,COMBINATION_PRODUCT
NCT02921152,has_title,Bone Marrow Micrometastases in Patients With Early Stage Breast Cancer
NCT02921152,has_status,UNKNOWN
NCT02921152,has_phase,
NCT02921152,sponsored_by,Acibadem University
NCT02921152,tests,bone marrow aspiration /trephine biopsy
bone marrow aspiration /trephine biopsy,has_type,PROCEDURE
NCT05435352,has_title,Prospective Evaluation of Image-based Artificial Intelligence Research and Development Tool for Prec
NCT05435352,has_status,RECRUITING
NCT05435352,has_phase,
NCT05435352,sponsored_by,"Ourotech, Inc."
NCT05435352,tests,Core needle biopsy
Core needle biopsy,has_type,PROCEDURE
NCT03295552,has_title,Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer
NCT03295552,has_status,TERMINATED
NCT03295552,has_phase,
NCT03295552,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT03295552,tests,Decitabine
Decitabine,has_type,DRUG
NCT03295552,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02624700,has_title,Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative B
NCT02624700,has_status,TERMINATED
NCT02624700,has_phase,
NCT02624700,sponsored_by,Virginia Commonwealth University
NCT02624700,tests,Experimental Arm A: Pemetrexed
Experimental Arm A: Pemetrexed,has_type,DRUG
NCT02624700,tests,Experimental Arm A: Sorafenib
Experimental Arm A: Sorafenib,has_type,DRUG
NCT02624700,tests,Experimental Arm B: Pemetrexed
Experimental Arm B: Pemetrexed,has_type,DRUG
NCT02624700,tests,Experimental Arm B: Sorafenib
Experimental Arm B: Sorafenib,has_type,DRUG
NCT01238952,has_title,A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Foll
NCT01238952,has_status,COMPLETED
NCT01238952,has_phase,
NCT01238952,sponsored_by,"Nippon Kayaku Co., Ltd."
NCT01238952,tests,NK012 and carboplatin
NK012 and carboplatin,has_type,DRUG
NCT05909332,has_title,"A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Stand"
NCT05909332,has_status,RECRUITING
NCT05909332,has_phase,
NCT05909332,sponsored_by,Fudan University
NCT05909332,tests,Antivascular therapy
Antivascular therapy,has_type,DRUG
NCT05909332,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT06273800,has_title,Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients
NCT06273800,has_status,NOT_YET_RECRUITING
NCT06273800,has_phase,
NCT06273800,sponsored_by,The Netherlands Cancer Institute
NCT06273800,tests,Blood sample
Blood sample,has_type,PROCEDURE
NCT01251900,has_title,BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects
NCT01251900,has_status,COMPLETED
NCT01251900,has_phase,
NCT01251900,sponsored_by,National Cancer Institute (NCI)
NCT05306600,has_title,Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System
NCT05306600,has_status,RECRUITING
NCT05306600,has_phase,
NCT05306600,sponsored_by,Hospital Moinhos de Vento
NCT05306600,tests,whole exome and whole genome sequencing analysis
whole exome and whole genome sequencing analysis,has_type,DIAGNOSTIC_TEST
NCT02358200,has_title,"Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carbo"
NCT02358200,has_status,TERMINATED
NCT02358200,has_phase,
NCT02358200,sponsored_by,Pamela Munster
NCT02358200,tests,BMN-673
BMN-673,has_type,DRUG
NCT02358200,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02358200,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05757232,has_title,Construction of an Ultrasound Profile and a Mammography Profile Corresponding to the Different Molec
NCT05757232,has_status,COMPLETED
NCT05757232,has_phase,
NCT05757232,sponsored_by,Elsan
NCT06959537,has_title,A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axat
NCT06959537,has_status,NOT_YET_RECRUITING
NCT06959537,has_phase,
NCT06959537,sponsored_by,M.D. Anderson Cancer Center
NCT06959537,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06959537,tests,Axatilimab (SNDX-6352)
Axatilimab (SNDX-6352),has_type,DRUG
NCT06959537,tests,Retifanlimab
Retifanlimab,has_type,DRUG
NCT06052852,has_title,"A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and i"
NCT06052852,has_status,ACTIVE_NOT_RECRUITING
NCT06052852,has_phase,
NCT06052852,sponsored_by,"Bolt Biotherapeutics, Inc."
NCT06052852,tests,BDC-3042
BDC-3042,has_type,DRUG
NCT06052852,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT05174832,has_title,Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance i
NCT05174832,has_status,UNKNOWN
NCT05174832,has_phase,
NCT05174832,sponsored_by,Fudan University
NCT05174832,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT05174832,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05174832,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05174832,tests,Olaparib
Olaparib,has_type,DRUG
NCT01306032,has_title,Phase II Randomized Trial of ABT-888 in Combination With Metronomic Oral Cyclophosphamide in Refract
NCT01306032,has_status,COMPLETED
NCT01306032,has_phase,
NCT01306032,sponsored_by,National Cancer Institute (NCI)
NCT01306032,tests,ABT-888
ABT-888,has_type,DRUG
NCT01306032,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06793332,has_title,"Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined with TROP2 ADC in the Treatment o"
NCT06793332,has_status,RECRUITING
NCT06793332,has_phase,
NCT06793332,sponsored_by,Fudan University
NCT06793332,tests,Ivonescimab Combined With TROP2 ADC
Ivonescimab Combined With TROP2 ADC,has_type,DRUG
NCT06274515,has_title,A Multi Cohort Translational Research Study to Investigate Mechanisms of Resistance to Breast Cancer
NCT06274515,has_status,RECRUITING
NCT06274515,has_phase,
NCT06274515,sponsored_by,Hoffmann-La Roche
NCT06274515,tests,Tumor Tissue and Blood Draw
Tumor Tissue and Blood Draw,has_type,PROCEDURE
NCT06582615,has_title,Food for Thought - Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for 
NCT06582615,has_status,RECRUITING
NCT06582615,has_phase,
NCT06582615,sponsored_by,Ohio State University Comprehensive Cancer Center
NCT06582615,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06582615,tests,Cognitive Assessment
Cognitive Assessment,has_type,PROCEDURE
NCT06582615,tests,Dietary Intervention
Dietary Intervention,has_type,OTHER
NCT06582615,tests,Dietary Intervention
Dietary Intervention,has_type,OTHER
NCT06582615,tests,Dietary Intervention
Dietary Intervention,has_type,OTHER
NCT06582615,tests,Medical Device Usage and Evaluation
Medical Device Usage and Evaluation,has_type,OTHER
NCT06582615,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT02247037,has_title,Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
NCT02247037,has_status,COMPLETED
NCT02247037,has_phase,
NCT02247037,sponsored_by,Icahn School of Medicine at Mount Sinai
NCT02247037,tests,Chemotherapy
Chemotherapy,has_type,OTHER
NCT01629615,has_title,A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Can
NCT01629615,has_status,COMPLETED
NCT01629615,has_phase,
NCT01629615,sponsored_by,SOLTI Breast Cancer Research Group
NCT01629615,tests,BKM120
BKM120,has_type,DRUG
NCT04148937,has_title,A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or 
NCT04148937,has_status,COMPLETED
NCT04148937,has_phase,
NCT04148937,sponsored_by,Eli Lilly and Company
NCT04148937,tests,LY3475070
LY3475070,has_type,DRUG
NCT04148937,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03106415,has_title,Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced o
NCT03106415,has_status,COMPLETED
NCT03106415,has_phase,
NCT03106415,sponsored_by,Mayo Clinic
NCT03106415,tests,Binimetinib
Binimetinib,has_type,DRUG
NCT03106415,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03106415,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02509507,has_title,"A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepv"
NCT02509507,has_status,COMPLETED
NCT02509507,has_phase,
NCT02509507,sponsored_by,Amgen
NCT02509507,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,DRUG
NCT02509507,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05902988,has_title,A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
NCT05902988,has_status,RECRUITING
NCT05902988,has_phase,
NCT05902988,sponsored_by,"Volastra Therapeutics, Inc."
NCT05902988,tests,VLS-1488
VLS-1488,has_type,DRUG
NCT02158507,has_title,"An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic"
NCT02158507,has_status,COMPLETED
NCT02158507,has_phase,
NCT02158507,sponsored_by,University of Alabama at Birmingham
NCT02158507,tests,Combination of Veliparib + Lapatinib
Combination of Veliparib + Lapatinib,has_type,DRUG
NCT05272709,has_title,"CURATE: A Cancer Research UK Phase I/II, Dose Escalation and Expansion Trial of TT-702, A Selective "
NCT05272709,has_status,RECRUITING
NCT05272709,has_phase,
NCT05272709,sponsored_by,Cancer Research UK
NCT05272709,tests,TT-702
TT-702,has_type,DRUG
NCT05272709,tests,Darolutamide
Darolutamide,has_type,DRUG
NCT01990209,has_title,A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That 
NCT01990209,has_status,COMPLETED
NCT01990209,has_phase,
NCT01990209,sponsored_by,"SCRI Development Innovations, LLC"
NCT01990209,tests,Orteronel
Orteronel,has_type,DRUG
NCT05953909,has_title,Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast 
NCT05953909,has_status,UNKNOWN
NCT05953909,has_phase,
NCT05953909,sponsored_by,Fujian Cancer Hospital
NCT05953909,tests,Eribulin-Based Regimen
Eribulin-Based Regimen,has_type,DRUG
NCT05953909,tests,nab-paclitaxel based regimen
nab-paclitaxel based regimen,has_type,DRUG
NCT05953909,tests,Other Chemotherapy Regimen
Other Chemotherapy Regimen,has_type,DRUG
NCT02670109,has_title,High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment
NCT02670109,has_status,UNKNOWN
NCT02670109,has_phase,
NCT02670109,sponsored_by,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
NCT02670109,tests,Carmustine
Carmustine,has_type,DRUG
NCT02670109,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02670109,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02670109,tests,Autologous Hematopoietic Stem Cell Transplantation
Autologous Hematopoietic Stem Cell Transplantation,has_type,PROCEDURE
NCT02670109,tests,Busulfan
Busulfan,has_type,DRUG
NCT06371807,has_title,Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline Versus Carboplatin/
NCT06371807,has_status,NOT_YET_RECRUITING
NCT06371807,has_phase,
NCT06371807,sponsored_by,Fundacao Champalimaud
NCT06371807,tests,Pembrolizumab injection
Pembrolizumab injection,has_type,DRUG
NCT02876107,has_title,A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplati
NCT02876107,has_status,ACTIVE_NOT_RECRUITING
NCT02876107,has_phase,
NCT02876107,sponsored_by,M.D. Anderson Cancer Center
NCT02876107,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02876107,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02876107,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02876107,tests,Panitumumab
Panitumumab,has_type,BIOLOGICAL
NCT05504707,has_title,"Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells "
NCT05504707,has_status,ACTIVE_NOT_RECRUITING
NCT05504707,has_phase,
NCT05504707,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05504707,tests,HER2 - primed Dendritic cells
HER2 - primed Dendritic cells,has_type,BIOLOGICAL
NCT05504707,tests,HER3 - primed Dendritic cells
HER3 - primed Dendritic cells,has_type,BIOLOGICAL
NCT06189209,has_title,"A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisi"
NCT06189209,has_status,RECRUITING
NCT06189209,has_phase,
NCT06189209,sponsored_by,Rhizen Pharmaceuticals SA
NCT06189209,tests,Tenalisib
Tenalisib,has_type,DRUG
NCT02101385,has_title,A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemothera
NCT02101385,has_status,COMPLETED
NCT02101385,has_phase,
NCT02101385,sponsored_by,"Bryan Schneider, MD"
NCT02101385,tests,Genomically Directed Monotherapy
Genomically Directed Monotherapy,has_type,DRUG
NCT02101385,tests,Observation/Standard Therapy
Observation/Standard Therapy,has_type,OTHER
NCT02607215,has_title,Platinum Retreated in Second- or Third-line Patients With Platinum Sensitive Metastatic Triple Negat
NCT02607215,has_status,UNKNOWN
NCT02607215,has_phase,
NCT02607215,sponsored_by,Fudan University
NCT02607215,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT02607215,tests,DDP
DDP,has_type,DRUG
NCT04300556,has_title,"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb"
NCT04300556,has_status,RECRUITING
NCT04300556,has_phase,
NCT04300556,sponsored_by,Eisai Inc.
NCT04300556,tests,Farletuzumab ecteribulin
Farletuzumab ecteribulin,has_type,DRUG
NCT04300556,tests,Prednisone
Prednisone,has_type,DRUG
NCT04300556,tests,Prednisolone
Prednisolone,has_type,DRUG
NCT04300556,tests,Dexamethasone
Dexamethasone,has_type,DRUG
NCT05675085,has_title,Risk-Based Breast Screening (RIBBS) in Young Women: Personalized Imaging Protocols
NCT05675085,has_status,ACTIVE_NOT_RECRUITING
NCT05675085,has_phase,
NCT05675085,sponsored_by,Istituto Oncologico Veneto IRCCS
NCT05675085,tests,Personalized screening protocol
Personalized screening protocol,has_type,DIAGNOSTIC_TEST
NCT02720185,has_title,Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epi
NCT02720185,has_status,TERMINATED
NCT02720185,has_phase,
NCT02720185,sponsored_by,"University of Wisconsin, Madison"
NCT02720185,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT02720185,tests,Conventional Surgery
Conventional Surgery,has_type,PROCEDURE
NCT02720185,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03818685,has_title,"A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-oper"
NCT03818685,has_status,ACTIVE_NOT_RECRUITING
NCT03818685,has_phase,
NCT03818685,sponsored_by,Centre Leon Berard
NCT03818685,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03818685,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT03818685,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT00546156,has_title,A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by P
NCT00546156,has_status,COMPLETED
NCT00546156,has_phase,
NCT00546156,sponsored_by,"Ian E. Krop, MD, PhD"
NCT00546156,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT00546156,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00546156,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00546156,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT06104085,has_title,99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
NCT06104085,has_status,RECRUITING
NCT06104085,has_phase,
NCT06104085,sponsored_by,Peking Union Medical College Hospital
NCT06104085,tests,99mTc-MY6349 SPECT/CT scan
99mTc-MY6349 SPECT/CT scan,has_type,DIAGNOSTIC_TEST
NCT04580485,has_title,"A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunot"
NCT04580485,has_status,COMPLETED
NCT04580485,has_phase,
NCT04580485,sponsored_by,Incyte Corporation
NCT04580485,tests,INCB106385
INCB106385,has_type,DRUG
NCT04580485,tests,INCMGA00012
INCMGA00012,has_type,DRUG
NCT04551885,has_title,"A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subje"
NCT04551885,has_status,TERMINATED
NCT04551885,has_phase,
NCT04551885,sponsored_by,Fate Therapeutics
NCT04551885,tests,FT516
FT516,has_type,DRUG
NCT04551885,tests,Avelumab
Avelumab,has_type,DRUG
NCT04551885,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04551885,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT04551885,tests,IL-2
IL-2,has_type,DRUG
NCT01138085,has_title,"A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine "
NCT01138085,has_status,COMPLETED
NCT01138085,has_phase,
NCT01138085,sponsored_by,GlaxoSmithKline
NCT01138085,tests,GSK1120212
GSK1120212,has_type,DRUG
NCT01138085,tests,GSK2141795
GSK2141795,has_type,DRUG
NCT01165385,has_title,An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With C
NCT01165385,has_status,COMPLETED
NCT01165385,has_phase,
NCT01165385,sponsored_by,UNICANCER
NCT01165385,tests,cisplatin
cisplatin,has_type,DRUG
NCT01165385,tests,Pazopanib
Pazopanib,has_type,DRUG
NCT00759785,has_title,A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer
NCT00759785,has_status,COMPLETED
NCT00759785,has_phase,
NCT00759785,sponsored_by,Merck Sharp & Dohme LLC
NCT00759785,tests,dalotuzumab (MK0646)
dalotuzumab (MK0646),has_type,DRUG
NCT06230185,has_title,Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with E
NCT06230185,has_status,RECRUITING
NCT06230185,has_phase,
NCT06230185,sponsored_by,Personalis Inc.
NCT04609215,has_title,"""ImmunoBreast - A Phase Ib Study to Investigate the Safety, Tolerability and Trends of Efficacy of A"
NCT04609215,has_status,UNKNOWN
NCT04609215,has_phase,
NCT04609215,sponsored_by,Henrik Ditzel
NCT04609215,tests,ALECSAT
ALECSAT,has_type,OTHER
NCT06150885,has_title,"A Single Arm, Open Label, Dose-escalation Phase I and Dose-expansion Phase IIa Clinical Study to Eva"
NCT06150885,has_status,RECRUITING
NCT06150885,has_phase,
NCT06150885,sponsored_by,"Ever Supreme Bio Technology Co., Ltd."
NCT06150885,tests,HLA-G-CAR.BiTE allogeneic γδ T cells
HLA-G-CAR.BiTE allogeneic γδ T cells,has_type,BIOLOGICAL
NCT05806385,has_title,Local Therapy Optimization by Grouping Immune-modulation With Cryoablation (LOGIC) for High Risk Bre
NCT05806385,has_status,NOT_YET_RECRUITING
NCT05806385,has_phase,
NCT05806385,sponsored_by,Texas Tech University Health Sciences Center
NCT05806385,tests,Cryoablation
Cryoablation,has_type,DEVICE
NCT05806385,tests,Cryoablation combined with PD1 Inhibitor
Cryoablation combined with PD1 Inhibitor,has_type,COMBINATION_PRODUCT
NCT05550415,has_title,Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combinatio
NCT05550415,has_status,RECRUITING
NCT05550415,has_phase,
NCT05550415,sponsored_by,Indonesia University
NCT05550415,tests,Simvastatin 40mg
Simvastatin 40mg,has_type,DRUG
NCT05550415,tests,Placebo
Placebo,has_type,DRUG
NCT05266937,has_title,A Phase II Trial of Atezolizumab Plus CArboplatin Plus Nab-paclitaxel as First-line Therapy in Metas
NCT05266937,has_status,ACTIVE_NOT_RECRUITING
NCT05266937,has_phase,
NCT05266937,sponsored_by,Consorzio Oncotech
NCT05266937,tests,"Atezolizumab,Paclitaxel, Carboplatin"
"Atezolizumab,Paclitaxel, Carboplatin",has_type,COMBINATION_PRODUCT
NCT03562637,has_title,"The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simo"
NCT03562637,has_status,ACTIVE_NOT_RECRUITING
NCT03562637,has_phase,
NCT03562637,sponsored_by,"OBI Pharma, Inc"
NCT03562637,tests,adagloxad simolenin combined with OBI-821
adagloxad simolenin combined with OBI-821,has_type,BIOLOGICAL
NCT03562637,tests,Globo H IHC Assay
Globo H IHC Assay,has_type,DEVICE
NCT03562637,tests,Standard of care treatment
Standard of care treatment,has_type,OTHER
NCT03717415,has_title,"An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplati"
NCT03717415,has_status,TERMINATED
NCT03717415,has_phase,
NCT03717415,sponsored_by,"Deciphera Pharmaceuticals, LLC"
NCT03717415,tests,Rebastinib
Rebastinib,has_type,DRUG
NCT03717415,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05339685,has_title,"Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pre"
NCT05339685,has_status,RECRUITING
NCT05339685,has_phase,
NCT05339685,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT05339685,tests,BL-M02D1
BL-M02D1,has_type,DRUG
NCT06039956,has_title,De-escalating Axillary Surgery After Neoadjuvant Chemotherapy in Node Positive Breast Cancer Patient
NCT06039956,has_status,NOT_YET_RECRUITING
NCT06039956,has_phase,
NCT06039956,sponsored_by,Nova Scotia Health Authority
NCT06039956,tests,Sentinel lymph Node Biopsy
Sentinel lymph Node Biopsy,has_type,PROCEDURE
NCT02752685,has_title,Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NCT02752685,has_status,ACTIVE_NOT_RECRUITING
NCT02752685,has_phase,
NCT02752685,sponsored_by,NYU Langone Health
NCT02752685,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02752685,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT02506556,has_title,"A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidyl"
NCT02506556,has_status,COMPLETED
NCT02506556,has_phase,
NCT02506556,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT02506556,tests,BYl719
BYl719,has_type,DRUG
NCT03345485,has_title,"A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-C"
NCT03345485,has_status,COMPLETED
NCT03345485,has_phase,
NCT03345485,sponsored_by,Mundipharma Research Limited
NCT03345485,tests,Tinostamustine 60mg/m2 over 30min
Tinostamustine 60mg/m2 over 30min,has_type,DRUG
NCT03345485,tests,Tinostamustine 80mg/m2 over 30min
Tinostamustine 80mg/m2 over 30min,has_type,DRUG
NCT03345485,tests,Tinostamustine 100mg/m2 over 30min
Tinostamustine 100mg/m2 over 30min,has_type,DRUG
NCT03345485,tests,Tinostamustine 60mg/m2 over 60min
Tinostamustine 60mg/m2 over 60min,has_type,DRUG
NCT03345485,tests,Tinostamustine 80mg/m2 over 60min
Tinostamustine 80mg/m2 over 60min,has_type,DRUG
NCT03345485,tests,Tinostamustine 100mg/m2 over 60min
Tinostamustine 100mg/m2 over 60min,has_type,DRUG
NCT03345485,tests,Tinostamustine 80mg/m2 over 80min
Tinostamustine 80mg/m2 over 80min,has_type,DRUG
NCT02379585,has_title,A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Bre
NCT02379585,has_status,TERMINATED
NCT02379585,has_phase,
NCT02379585,sponsored_by,Western Regional Medical Center
NCT02379585,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02379585,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT02379585,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT02379585,tests,docetaxel
docetaxel,has_type,DRUG
NCT02379585,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02379585,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT03304756,has_title,Phase II Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer Patients With the CAP Regi
NCT03304756,has_status,COMPLETED
NCT03304756,has_phase,
NCT03304756,sponsored_by,"Instituto Nacional de Cancer, Brazil"
NCT03304756,tests,CAP
CAP,has_type,DRUG
NCT02628132,has_title,"Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody"
NCT02628132,has_status,COMPLETED
NCT02628132,has_phase,
NCT02628132,sponsored_by,King Faisal Specialist Hospital & Research Center
NCT02628132,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02628132,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT01790932,has_title,A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer
NCT01790932,has_status,COMPLETED
NCT01790932,has_phase,
NCT01790932,sponsored_by,Dana-Farber Cancer Institute
NCT01790932,tests,BKM120
BKM120,has_type,DRUG
NCT04024800,has_title,A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients 
NCT04024800,has_status,UNKNOWN
NCT04024800,has_phase,
NCT04024800,sponsored_by,NuGenerex Immuno-Oncology
NCT04024800,tests,AE37 Peptide vaccine
AE37 Peptide vaccine,has_type,BIOLOGICAL
NCT04024800,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03277352,has_title,A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subject
NCT03277352,has_status,TERMINATED
NCT03277352,has_phase,
NCT03277352,sponsored_by,Incyte Biosciences International Sàrl
NCT03277352,tests,INCAGN01876
INCAGN01876,has_type,DRUG
NCT03277352,tests,Epacadostat
Epacadostat,has_type,DRUG
NCT03277352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06273852,has_title,A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration 
NCT06273852,has_status,RECRUITING
NCT06273852,has_phase,
NCT06273852,sponsored_by,Pure Biologics S.A.
NCT06273852,tests,PBA-0405
PBA-0405,has_type,DRUG
NCT04244552,has_title,"A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokine"
NCT04244552,has_status,TERMINATED
NCT04244552,has_phase,
NCT04244552,sponsored_by,"Atreca, Inc."
NCT04244552,tests,ATRC-101
ATRC-101,has_type,BIOLOGICAL
NCT04244552,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04244552,tests,Pegylated liposomal doxorubicin (PLD)
Pegylated liposomal doxorubicin (PLD),has_type,DRUG
NCT02789332,has_title,A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Pacli
NCT02789332,has_status,COMPLETED
NCT02789332,has_phase,
NCT02789332,sponsored_by,GBG Forschungs GmbH
NCT02789332,tests,PwO
PwO,has_type,DRUG
NCT02789332,tests,PwCb
PwCb,has_type,DRUG
NCT02789332,tests,EC
EC,has_type,DRUG
NCT02789332,tests,Surgery after neoadjuvant Therapy
Surgery after neoadjuvant Therapy,has_type,PROCEDURE
NCT02789332,tests,Stratification
Stratification,has_type,OTHER
NCT01669252,has_title,"A Phase II, Open-label, Single-arm, Exploratory Pharmacogenomic Study of Single Agent Eribulin (HALA"
NCT01669252,has_status,COMPLETED
NCT01669252,has_phase,
NCT01669252,sponsored_by,SOLTI Breast Cancer Research Group
NCT01669252,tests,Eribulin
Eribulin,has_type,DRUG
NCT05329532,has_title,"A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian"
NCT05329532,has_status,RECRUITING
NCT05329532,has_phase,
NCT05329532,sponsored_by,Scancell Ltd
NCT05329532,tests,Modi-1/Modi-1v
Modi-1/Modi-1v,has_type,BIOLOGICAL
NCT05329532,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05329532,tests,MicronJet600™ microneedle device (NanoPass)
MicronJet600™ microneedle device (NanoPass),has_type,DEVICE
NCT04460456,has_title,"A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination Wi"
NCT04460456,has_status,UNKNOWN
NCT04460456,has_phase,
NCT04460456,sponsored_by,Silverback Therapeutics
NCT04460456,tests,SBT6050
SBT6050,has_type,DRUG
NCT04460456,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT04460456,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT06154109,has_title,Comparative Efficacy of Xiaopi Granules and Decoction in Improving Pathological Complete Response of
NCT06154109,has_status,NOT_YET_RECRUITING
NCT06154109,has_phase,
NCT06154109,sponsored_by,Zhiyu Wang
NCT06154109,tests,Xiaopi granules
Xiaopi granules,has_type,DRUG
NCT06154109,tests,Xiaopi decoction
Xiaopi decoction,has_type,DRUG
NCT06154109,tests,Placebo
Placebo,has_type,DRUG
NCT04030507,has_title,Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed 
NCT04030507,has_status,RECRUITING
NCT04030507,has_phase,
NCT04030507,sponsored_by,Dana-Farber Cancer Institute
NCT04030507,tests,MRI
MRI,has_type,DEVICE
NCT03554109,has_title,An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) 
NCT03554109,has_status,WITHDRAWN
NCT03554109,has_phase,
NCT03554109,sponsored_by,"ImmunityBio, Inc."
NCT03554109,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT03554109,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT03554109,tests,Aldoxorubicin HCl
Aldoxorubicin HCl,has_type,DRUG
NCT03554109,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT03554109,tests,ETBX-011
ETBX-011,has_type,BIOLOGICAL
NCT03554109,tests,ETBX-051
ETBX-051,has_type,BIOLOGICAL
NCT03554109,tests,ETBX-061
ETBX-061,has_type,BIOLOGICAL
NCT03554109,tests,GI-4000
GI-4000,has_type,BIOLOGICAL
NCT03554109,tests,GI-6207
GI-6207,has_type,BIOLOGICAL
NCT03554109,tests,GI-6301
GI-6301,has_type,BIOLOGICAL
NCT03554109,tests,Avelumab
Avelumab,has_type,DRUG
NCT03554109,tests,ALT-803
ALT-803,has_type,BIOLOGICAL
NCT03554109,tests,haNK
haNK,has_type,BIOLOGICAL
NCT03554109,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03554109,tests,Doxorubicin HCL
Doxorubicin HCL,has_type,DRUG
NCT03554109,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT04837209,has_title,"A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunot"
NCT04837209,has_status,RECRUITING
NCT04837209,has_phase,
NCT04837209,sponsored_by,Massachusetts General Hospital
NCT04837209,tests,Niraparib
Niraparib,has_type,DRUG
NCT04837209,tests,Dostarlimab
Dostarlimab,has_type,DRUG
NCT04837209,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT03853707,has_title,"A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capeci"
NCT03853707,has_status,COMPLETED
NCT03853707,has_phase,
NCT03853707,sponsored_by,City of Hope Medical Center
NCT03853707,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03853707,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03853707,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03853707,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03853707,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03853707,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03853707,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT03971409,has_title,Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicen
NCT03971409,has_status,RECRUITING
NCT03971409,has_phase,
NCT03971409,sponsored_by,"Laura Huppert, MD, BA"
NCT03971409,tests,Anti-OX40 Antibody PF-04518600
Anti-OX40 Antibody PF-04518600,has_type,BIOLOGICAL
NCT03971409,tests,Avelumab
Avelumab,has_type,DRUG
NCT03971409,tests,Binimetinib
Binimetinib,has_type,DRUG
NCT03971409,tests,Utomilumab
Utomilumab,has_type,BIOLOGICAL
NCT03971409,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
NCT03971409,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT02898207,has_title,A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Sol
NCT02898207,has_status,COMPLETED
NCT02898207,has_phase,
NCT02898207,sponsored_by,National Cancer Institute (NCI)
NCT02898207,tests,Olaparib
Olaparib,has_type,DRUG
NCT02898207,tests,Onalespib
Onalespib,has_type,DRUG
NCT05035407,has_title,"A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lun"
NCT05035407,has_status,RECRUITING
NCT05035407,has_phase,
NCT05035407,sponsored_by,National Cancer Institute (NCI)
NCT05035407,tests,IL-2 (Aldesleukin)
IL-2 (Aldesleukin),has_type,DRUG
NCT05035407,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05035407,tests,KK-LC-1 TCR
KK-LC-1 TCR,has_type,BIOLOGICAL
NCT05035407,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT03333915,has_title,"An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese S"
NCT03333915,has_status,COMPLETED
NCT03333915,has_phase,
NCT03333915,sponsored_by,BeiGene
NCT03333915,tests,Pamiparib
Pamiparib,has_type,DRUG
NCT03417115,has_title,Treatment and Outcome of Patients With Breast Cancer: Clinical Research Platform for Real World Data
NCT03417115,has_status,ACTIVE_NOT_RECRUITING
NCT03417115,has_phase,
NCT03417115,sponsored_by,iOMEDICO AG
NCT04241237,has_title,Concordance Between Liquid and Tissue Biopsy in Newly Diagnosed Metastatic Breast Cancer
NCT04241237,has_status,UNKNOWN
NCT04241237,has_phase,
NCT04241237,sponsored_by,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT04241237,tests,Blood Draw
Blood Draw,has_type,PROCEDURE
NCT02014337,has_title,Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metasta
NCT02014337,has_status,COMPLETED
NCT02014337,has_phase,
NCT02014337,sponsored_by,Corcept Therapeutics
NCT02014337,tests,Mifepristone and Eribulin in combination
Mifepristone and Eribulin in combination,has_type,DRUG
NCT04454437,has_title,"A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metasta"
NCT04454437,has_status,ACTIVE_NOT_RECRUITING
NCT04454437,has_phase,
NCT04454437,sponsored_by,Gilead Sciences
NCT04454437,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT01009437,has_title,A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Can
NCT01009437,has_status,COMPLETED
NCT01009437,has_phase,
NCT01009437,sponsored_by,"Masonic Cancer Center, University of Minnesota"
NCT01009437,tests,ritonavir
ritonavir,has_type,DRUG
NCT01009437,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT04895709,has_title,A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Par
NCT04895709,has_status,RECRUITING
NCT04895709,has_phase,
NCT04895709,sponsored_by,Bristol-Myers Squibb
NCT04895709,tests,BMS-986340
BMS-986340,has_type,DRUG
NCT04895709,tests,BMS-936558-01
BMS-936558-01,has_type,DRUG
NCT04895709,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT00721409,has_title,"PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE P"
NCT00721409,has_status,COMPLETED
NCT00721409,has_phase,
NCT00721409,sponsored_by,Pfizer
NCT00721409,tests,PD 0332991
PD 0332991,has_type,DRUG
NCT00721409,tests,letrozole
letrozole,has_type,DRUG
NCT00721409,tests,letrozole
letrozole,has_type,DRUG
NCT04230109,has_title,A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Loc
NCT04230109,has_status,RECRUITING
NCT04230109,has_phase,
NCT04230109,sponsored_by,Massachusetts General Hospital
NCT04230109,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT04230109,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06771609,has_title,Evaluate the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemother
NCT06771609,has_status,RECRUITING
NCT06771609,has_phase,
NCT06771609,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06771609,tests,Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
Adebry single antibody + VEX metronomic chemotherapy + radiotherapy,has_type,DRUG
NCT06771609,tests,debry single antibody + VEX metronomic chemotherapy
debry single antibody + VEX metronomic chemotherapy,has_type,DRUG
NCT00986609,has_title,Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer
NCT00986609,has_status,COMPLETED
NCT00986609,has_phase,
NCT00986609,sponsored_by,"Joseph Baar, MD, PhD"
NCT00986609,tests,MUC-1 peptide vaccine
MUC-1 peptide vaccine,has_type,BIOLOGICAL
NCT00986609,tests,poly ICLC
poly ICLC,has_type,BIOLOGICAL
NCT00986609,tests,MUC1 peptide-poly-ICLC adjuvant vaccine
MUC1 peptide-poly-ICLC adjuvant vaccine,has_type,BIOLOGICAL
NCT00986609,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT00986609,tests,enzyme-linked immunosorbent assay
enzyme-linked immunosorbent assay,has_type,OTHER
NCT00986609,tests,flow cytometry
flow cytometry,has_type,OTHER
NCT05989828,has_title,Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed
NCT05989828,has_status,RECRUITING
NCT05989828,has_phase,
NCT05989828,sponsored_by,University of Southern California
NCT05989828,tests,Aldesleukin
Aldesleukin,has_type,BIOLOGICAL
NCT05989828,tests,Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes,has_type,BIOLOGICAL
NCT05989828,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05989828,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05989828,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05989828,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05989828,tests,Echocardiography
Echocardiography,has_type,PROCEDURE
NCT05989828,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05989828,tests,Leukapheresis
Leukapheresis,has_type,PROCEDURE
NCT05989828,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05989828,tests,Mammogram
Mammogram,has_type,PROCEDURE
NCT05989828,tests,Multigated Acquisition Scan
Multigated Acquisition Scan,has_type,PROCEDURE
NCT05989828,tests,Ultrasound Imaging
Ultrasound Imaging,has_type,PROCEDURE
NCT05914961,has_title,ICK-Breast: Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
NCT05914961,has_status,RECRUITING
NCT05914961,has_phase,
NCT05914961,sponsored_by,University Hospital Tuebingen
NCT01662128,has_title,Randomized Controlled Trials of Efficacy and Safety With Xeloda as Sequential Adjuvant Therapy After
NCT01662128,has_status,UNKNOWN
NCT01662128,has_phase,
NCT01662128,sponsored_by,Tianjin Medical University
NCT01662128,tests,Xeloda
Xeloda,has_type,DRUG
NCT02971761,has_title,A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulat
NCT02971761,has_status,COMPLETED
NCT02971761,has_phase,
NCT02971761,sponsored_by,City of Hope Medical Center
NCT02971761,tests,Enobosarm
Enobosarm,has_type,DRUG
NCT02971761,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02971761,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03538028,has_title,"A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants "
NCT03538028,has_status,COMPLETED
NCT03538028,has_phase,
NCT03538028,sponsored_by,Incyte Biosciences International Sàrl
NCT03538028,tests,INCAGN02385
INCAGN02385,has_type,BIOLOGICAL
NCT03411161,has_title,Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate th
NCT03411161,has_status,COMPLETED
NCT03411161,has_phase,
NCT03411161,sponsored_by,Institut de Recherches Internationales Servier
NCT03411161,tests,Combination therapy (S81694 + paclitaxel) phase I
Combination therapy (S81694 + paclitaxel) phase I,has_type,DRUG
NCT03411161,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03411161,tests,Combination therapy (S81694 + paclitaxel) phase II
Combination therapy (S81694 + paclitaxel) phase II,has_type,DRUG
NCT01653561,has_title,"A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Br"
NCT01653561,has_status,COMPLETED
NCT01653561,has_phase,
NCT01653561,sponsored_by,Fudan University
NCT01653561,tests,Apatinib
Apatinib,has_type,DRUG
NCT04861077,has_title,Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
NCT04861077,has_status,NOT_YET_RECRUITING
NCT04861077,has_phase,
NCT04861077,sponsored_by,University of Alabama at Birmingham
NCT04861077,tests,[18F]FMISO-PET with contrast-enhanced MRI
[18F]FMISO-PET with contrast-enhanced MRI,has_type,DRUG
NCT04137653,has_title,Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a P
NCT04137653,has_status,RECRUITING
NCT04137653,has_phase,
NCT04137653,sponsored_by,Shengjing Hospital
NCT04137653,tests,nab-Paclitaxel+carboplatin
nab-Paclitaxel+carboplatin,has_type,DRUG
NCT04137653,tests,Paclitaxel+carboplatin
Paclitaxel+carboplatin,has_type,DRUG
NCT03599453,has_title,Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhanc
NCT03599453,has_status,COMPLETED
NCT03599453,has_phase,
NCT03599453,sponsored_by,Roswell Park Cancer Institute
NCT03599453,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03599453,tests,Chemokine Modulation Therapy
Chemokine Modulation Therapy,has_type,PROCEDURE
NCT03599453,tests,Celecoxib
Celecoxib,has_type,DRUG
NCT03599453,tests,Recombinant Interferon Alfa-2b
Recombinant Interferon Alfa-2b,has_type,BIOLOGICAL
NCT03599453,tests,Rintatolimod
Rintatolimod,has_type,DRUG
NCT03599453,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04985253,has_title,"Correlation of Predictive Accuracy of PREDICT Version 2.2, (PREDICT V2.2) on a Retrospective Cohort "
NCT04985253,has_status,UNKNOWN
NCT04985253,has_phase,
NCT04985253,sponsored_by,Tata Memorial Centre
NCT04985253,tests,prediction of overall survival using Web based PREDICTV2.0 portal
prediction of overall survival using Web based PREDICTV2.0 portal,has_type,OTHER
NCT03012477,has_title,A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation o
NCT03012477,has_status,COMPLETED
NCT03012477,has_phase,
NCT03012477,sponsored_by,Dana-Farber Cancer Institute
NCT03012477,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03012477,tests,AZD1775
AZD1775,has_type,DRUG
NCT03891953,has_title,"A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PD"
NCT03891953,has_status,ACTIVE_NOT_RECRUITING
NCT03891953,has_phase,
NCT03891953,sponsored_by,Novartis Pharmaceuticals
NCT03891953,tests,DKY709
DKY709,has_type,DRUG
NCT03891953,tests,PDR001
PDR001,has_type,DRUG
NCT06994377,has_title,The Impact of Emotional Distress on First Line Therapy in Patients With Metastatic Breast Cancer (EI
NCT06994377,has_status,RECRUITING
NCT06994377,has_phase,
NCT06994377,sponsored_by,European Institute of Oncology
NCT06994377,tests,ED and quality of life assessment
ED and quality of life assessment,has_type,BEHAVIORAL
NCT01676753,has_title,A Phase 1b Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizum
NCT01676753,has_status,COMPLETED
NCT01676753,has_phase,
NCT01676753,sponsored_by,Jo Chien
NCT01676753,tests,Dinaciclib
Dinaciclib,has_type,DRUG
NCT01676753,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05169853,has_title,Correlation Between Programmed Death-Ligand1 Expression and Clinical Outcomes After Neoadjuvant Syst
NCT05169853,has_status,ACTIVE_NOT_RECRUITING
NCT05169853,has_phase,
NCT05169853,sponsored_by,Ain Shams University
NCT02723877,has_title,"An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR"
NCT02723877,has_status,COMPLETED
NCT02723877,has_phase,
NCT02723877,sponsored_by,PIQUR Therapeutics AG
NCT02723877,tests,PQR309
PQR309,has_type,DRUG
NCT02723877,tests,Eribulin
Eribulin,has_type,DRUG
NCT03475953,has_title,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
NCT03475953,has_status,RECRUITING
NCT03475953,has_phase,
NCT03475953,sponsored_by,Institut Bergonié
NCT03475953,tests,Phase 1 : Regorafenib
Phase 1 : Regorafenib,has_type,DRUG
NCT03475953,tests,Phase 1 : Avelumab
Phase 1 : Avelumab,has_type,DRUG
NCT03475953,tests,Phase 2 : Regorafenib
Phase 2 : Regorafenib,has_type,DRUG
NCT03475953,tests,Phase 2 : Avelumab
Phase 2 : Avelumab,has_type,DRUG
NCT03475953,tests,Phase 2: low-dose Regorafenib
Phase 2: low-dose Regorafenib,has_type,DRUG
NCT06840483,has_title,Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer
NCT06840483,has_status,RECRUITING
NCT06840483,has_phase,
NCT06840483,sponsored_by,BicycleTx Limited
NCT06840483,tests,Zelenectide pevedotin (BT8009)
Zelenectide pevedotin (BT8009),has_type,DRUG
NCT07005583,has_title,Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously 
NCT07005583,has_status,NOT_YET_RECRUITING
NCT07005583,has_phase,
NCT07005583,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT07005583,tests,QL1706 Plus Olaparib
QL1706 Plus Olaparib,has_type,DRUG
NCT01292083,has_title,A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression 
NCT01292083,has_status,WITHDRAWN
NCT01292083,has_phase,
NCT01292083,sponsored_by,University of Southern California
NCT01292083,tests,azacitidine
azacitidine,has_type,DRUG
NCT01292083,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01292083,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,OTHER
NCT01292083,tests,polymerase chain reaction
polymerase chain reaction,has_type,GENETIC
NCT01292083,tests,western blotting
western blotting,has_type,GENETIC
NCT01292083,tests,nucleic acid sequencing
nucleic acid sequencing,has_type,GENETIC
NCT01292083,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT02984683,has_title,Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 
NCT02984683,has_status,TERMINATED
NCT02984683,has_phase,
NCT02984683,sponsored_by,Sanofi
NCT02984683,tests,SAR566658 (ACT14884)
SAR566658 (ACT14884),has_type,DRUG
NCT05491083,has_title,A Phase 1b Followed by Phase II Expansion Trial of Combination of Pembrolizumab and ADG106 in Advanc
NCT05491083,has_status,RECRUITING
NCT05491083,has_phase,
NCT05491083,sponsored_by,"National University Hospital, Singapore"
NCT05491083,tests,Pembrolizumab & ADG106 (Phase Ib)
Pembrolizumab & ADG106 (Phase Ib),has_type,DRUG
NCT05491083,tests,Pembrolizumab & ADG106 (Phase II)
Pembrolizumab & ADG106 (Phase II),has_type,DRUG
NCT06460298,has_title,"Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in"
NCT06460298,has_status,RECRUITING
NCT06460298,has_phase,
NCT06460298,sponsored_by,"ProDa BioTech, LLC"
NCT06460298,tests,"ProAgio Dose Levels (DL) 1,2,3,4"
"ProAgio Dose Levels (DL) 1,2,3,4",has_type,DRUG
NCT06460298,tests,ProAgio Dose Expansion
ProAgio Dose Expansion,has_type,DRUG
NCT06468098,has_title,"Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IBI363 Combination T"
NCT06468098,has_status,RECRUITING
NCT06468098,has_phase,
NCT06468098,sponsored_by,Innovent Biologics (Suzhou) Co. Ltd.
NCT06468098,tests,IBI363 + chemotherapy
IBI363 + chemotherapy,has_type,DRUG
NCT06468098,tests,IBI363 + Investigator's Choice SOC
IBI363 + Investigator's Choice SOC,has_type,DRUG
NCT00861705,has_title,Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuv
NCT00861705,has_status,ACTIVE_NOT_RECRUITING
NCT00861705,has_phase,
NCT00861705,sponsored_by,National Cancer Institute (NCI)
NCT00861705,tests,Bevacizumab
Bevacizumab,has_type,BIOLOGICAL
NCT00861705,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00861705,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00861705,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT00861705,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00861705,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00940498,has_title,A Phase 1 Study Of Pf-05212384 (Also Known As Pki-587) Administered As An Intravenous Infusion To Pa
NCT00940498,has_status,COMPLETED
NCT00940498,has_phase,
NCT00940498,sponsored_by,Pfizer
NCT00940498,tests,PF-05212384 (also known as PKI-587)
PF-05212384 (also known as PKI-587),has_type,DRUG
NCT05891197,has_title,A Biomarker Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Saf
NCT05891197,has_status,TERMINATED
NCT05891197,has_phase,
NCT05891197,sponsored_by,"Lyell Immunopharma, Inc."
NCT02365805,has_title,"Randomized Open-label, Multicentric, Phase II Clinical Trial to Evaluate the Efficacy of a Neoadjuva"
NCT02365805,has_status,COMPLETED
NCT02365805,has_phase,
NCT02365805,sponsored_by,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT02365805,tests,Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel,has_type,DRUG
NCT02365805,tests,Epirubicin + Cisplatin + Fluorouracil
Epirubicin + Cisplatin + Fluorouracil,has_type,DRUG
NCT02365805,tests,Docetaxel + Ciclofosfamide
Docetaxel + Ciclofosfamide,has_type,DRUG
NCT05216432,has_title,"A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced "
NCT05216432,has_status,RECRUITING
NCT05216432,has_phase,
NCT05216432,sponsored_by,"Relay Therapeutics, Inc."
NCT05216432,tests,RLY-2608
RLY-2608,has_type,DRUG
NCT05216432,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT05216432,tests,Palbociclib 125mg
Palbociclib 125mg,has_type,DRUG
NCT05216432,tests,Ribociclib 400mg
Ribociclib 400mg,has_type,DRUG
NCT05216432,tests,Ribociclib 600mg
Ribociclib 600mg,has_type,DRUG
NCT05216432,tests,PF-07220060 100mg
PF-07220060 100mg,has_type,DRUG
NCT05216432,tests,PF-07220060 300 mg
PF-07220060 300 mg,has_type,DRUG
NCT02078752,has_title,"A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT "
NCT02078752,has_status,TERMINATED
NCT02078752,has_phase,
NCT02078752,sponsored_by,Pfizer
NCT02078752,tests,PF-06647263
PF-06647263,has_type,DRUG
NCT02078752,tests,PF-06647263
PF-06647263,has_type,DRUG
NCT04726332,has_title,A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent an
NCT04726332,has_status,TERMINATED
NCT04726332,has_phase,
NCT04726332,sponsored_by,Exelixis
NCT04726332,tests,XL102
XL102,has_type,DRUG
NCT04726332,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04726332,tests,Abiraterone
Abiraterone,has_type,DRUG
NCT04726332,tests,Prednisone
Prednisone,has_type,DRUG
NCT06355037,has_title,a Pilot Study to Explore the Efficacy and Safety of Dasatinib Combined With Quercetin to Reverse Che
NCT06355037,has_status,RECRUITING
NCT06355037,has_phase,
NCT06355037,sponsored_by,Fudan University
NCT06355037,tests,Quercetin
Quercetin,has_type,DRUG
NCT06355037,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT06355037,tests,Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum,has_type,DRUG
NCT03186937,has_title,A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
NCT03186937,has_status,TERMINATED
NCT03186937,has_phase,
NCT03186937,sponsored_by,"University of Wisconsin, Madison"
NCT03186937,tests,hominex-2
hominex-2,has_type,DIETARY_SUPPLEMENT
NCT01363232,has_title,"A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered "
NCT01363232,has_status,COMPLETED
NCT01363232,has_phase,
NCT01363232,sponsored_by,"Array Biopharma, now a wholly owned subsidiary of Pfizer"
NCT01363232,tests,BKM120 + MEK162
BKM120 + MEK162,has_type,DRUG
NCT01333137,has_title,An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-
NCT01333137,has_status,TERMINATED
NCT01333137,has_phase,
NCT01333137,sponsored_by,Piramal Enterprises Limited
NCT01333137,tests,Gemcitabine and Carboplatin
Gemcitabine and Carboplatin,has_type,DRUG
NCT01333137,tests,P276-00 along with Gemcitabine and carboplatin
P276-00 along with Gemcitabine and carboplatin,has_type,DRUG
NCT01969032,has_title,Phase 2 Study of Two Consequent Chemotherapy Regimens as Induction Preoperative Therapy for Patients
NCT01969032,has_status,COMPLETED
NCT01969032,has_phase,
NCT01969032,sponsored_by,Russian Academy of Medical Sciences
NCT01969032,tests,"Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine"
"Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine",has_type,DRUG
NCT05037825,has_title,The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825,has_status,RECRUITING
NCT05037825,has_phase,
NCT05037825,sponsored_by,VastBiome
NCT05037825,tests,"Checkpoint Inhibitor, Immune"
"Checkpoint Inhibitor, Immune",has_type,DRUG
NCT01116648,has_title,Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serou
NCT01116648,has_status,ACTIVE_NOT_RECRUITING
NCT01116648,has_phase,
NCT01116648,sponsored_by,National Cancer Institute (NCI)
NCT01116648,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT01116648,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT01116648,tests,Cediranib Maleate
Cediranib Maleate,has_type,DRUG
NCT01116648,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT01116648,tests,Echocardiography Test
Echocardiography Test,has_type,PROCEDURE
NCT01116648,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT01116648,tests,Multigated Acquisition Scan
Multigated Acquisition Scan,has_type,PROCEDURE
NCT01116648,tests,Olaparib
Olaparib,has_type,DRUG
NCT01881230,has_title,"A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination Wit"
NCT01881230,has_status,COMPLETED
NCT01881230,has_phase,
NCT01881230,sponsored_by,Celgene
NCT01881230,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT01881230,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01881230,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06353997,has_title,"A Phase 2a, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Ago"
NCT06353997,has_status,RECRUITING
NCT06353997,has_phase,
NCT06353997,sponsored_by,Providence Health & Services
NCT06353997,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06353997,tests,INBRX-106
INBRX-106,has_type,DRUG
NCT01173497,has_title,"A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Trea"
NCT01173497,has_status,COMPLETED
NCT01173497,has_phase,
NCT01173497,sponsored_by,Sanofi
NCT01173497,tests,INIPARIB + irinotecan
INIPARIB + irinotecan,has_type,DRUG
NCT05955105,has_title,"A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced S"
NCT05955105,has_status,RECRUITING
NCT05955105,has_phase,
NCT05955105,sponsored_by,Innolake Biopharm
NCT05955105,tests,ILB-2109
ILB-2109,has_type,DRUG
NCT05955105,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT03981705,has_title,Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
NCT03981705,has_status,COMPLETED
NCT03981705,has_phase,
NCT03981705,sponsored_by,"Masonic Cancer Center, University of Minnesota"
NCT03981705,tests,Standard Trimodality Breast Imaging
Standard Trimodality Breast Imaging,has_type,RADIATION
NCT06471205,has_title,A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody C
NCT06471205,has_status,RECRUITING
NCT06471205,has_phase,
NCT06471205,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT06471205,tests,BL-B01D1
BL-B01D1,has_type,DRUG
NCT06471205,tests,PD-1 Monoclonal Antibody
PD-1 Monoclonal Antibody,has_type,DRUG
NCT03197805,has_title,Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment
NCT03197805,has_status,TERMINATED
NCT03197805,has_phase,
NCT03197805,sponsored_by,Centre Jean Perrin
NCT03197805,tests,PAM 50 test
PAM 50 test,has_type,DIAGNOSTIC_TEST
NCT06225505,has_title,Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
NCT06225505,has_status,NOT_YET_RECRUITING
NCT06225505,has_phase,
NCT06225505,sponsored_by,Institut Curie
NCT06225505,tests,ctDNA monitoring
ctDNA monitoring,has_type,DIAGNOSTIC_TEST
NCT06225505,tests,68Ga-FAPI-46-PET-CT
68Ga-FAPI-46-PET-CT,has_type,DIAGNOSTIC_TEST
NCT04332653,has_title,An Open-label Phase 1b/2a Study of NT-I7 (efineptakin Alfa) in Combination with Pembrolizumab in Sub
NCT04332653,has_status,ACTIVE_NOT_RECRUITING
NCT04332653,has_phase,
NCT04332653,sponsored_by,NeoImmuneTech
NCT04332653,tests,NT-I7
NT-I7,has_type,DRUG
NCT04332653,tests,pembrolizumab (KEYTRUDA®)
pembrolizumab (KEYTRUDA®),has_type,DRUG
NCT02309177,has_title,"A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-p"
NCT02309177,has_status,COMPLETED
NCT02309177,has_phase,
NCT02309177,sponsored_by,Celgene
NCT02309177,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT02309177,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02309177,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02309177,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03652077,has_title,"A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants"
NCT03652077,has_status,COMPLETED
NCT03652077,has_phase,
NCT03652077,sponsored_by,Incyte Corporation
NCT03652077,tests,INCAGN02390
INCAGN02390,has_type,DRUG
NCT01289353,has_title,Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)
NCT01289353,has_status,COMPLETED
NCT01289353,has_phase,
NCT01289353,sponsored_by,NYU Langone Health
NCT01289353,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01289353,tests,3D-RT or IMRT
3D-RT or IMRT,has_type,RADIATION
NCT05831553,has_title,Evaluation of a Tissue Immune Profile (TIP) in Patients Affected by Metastatic TNBC Treated With Upf
NCT05831553,has_status,RECRUITING
NCT05831553,has_phase,
NCT05831553,sponsored_by,Fondazione per la Medicina Personalizzata
NCT05831553,tests,Tissue Immune Profile
Tissue Immune Profile,has_type,DIAGNOSTIC_TEST
NCT07018505,has_title,EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins
NCT07018505,has_status,NOT_YET_RECRUITING
NCT07018505,has_phase,
NCT07018505,sponsored_by,Yunnan Cancer Hospital
NCT07018505,tests,SERS detection
SERS detection,has_type,DIAGNOSTIC_TEST
NCT03674242,has_title,A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemothera
NCT03674242,has_status,TERMINATED
NCT03674242,has_phase,
NCT03674242,sponsored_by,ERYtech Pharma
NCT03674242,tests,eryaspase (L-asparaginase encapsulated in red blood cells)
eryaspase (L-asparaginase encapsulated in red blood cells),has_type,DRUG
NCT03674242,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03674242,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00887575,has_title,Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patient
NCT00887575,has_status,COMPLETED
NCT00887575,has_phase,
NCT00887575,sponsored_by,"SCRI Development Innovations, LLC"
NCT00887575,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00887575,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00887575,tests,Sunitinib
Sunitinib,has_type,DRUG
NCT06008275,has_title,Pilot Clinical Trial Examining the Safety and Efficacy of Neratinib in Combination With Ruxolitinib 
NCT06008275,has_status,RECRUITING
NCT06008275,has_phase,
NCT06008275,sponsored_by,Baylor Research Institute
NCT06008275,tests,Neratinib Oral Tablet
Neratinib Oral Tablet,has_type,DRUG
NCT06008275,tests,Ruxolitinib Oral Tablet
Ruxolitinib Oral Tablet,has_type,DRUG
NCT06825975,has_title,A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the 
NCT06825975,has_status,NOT_YET_RECRUITING
NCT06825975,has_phase,
NCT06825975,sponsored_by,Guangdong Provincial People's Hospital
NCT06825975,tests,Hyperbaric oxygen treatment
Hyperbaric oxygen treatment,has_type,DEVICE
NCT04296175,has_title,"A Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficac"
NCT04296175,has_status,ACTIVE_NOT_RECRUITING
NCT04296175,has_phase,
NCT04296175,sponsored_by,Fudan University
NCT04296175,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04296175,tests,CTX
CTX,has_type,DRUG
NCT04296175,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04296175,tests,ddEpirubicin
ddEpirubicin,has_type,DRUG
NCT04296175,tests,ddCTX
ddCTX,has_type,DRUG
NCT04296175,tests,Paclitaxel(with carbo)
Paclitaxel(with carbo),has_type,DRUG
NCT04296175,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01401959,has_title,Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Followi
NCT01401959,has_status,COMPLETED
NCT01401959,has_phase,
NCT01401959,sponsored_by,"SCRI Development Innovations, LLC"
NCT01401959,tests,Eribulin
Eribulin,has_type,DRUG
NCT01401959,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04718675,has_title,"Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patient"
NCT04718675,has_status,TERMINATED
NCT04718675,has_phase,
NCT04718675,sponsored_by,Kronos Bio
NCT04718675,tests,KB-0742
KB-0742,has_type,DRUG
NCT02812875,has_title,"A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinet"
NCT02812875,has_status,COMPLETED
NCT02812875,has_phase,
NCT02812875,sponsored_by,"Curis, Inc."
NCT02812875,tests,CA-170
CA-170,has_type,DRUG
NCT03253575,has_title,"CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observ"
NCT03253575,has_status,SUSPENDED
NCT03253575,has_phase,
NCT03253575,sponsored_by,"Mitra RxDx, Inc."
NCT03253575,tests,CANscript
CANscript,has_type,DIAGNOSTIC_TEST
NCT06746870,has_title,"A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy "
NCT06746870,has_status,NOT_YET_RECRUITING
NCT06746870,has_phase,
NCT06746870,sponsored_by,ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT06746870,tests,IMM2510
IMM2510,has_type,DRUG
NCT06746870,tests,Chemotherapy (pemetrexed + cisplatin/carboplatin)
Chemotherapy (pemetrexed + cisplatin/carboplatin),has_type,DRUG
NCT06746870,tests,Chemotherapy (paclitaxel + cisplatin/carboplatin)
Chemotherapy (paclitaxel + cisplatin/carboplatin),has_type,DRUG
NCT06746870,tests,Chemotherapy(Nab-paclitaxel)
Chemotherapy(Nab-paclitaxel),has_type,DRUG
NCT06134375,has_title,Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Rando
NCT06134375,has_status,RECRUITING
NCT06134375,has_phase,
NCT06134375,sponsored_by,Dartmouth-Hitchcock Medical Center
NCT06134375,tests,Tetrathiomolybdate
Tetrathiomolybdate,has_type,DRUG
NCT06134375,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06134375,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04313075,has_title,A Compassionate Use Study of Leronlimab (PRO 140) in Combination With Treatment of Physician's Choic
NCT04313075,has_status,NO_LONGER_AVAILABLE
NCT04313075,has_phase,
NCT04313075,sponsored_by,"CytoDyn, Inc."
NCT04313075,tests,Leronlimab
Leronlimab,has_type,DRUG
NCT02208375,has_title,A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the
NCT02208375,has_status,ACTIVE_NOT_RECRUITING
NCT02208375,has_phase,
NCT02208375,sponsored_by,M.D. Anderson Cancer Center
NCT02208375,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT02208375,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02208375,tests,Olaparib
Olaparib,has_type,DRUG
NCT02208375,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02208375,tests,Vistusertib
Vistusertib,has_type,DRUG
NCT01349959,has_title,Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer
NCT01349959,has_status,COMPLETED
NCT01349959,has_phase,
NCT01349959,sponsored_by,National Cancer Institute (NCI)
NCT01349959,tests,Azacitidine
Azacitidine,has_type,DRUG
NCT01349959,tests,Entinostat
Entinostat,has_type,DRUG
NCT01349959,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01349959,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT04020575,has_title,Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered 
NCT04020575,has_status,RECRUITING
NCT04020575,has_phase,
NCT04020575,sponsored_by,Minerva Biotechnologies Corporation
NCT04020575,tests,huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells,has_type,BIOLOGICAL
NCT04020575,tests,huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D,has_type,BIOLOGICAL
NCT02672475,has_title,A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Nega
NCT02672475,has_status,COMPLETED
NCT02672475,has_phase,
NCT02672475,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT02672475,tests,Galunisertib
Galunisertib,has_type,DRUG
NCT02672475,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02672475,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01111175,has_title,Triple Negative Breast Cancer Biomarker Study
NCT01111175,has_status,COMPLETED
NCT01111175,has_phase,
NCT01111175,sponsored_by,US Oncology Research
NCT05749575,has_title,"A Prospective, Open-label, Phase II Clinical Trial of Chidamide, PD-1 Monoclonal Antibody and Paclit"
NCT05749575,has_status,UNKNOWN
NCT05749575,has_phase,
NCT05749575,sponsored_by,Sun Yat-sen University
NCT05749575,tests,Chidamide Plus Toripalimab Plus Paclitaxel
Chidamide Plus Toripalimab Plus Paclitaxel,has_type,DRUG
NCT03480659,has_title,"Breast Cancer Screening Using DNA Methylation Changes in Circulated Tumor, PBMC and T-cells DNA."
NCT03480659,has_status,TERMINATED
NCT03480659,has_phase,
NCT03480659,sponsored_by,HKGepitherapeutics
NCT06492759,has_title,A Phase II Study of High Dose Radiotherapy in Combination With Pembrolizumab Plus Chemotherapy in Pa
NCT06492759,has_status,NOT_YET_RECRUITING
NCT06492759,has_phase,
NCT06492759,sponsored_by,Emory University
NCT06492759,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT06492759,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06492759,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06492759,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06492759,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06492759,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06492759,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT06492759,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT06492759,tests,Bone Scan
Bone Scan,has_type,PROCEDURE
NCT06492759,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06492759,tests,Medical Chart Review
Medical Chart Review,has_type,OTHER
NCT05082259,has_title,ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours
NCT05082259,has_status,RECRUITING
NCT05082259,has_phase,
NCT05082259,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT05082259,tests,ASTX660
ASTX660,has_type,DRUG
NCT05082259,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02737475,has_title,A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimum
NCT02737475,has_status,COMPLETED
NCT02737475,has_phase,
NCT02737475,sponsored_by,Bristol-Myers Squibb
NCT02737475,tests,BMS-986178
BMS-986178,has_type,DRUG
NCT02737475,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02737475,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT02737475,tests,Tetanus vaccine
Tetanus vaccine,has_type,BIOLOGICAL
NCT02737475,tests,DPV-001 vaccine
DPV-001 vaccine,has_type,BIOLOGICAL
NCT02737475,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00601159,has_title,Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple
NCT00601159,has_status,COMPLETED
NCT00601159,has_phase,
NCT00601159,sponsored_by,Fudan University
NCT00601159,tests,gemcitabine and cisplatin
gemcitabine and cisplatin,has_type,DRUG
NCT06533059,has_title,AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors Wi
NCT06533059,has_status,RECRUITING
NCT06533059,has_phase,
NCT06533059,sponsored_by,"Alterome Therapeutics, Inc."
NCT06533059,tests,ALTA2618
ALTA2618,has_type,DRUG
NCT04691375,has_title,"A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacod"
NCT04691375,has_status,TERMINATED
NCT04691375,has_phase,
NCT04691375,sponsored_by,Ikena Oncology
NCT04691375,tests,PY314
PY314,has_type,DRUG
NCT04691375,tests,Combination Therapy: PY314 + Pembrolizumab
Combination Therapy: PY314 + Pembrolizumab,has_type,DRUG
NCT02685059,has_title,A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthr
NCT02685059,has_status,COMPLETED
NCT02685059,has_phase,
NCT02685059,sponsored_by,GBG Forschungs GmbH
NCT02685059,tests,MEDI4736 (Anti PD-L1)
MEDI4736 (Anti PD-L1),has_type,DRUG
NCT02685059,tests,Placebo
Placebo,has_type,DRUG
NCT02685059,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT02685059,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02685059,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01562275,has_title,"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GD"
NCT01562275,has_status,COMPLETED
NCT01562275,has_phase,
NCT01562275,sponsored_by,"Genentech, Inc."
NCT01562275,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT01562275,tests,Cobimetinib
Cobimetinib,has_type,DRUG
NCT01130259,has_title,"An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in P"
NCT01130259,has_status,NO_LONGER_AVAILABLE
NCT01130259,has_phase,
NCT01130259,sponsored_by,Sanofi
NCT01130259,tests,iniparib
iniparib,has_type,DRUG
NCT02637375,has_title,A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
NCT02637375,has_status,WITHDRAWN
NCT02637375,has_phase,
NCT02637375,sponsored_by,University of Chicago
NCT02637375,tests,Ganetespib
Ganetespib,has_type,DRUG
NCT02637375,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02637375,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02637375,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01104259,has_title,Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Tr
NCT01104259,has_status,COMPLETED
NCT01104259,has_phase,
NCT01104259,sponsored_by,University of Washington
NCT01104259,tests,veliparib
veliparib,has_type,DRUG
NCT01104259,tests,cisplatin
cisplatin,has_type,DRUG
NCT01104259,tests,vinorelbine tartrate
vinorelbine tartrate,has_type,DRUG
NCT01104259,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01104259,tests,pharmacological study
pharmacological study,has_type,OTHER
NCT02950259,has_title,"A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 I"
NCT02950259,has_status,ACTIVE_NOT_RECRUITING
NCT02950259,has_phase,
NCT02950259,sponsored_by,Providence Health & Services
NCT02950259,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02950259,tests,Indomethacin
Indomethacin,has_type,DRUG
NCT02950259,tests,Omeprazole
Omeprazole,has_type,DRUG
NCT02950259,tests,Multivitamin
Multivitamin,has_type,DIETARY_SUPPLEMENT
NCT03715959,has_title,Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid
NCT03715959,has_status,COMPLETED
NCT03715959,has_phase,
NCT03715959,sponsored_by,Ohio State University Comprehensive Cancer Center
NCT03715959,tests,Aspiration of Breast
Aspiration of Breast,has_type,PROCEDURE
NCT03715959,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04457700,has_title,Computed Tomography-based Radiomics of Axillary Lymph Node Pathological Complete Remission (ypN0) in
NCT04457700,has_status,UNKNOWN
NCT04457700,has_phase,
NCT04457700,sponsored_by,Peking University
NCT05586659,has_title,Epidemiology of Triple Negative Breast Cancer in Asyut Clinical Oncology Department From 2015 to 202
NCT05586659,has_status,UNKNOWN
NCT05586659,has_phase,
NCT05586659,sponsored_by,Assiut University
NCT03361800,has_title,"A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exem"
NCT03361800,has_status,TERMINATED
NCT03361800,has_phase,
NCT03361800,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT03361800,tests,Entinostat
Entinostat,has_type,DRUG
NCT04461600,has_title,"A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Ac"
NCT04461600,has_status,TERMINATED
NCT04461600,has_phase,
NCT04461600,sponsored_by,"Ayala Pharmaceuticals, Inc,"
NCT04461600,tests,AL101
AL101,has_type,DRUG
NCT06999187,has_title,"A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate t"
NCT06999187,has_status,RECRUITING
NCT06999187,has_phase,
NCT06999187,sponsored_by,Dren Bio
NCT06999187,tests,DR-0202
DR-0202,has_type,DRUG
NCT03281954,has_title,"A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab o"
NCT03281954,has_status,ACTIVE_NOT_RECRUITING
NCT03281954,has_phase,
NCT03281954,sponsored_by,NSABP Foundation Inc
NCT03281954,tests,Placebo
Placebo,has_type,DRUG
NCT03281954,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT01997333,has_title,"A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB O"
NCT01997333,has_status,COMPLETED
NCT01997333,has_phase,
NCT01997333,sponsored_by,Celldex Therapeutics
NCT01997333,tests,CDX-011
CDX-011,has_type,DRUG
NCT01997333,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT00371254,has_title,Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
NCT00371254,has_status,COMPLETED
NCT00371254,has_phase,
NCT00371254,sponsored_by,Bristol-Myers Squibb
NCT00371254,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT00371254,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT04315233,has_title,A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients
NCT04315233,has_status,RECRUITING
NCT04315233,has_phase,
NCT04315233,sponsored_by,University of Utah
NCT04315233,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT04315233,tests,Belinostat
Belinostat,has_type,DRUG
NCT01238133,has_title,A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combinat
NCT01238133,has_status,TERMINATED
NCT01238133,has_phase,
NCT01238133,sponsored_by,National Cancer Institute (NCI)
NCT01238133,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01238133,tests,Gamma-Secretase Inhibitor RO4929097
Gamma-Secretase Inhibitor RO4929097,has_type,DRUG
NCT01238133,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01238133,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01238133,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01238133,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT02441933,has_title,"A Randomized, Multicenter, Open-label, Phase III Trial Comparing Anthracyclines Followed by Taxane V"
NCT02441933,has_status,ACTIVE_NOT_RECRUITING
NCT02441933,has_phase,
NCT02441933,sponsored_by,Yonsei University
NCT02441933,tests,taxane plus carboplatin
taxane plus carboplatin,has_type,DRUG
NCT02441933,tests,Taxane
Taxane,has_type,DRUG
NCT05967533,has_title,Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementat
NCT05967533,has_status,RECRUITING
NCT05967533,has_phase,
NCT05967533,sponsored_by,"University of California, Davis"
NCT05967533,tests,Fermented Wheat Germ Extract
Fermented Wheat Germ Extract,has_type,DRUG
NCT01378533,has_title,Randomized Phase Ⅲ Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel
NCT01378533,has_status,UNKNOWN
NCT01378533,has_phase,
NCT01378533,sponsored_by,Chinese Academy of Medical Sciences
NCT01378533,tests,"epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF"
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF",has_type,DRUG
NCT04520386,has_title,"A Multi-site, Single Arm, Phase II Clinical Trial, to Evaluate the Efficacy of OMT-111 in Supporting"
NCT04520386,has_status,UNKNOWN
NCT04520386,has_phase,
NCT04520386,sponsored_by,MetiMedi Pharmaceuticals
NCT04520386,tests,OMT-111
OMT-111,has_type,DRUG
NCT03044730,has_title,Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory
NCT03044730,has_status,UNKNOWN
NCT03044730,has_phase,
NCT03044730,sponsored_by,Northwestern University
NCT03044730,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03044730,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03044730,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT07018427,has_title,"Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Unresectable Locally Advanced, Re"
NCT07018427,has_status,ACTIVE_NOT_RECRUITING
NCT07018427,has_phase,
NCT07018427,sponsored_by,Peking University Cancer Hospital & Institute
NCT07018427,tests,Sacituzumab Govitecan Monotherapy or Combination Therapy
Sacituzumab Govitecan Monotherapy or Combination Therapy,has_type,DRUG
NCT03674827,has_title,"A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES A"
NCT03674827,has_status,TERMINATED
NCT03674827,has_phase,
NCT03674827,sponsored_by,Pfizer
NCT03674827,tests,PF-06936308
PF-06936308,has_type,BIOLOGICAL
NCT02474173,has_title,"Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients Wi"
NCT02474173,has_status,TERMINATED
NCT02474173,has_phase,
NCT02474173,sponsored_by,National Cancer Institute (NCI)
NCT02474173,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02474173,tests,Onalespib
Onalespib,has_type,DRUG
NCT02474173,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02474173,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT06767527,has_title,"A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Plus Nab-paclitaxel Versus "
NCT06767527,has_status,NOT_YET_RECRUITING
NCT06767527,has_phase,
NCT06767527,sponsored_by,Akeso
NCT06767527,tests,AK112
AK112,has_type,DRUG
NCT06767527,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06767527,tests,Placebo
Placebo,has_type,DRUG
NCT03244358,has_title,"Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phas"
NCT03244358,has_status,TERMINATED
NCT03244358,has_phase,
NCT03244358,sponsored_by,Sun Yat-sen University
NCT03244358,tests,Epalrestat
Epalrestat,has_type,DRUG
NCT05498896,has_title,"A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant "
NCT05498896,has_status,ACTIVE_NOT_RECRUITING
NCT05498896,has_phase,
NCT05498896,sponsored_by,Queen Mary University of London
NCT05498896,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT05498896,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT05498896,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05498896,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05498896,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04348916,has_title,"A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic He"
NCT04348916,has_status,TERMINATED
NCT04348916,has_phase,
NCT04348916,sponsored_by,"Oncorus, Inc."
NCT04348916,tests,ONCR-177
ONCR-177,has_type,BIOLOGICAL
NCT04348916,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT01752686,has_title,A Phase III Trial of Carboplatin as Adjuvant Chemotherapy Versus Observation in Triple Negative Brea
NCT01752686,has_status,UNKNOWN
NCT01752686,has_phase,
NCT01752686,sponsored_by,Severance Hospital
NCT01752686,tests,carboplatin
carboplatin,has_type,DRUG
NCT04504916,has_title,A Phase 2 Study of VLS-101 in Patients With Solid Tumors
NCT04504916,has_status,TERMINATED
NCT04504916,has_phase,
NCT04504916,sponsored_by,"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
NCT04504916,tests,Zilovertamab vedotin
Zilovertamab vedotin,has_type,DRUG
NCT04602117,has_title,ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Pat
NCT04602117,has_status,WITHDRAWN
NCT04602117,has_phase,
NCT04602117,sponsored_by,QuantumLeap Healthcare Collaborative
NCT04602117,tests,Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,has_type,DRUG
NCT02460224,has_title,"A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in"
NCT02460224,has_status,COMPLETED
NCT02460224,has_phase,
NCT02460224,sponsored_by,Novartis Pharmaceuticals
NCT02460224,tests,LAG525
LAG525,has_type,DRUG
NCT02460224,tests,PDR001
PDR001,has_type,DRUG
NCT01964924,has_title,"A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With G"
NCT01964924,has_status,COMPLETED
NCT01964924,has_phase,
NCT01964924,sponsored_by,National Cancer Institute (NCI)
NCT01964924,tests,Akt Inhibitor GSK2141795
Akt Inhibitor GSK2141795,has_type,DRUG
NCT01964924,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01964924,tests,Trametinib
Trametinib,has_type,DRUG
NCT02527434,has_title,"A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Sol"
NCT02527434,has_status,COMPLETED
NCT02527434,has_phase,
NCT02527434,sponsored_by,AstraZeneca
NCT02527434,tests,Tremelimumab monotherapy
Tremelimumab monotherapy,has_type,BIOLOGICAL
NCT02527434,tests,MEDI4736 monotherapy
MEDI4736 monotherapy,has_type,BIOLOGICAL
NCT02527434,tests,MEDI4736 + tremelimumab combination therapy
MEDI4736 + tremelimumab combination therapy,has_type,BIOLOGICAL
NCT05905341,has_title,"A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY,"
NCT05905341,has_status,WITHDRAWN
NCT05905341,has_phase,
NCT05905341,sponsored_by,Pfizer
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT07020117,has_title,"NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety an"
NCT07020117,has_status,RECRUITING
NCT07020117,has_phase,
NCT07020117,sponsored_by,"Aktis Oncology, Inc."
NCT07020117,tests,[225Ac]Ac-AKY-1189 (therapeutic)
[225Ac]Ac-AKY-1189 (therapeutic),has_type,DRUG
NCT07020117,tests,[64Cu]Cu-AKY-1189 (imaging)
[64Cu]Cu-AKY-1189 (imaging),has_type,DRUG
NCT03213041,has_title,"I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With C"
NCT03213041,has_status,RECRUITING
NCT03213041,has_phase,
NCT03213041,sponsored_by,Northwestern University
NCT03213041,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03213041,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03213041,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03617341,has_title,Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer
NCT03617341,has_status,UNKNOWN
NCT03617341,has_phase,
NCT03617341,sponsored_by,Yonsei University
NCT03617341,tests,Brain MRI
Brain MRI,has_type,PROCEDURE
NCT02067741,has_title,"A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Resp"
NCT02067741,has_status,TERMINATED
NCT02067741,has_phase,
NCT02067741,sponsored_by,Swiss Group for Clinical Cancer Research
NCT02067741,tests,CR1447
CR1447,has_type,DRUG
NCT04711824,has_title,Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response 
NCT04711824,has_status,RECRUITING
NCT04711824,has_phase,
NCT04711824,sponsored_by,Colette Shen
NCT04711824,tests,Olaparib
Olaparib,has_type,DRUG
NCT04711824,tests,Stereotactic Radiosurgery
Stereotactic Radiosurgery,has_type,RADIATION
NCT04711824,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04711824,tests,Physicians Choice systemic chemotherapy
Physicians Choice systemic chemotherapy,has_type,DRUG
NCT06355024,has_title,a Pilot Study to Explore the Efficacy of Inosine Reversing Chemo Resistance in Triple Negative Breas
NCT06355024,has_status,NOT_YET_RECRUITING
NCT06355024,has_phase,
NCT06355024,sponsored_by,Fudan University
NCT06355024,tests,Inosine
Inosine,has_type,DRUG
NCT06355024,tests,Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum,has_type,DRUG
NCT05128734,has_title,A Randomized Phase II Study of Temozolomide Monotherapy or in Combination With Olaparib in Patients 
NCT05128734,has_status,NOT_YET_RECRUITING
NCT05128734,has_phase,
NCT05128734,sponsored_by,AHS Cancer Control Alberta
NCT05128734,tests,Temozolomide
Temozolomide,has_type,DRUG
NCT05128734,tests,Olaparib
Olaparib,has_type,DRUG
NCT03337724,has_title,"A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Pa"
NCT03337724,has_status,COMPLETED
NCT03337724,has_phase,
NCT03337724,sponsored_by,Hoffmann-La Roche
NCT03337724,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03337724,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03337724,tests,Placebo
Placebo,has_type,DRUG
NCT05386524,has_title,Efficacy and Safety of Sintilimab and Bevacizumab Biosimilar Combined With Pegylated Liposomal Doxor
NCT05386524,has_status,UNKNOWN
NCT05386524,has_phase,
NCT05386524,sponsored_by,Fudan University
NCT05386524,tests,sintilimab
sintilimab,has_type,DRUG
NCT05386524,tests,bevacizumab biosimilar
bevacizumab biosimilar,has_type,DRUG
NCT05386524,tests,pegylated liposomal doxorubicin
pegylated liposomal doxorubicin,has_type,DRUG
NCT06958224,has_title,"Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers, Not Eligible "
NCT06958224,has_status,NOT_YET_RECRUITING
NCT06958224,has_phase,
NCT06958224,sponsored_by,"University Hospital, Lille"
NCT06958224,tests,Large and early multigene sequencing
Large and early multigene sequencing,has_type,GENETIC
NCT02012634,has_title,"A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemothera"
NCT02012634,has_status,UNKNOWN
NCT02012634,has_phase,
NCT02012634,sponsored_by,Xijing Hospital
NCT00868634,has_title,Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Loc
NCT00868634,has_status,COMPLETED
NCT00868634,has_phase,
NCT00868634,sponsored_by,iOMEDICO AG
NCT00868634,tests,capecitabine
capecitabine,has_type,DRUG
NCT00868634,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT00868634,tests,capecitabine
capecitabine,has_type,DRUG
NCT00868634,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT00868634,tests,vinorelbine
vinorelbine,has_type,DRUG
NCT04540224,has_title,"The Relationship Between the Differences in Blood Cytokine Values and Disease Stage in Luminal A, Lu"
NCT04540224,has_status,COMPLETED
NCT04540224,has_phase,
NCT04540224,sponsored_by,Istanbul Training and Research Hospital
NCT04540224,tests,Flow-Cytometric analysis
Flow-Cytometric analysis,has_type,DIAGNOSTIC_TEST
NCT03686124,has_title,Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Canc
NCT03686124,has_status,RECRUITING
NCT03686124,has_phase,
NCT03686124,sponsored_by,"Immatics US, Inc."
NCT03686124,tests,IMA203 Product
IMA203 Product,has_type,BIOLOGICAL
NCT03686124,tests,IMA203 product- flat dose
IMA203 product- flat dose,has_type,BIOLOGICAL
NCT03686124,tests,IMA203CD8 Product
IMA203CD8 Product,has_type,BIOLOGICAL
NCT03686124,tests,nivolumab (Opdivo®)
nivolumab (Opdivo®),has_type,DRUG
NCT03686124,tests,IMADetect®
IMADetect®,has_type,DEVICE
NCT02546934,has_title,"A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cispla"
NCT02546934,has_status,COMPLETED
NCT02546934,has_phase,
NCT02546934,sponsored_by,Fudan University
NCT02546934,tests,"ABX, cisplatin"
"ABX, cisplatin",has_type,DRUG
NCT02546934,tests,"Gemcitabine, Cisplatin"
"Gemcitabine, Cisplatin",has_type,DRUG
NCT05347134,has_title,"A Randomized, Controlled, Open-label, Multi-center Phase III Clinical Trial of SKB264 for Injection "
NCT05347134,has_status,ACTIVE_NOT_RECRUITING
NCT05347134,has_phase,
NCT05347134,sponsored_by,"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd."
NCT05347134,tests,SKB264
SKB264,has_type,DRUG
NCT05585034,has_title,"A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Ph"
NCT05585034,has_status,ACTIVE_NOT_RECRUITING
NCT05585034,has_phase,
NCT05585034,sponsored_by,"Xencor, Inc."
NCT05585034,tests,XmAb®808
XmAb®808,has_type,BIOLOGICAL
NCT05585034,tests,Keytruda® (pembrolizumab)
Keytruda® (pembrolizumab),has_type,BIOLOGICAL
NCT03371017,has_title,"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Saf"
NCT03371017,has_status,COMPLETED
NCT03371017,has_phase,
NCT03371017,sponsored_by,Hoffmann-La Roche
NCT03371017,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03371017,tests,Placebo
Placebo,has_type,DRUG
NCT03371017,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03371017,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03371017,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05969041,has_title,"MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety"
NCT05969041,has_status,RECRUITING
NCT05969041,has_phase,
NCT05969041,sponsored_by,Myeloid Therapeutics
NCT05969041,tests,MT-302 (A)
MT-302 (A),has_type,DRUG
NCT05103917,has_title,"An Open Label, Phase Ib/II Trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001"
NCT05103917,has_status,UNKNOWN
NCT05103917,has_phase,
NCT05103917,sponsored_by,"Abbisko Therapeutics Co, Ltd"
NCT05103917,tests,X4P-001
X4P-001,has_type,DRUG
NCT02404441,has_title,Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patient
NCT02404441,has_status,COMPLETED
NCT02404441,has_phase,
NCT02404441,sponsored_by,Novartis Pharmaceuticals
NCT02404441,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT04360941,has_title,PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
NCT04360941,has_status,RECRUITING
NCT04360941,has_phase,
NCT04360941,sponsored_by,Royal Marsden NHS Foundation Trust
NCT04360941,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT04360941,tests,Avelumab
Avelumab,has_type,DRUG
NCT01272141,has_title,Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally 
NCT01272141,has_status,TERMINATED
NCT01272141,has_phase,
NCT01272141,sponsored_by,Emory University
NCT01272141,tests,Lapatinib and Everolimus
Lapatinib and Everolimus,has_type,DRUG
NCT01929941,has_title,"A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With"
NCT01929941,has_status,TERMINATED
NCT01929941,has_phase,
NCT01929941,sponsored_by,Incyte Corporation
NCT01929941,tests,INCB047986
INCB047986,has_type,DRUG
NCT01929941,tests,INCB047986
INCB047986,has_type,DRUG
NCT01929941,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01929941,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT06309459,has_title,Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Facto
NCT06309459,has_status,COMPLETED
NCT06309459,has_phase,
NCT06309459,sponsored_by,Kahramanmaras Sutcu Imam University
NCT06309459,tests,Carbonic anhydrase staining levels
Carbonic anhydrase staining levels,has_type,DIAGNOSTIC_TEST
NCT06190600,has_title,Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy
NCT06190600,has_status,ACTIVE_NOT_RECRUITING
NCT06190600,has_phase,
NCT06190600,sponsored_by,The Greater Poland Cancer Centre
NCT06190600,tests,High Intensity Interval Training (HIIT)
High Intensity Interval Training (HIIT),has_type,OTHER
NCT06190600,tests,"neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)"
"neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)",has_type,DRUG
NCT06190600,tests,Standard Supportive Care
Standard Supportive Care,has_type,OTHER
NCT03012100,has_title,"Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Fo"
NCT03012100,has_status,ACTIVE_NOT_RECRUITING
NCT03012100,has_phase,
NCT03012100,sponsored_by,Academic and Community Cancer Research United
NCT03012100,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03012100,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03012100,tests,Multi-epitope Folate Receptor Alpha Peptide Vaccine
Multi-epitope Folate Receptor Alpha Peptide Vaccine,has_type,BIOLOGICAL
NCT03012100,tests,Placebo Administration
Placebo Administration,has_type,OTHER
NCT03012100,tests,Sargramostim
Sargramostim,has_type,BIOLOGICAL
NCT04742959,has_title,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Re"
NCT04742959,has_status,COMPLETED
NCT04742959,has_phase,
NCT04742959,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT04742959,tests,TT-00420
TT-00420,has_type,DRUG
NCT04742959,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,COMBINATION_PRODUCT
NCT02048059,has_title,"A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain"
NCT02048059,has_status,COMPLETED
NCT02048059,has_phase,
NCT02048059,sponsored_by,Angiochem Inc
NCT02048059,tests,ANG1005
ANG1005,has_type,DRUG
NCT02863900,has_title,From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspec
NCT02863900,has_status,UNKNOWN
NCT02863900,has_phase,
NCT02863900,sponsored_by,Institut Claudius Regaud
NCT02863900,tests,cohort of BC of each subtypes
cohort of BC of each subtypes,has_type,OTHER
NCT05673200,has_title,Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
NCT05673200,has_status,SUSPENDED
NCT05673200,has_phase,
NCT05673200,sponsored_by,National Cancer Institute (NCI)
NCT05673200,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT05673200,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05673200,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05673200,tests,Decitabine and Cedazuridine
Decitabine and Cedazuridine,has_type,DRUG
NCT05673200,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05673200,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05673200,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06165900,has_title,"A Multicenter, Randomized Trial of Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-"
NCT06165900,has_status,RECRUITING
NCT06165900,has_phase,
NCT06165900,sponsored_by,Shengjing Hospital
NCT06165900,tests,adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),has_type,DRUG
NCT06165900,tests,adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),has_type,DRUG
NCT03364400,has_title,"A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients "
NCT03364400,has_status,UNKNOWN
NCT03364400,has_phase,
NCT03364400,sponsored_by,"Vigeo Therapeutics, Inc."
NCT03364400,tests,VT1021
VT1021,has_type,DRUG
NCT03057600,has_title,A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Pa
NCT03057600,has_status,COMPLETED
NCT03057600,has_phase,
NCT03057600,sponsored_by,"Calithera Biosciences, Inc"
NCT03057600,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03057600,tests,CB-839
CB-839,has_type,DRUG
NCT01641406,has_title,"""Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of"
NCT01641406,has_status,UNKNOWN
NCT01641406,has_phase,
NCT01641406,sponsored_by,Auxilio Mutuo Cancer Center
NCT01641406,tests,"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab"
"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab",has_type,DRUG
NCT01641406,tests,"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab"
"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab",has_type,DRUG
NCT01641406,tests,"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab"
"Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab",has_type,DRUG
NCT04335006,has_title,"A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-pa"
NCT04335006,has_status,TERMINATED
NCT04335006,has_phase,
NCT04335006,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT04335006,tests,Carelizumab
Carelizumab,has_type,DRUG
NCT04335006,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04335006,tests,Apatinib
Apatinib,has_type,DRUG
NCT05234606,has_title,"A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination Wit"
NCT05234606,has_status,WITHDRAWN
NCT05234606,has_phase,
NCT05234606,sponsored_by,Silverback Therapeutics
NCT05234606,tests,SBT6290
SBT6290,has_type,DRUG
NCT05234606,tests,SBT6290
SBT6290,has_type,DRUG
NCT05234606,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT04152499,has_title,"A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metasta"
NCT04152499,has_status,ACTIVE_NOT_RECRUITING
NCT04152499,has_phase,
NCT04152499,sponsored_by,Klus Pharma Inc.
NCT04152499,tests,SKB264
SKB264,has_type,DRUG
NCT01650506,has_title,Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT01650506,has_status,COMPLETED
NCT01650506,has_phase,
NCT01650506,sponsored_by,Columbia University
NCT01650506,tests,Metformin
Metformin,has_type,DRUG
NCT01650506,tests,Erlotinib
Erlotinib,has_type,DRUG
NCT06182306,has_title,Prospective Evaluation of AI R&D Tool for Patient Stratification - Mechanism of Action Evaluation in
NCT06182306,has_status,RECRUITING
NCT06182306,has_phase,
NCT06182306,sponsored_by,"Ourotech, Inc."
NCT06182306,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT01818999,has_title,A Phase II Trial Of Ixabepilone and Stereotactic Body Radiation Therapy (SBRT) For Patients With Tri
NCT01818999,has_status,WITHDRAWN
NCT01818999,has_phase,
NCT01818999,sponsored_by,University of Texas Southwestern Medical Center
NCT01818999,tests,IXABEPILONE
IXABEPILONE,has_type,DRUG
NCT01818999,tests,STEREOTACTIC BODY RADIATION THERAPY
STEREOTACTIC BODY RADIATION THERAPY,has_type,RADIATION
NCT04450706,has_title,FORESEE: Functional Precision Oncology for Metastatic Breast Cancer: a Feasibility Trial
NCT04450706,has_status,COMPLETED
NCT04450706,has_phase,
NCT04450706,sponsored_by,University of Utah
NCT04450706,tests,Precision Medicine
Precision Medicine,has_type,OTHER
NCT04450706,tests,Physican Decision Making
Physican Decision Making,has_type,OTHER
NCT05029999,has_title,Phase 1 Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Li
NCT05029999,has_status,RECRUITING
NCT05029999,has_phase,
NCT05029999,sponsored_by,University of Texas Southwestern Medical Center
NCT05029999,tests,PLD Chemotherapy
PLD Chemotherapy,has_type,DRUG
NCT05029999,tests,CDX-1140
CDX-1140,has_type,DRUG
NCT05029999,tests,CDX-301
CDX-301,has_type,DRUG
NCT04954599,has_title,Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor
NCT04954599,has_status,RECRUITING
NCT04954599,has_phase,
NCT04954599,sponsored_by,Maastricht University Medical Center
NCT04954599,tests,CP-506
CP-506,has_type,DRUG
NCT04954599,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04954599,tests,Immune checkpoint inhibitor
Immune checkpoint inhibitor,has_type,DRUG
NCT07029399,has_title,"A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminar"
NCT07029399,has_status,RECRUITING
NCT07029399,has_phase,
NCT07029399,sponsored_by,"NiKang Therapeutics, Inc."
NCT07029399,tests,NKT5097 CDK2/CDK4 dual degrader
NKT5097 CDK2/CDK4 dual degrader,has_type,DRUG
NCT05368506,has_title,"An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors"
NCT05368506,has_status,WITHDRAWN
NCT05368506,has_phase,
NCT05368506,sponsored_by,OHSU Knight Cancer Institute
NCT05368506,tests,Wee1 Inhibitor ZN-c3
Wee1 Inhibitor ZN-c3,has_type,DRUG
NCT06382142,has_title,A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's
NCT06382142,has_status,RECRUITING
NCT06382142,has_phase,
NCT06382142,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT06382142,tests,BL-B01D1
BL-B01D1,has_type,DRUG
NCT06382142,tests,Eribulin
Eribulin,has_type,DRUG
NCT06382142,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT06382142,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06382142,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05582499,has_title,Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant T
NCT05582499,has_status,RECRUITING
NCT05582499,has_phase,
NCT05582499,sponsored_by,Fudan University
NCT05582499,tests,Dalpiciclib
Dalpiciclib,has_type,DRUG
NCT05582499,tests,Pyrotinib
Pyrotinib,has_type,DRUG
NCT05582499,tests,SHR-A1811
SHR-A1811,has_type,DRUG
NCT05582499,tests,SHR-1316
SHR-1316,has_type,DRUG
NCT05582499,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT05582499,tests,SHR-A1921
SHR-A1921,has_type,DRUG
NCT05582499,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT05582499,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05582499,tests,Goserelin
Goserelin,has_type,DRUG
NCT05582499,tests,Letrozole
Letrozole,has_type,DRUG
NCT05582499,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT05582499,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05582499,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05582499,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05582499,tests,Fluzoparib
Fluzoparib,has_type,DRUG
NCT05582499,tests,Apatinib
Apatinib,has_type,DRUG
NCT05582499,tests,Famitinib
Famitinib,has_type,DRUG
NCT05954442,has_title,"An Open, Randomized Phase III Study of Everolimus With Investigator's Choice of Chemotherapy Versus "
NCT05954442,has_status,RECRUITING
NCT05954442,has_phase,
NCT05954442,sponsored_by,Fudan University
NCT05954442,tests,Everolimus
Everolimus,has_type,DRUG
NCT05954442,tests,Investigator's Choice of Chemotherapy
Investigator's Choice of Chemotherapy,has_type,DRUG
NCT02583542,has_title,A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
NCT02583542,has_status,UNKNOWN
NCT02583542,has_phase,
NCT02583542,sponsored_by,Queen Mary University of London
NCT02583542,tests,AZD2014
AZD2014,has_type,DRUG
NCT02583542,tests,AZD6244
AZD6244,has_type,DRUG
NCT07016399,has_title,A Phase II Neoadjuvant Clinical Trial of the Androgen Receptor Inhibitor Darolutamide in Early-Stage
NCT07016399,has_status,NOT_YET_RECRUITING
NCT07016399,has_phase,
NCT07016399,sponsored_by,Vandana Abramson
NCT07016399,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT07016399,tests,Breast Biopsy Procedure
Breast Biopsy Procedure,has_type,PROCEDURE
NCT07016399,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT07016399,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT07016399,tests,Darolutamide
Darolutamide,has_type,DRUG
NCT07016399,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT07016399,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT07016399,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT07016399,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT07016399,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT07016399,tests,Surgical Procedure
Surgical Procedure,has_type,PROCEDURE
NCT07016399,tests,Ultrasound Imaging
Ultrasound Imaging,has_type,PROCEDURE
NCT06851299,has_title,Randomized Controlled Clinical Study of Efficacy and Safety of Trop2-ADC Monotherapy or Combination 
NCT06851299,has_status,RECRUITING
NCT06851299,has_phase,
NCT06851299,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06851299,tests,trop2-ADC
trop2-ADC,has_type,DRUG
NCT06851299,tests,ADC +anti-angiogenic drug
ADC +anti-angiogenic drug,has_type,DRUG
NCT06851299,tests,ADC + PD1 monoclonal antibody +anti-angiogenic drug
ADC + PD1 monoclonal antibody +anti-angiogenic drug,has_type,DRUG
NCT02732119,has_title,"A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane"
NCT02732119,has_status,COMPLETED
NCT02732119,has_phase,
NCT02732119,sponsored_by,Novartis Pharmaceuticals
NCT02732119,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT02732119,tests,Everolimus
Everolimus,has_type,DRUG
NCT02732119,tests,Exemestane
Exemestane,has_type,DRUG
NCT02539017,has_title,
NCT02539017,has_status,WITHDRAWN
NCT02539017,has_phase,
NCT02539017,sponsored_by,First Affiliated Hospital Xi'an Jiaotong University
NCT02539017,tests,Chemo
Chemo,has_type,DRUG
NCT02539017,tests,Immunotherapy
Immunotherapy,has_type,BIOLOGICAL
NCT05455619,has_title,Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt 
NCT05455619,has_status,RECRUITING
NCT05455619,has_phase,
NCT05455619,sponsored_by,"SynDevRx, Inc."
NCT05455619,tests,Evexomostat
Evexomostat,has_type,DRUG
NCT02485119,has_title,"An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343"
NCT02485119,has_status,COMPLETED
NCT02485119,has_phase,
NCT02485119,sponsored_by,Bayer
NCT02485119,tests,BAY94-9343
BAY94-9343,has_type,DRUG
NCT06819319,has_title,A Phase II Study of SHR-A2102 in Combination With Adebrelimab as Neoadjuvant Therapy for Early Tripl
NCT06819319,has_status,NOT_YET_RECRUITING
NCT06819319,has_phase,
NCT06819319,sponsored_by,Henan Cancer Hospital
NCT06819319,tests,SHR-A2102
SHR-A2102,has_type,DRUG
NCT06476119,has_title,OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With Hig
NCT06476119,has_status,RECRUITING
NCT06476119,has_phase,
NCT06476119,sponsored_by,The Netherlands Cancer Institute
NCT06476119,tests,Adjuvant chemotherapy
Adjuvant chemotherapy,has_type,DRUG
NCT06476119,tests,No adjuvant chemotherapy
No adjuvant chemotherapy,has_type,OTHER
NCT01624441,has_title,A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Pat
NCT01624441,has_status,COMPLETED
NCT01624441,has_phase,
NCT01624441,sponsored_by,National Cancer Institute (NCI)
NCT01624441,tests,Dinaciclib
Dinaciclib,has_type,DRUG
NCT01624441,tests,Epirubicin Hydrochloride
Epirubicin Hydrochloride,has_type,DRUG
NCT01624441,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02001519,has_title,A Phase ll Trial of Impact of Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negat
NCT02001519,has_status,COMPLETED
NCT02001519,has_phase,
NCT02001519,sponsored_by,Asan Medical Center
NCT02001519,tests,AC4-CDDP4
AC4-CDDP4,has_type,DRUG
NCT05720117,has_title,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerabili"
NCT05720117,has_status,RECRUITING
NCT05720117,has_phase,
NCT05720117,sponsored_by,"Pyxis Oncology, Inc"
NCT05720117,tests,PYX-201
PYX-201,has_type,DRUG
NCT04225117,has_title,"An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects Wi"
NCT04225117,has_status,ACTIVE_NOT_RECRUITING
NCT04225117,has_phase,
NCT04225117,sponsored_by,"Astellas Pharma Global Development, Inc."
NCT04225117,tests,enfortumab vedotin
enfortumab vedotin,has_type,DRUG
NCT04225117,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT01083641,has_title,A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer
NCT01083641,has_status,TERMINATED
NCT01083641,has_phase,
NCT01083641,sponsored_by,"University of Wisconsin, Madison"
NCT01083641,tests,Estradiol
Estradiol,has_type,DRUG
NCT04303741,has_title,"An Open-labeled, Single-arm, Investigator-initiated Phase II Trial of Camrelizumab (Anti-PD-1 Antibo"
NCT04303741,has_status,UNKNOWN
NCT04303741,has_phase,
NCT04303741,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04303741,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT04303741,tests,Apatinib
Apatinib,has_type,DRUG
NCT04303741,tests,Eribulin
Eribulin,has_type,DRUG
NCT02455141,has_title,Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breas
NCT02455141,has_status,ACTIVE_NOT_RECRUITING
NCT02455141,has_phase,
NCT02455141,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT02455141,tests,Epirubicin plus Cyclophosphamide
Epirubicin plus Cyclophosphamide,has_type,DRUG
NCT02455141,tests,Taxanes
Taxanes,has_type,DRUG
NCT02455141,tests,Taxanes plus Carboplatin
Taxanes plus Carboplatin,has_type,DRUG
NCT01898117,has_title,Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel W
NCT01898117,has_status,ACTIVE_NOT_RECRUITING
NCT01898117,has_phase,
NCT01898117,sponsored_by,The Netherlands Cancer Institute
NCT01898117,tests,Carbo/cyclo
Carbo/cyclo,has_type,DRUG
NCT01898117,tests,Carbo/cyclo + atezolizumab
Carbo/cyclo + atezolizumab,has_type,DRUG
NCT01898117,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01898117,tests,Paclitaxel + Atezolizumab
Paclitaxel + Atezolizumab,has_type,DRUG
NCT06666517,has_title,The Relationship Between the Density of Cancer-Associated Fibroblasts in the Peritumoral Stroma and 
NCT06666517,has_status,COMPLETED
NCT06666517,has_phase,
NCT06666517,sponsored_by,Haydarpasa Numune Training and Research Hospital
NCT06666517,tests,"surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines"
"surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines",has_type,PROCEDURE
NCT06666517,tests,Immunohistochemistry Analysis
Immunohistochemistry Analysis,has_type,OTHER
NCT06666517,tests,Second Biopsy
Second Biopsy,has_type,PROCEDURE
NCT05068141,has_title,"A Single-arm, Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SG001 i"
NCT05068141,has_status,UNKNOWN
NCT05068141,has_phase,
NCT05068141,sponsored_by,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
NCT05068141,tests,SG001
SG001,has_type,DRUG
NCT05068141,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05101096,has_title,A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumor
NCT05101096,has_status,ACTIVE_NOT_RECRUITING
NCT05101096,has_phase,
NCT05101096,sponsored_by,Gilead Sciences
NCT05101096,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT04424641,has_title,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN10"
NCT04424641,has_status,TERMINATED
NCT04424641,has_phase,
NCT04424641,sponsored_by,Genmab
NCT04424641,tests,GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,has_type,BIOLOGICAL
NCT01931163,has_title,Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients Wi
NCT01931163,has_status,COMPLETED
NCT01931163,has_phase,
NCT01931163,sponsored_by,"Jenny C. Chang, MD"
NCT01931163,tests,Everolimus
Everolimus,has_type,DRUG
NCT04191135,has_title,"An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus P"
NCT04191135,has_status,ACTIVE_NOT_RECRUITING
NCT04191135,has_phase,
NCT04191135,sponsored_by,Merck Sharp & Dohme LLC
NCT04191135,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04191135,tests,Olaparib
Olaparib,has_type,DRUG
NCT04191135,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04191135,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03164863,has_title,Feasibility Study of Motility Contrast Tomography for Predicting Therapeutic Response
NCT03164863,has_status,UNKNOWN
NCT03164863,has_phase,
NCT03164863,sponsored_by,"Animated Dynamics, Inc."
NCT03164863,tests,Onco4D Biodynamic Chemotherapy Selection Assay
Onco4D Biodynamic Chemotherapy Selection Assay,has_type,DIAGNOSTIC_TEST
NCT02018458,has_title,Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients Wit
NCT02018458,has_status,COMPLETED
NCT02018458,has_phase,
NCT02018458,sponsored_by,Baylor Research Institute
NCT02018458,tests,LA TNBC: DC vaccine+Preop chemo
LA TNBC: DC vaccine+Preop chemo,has_type,BIOLOGICAL
NCT02018458,tests,ER+/HER2-BC:DC vaccine+Preop chemo
ER+/HER2-BC:DC vaccine+Preop chemo,has_type,BIOLOGICAL
NCT04626635,has_title,A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemi
NCT04626635,has_status,RECRUITING
NCT04626635,has_phase,
NCT04626635,sponsored_by,Regeneron Pharmaceuticals
NCT04626635,tests,REGN7075
REGN7075,has_type,DRUG
NCT04626635,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT04626635,tests,Platinum-based doublet chemotherapy
Platinum-based doublet chemotherapy,has_type,DRUG
NCT04626635,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT04626635,tests,Trifluridine-tipiracil
Trifluridine-tipiracil,has_type,DRUG
NCT03821935,has_title,"A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, To"
NCT03821935,has_status,ACTIVE_NOT_RECRUITING
NCT03821935,has_phase,
NCT03821935,sponsored_by,AbbVie
NCT03821935,tests,Livmoniplimab
Livmoniplimab,has_type,DRUG
NCT03821935,tests,Budigalimab
Budigalimab,has_type,DRUG
NCT03326258,has_title,Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors
NCT03326258,has_status,WITHDRAWN
NCT03326258,has_phase,
NCT03326258,sponsored_by,National Cancer Institute (NCI)
NCT03326258,tests,Glembatumumab Vedotin
Glembatumumab Vedotin,has_type,DRUG
NCT03326258,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT03326258,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03326258,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03326258,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02451735,has_title,Genetic Counseling for Breast Cancer Survivors (GC for BC)
NCT02451735,has_status,COMPLETED
NCT02451735,has_phase,
NCT02451735,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02451735,tests,Video and Booklet
Video and Booklet,has_type,BEHAVIORAL
NCT02451735,tests,Factsheet
Factsheet,has_type,BEHAVIORAL
NCT05069935,has_title,"A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subje"
NCT05069935,has_status,TERMINATED
NCT05069935,has_phase,
NCT05069935,sponsored_by,Fate Therapeutics
NCT05069935,tests,FT538
FT538,has_type,DRUG
NCT05069935,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05069935,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05069935,tests,Monoclonal antibody - Dose Escalation
Monoclonal antibody - Dose Escalation,has_type,COMBINATION_PRODUCT
NCT05069935,tests,Monoclonal antibody - Dose Expansion
Monoclonal antibody - Dose Expansion,has_type,COMBINATION_PRODUCT
NCT04225858,has_title,Avoiding Sentinel Lymph Node Biopsy In Select Clinical Node Negative Breast Cancer Patients After Ne
NCT04225858,has_status,NOT_YET_RECRUITING
NCT04225858,has_phase,
NCT04225858,sponsored_by,The Netherlands Cancer Institute
NCT04225858,tests,Omission of sentinel lymph node biopsy
Omission of sentinel lymph node biopsy,has_type,PROCEDURE
NCT06797635,has_title,An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus
NCT06797635,has_status,RECRUITING
NCT06797635,has_phase,
NCT06797635,sponsored_by,Merck Sharp & Dohme LLC
NCT06797635,tests,Patritumab deruxtecan
Patritumab deruxtecan,has_type,BIOLOGICAL
NCT06797635,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06797635,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06797635,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06797635,tests,Doxorubicin hydrochloride
Doxorubicin hydrochloride,has_type,DRUG
NCT06797635,tests,Epirubicin hydrochloride
Epirubicin hydrochloride,has_type,DRUG
NCT06797635,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06797635,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06797635,tests,Olaparib
Olaparib,has_type,DRUG
NCT06604858,has_title,Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negat
NCT06604858,has_status,RECRUITING
NCT06604858,has_phase,
NCT06604858,sponsored_by,MedSIR
NCT06604858,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06604858,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06604858,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03855358,has_title,A Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative 
NCT03855358,has_status,UNKNOWN
NCT03855358,has_phase,
NCT03855358,sponsored_by,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
NCT03855358,tests,TQB2450 Injection and Anlotinib Hydrochioride Capsules
TQB2450 Injection and Anlotinib Hydrochioride Capsules,has_type,DRUG
NCT02806258,has_title,Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused 
NCT02806258,has_status,RECRUITING
NCT02806258,has_phase,
NCT02806258,sponsored_by,"University Hospital, Grenoble"
NCT02806258,tests,Accelerated partial breast irradiation
Accelerated partial breast irradiation,has_type,RADIATION
NCT02806258,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT07000396,has_title,The Role of Mucosal Associated Invariant t Lymphocytes in Breast Cancer
NCT07000396,has_status,NOT_YET_RECRUITING
NCT07000396,has_phase,
NCT07000396,sponsored_by,Assiut University
NCT04712396,has_title,"An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Capivasert"
NCT04712396,has_status,COMPLETED
NCT04712396,has_phase,
NCT04712396,sponsored_by,AstraZeneca
NCT04712396,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT04712396,tests,Itraconazole
Itraconazole,has_type,DRUG
NCT03794596,has_title,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Nega"
NCT03794596,has_status,WITHDRAWN
NCT03794596,has_phase,
NCT03794596,sponsored_by,The Christie NHS Foundation Trust
NCT03794596,tests,Avelumab
Avelumab,has_type,DRUG
NCT03794596,tests,Aspirin
Aspirin,has_type,DRUG
NCT03794596,tests,Lansoprazole (Proton Pump Inhibitor)
Lansoprazole (Proton Pump Inhibitor),has_type,DRUG
NCT01069796,has_title,A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel an
NCT01069796,has_status,TERMINATED
NCT01069796,has_phase,
NCT01069796,sponsored_by,ARCAGY/ GINECO GROUP
NCT01069796,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01069796,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01069796,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06590558,has_title,Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative 
NCT06590558,has_status,WITHDRAWN
NCT06590558,has_phase,
NCT06590558,sponsored_by,National Cancer Institute (NCI)
NCT06590558,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT06590558,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06590558,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT06590558,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT06590558,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT06590558,tests,Tolinapant
Tolinapant,has_type,DRUG
NCT06590558,tests,X-Ray Imaging
X-Ray Imaging,has_type,PROCEDURE
NCT02315196,has_title,"A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Brea"
NCT02315196,has_status,ACTIVE_NOT_RECRUITING
NCT02315196,has_phase,
NCT02315196,sponsored_by,"Rutgers, The State University of New Jersey"
NCT02315196,tests,pegylated liposomal doxorubicin hydrochloride
pegylated liposomal doxorubicin hydrochloride,has_type,DRUG
NCT02315196,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
NCT02315196,tests,carboplatin
carboplatin,has_type,DRUG
NCT02315196,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT02315196,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT02315196,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02315196,tests,quality-of-life assessment
quality-of-life assessment,has_type,OTHER
NCT02985658,has_title,Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associat
NCT02985658,has_status,NO_LONGER_AVAILABLE
NCT02985658,has_phase,
NCT02985658,sponsored_by,University of Washington
NCT02985658,tests,Veliparib
Veliparib,has_type,DRUG
NCT02985658,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02985658,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT01276496,has_title,"A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Propert"
NCT01276496,has_status,COMPLETED
NCT01276496,has_phase,
NCT01276496,sponsored_by,National Cancer Institute (NCI)
NCT01276496,tests,Cilengitide
Cilengitide,has_type,DRUG
NCT01276496,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01276496,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01276496,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01848834,has_title,A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
NCT01848834,has_status,COMPLETED
NCT01848834,has_phase,
NCT01848834,sponsored_by,Merck Sharp & Dohme LLC
NCT01848834,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06167317,has_title,A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination
NCT06167317,has_status,RECRUITING
NCT06167317,has_phase,
NCT06167317,sponsored_by,Gilead Sciences
NCT06167317,tests,GS-0201
GS-0201,has_type,DRUG
NCT06167317,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT03358017,has_title,"Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledrona"
NCT03358017,has_status,COMPLETED
NCT03358017,has_phase,
NCT03358017,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT03358017,tests,Zoledronate
Zoledronate,has_type,DRUG
NCT03358017,tests,Atorvastatin 80mg
Atorvastatin 80mg,has_type,DRUG
NCT03358017,tests,Standard neoadjuvant cht
Standard neoadjuvant cht,has_type,DRUG
NCT06938724,has_title,Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer: A
NCT06938724,has_status,NOT_YET_RECRUITING
NCT06938724,has_phase,
NCT06938724,sponsored_by,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
NCT06938724,tests,Omission of local therapies
Omission of local therapies,has_type,OTHER
NCT05565417,has_title,"A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Mono"
NCT05565417,has_status,RECRUITING
NCT05565417,has_phase,
NCT05565417,sponsored_by,Immunitas Therapeutics
NCT05565417,tests,IMT-009
IMT-009,has_type,DRUG
NCT05565417,tests,Fruquintinib
Fruquintinib,has_type,COMBINATION_PRODUCT
NCT02826434,has_title,A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Durv
NCT02826434,has_status,ACTIVE_NOT_RECRUITING
NCT02826434,has_phase,
NCT02826434,sponsored_by,Massachusetts General Hospital
NCT02826434,tests,PVX-410
PVX-410,has_type,BIOLOGICAL
NCT02826434,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT02826434,tests,Hiltonol
Hiltonol,has_type,DRUG
NCT03092934,has_title,A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherap
NCT03092934,has_status,COMPLETED
NCT03092934,has_phase,
NCT03092934,sponsored_by,Eli Lilly and Company
NCT03092934,tests,LY3295668
LY3295668,has_type,DRUG
NCT06885424,has_title,A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2Bio) Gene Therapy (GT
NCT06885424,has_status,NOT_YET_RECRUITING
NCT06885424,has_phase,
NCT06885424,sponsored_by,A2 Biotherapeutics Inc.
NCT06885424,tests,No additional intervention administered in this long term follow-up study
No additional intervention administered in this long term follow-up study,has_type,OTHER
NCT00540358,has_title,"A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without B"
NCT00540358,has_status,COMPLETED
NCT00540358,has_phase,
NCT00540358,sponsored_by,Sanofi
NCT00540358,tests,gemcitabine/carboplatin
gemcitabine/carboplatin,has_type,DRUG
NCT00540358,tests,iniparib
iniparib,has_type,DRUG
NCT02926196,has_title,Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody
NCT02926196,has_status,ACTIVE_NOT_RECRUITING
NCT02926196,has_phase,
NCT02926196,sponsored_by,Istituto Oncologico Veneto IRCCS
NCT02926196,tests,MSB0010718C
MSB0010718C,has_type,DRUG
NCT03184558,has_title,"A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previous"
NCT03184558,has_status,TERMINATED
NCT03184558,has_phase,
NCT03184558,sponsored_by,BerGenBio ASA
NCT03184558,tests,Bemcentinib
Bemcentinib,has_type,DRUG
NCT05455658,has_title,A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selecti
NCT05455658,has_status,RECRUITING
NCT05455658,has_phase,
NCT05455658,sponsored_by,University of Washington
NCT05455658,tests,CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,has_type,BIOLOGICAL
NCT05455658,tests,Sargramostim
Sargramostim,has_type,BIOLOGICAL
NCT02375958,has_title,"A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intrav"
NCT02375958,has_status,COMPLETED
NCT02375958,has_phase,
NCT02375958,sponsored_by,Novartis Pharmaceuticals
NCT02375958,tests,PCA062
PCA062,has_type,DRUG
NCT02299635,has_title,PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WI
NCT02299635,has_status,TERMINATED
NCT02299635,has_phase,
NCT02299635,sponsored_by,Pfizer
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01216124,has_title,"A Prospective, Open and Unicentric Phase II Clinical Trial of Docetaxel Combined With Oxaliplatin fo"
NCT01216124,has_status,AVAILABLE
NCT01216124,has_phase,
NCT01216124,sponsored_by,Fudan University
NCT01216124,tests,docetaxel oxaliplatin
docetaxel oxaliplatin,has_type,DRUG
NCT00516724,has_title,"A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With "
NCT00516724,has_status,COMPLETED
NCT00516724,has_phase,
NCT00516724,sponsored_by,AstraZeneca
NCT00516724,tests,KU-0059436 (AZD2281)(PARP inhibitor)
KU-0059436 (AZD2281)(PARP inhibitor),has_type,DRUG
NCT00516724,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00516724,tests,KU-0059436 (AZD2281)(PARP inhibitor)
KU-0059436 (AZD2281)(PARP inhibitor),has_type,DRUG
NCT00516724,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00516724,tests,KU-0059436 (AZD2281)(PARP inhibitor)
KU-0059436 (AZD2281)(PARP inhibitor),has_type,DRUG
NCT00516724,tests,Paclitaxel + Carboplatin
Paclitaxel + Carboplatin,has_type,DRUG
NCT03267316,has_title,"An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a"
NCT03267316,has_status,COMPLETED
NCT03267316,has_phase,
NCT03267316,sponsored_by,Cantargia AB
NCT03267316,tests,CAN04
CAN04,has_type,BIOLOGICAL
NCT03267316,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03267316,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03267316,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03267316,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03267316,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT03667716,has_title,A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjec
NCT03667716,has_status,COMPLETED
NCT03667716,has_phase,
NCT03667716,sponsored_by,Compugen Ltd
NCT03667716,tests,COM701
COM701,has_type,DRUG
NCT03667716,tests,COM701 with Opdivo (Nivolumab).
COM701 with Opdivo (Nivolumab).,has_type,DRUG
NCT01147016,has_title,A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvan
NCT01147016,has_status,TERMINATED
NCT01147016,has_phase,
NCT01147016,sponsored_by,Barbara Ann Karmanos Cancer Institute
NCT01147016,tests,HER2Bi-armed activated T cells
HER2Bi-armed activated T cells,has_type,BIOLOGICAL
NCT01147016,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT01147016,tests,doxorubicin hydrochloride
doxorubicin hydrochloride,has_type,DRUG
NCT01147016,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01147016,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01147016,tests,neoadjuvant therapy
neoadjuvant therapy,has_type,PROCEDURE
NCT01147016,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT02694224,has_title,A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to S
NCT02694224,has_status,UNKNOWN
NCT02694224,has_phase,
NCT02694224,sponsored_by,"Clinica Universidad de Navarra, Universidad de Navarra"
NCT02694224,tests,vismodegib
vismodegib,has_type,DRUG
NCT02694224,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02694224,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02694224,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06508216,has_title,"A Phase Ib/II, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore Safety, Tolerab"
NCT06508216,has_status,RECRUITING
NCT06508216,has_phase,
NCT06508216,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT06508216,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT06508216,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT05620134,has_title,"A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antib"
NCT05620134,has_status,ACTIVE_NOT_RECRUITING
NCT05620134,has_phase,
NCT05620134,sponsored_by,Salubris Biotherapeutics Inc
NCT05620134,tests,JK08
JK08,has_type,DRUG
NCT05620134,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05620134,tests,Lenvatinib Pill
Lenvatinib Pill,has_type,DRUG
NCT00491816,has_title,"Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative"
NCT00491816,has_status,UNKNOWN
NCT00491816,has_phase,
NCT00491816,sponsored_by,University of Kansas Medical Center
NCT00491816,tests,Erlotinib with neoadjuvant chemotherapy
Erlotinib with neoadjuvant chemotherapy,has_type,DRUG
NCT02978716,has_title,"Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Tri"
NCT02978716,has_status,TERMINATED
NCT02978716,has_phase,
NCT02978716,sponsored_by,"G1 Therapeutics, Inc."
NCT02978716,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT02978716,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02978716,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05807516,has_title,Study of the Impact of Neoadjuvant Therapy on the Heterogeneity of Triple Negative Breast Cancer Thr
NCT05807516,has_status,UNKNOWN
NCT05807516,has_phase,
NCT05807516,sponsored_by,Regina Elena Cancer Institute
NCT05807516,tests,"Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)"
"Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)",has_type,OTHER
NCT04677816,has_title,Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficie
NCT04677816,has_status,RECRUITING
NCT04677816,has_phase,
NCT04677816,sponsored_by,Wake Forest University Health Sciences
NCT04677816,tests,Standard of Care Neoadjuvant Chemotherapy (NAC)
Standard of Care Neoadjuvant Chemotherapy (NAC),has_type,DRUG
NCT04677816,tests,Vitamin D3
Vitamin D3,has_type,DIETARY_SUPPLEMENT
NCT04677816,tests,Drug Diary
Drug Diary,has_type,OTHER
NCT06380816,has_title,"A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preli"
NCT06380816,has_status,RECRUITING
NCT06380816,has_phase,
NCT06380816,sponsored_by,Cancer Research UK
NCT06380816,tests,UCB4594
UCB4594,has_type,DRUG
NCT03498716,has_title,"A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) "
NCT03498716,has_status,TERMINATED
NCT03498716,has_phase,
NCT03498716,sponsored_by,Hoffmann-La Roche
NCT03498716,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03498716,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03498716,tests,Dose-dense Doxorubicin or dose-dense Epirubicin
Dose-dense Doxorubicin or dose-dense Epirubicin,has_type,DRUG
NCT03498716,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04289935,has_title,Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogat
NCT04289935,has_status,RECRUITING
NCT04289935,has_phase,
NCT04289935,sponsored_by,"Klinik Hirslanden, Zurich"
NCT04289935,tests,Vacuum assisted biopsy (VAB)
Vacuum assisted biopsy (VAB),has_type,PROCEDURE
NCT06299163,has_title,A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With S
NCT06299163,has_status,TERMINATED
NCT06299163,has_phase,
NCT06299163,sponsored_by,Numab Therapeutics AG
NCT06299163,tests,NM32-2668
NM32-2668,has_type,BIOLOGICAL
NCT01495663,has_title,"A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapse"
NCT01495663,has_status,COMPLETED
NCT01495663,has_phase,
NCT01495663,sponsored_by,"Cellectar Biosciences, Inc."
NCT01495663,tests,I-131-CLR1404
I-131-CLR1404,has_type,DRUG
NCT01818063,has_title,"An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition o"
NCT01818063,has_status,COMPLETED
NCT01818063,has_phase,
NCT01818063,sponsored_by,Sidney Kimmel Cancer Center at Thomas Jefferson University
NCT01818063,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01818063,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01818063,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT01818063,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01818063,tests,Veliparib
Veliparib,has_type,DRUG
NCT03107663,has_title,A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Sele
NCT03107663,has_status,COMPLETED
NCT03107663,has_phase,
NCT03107663,sponsored_by,"ImaginAb, Inc."
NCT03107663,tests,⁸⁹Zr-Df-IAB22M2C Infusion
⁸⁹Zr-Df-IAB22M2C Infusion,has_type,DRUG
NCT02347163,has_title,"A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in T"
NCT02347163,has_status,TERMINATED
NCT02347163,has_phase,
NCT02347163,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT02347163,tests,Zoledronate
Zoledronate,has_type,DRUG
NCT04083963,has_title,BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and 
NCT04083963,has_status,ACTIVE_NOT_RECRUITING
NCT04083963,has_phase,
NCT04083963,sponsored_by,University of Illinois at Chicago
NCT04083963,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04083963,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04083963,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04083963,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00739063,has_title,"Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of"
NCT00739063,has_status,TERMINATED
NCT00739063,has_phase,
NCT00739063,sponsored_by,M.D. Anderson Cancer Center
NCT00739063,tests,Tarceva
Tarceva,has_type,DRUG
NCT06962163,has_title,"Prospective Phase 0 Pilot Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metas"
NCT06962163,has_status,NOT_YET_RECRUITING
NCT06962163,has_phase,
NCT06962163,sponsored_by,Institut Cancerologie de l'Ouest
NCT06962163,tests,[68Ga]Ga-PentixaFor PET/CT
[68Ga]Ga-PentixaFor PET/CT,has_type,DIAGNOSTIC_TEST
NCT01431196,has_title,Phase II Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negativ
NCT01431196,has_status,COMPLETED
NCT01431196,has_phase,
NCT01431196,sponsored_by,"Clinica Universidad de Navarra, Universidad de Navarra"
NCT01431196,tests,Autologous dendritic cell vaccination
Autologous dendritic cell vaccination,has_type,BIOLOGICAL
NCT06685796,has_title,A Phase II Study of BEBT-209 in Combination With Carboplatin and Gemcitabine for the Treatment of Ad
NCT06685796,has_status,RECRUITING
NCT06685796,has_phase,
NCT06685796,sponsored_by,BeBetter Med Inc
NCT06685796,tests,BEBT-209 capsules
BEBT-209 capsules,has_type,DRUG
NCT06685796,tests,Carboplatin injection
Carboplatin injection,has_type,DRUG
NCT06685796,tests,Gemcitabine hydrochloride for injection
Gemcitabine hydrochloride for injection,has_type,DRUG
NCT05377996,has_title,"A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participa"
NCT05377996,has_status,RECRUITING
NCT05377996,has_phase,
NCT05377996,sponsored_by,Mersana Therapeutics
NCT05377996,tests,XMT-1660
XMT-1660,has_type,DRUG
NCT05383196,has_title,A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breas
NCT05383196,has_status,ACTIVE_NOT_RECRUITING
NCT05383196,has_phase,
NCT05383196,sponsored_by,"Antonio Giordano, MD"
NCT05383196,tests,Onvansertib
Onvansertib,has_type,DRUG
NCT05383196,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06538896,has_title,"Exploratory Single-Arm, Multicenter Phase II Study of Tislelizumab Combined with Nab-Paclitaxel As F"
NCT06538896,has_status,RECRUITING
NCT06538896,has_phase,
NCT06538896,sponsored_by,Zhejiang Cancer Hospital
NCT06538896,tests,Tislelizumab + Nab-Paclitaxel
Tislelizumab + Nab-Paclitaxel,has_type,DRUG
NCT06538896,tests,Rankl inhibitor
Rankl inhibitor,has_type,OTHER
NCT02567396,has_title,A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and R
NCT02567396,has_status,WITHDRAWN
NCT02567396,has_phase,
NCT02567396,sponsored_by,National Cancer Institute (NCI)
NCT02567396,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02567396,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02567396,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT03594396,has_title,Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) Before Standard Neoadjuvant Chemot
NCT03594396,has_status,ACTIVE_NOT_RECRUITING
NCT03594396,has_phase,
NCT03594396,sponsored_by,Seoul National University Hospital
NCT03594396,tests,Olaparib
Olaparib,has_type,DRUG
NCT03594396,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04129996,has_title,Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First-line Treatment in Patients 
NCT04129996,has_status,UNKNOWN
NCT04129996,has_phase,
NCT04129996,sponsored_by,Fudan University
NCT04129996,tests,camrelizumab in combination with nab-paclitaxel and famitinib
camrelizumab in combination with nab-paclitaxel and famitinib,has_type,DRUG
NCT01319539,has_title,Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer
NCT01319539,has_status,TERMINATED
NCT01319539,has_phase,
NCT01319539,sponsored_by,National Cancer Institute (NCI)
NCT01319539,tests,Akt Inhibitor MK2206
Akt Inhibitor MK2206,has_type,DRUG
NCT01319539,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT01319539,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01319539,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT04135586,has_title,Effects of a Physical Exercise Intervention at the Molecular Systemic and Tumor Level Performed Duri
NCT04135586,has_status,RECRUITING
NCT04135586,has_phase,
NCT04135586,sponsored_by,Universidad Europea de Madrid
NCT04135586,tests,Exercise training
Exercise training,has_type,OTHER
NCT04135586,tests,Control
Control,has_type,OTHER
NCT02605486,has_title,Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastat
NCT02605486,has_status,ACTIVE_NOT_RECRUITING
NCT02605486,has_phase,
NCT02605486,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02605486,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT02605486,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT03876886,has_title,Randomized Phase Ⅲ Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel
NCT03876886,has_status,UNKNOWN
NCT03876886,has_phase,
NCT03876886,sponsored_by,Chinese Academy of Medical Sciences
NCT03876886,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03876886,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03876886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03876886,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03876886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03316586,has_title,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast
NCT03316586,has_status,COMPLETED
NCT03316586,has_phase,
NCT03316586,sponsored_by,Dana-Farber Cancer Institute
NCT03316586,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03316586,tests,Cabozantinib
Cabozantinib,has_type,DRUG
NCT04537286,has_title,"A Prospective, Single-arm, Open-Label, Phase II Study of Nab-paclitaxel Plus Cisplatin Plus Carilizu"
NCT04537286,has_status,RECRUITING
NCT04537286,has_phase,
NCT04537286,sponsored_by,Fudan University
NCT04537286,tests,nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1),has_type,DRUG
NCT04320030,has_title,Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 
NCT04320030,has_status,COMPLETED
NCT04320030,has_phase,
NCT04320030,sponsored_by,Institut Cancerologie de l'Ouest
NCT04320030,tests,[18F]-DPA-714 PET/CT scan
[18F]-DPA-714 PET/CT scan,has_type,DRUG
NCT05670925,has_title,"The Opportune Administration of Nab-paclitaxel in the First Line Treatment Strategy, Camrelizumab an"
NCT05670925,has_status,UNKNOWN
NCT05670925,has_phase,
NCT05670925,sponsored_by,Fudan University
NCT05670925,tests,Camrelizumab plus Famitinib with/without nab-Palitaxel
Camrelizumab plus Famitinib with/without nab-Palitaxel,has_type,DRUG
NCT02362230,has_title,Sun Yat-sen University Cancer Center
NCT02362230,has_status,TERMINATED
NCT02362230,has_phase,
NCT02362230,sponsored_by,Sun Yat-sen University
NCT02362230,tests,Icotinib
Icotinib,has_type,DRUG
NCT02531425,has_title,Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in P
NCT02531425,has_status,COMPLETED
NCT02531425,has_phase,
NCT02531425,sponsored_by,OncoSec Medical Incorporated
NCT02531425,tests,IT-pIL12-EP
IT-pIL12-EP,has_type,BIOLOGICAL
NCT03941730,has_title,Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
NCT03941730,has_status,ACTIVE_NOT_RECRUITING
NCT03941730,has_phase,
NCT03941730,sponsored_by,Mayo Clinic
NCT03941730,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03941730,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT03941730,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03941730,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT03941730,tests,Therapeutic Estradiol
Therapeutic Estradiol,has_type,BIOLOGICAL
NCT06606730,has_title,OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breas
NCT06606730,has_status,NOT_YET_RECRUITING
NCT06606730,has_phase,
NCT06606730,sponsored_by,UNICANCER
NCT06606730,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06606730,tests,Deescalation
Deescalation,has_type,OTHER
NCT01145430,has_title,"Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gyn"
NCT01145430,has_status,COMPLETED
NCT01145430,has_phase,
NCT01145430,sponsored_by,National Cancer Institute (NCI)
NCT01145430,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01145430,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
NCT01145430,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01145430,tests,Veliparib
Veliparib,has_type,DRUG
NCT04136782,has_title,Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoa
NCT04136782,has_status,RECRUITING
NCT04136782,has_phase,
NCT04136782,sponsored_by,Shengjing Hospital
NCT04136782,tests,Albumin-bound paclitaxel combined with carboplatin
Albumin-bound paclitaxel combined with carboplatin,has_type,DRUG
NCT04136782,tests,Epirubicin combined with docetaxel
Epirubicin combined with docetaxel,has_type,DRUG
NCT03735082,has_title,The Efficacy and Safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neo
NCT03735082,has_status,UNKNOWN
NCT03735082,has_phase,
NCT03735082,sponsored_by,Chinese Academy of Medical Sciences
NCT03735082,tests,Apatinib
Apatinib,has_type,DRUG
NCT03735082,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03735082,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02000882,has_title,Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Breast Cancer Patients With Br
NCT02000882,has_status,COMPLETED
NCT02000882,has_phase,
NCT02000882,sponsored_by,US Oncology Research
NCT02000882,tests,BKM120
BKM120,has_type,DRUG
NCT02000882,tests,capecitabine
capecitabine,has_type,DRUG
NCT02000882,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04455620,has_title,"Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Sa"
NCT04455620,has_status,TERMINATED
NCT04455620,has_phase,
NCT04455620,sponsored_by,BioNTech SE
NCT04455620,tests,BNT151
BNT151,has_type,BIOLOGICAL
NCT05333874,has_title,CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stag
NCT05333874,has_status,ACTIVE_NOT_RECRUITING
NCT05333874,has_phase,
NCT05333874,sponsored_by,"Rutgers, The State University of New Jersey"
NCT05333874,tests,Neoadjuvant chemotherapy administered before surgical extraction of a tumor
Neoadjuvant chemotherapy administered before surgical extraction of a tumor,has_type,DRUG
NCT05333874,tests,Observational
Observational,has_type,OTHER
NCT06926920,has_title,"A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Sched"
NCT06926920,has_status,RECRUITING
NCT06926920,has_phase,
NCT06926920,sponsored_by,Gilead Sciences
NCT06926920,tests,Sacituzumab Govitecan-hziy (SG)
Sacituzumab Govitecan-hziy (SG),has_type,DRUG
NCT05834582,has_title,Neoadjuvant Fluzoparib Combined With Chemotherapy in Germline BRCA-mutated Three-negative Breast Can
NCT05834582,has_status,RECRUITING
NCT05834582,has_phase,
NCT05834582,sponsored_by,The First Affiliated Hospital with Nanjing Medical University
NCT05834582,tests,Fluzoparib+Paclitaxel
Fluzoparib+Paclitaxel,has_type,DRUG
NCT05834582,tests,Epirubicin+Cyclophosphamide
Epirubicin+Cyclophosphamide,has_type,DRUG
NCT06672120,has_title,Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunother
NCT06672120,has_status,RECRUITING
NCT06672120,has_phase,
NCT06672120,sponsored_by,Technical University of Munich
NCT06672120,tests,Exercise training
Exercise training,has_type,BEHAVIORAL
NCT02413320,has_title,Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus P
NCT02413320,has_status,COMPLETED
NCT02413320,has_phase,
NCT02413320,sponsored_by,Priyanka Sharma
NCT02413320,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02413320,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02413320,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02413320,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02413320,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04105582,has_title,Phase I Clinical Study of Immunotherapy With Personalized Synthetic Vaccines in Patients With Triple
NCT04105582,has_status,COMPLETED
NCT04105582,has_phase,
NCT04105582,sponsored_by,Universidad Nacional de Colombia
NCT04105582,tests,Neo-antigen pulsed Dendritic cell
Neo-antigen pulsed Dendritic cell,has_type,BIOLOGICAL
NCT05770531,has_title,A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patient
NCT05770531,has_status,RECRUITING
NCT05770531,has_phase,
NCT05770531,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT05770531,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05770531,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05770531,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05770531,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05770531,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,BIOLOGICAL
NCT05868226,has_title,PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular 
NCT05868226,has_status,RECRUITING
NCT05868226,has_phase,
NCT05868226,sponsored_by,QuantumLeap Healthcare Collaborative
NCT05868226,tests,ALX148
ALX148,has_type,DRUG
NCT05868226,tests,Fam-Trastuzumab Deruxtecan-Nxki
Fam-Trastuzumab Deruxtecan-Nxki,has_type,DRUG
NCT05868226,tests,Zanidatamab
Zanidatamab,has_type,DRUG
NCT05868226,tests,Tucatinib
Tucatinib,has_type,DRUG
NCT01528826,has_title,A Prospective Phase II Trial of Vinorelbine Plus Oxaliplatin in Pretreated Metastatic Triple-negativ
NCT01528826,has_status,UNKNOWN
NCT01528826,has_phase,
NCT01528826,sponsored_by,Fudan University
NCT01528826,tests,vinorelbine plus oxaliplatin
vinorelbine plus oxaliplatin,has_type,DRUG
NCT02833766,has_title,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Pos
NCT02833766,has_status,TERMINATED
NCT02833766,has_phase,
NCT02833766,sponsored_by,Swiss Group for Clinical Cancer Research
NCT02833766,tests,anti-EGFR-IL-dox
anti-EGFR-IL-dox,has_type,DRUG
NCT03719326,has_title,A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Particip
NCT03719326,has_status,COMPLETED
NCT03719326,has_phase,
NCT03719326,sponsored_by,"Arcus Biosciences, Inc."
NCT03719326,tests,Etrumadenant
Etrumadenant,has_type,DRUG
NCT03719326,tests,IPI-549
IPI-549,has_type,DRUG
NCT03719326,tests,Pegylated liposomal doxorubicin (PLD)
Pegylated liposomal doxorubicin (PLD),has_type,DRUG
NCT03719326,tests,nanoparticle albumin-bound paclitaxel (NP)
nanoparticle albumin-bound paclitaxel (NP),has_type,DRUG
NCT02535026,has_title,"Epidemiological, Prospective and Observational Study on the HER2 Status in Breast Invasive Carcinoma"
NCT02535026,has_status,COMPLETED
NCT02535026,has_phase,
NCT02535026,sponsored_by,Hoffmann-La Roche
NCT03932526,has_title,Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Recurrent or M
NCT03932526,has_status,UNKNOWN
NCT03932526,has_phase,
NCT03932526,sponsored_by,Liaoning Cancer Hospital & Institute
NCT03932526,tests,Vinorelbine + placebo
Vinorelbine + placebo,has_type,DRUG
NCT03932526,tests,Vinorelbine + Apatinib
Vinorelbine + Apatinib,has_type,DRUG
NCT05686720,has_title,"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast C"
NCT05686720,has_status,UNKNOWN
NCT05686720,has_phase,
NCT05686720,sponsored_by,First Affiliated Hospital of Shantou University Medical College
NCT05686720,tests,SZ011 CAR-NK
SZ011 CAR-NK,has_type,DRUG
NCT04613674,has_title,"A Multicentre, Randomized, Double-blind, Parallel-controlled Phase Ⅲ Study to Evaluate Camrelizumab "
NCT04613674,has_status,COMPLETED
NCT04613674,has_phase,
NCT04613674,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT04613674,tests,Camrelizumab Plus Chemotherapy
Camrelizumab Plus Chemotherapy,has_type,DRUG
NCT04613674,tests,placebo+chemotherapy
placebo+chemotherapy,has_type,DRUG
NCT00479674,has_title,"A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in ""Triple Negative"" (Demonstrating No Ex"
NCT00479674,has_status,COMPLETED
NCT00479674,has_phase,
NCT00479674,sponsored_by,Duke University
NCT00479674,tests,Abraxane
Abraxane,has_type,DRUG
NCT00479674,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00479674,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02464774,has_title,Impact of Breast-Conserving Therapy (BCT) on Recurrence in Patients With Triple-Negative Breast Canc
NCT02464774,has_status,UNKNOWN
NCT02464774,has_phase,
NCT02464774,sponsored_by,Xiaoming Xie
NCT02464774,tests,Breast-Conserving Therapy
Breast-Conserving Therapy,has_type,PROCEDURE
NCT02464774,tests,Mastectomy
Mastectomy,has_type,PROCEDURE
NCT02464774,tests,Adjuvant Chemotherapy
Adjuvant Chemotherapy,has_type,DRUG
NCT02464774,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT06085274,has_title,Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (S
NCT06085274,has_status,RECRUITING
NCT06085274,has_phase,
NCT06085274,sponsored_by,"University Health Network, Toronto"
NCT06085274,tests,ICG guided sentinel lymph node biopsy
ICG guided sentinel lymph node biopsy,has_type,PROCEDURE
NCT02954874,has_title,"A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adju"
NCT02954874,has_status,ACTIVE_NOT_RECRUITING
NCT02954874,has_phase,
NCT02954874,sponsored_by,National Cancer Institute (NCI)
NCT02954874,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT02954874,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02954874,tests,Patient Observation
Patient Observation,has_type,OTHER
NCT02954874,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02954874,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT02954874,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT02954874,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT03539965,has_title,Triple-negative Breast Cancer: a New Perspective on Predictive and Prognostic Biomarkers
NCT03539965,has_status,COMPLETED
NCT03539965,has_phase,
NCT03539965,sponsored_by,"Instituto Nacional de Cancer, Brazil"
NCT04595565,has_title,"Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Prim"
NCT04595565,has_status,ACTIVE_NOT_RECRUITING
NCT04595565,has_phase,
NCT04595565,sponsored_by,GBG Forschungs GmbH
NCT04595565,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04595565,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04595565,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04595565,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT05115474,has_title,Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
NCT05115474,has_status,RECRUITING
NCT05115474,has_phase,
NCT05115474,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05115474,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DIAGNOSTIC_TEST
NCT05318274,has_title,"Hypofractionated Radiation Therapy (1 Week) Compared With Standard Treatment (3.1 Weeks), Evaluation"
NCT05318274,has_status,RECRUITING
NCT05318274,has_phase,
NCT05318274,sponsored_by,"Coordinación de Investigación en Salud, Mexico"
NCT05318274,tests,Hypofractionated radiotherapy
Hypofractionated radiotherapy,has_type,RADIATION
NCT02622074,has_title,A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination 
NCT02622074,has_status,COMPLETED
NCT02622074,has_phase,
NCT02622074,sponsored_by,Merck Sharp & Dohme LLC
NCT02622074,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02622074,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02622074,tests,Anthracycline (doxorubicin)
Anthracycline (doxorubicin),has_type,DRUG
NCT02622074,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02622074,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02622074,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05107674,has_title,"A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma "
NCT05107674,has_status,RECRUITING
NCT05107674,has_phase,
NCT05107674,sponsored_by,"Nurix Therapeutics, Inc."
NCT05107674,tests,NX-1607
NX-1607,has_type,DRUG
NCT05107674,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05933265,has_title,A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metast
NCT05933265,has_status,RECRUITING
NCT05933265,has_phase,
NCT05933265,sponsored_by,Lantern Pharma Inc.
NCT05933265,tests,LP-184
LP-184,has_type,DRUG
NCT05933265,tests,Spironolactone
Spironolactone,has_type,DRUG
NCT05933265,tests,Olaparib
Olaparib,has_type,DRUG
NCT01251874,has_title,A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negat
NCT01251874,has_status,ACTIVE_NOT_RECRUITING
NCT01251874,has_phase,
NCT01251874,sponsored_by,National Cancer Institute (NCI)
NCT01251874,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT01251874,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01251874,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT01251874,tests,Fluorothymidine F-18
Fluorothymidine F-18,has_type,OTHER
NCT01251874,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT01251874,tests,Veliparib
Veliparib,has_type,DRUG
NCT05062174,has_title,Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study
NCT05062174,has_status,WITHDRAWN
NCT05062174,has_phase,
NCT05062174,sponsored_by,Indiana University
NCT05062174,tests,Mifepristone 200 MG
Mifepristone 200 MG,has_type,DRUG
NCT05062174,tests,Prophylactic mastectomy
Prophylactic mastectomy,has_type,PROCEDURE
NCT07062965,has_title,"An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestran"
NCT07062965,has_status,NOT_YET_RECRUITING
NCT07062965,has_phase,
NCT07062965,sponsored_by,Pfizer
NCT07062965,tests,PF-07248144
PF-07248144,has_type,DRUG
NCT07062965,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT07062965,tests,Everolimus
Everolimus,has_type,DRUG
NCT07062965,tests,Exemestane
Exemestane,has_type,DRUG
NCT03102320,has_title,Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expr
NCT03102320,has_status,COMPLETED
NCT03102320,has_phase,
NCT03102320,sponsored_by,Bayer
NCT03102320,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03102320,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03102320,tests,Anetumab ravtansine (BAY94-9343)
Anetumab ravtansine (BAY94-9343),has_type,DRUG
NCT04464174,has_title,"A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in "
NCT04464174,has_status,COMPLETED
NCT04464174,has_phase,
NCT04464174,sponsored_by,MedSIR
NCT04464174,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT04464174,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04464174,tests,Eribulin
Eribulin,has_type,DRUG
NCT04464174,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04464174,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT07012720,has_title,Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Tre
NCT07012720,has_status,RECRUITING
NCT07012720,has_phase,
NCT07012720,sponsored_by,Xijing Hospital
NCT07012720,tests,Single-cell sequencing and spatial transcriptome
Single-cell sequencing and spatial transcriptome,has_type,DIAGNOSTIC_TEST
NCT06371274,has_title,Efficacy and Safety Study of Oral All-trans Retinoic Acid Combined With Toripalimab in Patients With
NCT06371274,has_status,NOT_YET_RECRUITING
NCT06371274,has_phase,
NCT06371274,sponsored_by,First Affiliated Hospital of Zhejiang University
NCT06371274,tests,ATRA
ATRA,has_type,DRUG
NCT06371274,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT06087120,has_title,Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant 
NCT06087120,has_status,RECRUITING
NCT06087120,has_phase,
NCT06087120,sponsored_by,Gene Solutions
NCT03567720,has_title,"A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporat"
NCT03567720,has_status,UNKNOWN
NCT03567720,has_phase,
NCT03567720,sponsored_by,OncoSec Medical Incorporated
NCT03567720,tests,tavokinogene telseplasmid
tavokinogene telseplasmid,has_type,BIOLOGICAL
NCT03567720,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03567720,tests,Immunopulse
Immunopulse,has_type,DEVICE
NCT03567720,tests,nab paclitaxel
nab paclitaxel,has_type,DRUG
NCT03567720,tests,gemcitabine plus carboplatin
gemcitabine plus carboplatin,has_type,DRUG
NCT02266420,has_title,Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm 
NCT02266420,has_status,COMPLETED
NCT02266420,has_phase,
NCT02266420,sponsored_by,Institut Claudius Regaud
NCT02266420,tests,Blood samples of 10 mL
Blood samples of 10 mL,has_type,PROCEDURE
NCT02348320,has_title,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA
NCT02348320,has_status,COMPLETED
NCT02348320,has_phase,
NCT02348320,sponsored_by,Washington University School of Medicine
NCT02348320,tests,Personalized polyepitope DNA vaccine
Personalized polyepitope DNA vaccine,has_type,BIOLOGICAL
NCT06799065,has_title,"A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhi"
NCT06799065,has_status,RECRUITING
NCT06799065,has_phase,
NCT06799065,sponsored_by,Accent Therapeutics
NCT06799065,tests,ATX-295
ATX-295,has_type,DRUG
NCT01337765,has_title,"A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered "
NCT01337765,has_status,COMPLETED
NCT01337765,has_phase,
NCT01337765,sponsored_by,Pfizer
NCT01337765,tests,BEZ235 + MEK162
BEZ235 + MEK162,has_type,DRUG
NCT01201265,has_title,"A Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine "
NCT01201265,has_status,COMPLETED
NCT01201265,has_phase,
NCT01201265,sponsored_by,Hoffmann-La Roche
NCT01201265,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01201265,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01201265,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02576665,has_title,"A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients Wit"
NCT02576665,has_status,TERMINATED
NCT02576665,has_phase,
NCT02576665,sponsored_by,Tocagen Inc.
NCT02576665,tests,Toca 511
Toca 511,has_type,BIOLOGICAL
NCT02576665,tests,Toca FC
Toca FC,has_type,DRUG
NCT04959474,has_title,SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SAB
NCT04959474,has_status,RECRUITING
NCT04959474,has_phase,
NCT04959474,sponsored_by,Thomas Jefferson University
NCT04959474,tests,Best Practice
Best Practice,has_type,OTHER
NCT04959474,tests,Stereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy,has_type,RADIATION
NCT04959474,tests,Resection
Resection,has_type,PROCEDURE
NCT04959474,tests,Sentinel Lymph Node Biopsy
Sentinel Lymph Node Biopsy,has_type,PROCEDURE
NCT04959474,tests,Dietary Intervention
Dietary Intervention,has_type,OTHER
NCT04959474,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04959474,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03090165,has_title,"A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combi"
NCT03090165,has_status,RECRUITING
NCT03090165,has_phase,
NCT03090165,sponsored_by,Kari Wisinski
NCT03090165,tests,ribociclib
ribociclib,has_type,DRUG
NCT03090165,tests,ribociclib
ribociclib,has_type,DRUG
NCT03090165,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT06393374,has_title,"A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in C"
NCT06393374,has_status,RECRUITING
NCT06393374,has_phase,
NCT06393374,sponsored_by,Merck Sharp & Dohme LLC
NCT06393374,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06393374,tests,Sacituzumab tirumotecan
Sacituzumab tirumotecan,has_type,BIOLOGICAL
NCT06393374,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03575065,has_title,"An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatmen"
NCT03575065,has_status,COMPLETED
NCT03575065,has_phase,
NCT03575065,sponsored_by,BeiGene
NCT03575065,tests,BGB-290
BGB-290,has_type,DRUG
NCT03175666,has_title,NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC W
NCT03175666,has_status,WITHDRAWN
NCT03175666,has_phase,
NCT03175666,sponsored_by,"ImmunityBio, Inc."
NCT03175666,tests,avelumab
avelumab,has_type,BIOLOGICAL
NCT03175666,tests,bevacizumab
bevacizumab,has_type,BIOLOGICAL
NCT03175666,tests,capecitabine
capecitabine,has_type,DRUG
NCT03175666,tests,cisplatin
cisplatin,has_type,DRUG
NCT03175666,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT03175666,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT03175666,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT03175666,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03175666,tests,Lovaza
Lovaza,has_type,DRUG
NCT03175666,tests,Stereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy,has_type,RADIATION
NCT03175666,tests,ALT-803
ALT-803,has_type,BIOLOGICAL
NCT03175666,tests,ETBX-011
ETBX-011,has_type,BIOLOGICAL
NCT03175666,tests,ETBX-051
ETBX-051,has_type,BIOLOGICAL
NCT03175666,tests,ETBX-061
ETBX-061,has_type,BIOLOGICAL
NCT03175666,tests,GI-4000
GI-4000,has_type,BIOLOGICAL
NCT03175666,tests,GI-6207
GI-6207,has_type,BIOLOGICAL
NCT03175666,tests,GI-6301
GI-6301,has_type,BIOLOGICAL
NCT03175666,tests,haNK
haNK,has_type,BIOLOGICAL
NCT01112826,has_title,Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast 
NCT01112826,has_status,COMPLETED
NCT01112826,has_phase,
NCT01112826,sponsored_by,Sun Yat-sen University
NCT01112826,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06418126,has_title,Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer : TNBC-RT2023
NCT06418126,has_status,RECRUITING
NCT06418126,has_phase,
NCT06418126,sponsored_by,Institut de cancérologie Strasbourg Europe
NCT06418126,tests,blood sampling before radiotherapy
blood sampling before radiotherapy,has_type,BIOLOGICAL
NCT06418126,tests,blood sampling after the fourth radiotherapy session
blood sampling after the fourth radiotherapy session,has_type,BIOLOGICAL
NCT06418126,tests,collection of acute toxicity (radiodermatitis)
collection of acute toxicity (radiodermatitis),has_type,OTHER
NCT06418126,tests,collection of late toxicity
collection of late toxicity,has_type,OTHER
NCT06418126,tests,collection of disease status
collection of disease status,has_type,OTHER
NCT06418126,tests,Radiotherapy - Breast +/- lymph node areas
Radiotherapy - Breast +/- lymph node areas,has_type,RADIATION
NCT06418126,tests,Radiotherapy - Boost operating bed
Radiotherapy - Boost operating bed,has_type,RADIATION
NCT05491226,has_title,IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhi
NCT05491226,has_status,ACTIVE_NOT_RECRUITING
NCT05491226,has_phase,
NCT05491226,sponsored_by,Stephen Shiao
NCT05491226,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05491226,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT05491226,tests,Axatilimab
Axatilimab,has_type,DRUG
NCT05485766,has_title,Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pemb
NCT05485766,has_status,RECRUITING
NCT05485766,has_phase,
NCT05485766,sponsored_by,Okayama University
NCT05485766,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05485766,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05485766,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05485766,tests,Olaparib
Olaparib,has_type,DRUG
NCT05485766,tests,Definitive Surgery
Definitive Surgery,has_type,PROCEDURE
NCT01347866,has_title,"A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of T"
NCT01347866,has_status,TERMINATED
NCT01347866,has_phase,
NCT01347866,sponsored_by,Pfizer
NCT01347866,tests,PF-05212384
PF-05212384,has_type,DRUG
NCT01347866,tests,PD-0325901
PD-0325901,has_type,DRUG
NCT01347866,tests,PF-05212384
PF-05212384,has_type,DRUG
NCT01347866,tests,irinotecan
irinotecan,has_type,DRUG
NCT06786026,has_title,QL1706 Plus Nab-paclitaxel +/- Bevacizumab As 1L Treatment in Recurrent or Metastatic Triple-Negativ
NCT06786026,has_status,RECRUITING
NCT06786026,has_phase,
NCT06786026,sponsored_by,Fudan University
NCT06786026,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT06786026,tests,QL1706
QL1706,has_type,DRUG
NCT06786026,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT05113966,has_title,"A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-h"
NCT05113966,has_status,TERMINATED
NCT05113966,has_phase,
NCT05113966,sponsored_by,"G1 Therapeutics, Inc."
NCT05113966,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT05113966,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT05756166,has_title,Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (
NCT05756166,has_status,TERMINATED
NCT05756166,has_phase,
NCT05756166,sponsored_by,Roswell Park Cancer Institute
NCT05756166,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05756166,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05756166,tests,Celecoxib
Celecoxib,has_type,DRUG
NCT05756166,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05756166,tests,Interferon Alpha-2
Interferon Alpha-2,has_type,BIOLOGICAL
NCT05756166,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05756166,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05756166,tests,Rintatolimod
Rintatolimod,has_type,DRUG
NCT05325866,has_title,"A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzum"
NCT05325866,has_status,ACTIVE_NOT_RECRUITING
NCT05325866,has_phase,
NCT05325866,sponsored_by,Amgen
NCT05325866,tests,Bemarituzumab
Bemarituzumab,has_type,DRUG
NCT03355066,has_title,"A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetic"
NCT03355066,has_status,TERMINATED
NCT03355066,has_phase,
NCT03355066,sponsored_by,"Biosplice Therapeutics, Inc."
NCT03355066,tests,SM08502
SM08502,has_type,DRUG
NCT05684965,has_title,"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid"
NCT05684965,has_status,RECRUITING
NCT05684965,has_phase,
NCT05684965,sponsored_by,"Xilio Development, Inc."
NCT05684965,tests,XTX301
XTX301,has_type,DRUG
NCT05539365,has_title,A Phase II Study of Intratumorally Injected Autologous Dendritic Cells (DCs) in PD-L1-Negative Treat
NCT05539365,has_status,WITHDRAWN
NCT05539365,has_phase,
NCT05539365,sponsored_by,Roswell Park Cancer Institute
NCT05539365,tests,Alpha-type-1 Polarized Dendritic Cells
Alpha-type-1 Polarized Dendritic Cells,has_type,BIOLOGICAL
NCT05539365,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05539365,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05539365,tests,Leukapheresis
Leukapheresis,has_type,PROCEDURE
NCT05539365,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05539365,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT06586866,has_title,"A Multicenter, Single-Arm, Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of JK"
NCT06586866,has_status,NOT_YET_RECRUITING
NCT06586866,has_phase,
NCT06586866,sponsored_by,"JenKem Technology Co., Ltd."
NCT06586866,tests,JK-1201I
JK-1201I,has_type,DRUG
NCT01576666,has_title,"A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 1"
NCT01576666,has_status,COMPLETED
NCT01576666,has_phase,
NCT01576666,sponsored_by,Novartis Pharmaceuticals
NCT01576666,tests,LDE225
LDE225,has_type,DRUG
NCT01576666,tests,BKM120
BKM120,has_type,DRUG
NCT01514565,has_title,Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer.
NCT01514565,has_status,UNKNOWN
NCT01514565,has_phase,
NCT01514565,sponsored_by,Thomas Jefferson University
NCT06328465,has_title,fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
NCT06328465,has_status,RECRUITING
NCT06328465,has_phase,
NCT06328465,sponsored_by,European Institute of Oncology
NCT06328465,tests,Diffusion whole body MRI
Diffusion whole body MRI,has_type,DIAGNOSTIC_TEST
NCT06744465,has_title,NearWave Optical Molecular Monitoring for Predicting Complete Pathological Response (pCR) to Neoadju
NCT06744465,has_status,RECRUITING
NCT06744465,has_phase,
NCT06744465,sponsored_by,Indiana University
NCT06744465,tests,NearWave monitoring
NearWave monitoring,has_type,DEVICE
NCT03518242,has_title,Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications
NCT03518242,has_status,COMPLETED
NCT03518242,has_phase,
NCT03518242,sponsored_by,Fred Hutchinson Cancer Center
NCT03518242,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03518242,tests,Methotrexate
Methotrexate,has_type,DRUG
NCT03518242,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03518242,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06700070,has_title,A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration 
NCT06700070,has_status,NOT_YET_RECRUITING
NCT06700070,has_phase,
NCT06700070,sponsored_by,Pure Biologics S.A.
NCT06700070,tests,PBA-0111
PBA-0111,has_type,DRUG
NCT04739670,has_title,"A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitab"
NCT04739670,has_status,RECRUITING
NCT04739670,has_phase,
NCT04739670,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT04739670,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04739670,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT04739670,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04739670,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05776875,has_title,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
NCT05776875,has_status,TERMINATED
NCT05776875,has_phase,
NCT05776875,sponsored_by,Yale University
NCT05776875,tests,Atezolizumab Injection
Atezolizumab Injection,has_type,DRUG
NCT05776875,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05776875,tests,Transarterial chemoembolization
Transarterial chemoembolization,has_type,COMBINATION_PRODUCT
NCT04491942,has_title,A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Pl
NCT04491942,has_status,ACTIVE_NOT_RECRUITING
NCT04491942,has_phase,
NCT04491942,sponsored_by,National Cancer Institute (NCI)
NCT04491942,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04491942,tests,Elimusertib
Elimusertib,has_type,DRUG
NCT04491942,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT01815242,has_title,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy R
NCT01815242,has_status,COMPLETED
NCT01815242,has_phase,
NCT01815242,sponsored_by,West German Study Group
NCT01815242,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT01815242,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01815242,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04787042,has_title,"A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Witho"
NCT04787042,has_status,RECRUITING
NCT04787042,has_phase,
NCT04787042,sponsored_by,"Simcha IL-18, Inc."
NCT04787042,tests,ST-067
ST-067,has_type,BIOLOGICAL
NCT04787042,tests,Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],has_type,BIOLOGICAL
NCT04787042,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT06519370,has_title,"A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy i"
NCT06519370,has_status,RECRUITING
NCT06519370,has_phase,
NCT06519370,sponsored_by,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
NCT06519370,tests,FDA018-ADC
FDA018-ADC,has_type,DRUG
NCT06519370,tests,Eribulin
Eribulin,has_type,DRUG
NCT06519370,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06519370,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06519370,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT03542175,has_title,A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients W
NCT03542175,has_status,ACTIVE_NOT_RECRUITING
NCT03542175,has_phase,
NCT03542175,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT03542175,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT03542175,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT06829199,has_title,"A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigati"
NCT06829199,has_status,WITHDRAWN
NCT06829199,has_phase,
NCT06829199,sponsored_by,Merck Sharp & Dohme LLC
NCT06829199,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06829199,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06829199,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06829199,tests,Doxorubicin (hydrochloride)
Doxorubicin (hydrochloride),has_type,DRUG
NCT06829199,tests,Boserolimab
Boserolimab,has_type,BIOLOGICAL
NCT06829199,tests,Epirubicin Hydrochloride
Epirubicin Hydrochloride,has_type,DRUG
NCT06829199,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06829199,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06829199,tests,Olaparib (if approved/available locally)
Olaparib (if approved/available locally),has_type,DRUG
NCT01276899,has_title,Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple 
NCT01276899,has_status,COMPLETED
NCT01276899,has_phase,
NCT01276899,sponsored_by,Jewish General Hospital
NCT01276899,tests,Needle core biopsies
Needle core biopsies,has_type,PROCEDURE
NCT01276899,tests,Needle core biopsies of metastatic lesion
Needle core biopsies of metastatic lesion,has_type,PROCEDURE
NCT04745975,has_title,GUided Treatment Based on Mini-PDX in metastaTIc refractOry Triple Negative Breast Cancer(GUMPTION)：
NCT04745975,has_status,UNKNOWN
NCT04745975,has_phase,
NCT04745975,sponsored_by,Fudan University
NCT04745975,tests,Personalized treatment guided by mini-PDX and RNA sequencing
Personalized treatment guided by mini-PDX and RNA sequencing,has_type,DRUG
NCT04745975,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT04745975,tests,Eribulin
Eribulin,has_type,DRUG
NCT04745975,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT04745975,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04745975,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02866149,has_title,Analysis of Circulating Tumor Markers in the Blood
NCT02866149,has_status,COMPLETED
NCT02866149,has_phase,
NCT02866149,sponsored_by,Institut Curie
NCT02866149,tests,Blood sampling
Blood sampling,has_type,BIOLOGICAL
NCT02866149,tests,Tumor sampling
Tumor sampling,has_type,PROCEDURE
NCT02866149,tests,Stool sampling
Stool sampling,has_type,OTHER
NCT06270706,has_title,"A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolera"
NCT06270706,has_status,RECRUITING
NCT06270706,has_phase,
NCT06270706,sponsored_by,"Pliant Therapeutics, Inc."
NCT06270706,tests,PLN-101095
PLN-101095,has_type,DRUG
NCT06270706,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06078670,has_title,Phase Ib/II Clinical Study of PARP Inhibitor CVL218 in Combination With Therapy in Patients With Adv
NCT06078670,has_status,NOT_YET_RECRUITING
NCT06078670,has_phase,
NCT06078670,sponsored_by,Fujian Cancer Hospital
NCT06078670,tests,CVL218
CVL218,has_type,DRUG
NCT02302742,has_title,"PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for P"
NCT02302742,has_status,RECRUITING
NCT02302742,has_phase,
NCT02302742,sponsored_by,University of Kansas Medical Center
NCT05957042,has_title,Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Tri
NCT05957042,has_status,RECRUITING
NCT05957042,has_phase,
NCT05957042,sponsored_by,Milton S. Hershey Medical Center
NCT05957042,tests,Lumason
Lumason,has_type,DRUG
NCT02593175,has_title,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxe"
NCT02593175,has_status,COMPLETED
NCT02593175,has_phase,
NCT02593175,sponsored_by,M.D. Anderson Cancer Center
NCT02593175,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02593175,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02593175,tests,Panitumumab
Panitumumab,has_type,BIOLOGICAL
NCT00930930,has_title,"A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Tripl"
NCT00930930,has_status,COMPLETED
NCT00930930,has_phase,
NCT00930930,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT00930930,tests,cisplatin
cisplatin,has_type,DRUG
NCT00930930,tests,everolimus
everolimus,has_type,DRUG
NCT00930930,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT00930930,tests,placebo
placebo,has_type,OTHER
NCT00930930,tests,Venous blood draw
Venous blood draw,has_type,PROCEDURE
NCT05067530,has_title,"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a ""Window of Opportunity"" Study"
NCT05067530,has_status,NOT_YET_RECRUITING
NCT05067530,has_phase,
NCT05067530,sponsored_by,Medical University of Gdansk
NCT05067530,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT05067530,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05067530,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03012230,has_title,A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negati
NCT03012230,has_status,COMPLETED
NCT03012230,has_phase,
NCT03012230,sponsored_by,Mayo Clinic
NCT03012230,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03012230,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03012230,tests,Ruxolitinib Phosphate
Ruxolitinib Phosphate,has_type,DRUG
NCT05233696,has_title,Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With P
NCT05233696,has_status,WITHDRAWN
NCT05233696,has_phase,
NCT05233696,sponsored_by,"University of Colorado, Denver"
NCT05233696,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05233696,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05233696,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT05233696,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03729596,has_title,"A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug C"
NCT03729596,has_status,TERMINATED
NCT03729596,has_phase,
NCT03729596,sponsored_by,MacroGenics
NCT03729596,tests,vobramitamab duocarmazine
vobramitamab duocarmazine,has_type,BIOLOGICAL
NCT05177796,has_title,Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Stud
NCT05177796,has_status,WITHDRAWN
NCT05177796,has_phase,
NCT05177796,sponsored_by,M.D. Anderson Cancer Center
NCT05177796,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05177796,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05177796,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05177796,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05177796,tests,Panitumumab
Panitumumab,has_type,BIOLOGICAL
NCT05177796,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02203513,has_title,A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated
NCT02203513,has_status,TERMINATED
NCT02203513,has_phase,
NCT02203513,sponsored_by,National Cancer Institute (NCI)
NCT02203513,tests,LY2606368
LY2606368,has_type,DRUG
NCT04817813,has_title,"LIBREAST STUDY: Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retros"
NCT04817813,has_status,UNKNOWN
NCT04817813,has_phase,
NCT04817813,sponsored_by,Hospital Miguel Servet
NCT03958136,has_title,Prediction in Silico of Overall Survival in a Pilot Prospective Cohort Study of Metastatic Breast Ca
NCT03958136,has_status,RECRUITING
NCT03958136,has_phase,
NCT03958136,sponsored_by,Institut Cancerologie de l'Ouest
NCT03958136,tests,Metastasis biopsy
Metastasis biopsy,has_type,PROCEDURE
NCT03958136,tests,"Biomarkers blood, urine and microbiota samples"
"Biomarkers blood, urine and microbiota samples",has_type,BIOLOGICAL
NCT03958136,tests,Patient Reported Outcome (PRO)
Patient Reported Outcome (PRO),has_type,BEHAVIORAL
NCT04234113,has_title,A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101
NCT04234113,has_status,TERMINATED
NCT04234113,has_phase,
NCT04234113,sponsored_by,SOTIO Biotech AG
NCT04234113,tests,Nanrilkefusp alfa
Nanrilkefusp alfa,has_type,DRUG
NCT04234113,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03343613,has_title,A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Ant
NCT03343613,has_status,TERMINATED
NCT03343613,has_phase,
NCT03343613,sponsored_by,Eli Lilly and Company
NCT03343613,tests,LY3381916
LY3381916,has_type,DRUG
NCT03343613,tests,LY3300054
LY3300054,has_type,DRUG
NCT05747313,has_title,"A Prospective, Single-arm, Open-lable, Single-center Phase Ib/II Clinical Study of Chidamide in Comb"
NCT05747313,has_status,UNKNOWN
NCT05747313,has_phase,
NCT05747313,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT05747313,tests,Chidamide
Chidamide,has_type,DRUG
NCT03829436,has_title,"A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or "
NCT03829436,has_status,COMPLETED
NCT03829436,has_phase,
NCT03829436,sponsored_by,Tempest Therapeutics
NCT03829436,tests,Part 1 TPST-1120
Part 1 TPST-1120,has_type,DRUG
NCT03829436,tests,Part 2 TPST-1120 + nivolumab
Part 2 TPST-1120 + nivolumab,has_type,DRUG
NCT03829436,tests,Part 3 TPST-1120
Part 3 TPST-1120,has_type,DRUG
NCT03829436,tests,Part 4 TPST-1120 + nivolumab
Part 4 TPST-1120 + nivolumab,has_type,DRUG
NCT00600249,has_title,"Phase II Pilot Study Evaluating the Neoadjuvant Combination ""Taxotere (Docetaxel) and Erbitux (Cetux"
NCT00600249,has_status,COMPLETED
NCT00600249,has_phase,
NCT00600249,sponsored_by,Centre Jean Perrin
NCT00600249,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT00600249,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06057636,has_title,Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
NCT06057636,has_status,WITHDRAWN
NCT06057636,has_phase,
NCT06057636,sponsored_by,"The University of Tennessee, Knoxville"
NCT06057636,tests,Self-Administered Hypnosis
Self-Administered Hypnosis,has_type,BEHAVIORAL
NCT06057636,tests,Self-Administered White Noise Hypnosis
Self-Administered White Noise Hypnosis,has_type,BEHAVIORAL
NCT05112536,has_title,"A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemo"
NCT05112536,has_status,COMPLETED
NCT05112536,has_phase,
NCT05112536,sponsored_by,"G1 Therapeutics, Inc."
NCT05112536,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT05112536,tests,Cylophosphamide
Cylophosphamide,has_type,DRUG
NCT05112536,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05112536,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05112536,tests,Carboplatin (Investigator discretion)
Carboplatin (Investigator discretion),has_type,DRUG
NCT05112536,tests,Pembrolizumab (Investigator discretion)
Pembrolizumab (Investigator discretion),has_type,BIOLOGICAL
NCT03154749,has_title,Neoadjuvant Docetaxel + Carboplatin Versus Epirubicin+Cyclophosphamide Followed by Docetaxel in Trip
NCT03154749,has_status,COMPLETED
NCT03154749,has_phase,
NCT03154749,sponsored_by,Guangdong Provincial People's Hospital
NCT03154749,tests,DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe),has_type,DRUG
NCT01623349,has_title,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib 
NCT01623349,has_status,COMPLETED
NCT01623349,has_phase,
NCT01623349,sponsored_by,Dana-Farber Cancer Institute
NCT01623349,tests,BKM120 and Olaparib
BKM120 and Olaparib,has_type,DRUG
NCT01623349,tests,BYL719 and Olaparib
BYL719 and Olaparib,has_type,DRUG
NCT01151449,has_title,"A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Inv"
NCT01151449,has_status,TERMINATED
NCT01151449,has_phase,
NCT01151449,sponsored_by,National Cancer Institute (NCI)
NCT01151449,tests,gamma-secretase/Notch signalling pathway inhibitor RO4929097
gamma-secretase/Notch signalling pathway inhibitor RO4929097,has_type,DRUG
NCT01151449,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT06993506,has_title,Sacituzumab Tirumotecan Monotherapy or Combination Therapy in Patients With Unresectable Locally Adv
NCT06993506,has_status,NOT_YET_RECRUITING
NCT06993506,has_phase,
NCT06993506,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06993506,tests,SKB264 Monotherapy or Combination Therapy
SKB264 Monotherapy or Combination Therapy,has_type,DRUG
NCT04674306,has_title,Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic 
NCT04674306,has_status,ACTIVE_NOT_RECRUITING
NCT04674306,has_phase,
NCT04674306,sponsored_by,George T. Budd
NCT04674306,tests,α-lactalbumin vaccine
α-lactalbumin vaccine,has_type,BIOLOGICAL
NCT04674306,tests,Zymosan
Zymosan,has_type,BIOLOGICAL
NCT00674206,has_title,"A Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2NEU- (Triple Negative) Metastatic "
NCT00674206,has_status,TERMINATED
NCT00674206,has_phase,
NCT00674206,sponsored_by,Emory University
NCT00674206,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT00674206,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT02685306,has_title,A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects o
NCT02685306,has_status,WITHDRAWN
NCT02685306,has_phase,
NCT02685306,sponsored_by,Peregrine Pharmaceuticals
NCT02685306,tests,Bavituximab
Bavituximab,has_type,BIOLOGICAL
NCT02685306,tests,Taxane
Taxane,has_type,DRUG
NCT04333706,has_title,A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer 
NCT04333706,has_status,RECRUITING
NCT04333706,has_phase,
NCT04333706,sponsored_by,University of Southern California
NCT04333706,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04333706,tests,Sarilumab 150mg or 200 mg plus Capecitabine
Sarilumab 150mg or 200 mg plus Capecitabine,has_type,COMBINATION_PRODUCT
NCT04333706,tests,Sarilumab 150mg plus Capecitabine
Sarilumab 150mg plus Capecitabine,has_type,COMBINATION_PRODUCT
NCT05438706,has_title,A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carbop
NCT05438706,has_status,UNKNOWN
NCT05438706,has_phase,
NCT05438706,sponsored_by,Fudan University
NCT05438706,tests,chidamide
chidamide,has_type,DRUG
NCT05438706,tests,camrelizumab
camrelizumab,has_type,DRUG
NCT05438706,tests,carboplatin
carboplatin,has_type,DRUG
NCT05438706,tests,capecitabine
capecitabine,has_type,DRUG
NCT05215106,has_title,Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patient
NCT05215106,has_status,RECRUITING
NCT05215106,has_phase,
NCT05215106,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT05215106,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT02125006,has_title,"The Effect of an Inter-Disciplinary Program, Including Mindfulness-Based Stress Reduction, on Psycho"
NCT02125006,has_status,COMPLETED
NCT02125006,has_phase,
NCT02125006,sponsored_by,Ottawa Hospital Research Institute
NCT02125006,tests,Mindfulness-Based Stress Reduction
Mindfulness-Based Stress Reduction,has_type,BEHAVIORAL
NCT01918306,has_title,A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With An
NCT01918306,has_status,TERMINATED
NCT01918306,has_phase,
NCT01918306,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT01918306,tests,cisplatin
cisplatin,has_type,DRUG
NCT01918306,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01918306,tests,pharmacological study
pharmacological study,has_type,OTHER
NCT01918306,tests,"dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI"
"dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI",has_type,PROCEDURE
NCT01918306,tests,GDC -0941
GDC -0941,has_type,DRUG
NCT04441099,has_title,"A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With"
NCT04441099,has_status,TERMINATED
NCT04441099,has_phase,
NCT04441099,sponsored_by,NBE-Therapeutics AG
NCT04441099,tests,NBE-002
NBE-002,has_type,DRUG
NCT05007106,has_title,"A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684"
NCT05007106,has_status,ACTIVE_NOT_RECRUITING
NCT05007106,has_phase,
NCT05007106,sponsored_by,Merck Sharp & Dohme LLC
NCT05007106,tests,Pembrolizumab/Vibostolimab Co-Formulation
Pembrolizumab/Vibostolimab Co-Formulation,has_type,BIOLOGICAL
NCT05007106,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05007106,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT05007106,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT05007106,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT05007106,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05007106,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05007106,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05007106,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05007106,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05007106,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05007106,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT06798506,has_title,"A Real-world, Multicenter, Prospective Study to Evaluate the Patient-reported Outcome in Chinese Pat"
NCT06798506,has_status,NOT_YET_RECRUITING
NCT06798506,has_phase,
NCT06798506,sponsored_by,Fudan University
NCT03167619,has_title,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative B
NCT03167619,has_status,COMPLETED
NCT03167619,has_phase,
NCT03167619,sponsored_by,Duke University
NCT03167619,tests,Olaparib Oral Product
Olaparib Oral Product,has_type,DRUG
NCT03167619,tests,Olaparib Oral Product in combination with Durvalumab
Olaparib Oral Product in combination with Durvalumab,has_type,DRUG
NCT06827613,has_title,"A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602),"
NCT06827613,has_status,RECRUITING
NCT06827613,has_phase,
NCT06827613,sponsored_by,"Marengo Therapeutics, Inc."
NCT06827613,tests,STAR0602
STAR0602,has_type,DRUG
NCT06827613,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
NCT06827236,has_title,"A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacok"
NCT06827236,has_status,RECRUITING
NCT06827236,has_phase,
NCT06827236,sponsored_by,BioNTech SE
NCT06827236,tests,BNT323
BNT323,has_type,DRUG
NCT06827236,tests,BNT327
BNT327,has_type,DRUG
NCT00892736,has_title,"A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated"
NCT00892736,has_status,COMPLETED
NCT00892736,has_phase,
NCT00892736,sponsored_by,National Cancer Institute (NCI)
NCT00892736,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00892736,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT00892736,tests,Veliparib
Veliparib,has_type,DRUG
NCT05999149,has_title,"A Randomized, Open Label, Multicenter Phase III Study of Camrelizumab Plus Chemotherapy in Combinati"
NCT05999149,has_status,RECRUITING
NCT05999149,has_phase,
NCT05999149,sponsored_by,Fudan University
NCT05999149,tests,Camrelizumab Plus Chemotherapy and Famitinib
Camrelizumab Plus Chemotherapy and Famitinib,has_type,DRUG
NCT05999149,tests,Camrelizumab Plus Chemotherapy
Camrelizumab Plus Chemotherapy,has_type,DRUG
NCT04468113,has_title,"Prospective, Multicenter Registry Study Evaluating the Feasibility of Ultrasound-guided Clipping of "
NCT04468113,has_status,COMPLETED
NCT04468113,has_phase,
NCT04468113,sponsored_by,Kliniken Essen-Mitte
NCT04468113,tests,Tumark® Vision clip
Tumark® Vision clip,has_type,DEVICE
NCT00998036,has_title,"Phase I Study of Combined Temsirolimus, Erlotinib and Cisplatin in Advanced Solid Tumors"
NCT00998036,has_status,COMPLETED
NCT00998036,has_phase,
NCT00998036,sponsored_by,Columbia University
NCT00998036,tests,Temsirolimus
Temsirolimus,has_type,DRUG
NCT00998036,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT00998036,tests,Erlotinib
Erlotinib,has_type,DRUG
NCT03251313,has_title,Recombinant Humanized PD-1 Monoclonal Antibody (JS001) Combined With Gemcitabine and Cisplatin (GP) 
NCT03251313,has_status,UNKNOWN
NCT03251313,has_phase,
NCT03251313,sponsored_by,Fudan University
NCT03251313,tests,JS001 120mg+GP
JS001 120mg+GP,has_type,COMBINATION_PRODUCT
NCT03251313,tests,JS001 240mg+GP
JS001 240mg+GP,has_type,COMBINATION_PRODUCT
NCT03251313,tests,JS001 480mg+GP
JS001 480mg+GP,has_type,COMBINATION_PRODUCT
NCT03251313,tests,GP followed by JS001
GP followed by JS001,has_type,COMBINATION_PRODUCT
NCT03800836,has_title,"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combi"
NCT03800836,has_status,COMPLETED
NCT03800836,has_phase,
NCT03800836,sponsored_by,Hoffmann-La Roche
NCT03800836,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03800836,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03800836,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03800836,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03800836,tests,AC
AC,has_type,DRUG
NCT02035813,has_title,"DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Me"
NCT02035813,has_status,COMPLETED
NCT02035813,has_phase,
NCT02035813,sponsored_by,Prof. Wolfgang Janni
NCT02035813,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT02035813,tests,Eribulin
Eribulin,has_type,DRUG
NCT04485013,has_title,"A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in"
NCT04485013,has_status,RECRUITING
NCT04485013,has_phase,
NCT04485013,sponsored_by,"Tizona Therapeutics, Inc"
NCT04485013,tests,TTX-080
TTX-080,has_type,DRUG
NCT04485013,tests,TTX-080
TTX-080,has_type,DRUG
NCT04485013,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT04485013,tests,cetuximab
cetuximab,has_type,DRUG
NCT04485013,tests,FOLFIRI
FOLFIRI,has_type,DRUG
NCT04485013,tests,cetuximab
cetuximab,has_type,DRUG
NCT04485013,tests,TTX-080
TTX-080,has_type,DRUG
NCT04345913,has_title,A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in 
NCT04345913,has_status,ACTIVE_NOT_RECRUITING
NCT04345913,has_phase,
NCT04345913,sponsored_by,National Cancer Institute (NCI)
NCT04345913,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT04345913,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04345913,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT04345913,tests,Copanlisib Hydrochloride
Copanlisib Hydrochloride,has_type,DRUG
NCT04345913,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT04345913,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT06202313,has_title,"A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Me"
NCT06202313,has_status,NOT_YET_RECRUITING
NCT06202313,has_phase,
NCT06202313,sponsored_by,Shengjing Hospital
NCT06202313,tests,Cadonilimab
Cadonilimab,has_type,BIOLOGICAL
NCT06202313,tests,Eribulin
Eribulin,has_type,DRUG
NCT01150513,has_title,Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant
NCT01150513,has_status,COMPLETED
NCT01150513,has_phase,
NCT01150513,sponsored_by,Chinese Academy of Medical Sciences
NCT01150513,tests,EC-T
EC-T,has_type,DRUG
NCT01150513,tests,TP
TP,has_type,DRUG
NCT02498613,has_title,A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613,has_status,ACTIVE_NOT_RECRUITING
NCT02498613,has_phase,
NCT02498613,sponsored_by,National Cancer Institute (NCI)
NCT02498613,tests,18F-Fluoromisonidazole
18F-Fluoromisonidazole,has_type,OTHER
NCT02498613,tests,Cediranib Maleate
Cediranib Maleate,has_type,DRUG
NCT02498613,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02498613,tests,Olaparib
Olaparib,has_type,DRUG
NCT02498613,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT05250336,has_title,Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand
NCT05250336,has_status,UNKNOWN
NCT05250336,has_phase,
NCT05250336,sponsored_by,Sanjay Gandhi Postgraduate Institute of Medical Sciences
NCT05250336,tests,Observational Study
Observational Study,has_type,OTHER
NCT06876636,has_title,"Prospective, Open-Label, Single-Arm Clinical Study of Zoledronic Acid Combined with Neoadjuvant Chem"
NCT06876636,has_status,ACTIVE_NOT_RECRUITING
NCT06876636,has_phase,
NCT06876636,sponsored_by,Xijing Hospital
NCT06876636,tests,Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T),has_type,DRUG
NCT06505018,has_title,"A Randomized Phase III Study Comparing the Digital Telemonitoring Platform ""CUREETY TECHCARE"" to Usu"
NCT06505018,has_status,RECRUITING
NCT06505018,has_phase,
NCT06505018,sponsored_by,UNICANCER
NCT06505018,tests,Cureety techcare
Cureety techcare,has_type,DEVICE
NCT05866432,has_title,Phase II Study of Datopotamab-Deruxtecan (Dato-DXd; DS-1026a) in Triple-negative Breast Cancer Patie
NCT05866432,has_status,RECRUITING
NCT05866432,has_phase,
NCT05866432,sponsored_by,Medical University of Vienna
NCT05866432,tests,Datopotamab deruxtecan
Datopotamab deruxtecan,has_type,DRUG
NCT06351332,has_title,A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined with Carboplatin and Pembrolizumab in 
NCT06351332,has_status,RECRUITING
NCT06351332,has_phase,
NCT06351332,sponsored_by,"Filipa Lynce, MD"
NCT06351332,tests,Azenosertib
Azenosertib,has_type,DRUG
NCT06351332,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06351332,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01451632,has_title,A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Can
NCT01451632,has_status,COMPLETED
NCT01451632,has_phase,
NCT01451632,sponsored_by,Merrimack Pharmaceuticals
NCT01451632,tests,MM-121
MM-121,has_type,DRUG
NCT01451632,tests,Irinotecan
Irinotecan,has_type,DRUG
NCT01451632,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT00630032,has_title,"Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associ"
NCT00630032,has_status,COMPLETED
NCT00630032,has_phase,
NCT00630032,sponsored_by,UNICANCER
NCT00630032,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT00630032,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT00630032,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
NCT00630032,tests,fluorouracil
fluorouracil,has_type,DRUG
NCT00630032,tests,ixabepilone
ixabepilone,has_type,DRUG
NCT02531932,has_title,A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination
NCT02531932,has_status,COMPLETED
NCT02531932,has_phase,
NCT02531932,sponsored_by,Amy Tiersten
NCT02531932,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02531932,tests,Everolimus
Everolimus,has_type,DRUG
NCT03808337,has_title,PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (S
NCT03808337,has_status,RECRUITING
NCT03808337,has_phase,
NCT03808337,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT03808337,tests,Stereotactic Body Radiotherapy/SBRT
Stereotactic Body Radiotherapy/SBRT,has_type,RADIATION
NCT03808337,tests,Systemic Therapy/Standard of Care
Systemic Therapy/Standard of Care,has_type,DRUG
NCT05629585,has_title,"A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvaluma"
NCT05629585,has_status,ACTIVE_NOT_RECRUITING
NCT05629585,has_phase,
NCT05629585,sponsored_by,AstraZeneca
NCT05629585,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT05629585,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT05629585,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05629585,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01884285,has_title,"A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharm"
NCT01884285,has_status,COMPLETED
NCT01884285,has_phase,
NCT01884285,sponsored_by,AstraZeneca
NCT01884285,tests,Part A: AZD8186 monotherapy
Part A: AZD8186 monotherapy,has_type,DRUG
NCT01884285,tests,Part B: AZD8186 monotherapy
Part B: AZD8186 monotherapy,has_type,DRUG
NCT01884285,tests,Part C1: Abiraterone acetate combination with AZD8186
Part C1: Abiraterone acetate combination with AZD8186,has_type,DRUG
NCT01884285,tests,Part D1: AZD2014 combination with AZD8186
Part D1: AZD2014 combination with AZD8186,has_type,DRUG
NCT01884285,tests,Part D2 AZD2014 combination with AZD8186
Part D2 AZD2014 combination with AZD8186,has_type,DRUG
NCT01884285,tests,Part C2: Abiraterone acetate combination with AZD8186
Part C2: Abiraterone acetate combination with AZD8186,has_type,DRUG
NCT03121352,has_title,"Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast C"
NCT03121352,has_status,COMPLETED
NCT03121352,has_phase,
NCT03121352,sponsored_by,Case Comprehensive Cancer Center
NCT03121352,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03121352,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03121352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04958785,has_title,"A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or"
NCT04958785,has_status,TERMINATED
NCT04958785,has_phase,
NCT04958785,sponsored_by,Gilead Sciences
NCT04958785,tests,Magrolimab
Magrolimab,has_type,DRUG
NCT04958785,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04958785,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04958785,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT03387085,has_title,NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Com
NCT03387085,has_status,TERMINATED
NCT03387085,has_phase,
NCT03387085,sponsored_by,"ImmunityBio, Inc."
NCT03387085,tests,Aldoxorubicin HCl
Aldoxorubicin HCl,has_type,DRUG
NCT03387085,tests,N-803
N-803,has_type,BIOLOGICAL
NCT03387085,tests,ETBX-011
ETBX-011,has_type,BIOLOGICAL
NCT03387085,tests,ETBX-051
ETBX-051,has_type,BIOLOGICAL
NCT03387085,tests,ETBX-061
ETBX-061,has_type,BIOLOGICAL
NCT03387085,tests,GI-4000
GI-4000,has_type,BIOLOGICAL
NCT03387085,tests,GI-6207
GI-6207,has_type,BIOLOGICAL
NCT03387085,tests,GI-6301
GI-6301,has_type,BIOLOGICAL
NCT03387085,tests,haNK for Infusion
haNK for Infusion,has_type,BIOLOGICAL
NCT03387085,tests,avelumab
avelumab,has_type,BIOLOGICAL
NCT03387085,tests,bevacizumab
bevacizumab,has_type,BIOLOGICAL
NCT03387085,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03387085,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03387085,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03387085,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT03387085,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT03387085,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT03387085,tests,SBRT
SBRT,has_type,PROCEDURE
NCT02661100,has_title,A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC
NCT02661100,has_status,WITHDRAWN
NCT02661100,has_phase,
NCT02661100,sponsored_by,Case Comprehensive Cancer Center
NCT02661100,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02661100,tests,CDX-1401
CDX-1401,has_type,BIOLOGICAL
NCT02661100,tests,Poly-ICLC
Poly-ICLC,has_type,BIOLOGICAL
NCT05556200,has_title,A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-sta
NCT05556200,has_status,RECRUITING
NCT05556200,has_phase,
NCT05556200,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05556200,tests,Anti-PD-1 monoclonal antibody
Anti-PD-1 monoclonal antibody,has_type,DRUG
NCT05556200,tests,VEGFR2 Tyrosine Kinase Inhibitor
VEGFR2 Tyrosine Kinase Inhibitor,has_type,DRUG
NCT03907800,has_title,Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
NCT03907800,has_status,UNKNOWN
NCT03907800,has_phase,
NCT03907800,sponsored_by,Ruijin Hospital
NCT03907800,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03907800,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03907800,tests,Herceptin
Herceptin,has_type,DRUG
NCT03549000,has_title,"A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PD"
NCT03549000,has_status,TERMINATED
NCT03549000,has_phase,
NCT03549000,sponsored_by,Novartis Pharmaceuticals
NCT03549000,tests,NZV930
NZV930,has_type,OTHER
NCT03549000,tests,PDR001
PDR001,has_type,OTHER
NCT03549000,tests,NIR178
NIR178,has_type,DRUG
NCT03095352,has_title,"A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Comb"
NCT03095352,has_status,COMPLETED
NCT03095352,has_phase,
NCT03095352,sponsored_by,"Laura Huppert, MD, BA"
NCT03095352,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03095352,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03095352,tests,Trastuzumab
Trastuzumab,has_type,BIOLOGICAL
NCT04193059,has_title,Study Comparing the Efficacy and Safety of Epirubicin Combined With Cyclophosphamide Followed by Doc
NCT04193059,has_status,UNKNOWN
NCT04193059,has_phase,
NCT04193059,sponsored_by,Fudan University
NCT04193059,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04193059,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04193059,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04193059,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04193059,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04193059,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT04193059,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05809752,has_title,A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Pri
NCT05809752,has_status,RECRUITING
NCT05809752,has_phase,
NCT05809752,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05809752,tests,Dendritic Cell Vaccine
Dendritic Cell Vaccine,has_type,BIOLOGICAL
NCT01631552,has_title,A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cance
NCT01631552,has_status,COMPLETED
NCT01631552,has_phase,
NCT01631552,sponsored_by,Gilead Sciences
NCT01631552,tests,Sacituzumab Govitecan-hziy (SG)
Sacituzumab Govitecan-hziy (SG),has_type,DRUG
NCT06966700,has_title,"A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab "
NCT06966700,has_status,RECRUITING
NCT06966700,has_phase,
NCT06966700,sponsored_by,Merck Sharp & Dohme LLC
NCT06966700,tests,Sacituzumab tirumotecan
Sacituzumab tirumotecan,has_type,BIOLOGICAL
NCT06966700,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06966700,tests,Rescue Medication
Rescue Medication,has_type,DRUG
NCT06966700,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06966700,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06966700,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT06966700,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT06966700,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06966700,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06966700,tests,Olaparib
Olaparib,has_type,DRUG
NCT04304352,has_title,A Phase II Study of Metronomic Oral Chemotherapy With Cyclophosphamide Plus Capecitabine and Vinorel
NCT04304352,has_status,UNKNOWN
NCT04304352,has_phase,
NCT04304352,sponsored_by,European Institute of Oncology
NCT04304352,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT04304352,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04304352,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02783300,has_title,"A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacody"
NCT02783300,has_status,COMPLETED
NCT02783300,has_phase,
NCT02783300,sponsored_by,GlaxoSmithKline
NCT02783300,tests,GSK3326595
GSK3326595,has_type,DRUG
NCT02783300,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01075100,has_title,Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPS
NCT01075100,has_status,COMPLETED
NCT01075100,has_phase,
NCT01075100,sponsored_by,US Oncology Research
NCT01075100,tests,Ixabepilone
Ixabepilone,has_type,DRUG
NCT01075100,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00938652,has_title,"A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BS"
NCT00938652,has_status,COMPLETED
NCT00938652,has_phase,
NCT00938652,sponsored_by,Sanofi
NCT00938652,tests,gemcitabine/carboplatin
gemcitabine/carboplatin,has_type,DRUG
NCT00938652,tests,Iniparib
Iniparib,has_type,DRUG
NCT02130700,has_title,A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic
NCT02130700,has_status,COMPLETED
NCT02130700,has_phase,
NCT02130700,sponsored_by,Innocrin Pharmaceutical
NCT02130700,tests,VT-464: given orally twice daily in 28-day cycles
VT-464: given orally twice daily in 28-day cycles,has_type,DRUG
NCT02130700,tests,VT-464: given orally once daily in 28-day cycles
VT-464: given orally once daily in 28-day cycles,has_type,DRUG
NCT04986852,has_title,"A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patien"
NCT04986852,has_status,RECRUITING
NCT04986852,has_phase,
NCT04986852,sponsored_by,PharmAbcine
NCT04986852,tests,Olinvacimab
Olinvacimab,has_type,DRUG
NCT05877859,has_title,Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer
NCT05877859,has_status,RECRUITING
NCT05877859,has_phase,
NCT05877859,sponsored_by,Emory University
NCT06431100,has_title,Clinical Study on the Safety and Efficacy of GK01 Autologous Tumor-reactive T Cells (TRT) in Patient
NCT06431100,has_status,RECRUITING
NCT06431100,has_phase,
NCT06431100,sponsored_by,"Beijing Geekgene Technology Co., LTD"
NCT06431100,tests,TCR T-cells
TCR T-cells,has_type,BIOLOGICAL
NCT05749588,has_title,Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A
NCT05749588,has_status,RECRUITING
NCT05749588,has_phase,
NCT05749588,sponsored_by,Fudan University
NCT05749588,tests,A1: SHR-A1811
A1: SHR-A1811,has_type,DRUG
NCT05749588,tests,A2: SHR-A1811 with Camrelizumab
A2: SHR-A1811 with Camrelizumab,has_type,DRUG
NCT05749588,tests,B1: TROP2 ADC
B1: TROP2 ADC,has_type,DRUG
NCT05749588,tests,B2: TROP2 ADC with Camrelizumab
B2: TROP2 ADC with Camrelizumab,has_type,DRUG
NCT05749588,tests,C1: SHR-A1811
C1: SHR-A1811,has_type,DRUG
NCT05749588,tests,C2: SHR-A1811 with BP102
C2: SHR-A1811 with BP102,has_type,DRUG
NCT05749588,tests,D1: TROP2 ADC
D1: TROP2 ADC,has_type,DRUG
NCT05749588,tests,D2: TROP2 ADC with BP102
D2: TROP2 ADC with BP102,has_type,DRUG
NCT05749588,tests,E1: SHR-A1811
E1: SHR-A1811,has_type,DRUG
NCT05749588,tests,F1: TROP2 ADC
F1: TROP2 ADC,has_type,DRUG
NCT05749588,tests,G1: SHR-A1811
G1: SHR-A1811,has_type,DRUG
NCT05749588,tests,H1: TROP2 ADC
H1: TROP2 ADC,has_type,DRUG
NCT03251378,has_title,"A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, a"
NCT03251378,has_status,COMPLETED
NCT03251378,has_phase,
NCT03251378,sponsored_by,Hutchison Medipharma Limited
NCT03251378,tests,Fruquintinib (HMPL-013)
Fruquintinib (HMPL-013),has_type,DRUG
NCT03918278,has_title,"A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics"
NCT03918278,has_status,COMPLETED
NCT03918278,has_phase,
NCT03918278,sponsored_by,Merck Sharp & Dohme LLC
NCT03918278,tests,MK-0482
MK-0482,has_type,BIOLOGICAL
NCT03918278,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT03918278,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03918278,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03918278,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03918278,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03918278,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT06367088,has_title,"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"
NCT06367088,has_status,RECRUITING
NCT06367088,has_phase,
NCT06367088,sponsored_by,"Wuhan Union Hospital, China"
NCT06367088,tests,Cadonilimab
Cadonilimab,has_type,DRUG
NCT04303988,has_title,"A Prospective, Single-arm, Single-center, Phase II Clinical Study of Triple-negative Breast Cancer B"
NCT04303988,has_status,RECRUITING
NCT04303988,has_phase,
NCT04303988,sponsored_by,Fudan University
NCT04303988,tests,SHR-1316
SHR-1316,has_type,DRUG
NCT04303988,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT04303988,tests,Cisplatin/Carboplatin
Cisplatin/Carboplatin,has_type,DRUG
NCT04711109,has_title,"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to"
NCT04711109,has_status,ACTIVE_NOT_RECRUITING
NCT04711109,has_phase,
NCT04711109,sponsored_by,Alliance for Clinical Trials in Oncology
NCT04711109,tests,Denosumab
Denosumab,has_type,DRUG
NCT04711109,tests,Placebo
Placebo,has_type,DRUG
NCT04711109,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT00707707,has_title,"Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Give"
NCT00707707,has_status,COMPLETED
NCT00707707,has_phase,
NCT00707707,sponsored_by,AstraZeneca
NCT00707707,tests,AZD2281
AZD2281,has_type,DRUG
NCT00707707,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04254107,has_title,A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
NCT04254107,has_status,TERMINATED
NCT04254107,has_phase,
NCT04254107,sponsored_by,Seagen Inc.
NCT04254107,tests,SEA-TGT
SEA-TGT,has_type,DRUG
NCT04254107,tests,sasanlimab
sasanlimab,has_type,DRUG
NCT04254107,tests,brentuximab vedotin
brentuximab vedotin,has_type,DRUG
NCT03920488,has_title,Evaluating the Feasibility of Next-Generation Sequencing - Based Germline and Somatic Genetic Testin
NCT03920488,has_status,UNKNOWN
NCT03920488,has_phase,
NCT03920488,sponsored_by,European Institute of Oncology
NCT06889688,has_title,"A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribu"
NCT06889688,has_status,ACTIVE_NOT_RECRUITING
NCT06889688,has_phase,
NCT06889688,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06889688,tests,Camrelizumab+Apatinib+Eribulin
Camrelizumab+Apatinib+Eribulin,has_type,DRUG
NCT06889688,tests,Physician's choice chemotherapy
Physician's choice chemotherapy,has_type,DRUG
NCT06318507,has_title,The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
NCT06318507,has_status,RECRUITING
NCT06318507,has_phase,
NCT06318507,sponsored_by,Pennington Biomedical Research Center
NCT06318507,tests,Fecal microbial diversity
Fecal microbial diversity,has_type,COMBINATION_PRODUCT
NCT03517488,has_title,A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With
NCT03517488,has_status,COMPLETED
NCT03517488,has_phase,
NCT03517488,sponsored_by,"Xencor, Inc."
NCT03517488,tests,XmAb20717
XmAb20717,has_type,BIOLOGICAL
NCT05760378,has_title,"An Open, Randomized Phase III Study of Famitinib With Camrelizumab Plus Treatment of Physician's Cho"
NCT05760378,has_status,RECRUITING
NCT05760378,has_phase,
NCT05760378,sponsored_by,Fudan University
NCT05760378,tests,Famitinib
Famitinib,has_type,DRUG
NCT05760378,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT05760378,tests,nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,has_type,DRUG
NCT02264678,has_title,"A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetic"
NCT02264678,has_status,ACTIVE_NOT_RECRUITING
NCT02264678,has_phase,
NCT02264678,sponsored_by,AstraZeneca
NCT02264678,tests,Administration of ceralasertib
Administration of ceralasertib,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib in combination with olaparib
Administration of ceralasertib in combination with olaparib,has_type,DRUG
NCT02264678,tests,Administation of ceralasertib in combination with durvalumab
Administation of ceralasertib in combination with durvalumab,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib monotherapy
Administration of ceralasertib monotherapy,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib and olaparib
Administration of ceralasertib and olaparib,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib and durvalumab
Administration of ceralasertib and durvalumab,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib in combination with AZD5305
Administration of ceralasertib in combination with AZD5305,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib in combination with carboplatin
Administration of ceralasertib in combination with carboplatin,has_type,DRUG
NCT06950671,has_title,Role of TREM-1 as a Novel Biomarker in HER-2 Negative Breast Cancer: a Molecular and Clinical Study
NCT06950671,has_status,NOT_YET_RECRUITING
NCT06950671,has_phase,
NCT06950671,sponsored_by,Rahma Esam Salama Esawi
NCT01672671,has_title,Identification of BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Bre
NCT01672671,has_status,COMPLETED
NCT01672671,has_phase,
NCT01672671,sponsored_by,Russian Academy of Medical Sciences
NCT01672671,tests,"Doxorubicin, Paclitaxel, Cisplatin"
"Doxorubicin, Paclitaxel, Cisplatin",has_type,DRUG
NCT03036488,has_title,"A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo P"
NCT03036488,has_status,ACTIVE_NOT_RECRUITING
NCT03036488,has_phase,
NCT03036488,sponsored_by,Merck Sharp & Dohme LLC
NCT03036488,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03036488,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03036488,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03036488,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT03036488,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03036488,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03036488,tests,Placebo
Placebo,has_type,DRUG
NCT03036488,tests,Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,has_type,BIOLOGICAL
NCT05099978,has_title,Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN
NCT05099978,has_status,ACTIVE_NOT_RECRUITING
NCT05099978,has_phase,
NCT05099978,sponsored_by,"National Cancer Center, Japan"
NCT05099978,tests,NGS analysis of ctDNA
NGS analysis of ctDNA,has_type,GENETIC
NCT05219578,has_title,A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
NCT05219578,has_status,TERMINATED
NCT05219578,has_phase,
NCT05219578,sponsored_by,Rubius Therapeutics
NCT05219578,tests,RTX-224
RTX-224,has_type,DRUG
NCT03504488,has_title,"A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and "
NCT03504488,has_status,COMPLETED
NCT03504488,has_phase,
NCT03504488,sponsored_by,"BioAtla, Inc."
NCT03504488,tests,CAB-ROR2-ADC
CAB-ROR2-ADC,has_type,BIOLOGICAL
NCT03504488,tests,PD-1 inhibitor
PD-1 inhibitor,has_type,BIOLOGICAL
NCT05302778,has_title,Observational Study Evaluating the Role of Eribulin as a Second-line Treatment in Triple-negative Ad
NCT05302778,has_status,UNKNOWN
NCT05302778,has_phase,
NCT05302778,sponsored_by,University of Milano Bicocca
NCT02353988,has_title,Bicalutamide in Treating Patients With AR-positive Metastatic Triple Negative Breast Cancer
NCT02353988,has_status,UNKNOWN
NCT02353988,has_phase,
NCT02353988,sponsored_by,"Jinling Hospital, China"
NCT02353988,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT02353988,tests,Physician's Choice
Physician's Choice,has_type,OTHER
NCT02301988,has_title,"A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combin"
NCT02301988,has_status,COMPLETED
NCT02301988,has_phase,
NCT02301988,sponsored_by,"Genentech, Inc."
NCT02301988,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT02301988,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02301988,tests,Placebo
Placebo,has_type,DRUG
NCT03872388,has_title,Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Compl
NCT03872388,has_status,TERMINATED
NCT03872388,has_phase,
NCT03872388,sponsored_by,M.D. Anderson Cancer Center
NCT03872388,tests,Atorvastatin
Atorvastatin,has_type,DRUG
NCT03872388,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT00463788,has_title,"Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative"
NCT00463788,has_status,COMPLETED
NCT00463788,has_phase,
NCT00463788,sponsored_by,"Merck KGaA, Darmstadt, Germany"
NCT00463788,tests,"cetuximab, cisplatin"
"cetuximab, cisplatin",has_type,DRUG
NCT00463788,tests,cisplatin
cisplatin,has_type,DRUG
NCT05145907,has_title,"A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerabili"
NCT05145907,has_status,ACTIVE_NOT_RECRUITING
NCT05145907,has_phase,
NCT05145907,sponsored_by,"TJ Biopharma Co., Ltd."
NCT05145907,tests,TJ107 +Pembrolizumab
TJ107 +Pembrolizumab,has_type,BIOLOGICAL
NCT05812807,has_title,OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvan
NCT05812807,has_status,RECRUITING
NCT05812807,has_phase,
NCT05812807,sponsored_by,Alliance for Clinical Trials in Oncology
NCT05812807,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05812807,tests,Patient Observation
Patient Observation,has_type,OTHER
NCT05812807,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05812807,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05812807,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT05812807,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT06365788,has_title,A Multicenter Single Arm Phase II Study With Bicalutamide in Combination With Abemaciclib in 4 Cohor
NCT06365788,has_status,RECRUITING
NCT06365788,has_phase,
NCT06365788,sponsored_by,Universitaire Ziekenhuizen KU Leuven
NCT06365788,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT06365788,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT06682793,has_title,"A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated "
NCT06682793,has_status,RECRUITING
NCT06682793,has_phase,
NCT06682793,sponsored_by,A2 Biotherapeutics Inc.
NCT06682793,tests,A2B395
A2B395,has_type,BIOLOGICAL
NCT06682793,tests,xT CDx with HLA-LOH assay
xT CDx with HLA-LOH assay,has_type,DIAGNOSTIC_TEST
NCT03232593,has_title,Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
NCT03232593,has_status,COMPLETED
NCT03232593,has_phase,
NCT03232593,sponsored_by,Hoffmann-La Roche
NCT03232593,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT05891171,has_title,A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Ther
NCT05891171,has_status,RECRUITING
NCT05891171,has_phase,
NCT05891171,sponsored_by,"Arcus Biosciences, Inc."
NCT05891171,tests,AB598
AB598,has_type,DRUG
NCT05891171,tests,Zimberelimab
Zimberelimab,has_type,DRUG
NCT05891171,tests,Fluorouracil
Fluorouracil,has_type,DRUG
NCT05891171,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT05891171,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT03915678,has_title,Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumor
NCT03915678,has_status,RECRUITING
NCT03915678,has_phase,
NCT03915678,sponsored_by,Institut Bergonié
NCT03915678,tests,Association atezolizumab + BDB001 + RT
Association atezolizumab + BDB001 + RT,has_type,DRUG
NCT03915678,tests,Association atezolizumab + BDB001+ RT
Association atezolizumab + BDB001+ RT,has_type,DRUG
NCT03915678,tests,Association atezolizumab + BDB001+ RT
Association atezolizumab + BDB001+ RT,has_type,DRUG
NCT03915678,tests,Association atezolizumab + BDB001 + RT
Association atezolizumab + BDB001 + RT,has_type,DRUG
NCT03915678,tests,Association atezolizumab + BDB001 + RT
Association atezolizumab + BDB001 + RT,has_type,DRUG
NCT03915678,tests,Association atezolizumab + BDB001 + RT
Association atezolizumab + BDB001 + RT,has_type,DRUG
NCT04722978,has_title,Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breas
NCT04722978,has_status,RECRUITING
NCT04722978,has_phase,
NCT04722978,sponsored_by,Sun Yat-sen University
NCT04722978,tests,Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
Gemcitabine and carboplatin plus antibiotic (moxifloxacin),has_type,DRUG
NCT04722978,tests,Gemcitabine combined with carboplatin plus placebo
Gemcitabine combined with carboplatin plus placebo,has_type,DRUG
NCT00834678,has_title,Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Br
NCT00834678,has_status,COMPLETED
NCT00834678,has_phase,
NCT00834678,sponsored_by,Ohio State University Comprehensive Cancer Center
NCT00834678,tests,bendamustine
bendamustine,has_type,DRUG
NCT00834678,tests,erlotinib
erlotinib,has_type,DRUG
NCT00834678,tests,Maintenance erlotinib
Maintenance erlotinib,has_type,DRUG
NCT02403271,has_title,"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With"
NCT02403271,has_status,COMPLETED
NCT02403271,has_phase,
NCT02403271,sponsored_by,Pharmacyclics LLC.
NCT02403271,tests,Ibrutinib
Ibrutinib,has_type,DRUG
NCT02403271,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04879888,has_title,Estudio clínico Fase I de Inmunoterapia Con Vacunas sintéticas Personalizadas en Pacientes Con cánce
NCT04879888,has_status,COMPLETED
NCT04879888,has_phase,
NCT04879888,sponsored_by,Universidad Nacional de Colombia
NCT04879888,tests,Peptide pulsed Dendritic cell
Peptide pulsed Dendritic cell,has_type,BIOLOGICAL
NCT04771871,has_title,Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patients Receiving Standar
NCT04771871,has_status,UNKNOWN
NCT04771871,has_phase,
NCT04771871,sponsored_by,"University College Hospital, Ibadan"
NCT04771871,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04771871,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04771871,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04771871,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01642771,has_title,"A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety"
NCT01642771,has_status,UNKNOWN
NCT01642771,has_phase,
NCT01642771,sponsored_by,China Breast Cancer Clinical Study Group
NCT01642771,tests,5-Fu/epirubicin/CTX following Docetaxel
5-Fu/epirubicin/CTX following Docetaxel,has_type,DRUG
NCT01642771,tests,Docetaxel/capecitabine followed by XEC
Docetaxel/capecitabine followed by XEC,has_type,DRUG
NCT04180371,has_title,"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Pat"
NCT04180371,has_status,RECRUITING
NCT04180371,has_phase,
NCT04180371,sponsored_by,BicycleTx Limited
NCT04180371,tests,BT5528
BT5528,has_type,DRUG
NCT04180371,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04498793,has_title,Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as Perioperative Treatment in Particip
NCT04498793,has_status,UNKNOWN
NCT04498793,has_phase,
NCT04498793,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT04498793,tests,Tislelizumab
Tislelizumab,has_type,BIOLOGICAL
NCT04498793,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT04498793,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04498793,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04498793,tests,Cyclophosphamide
Cyclophosphamide,has_type,DEVICE
NCT05244993,has_title,AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patie
NCT05244993,has_status,UNKNOWN
NCT05244993,has_phase,
NCT05244993,sponsored_by,Liaoning Cancer Hospital & Institute
NCT05244993,tests,AK105
AK105,has_type,DRUG
NCT05244993,tests,Anlotinib hydrochloride
Anlotinib hydrochloride,has_type,DRUG
NCT05244993,tests,Albumin Paclitaxel
Albumin Paclitaxel,has_type,DRUG
NCT03740893,has_title,PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomar
NCT03740893,has_status,RECRUITING
NCT03740893,has_phase,
NCT03740893,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT03740893,tests,AZD6738
AZD6738,has_type,DRUG
NCT03740893,tests,Olaparib
Olaparib,has_type,DRUG
NCT03740893,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT06110793,has_title,A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative
NCT06110793,has_status,RECRUITING
NCT06110793,has_phase,
NCT06110793,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT06110793,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT06110793,tests,Pembrolizuma
Pembrolizuma,has_type,DRUG
NCT06110793,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04320693,has_title,Expanded Access for IMMU-132
NCT04320693,has_status,APPROVED_FOR_MARKETING
NCT04320693,has_phase,
NCT04320693,sponsored_by,Gilead Sciences
NCT04320693,tests,IMMU-132
IMMU-132,has_type,DRUG
NCT03045393,has_title,"Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple"
NCT03045393,has_status,WITHDRAWN
NCT03045393,has_phase,
NCT03045393,sponsored_by,Duke University
NCT03045393,tests,Mirvetuximab Soravtansine (IMGN853)
Mirvetuximab Soravtansine (IMGN853),has_type,DRUG
NCT00472693,has_title,"A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hor"
NCT00472693,has_status,COMPLETED
NCT00472693,has_phase,
NCT00472693,sponsored_by,Abramson Cancer Center at Penn Medicine
NCT00472693,tests,"Bevacizumab, Abraxane"
"Bevacizumab, Abraxane",has_type,DRUG
NCT04185311,has_title,"A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Loca"
NCT04185311,has_status,TERMINATED
NCT04185311,has_phase,
NCT04185311,sponsored_by,Jonsson Comprehensive Cancer Center
NCT04185311,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT04185311,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT04185311,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,BIOLOGICAL
NCT04139993,has_title,"A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immu"
NCT04139993,has_status,TERMINATED
NCT04139993,has_phase,
NCT04139993,sponsored_by,Mayo Clinic
NCT04139993,tests,Microbiota-based Formulation RBX7455
Microbiota-based Formulation RBX7455,has_type,DRUG
NCT01857193,has_title,A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment o
NCT01857193,has_status,COMPLETED
NCT01857193,has_phase,
NCT01857193,sponsored_by,Novartis Pharmaceuticals
NCT01857193,tests,ribociclib (LEE011)
ribociclib (LEE011),has_type,DRUG
NCT01857193,tests,Exemestane
Exemestane,has_type,DRUG
NCT01857193,tests,Everolimus (RAD001)
Everolimus (RAD001),has_type,DRUG
NCT04427293,has_title,BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Tri
NCT04427293,has_status,RECRUITING
NCT04427293,has_phase,
NCT04427293,sponsored_by,University of Illinois at Chicago
NCT04427293,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT04427293,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06231693,has_title,Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-worl
NCT06231693,has_status,TERMINATED
NCT06231693,has_phase,
NCT06231693,sponsored_by,AstraZeneca
NCT06231693,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
NCT02682693,has_title,Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primar
NCT02682693,has_status,COMPLETED
NCT02682693,has_phase,
NCT02682693,sponsored_by,GBG Forschungs GmbH
NCT02682693,tests,Denosumab
Denosumab,has_type,DRUG
NCT02682693,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT02682693,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02682693,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02682693,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02682693,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02682693,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT03363893,has_title,"A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability"
NCT03363893,has_status,COMPLETED
NCT03363893,has_phase,
NCT03363893,sponsored_by,Carrick Therapeutics Limited
NCT03363893,tests,CT7001
CT7001,has_type,DRUG
NCT03363893,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04039893,has_title,Prospective Trial to Evaluate MUltimodal Targeted Axillary Surgery (MUTAS) Approaches in Breast Canc
NCT04039893,has_status,UNKNOWN
NCT04039893,has_phase,
NCT04039893,sponsored_by,Parc de Salut Mar
NCT04039893,tests,Systematic axillary ultrasound imaging
Systematic axillary ultrasound imaging,has_type,DIAGNOSTIC_TEST
NCT04039893,tests,Sentinel node
Sentinel node,has_type,DIAGNOSTIC_TEST
NCT04039893,tests,Excision of suspicious lymph nodes
Excision of suspicious lymph nodes,has_type,PROCEDURE
NCT04039893,tests,Two steps axillary node clearance
Two steps axillary node clearance,has_type,PROCEDURE
NCT05131893,has_title,"Neoadjuvant Treatment of Breast Cancer - a Prospective Observational Study, PANnon ONCology (PANONC)"
NCT05131893,has_status,NOT_YET_RECRUITING
NCT05131893,has_phase,
NCT05131893,sponsored_by,"National Institute of Oncology, Hungary"
NCT05131893,tests,Tamoxifen
Tamoxifen,has_type,DRUG
NCT05131893,tests,Goserelin
Goserelin,has_type,DRUG
NCT05131893,tests,Letrozole 2.5Mg Tab
Letrozole 2.5Mg Tab,has_type,DRUG
NCT05131893,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05131893,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT05131893,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05131893,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT05131893,tests,trastuzumab
trastuzumab,has_type,DRUG
NCT05131893,tests,pertuzumab
pertuzumab,has_type,DRUG
NCT05131893,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02449993,has_title,"Evaluation of the MammaTyper Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Patie"
NCT02449993,has_status,COMPLETED
NCT02449993,has_phase,
NCT02449993,sponsored_by,BioNTech Diagnostics GmbH
NCT02449993,tests,MammaTyper™
MammaTyper™,has_type,DEVICE
NCT06894771,has_title,"A Phase 1 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Ph"
NCT06894771,has_status,RECRUITING
NCT06894771,has_phase,
NCT06894771,sponsored_by,Merck Sharp & Dohme LLC
NCT06894771,tests,MK-4700
MK-4700,has_type,BIOLOGICAL
NCT06894771,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03609671,has_title,A Pilot Study: Emotions Immunology and Breast Cancer
NCT03609671,has_status,COMPLETED
NCT03609671,has_phase,
NCT03609671,sponsored_by,"Luz A. Venta, MD"
NCT03609671,tests,Standard of Care + Experimental Individualized Therapy
Standard of Care + Experimental Individualized Therapy,has_type,BEHAVIORAL
NCT03609671,tests,Control: Standard of Care
Control: Standard of Care,has_type,OTHER
NCT04913571,has_title,Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted Tr
NCT04913571,has_status,UNKNOWN
NCT04913571,has_phase,
NCT04913571,sponsored_by,Fudan University
NCT04913571,tests,Eribulin
Eribulin,has_type,DRUG
NCT04913571,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT03519178,has_title,"PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHA"
NCT03519178,has_status,TERMINATED
NCT03519178,has_phase,
NCT03519178,sponsored_by,Pfizer
NCT03519178,tests,PF-06873600
PF-06873600,has_type,DRUG
NCT03519178,tests,Endocrine Therapy 1
Endocrine Therapy 1,has_type,DRUG
NCT03519178,tests,Endocrine Therapy 2
Endocrine Therapy 2,has_type,DRUG
NCT05475678,has_title,"A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Co"
NCT05475678,has_status,RECRUITING
NCT05475678,has_phase,
NCT05475678,sponsored_by,Zhenzhen Liu
NCT05475678,tests,（Carrelizumab + TCb） regimen
（Carrelizumab + TCb） regimen,has_type,DRUG
NCT05475678,tests,TCb regimen
TCb regimen,has_type,DRUG
NCT03401385,has_title,"Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subje"
NCT03401385,has_status,ACTIVE_NOT_RECRUITING
NCT03401385,has_phase,
NCT03401385,sponsored_by,"Daiichi Sankyo Co., Ltd."
NCT03401385,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
NCT03401385,tests,Steroid Containing Mouthwash
Steroid Containing Mouthwash,has_type,DRUG
NCT03401385,tests,Non-Steroid Containing Mouthwash
Non-Steroid Containing Mouthwash,has_type,OTHER
NCT06955156,has_title,Trilaciclib in Combination With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Adva
NCT06955156,has_status,RECRUITING
NCT06955156,has_phase,
NCT06955156,sponsored_by,QIAO LI
NCT06955156,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT03205761,has_title,A Phase II Clinical Trial to Analyse Olaparib Response in Patients With BRCA1 and/or 2 Promoter Meth
NCT03205761,has_status,COMPLETED
NCT03205761,has_phase,
NCT03205761,sponsored_by,Spanish Breast Cancer Research Group
NCT03205761,tests,Olaparib
Olaparib,has_type,DRUG
NCT06067061,has_title,"""neoBREASTIM"": A Phase 2 Study of Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant S"
NCT06067061,has_status,TERMINATED
NCT06067061,has_phase,
NCT06067061,sponsored_by,Institut Curie
NCT06067061,tests,Atezolizumab + RP1
Atezolizumab + RP1,has_type,COMBINATION_PRODUCT
NCT03201861,has_title,Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early 
NCT03201861,has_status,RECRUITING
NCT03201861,has_phase,
NCT03201861,sponsored_by,RenJi Hospital
NCT03201861,tests,"Paclitaxel, Cisplatin"
"Paclitaxel, Cisplatin",has_type,DRUG
NCT03201861,tests,EC to docetaxel or paclitaxel
EC to docetaxel or paclitaxel,has_type,DRUG
NCT04468061,has_title,Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD
NCT04468061,has_status,RECRUITING
NCT04468061,has_phase,
NCT04468061,sponsored_by,Dana-Farber Cancer Institute
NCT04468061,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT04468061,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT00640861,has_title,MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas
NCT00640861,has_status,COMPLETED
NCT00640861,has_phase,
NCT00640861,sponsored_by,Mayo Clinic
NCT00640861,tests,CpG oligodeoxynucleotide
CpG oligodeoxynucleotide,has_type,BIOLOGICAL
NCT00640861,tests,HER-2/neu peptide vaccine
HER-2/neu peptide vaccine,has_type,BIOLOGICAL
NCT00640861,tests,MUC-1 peptide vaccine
MUC-1 peptide vaccine,has_type,BIOLOGICAL
NCT00640861,tests,incomplete Freund's adjuvant
incomplete Freund's adjuvant,has_type,BIOLOGICAL
NCT00640861,tests,sargramostim
sargramostim,has_type,BIOLOGICAL
NCT00640861,tests,immunoenzyme technique
immunoenzyme technique,has_type,OTHER
NCT00640861,tests,immunologic technique
immunologic technique,has_type,OTHER
NCT01920061,has_title,A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212
NCT01920061,has_status,COMPLETED
NCT01920061,has_phase,
NCT01920061,sponsored_by,Pfizer
NCT01920061,tests,PF-05212384 (gedatolisib)
PF-05212384 (gedatolisib),has_type,DRUG
NCT01920061,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01920061,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01920061,tests,Dacomitinib
Dacomitinib,has_type,DRUG
NCT07021261,has_title,"A Multicenter, Open-Label, Randomized, Phase III Study Comparing UTD2 Combined With Capecitabine to "
NCT07021261,has_status,NOT_YET_RECRUITING
NCT07021261,has_phase,
NCT07021261,sponsored_by,Fudan University
NCT07021261,tests,Utidelone plus capecitabine
Utidelone plus capecitabine,has_type,DRUG
NCT07021261,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04836156,has_title,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters
NCT04836156,has_status,RECRUITING
NCT04836156,has_phase,
NCT04836156,sponsored_by,Peking University People's Hospital
NCT04836156,tests,neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer,has_type,DRUG
NCT04836156,tests,neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer,has_type,DRUG
NCT02411656,has_title,A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Canc
NCT02411656,has_status,ACTIVE_NOT_RECRUITING
NCT02411656,has_phase,
NCT02411656,sponsored_by,M.D. Anderson Cancer Center
NCT02411656,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02411656,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02038699,has_title,A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing o
NCT02038699,has_status,WITHDRAWN
NCT02038699,has_phase,
NCT02038699,sponsored_by,Chimerix
NCT02038699,tests,ONC201
ONC201,has_type,DRUG
NCT05382299,has_title,"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Cho"
NCT05382299,has_status,RECRUITING
NCT05382299,has_phase,
NCT05382299,sponsored_by,Gilead Sciences
NCT05382299,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT05382299,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05382299,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT05382299,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05382299,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02221999,has_title,"A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin Wit"
NCT02221999,has_status,ACTIVE_NOT_RECRUITING
NCT02221999,has_phase,
NCT02221999,sponsored_by,RenJi Hospital
NCT02221999,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02221999,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02221999,tests,Gonadotropin-releasing hormone agonist
Gonadotropin-releasing hormone agonist,has_type,DRUG
NCT02221999,tests,Letrozole
Letrozole,has_type,DRUG
NCT04138719,has_title,Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoad
NCT04138719,has_status,UNKNOWN
NCT04138719,has_phase,
NCT04138719,sponsored_by,Hebei Medical University Fourth Hospital
NCT04138719,tests,Nab-paclitaxel + Carboplatin
Nab-paclitaxel + Carboplatin,has_type,DRUG
NCT04138719,tests,Nab-paclitaxel + Epirubicin
Nab-paclitaxel + Epirubicin,has_type,DRUG
NCT03805399,has_title,Precision Treatment of Refractory Triple Negative Breast Cancer Based on Molecular Subtyping --FUSCC
NCT03805399,has_status,UNKNOWN
NCT03805399,has_phase,
NCT03805399,sponsored_by,Fudan University
NCT03805399,tests,Pyrotinib with Capecitabine
Pyrotinib with Capecitabine,has_type,DRUG
NCT03805399,tests,"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)"
"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)",has_type,DRUG
NCT03805399,tests,anti PD-1 with nab-paclitaxel
anti PD-1 with nab-paclitaxel,has_type,DRUG
NCT03805399,tests,PARP inhibitor included therapy
PARP inhibitor included therapy,has_type,DRUG
NCT03805399,tests,BLIS with anti-VEGFR included therapy
BLIS with anti-VEGFR included therapy,has_type,DRUG
NCT03805399,tests,MES with anti-VEGFR included therapy
MES with anti-VEGFR included therapy,has_type,DRUG
NCT03805399,tests,mTOR inhibitor with nab-paclitaxel
mTOR inhibitor with nab-paclitaxel,has_type,DRUG
NCT06439771,has_title,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL"
NCT06439771,has_status,RECRUITING
NCT06439771,has_phase,
NCT06439771,sponsored_by,"MediLink Therapeutics (Suzhou) Co., Ltd."
NCT06439771,tests,YL202 should be intravenously infused
YL202 should be intravenously infused,has_type,DRUG
NCT00022516,has_title,"Low-dose Cytotoxics as ""Anti-angiogenesis Treatment"" Following Adjuvant Induction Chemotherapy for P"
NCT00022516,has_status,COMPLETED
NCT00022516,has_phase,
NCT00022516,sponsored_by,ETOP IBCSG Partners Foundation
NCT00022516,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00022516,tests,Methotrexate
Methotrexate,has_type,DRUG
NCT01777932,has_title,"A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits of Bevacizumab (Avas"
NCT01777932,has_status,COMPLETED
NCT01777932,has_phase,
NCT01777932,sponsored_by,Hoffmann-La Roche
NCT02639832,has_title,
NCT02639832,has_status,UNKNOWN
NCT02639832,has_phase,
NCT02639832,sponsored_by,Cynvenio Biosystems
NCT02639832,tests,"LiquidBiopsy®, NK VueTM"
"LiquidBiopsy®, NK VueTM",has_type,DEVICE
NCT00813956,has_title,
NCT00813956,has_status,COMPLETED
NCT00813956,has_phase,
NCT00813956,sponsored_by,Sanofi
NCT00813956,tests,gemcitabine plus carboplatin plus BSI-201
gemcitabine plus carboplatin plus BSI-201,has_type,DRUG
NCT01395056,has_title,Study of Chemotherapy Combined With Adoptive Cellular Therapy With Dendritic and Cytokine-induced Ki
NCT01395056,has_status,COMPLETED
NCT01395056,has_phase,
NCT01395056,sponsored_by,Peking University Cancer Hospital & Institute
NCT05768932,has_title,A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy in Patients With Adva
NCT05768932,has_status,RECRUITING
NCT05768932,has_phase,
NCT05768932,sponsored_by,"SillaJen, Inc."
NCT05768932,tests,BAL0891
BAL0891,has_type,DRUG
NCT05768932,tests,Carboplatin
Carboplatin,has_type,COMBINATION_PRODUCT
NCT05768932,tests,Paclitaxel
Paclitaxel,has_type,COMBINATION_PRODUCT
NCT06342037,has_title,NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 T
NCT06342037,has_status,RECRUITING
NCT06342037,has_phase,
NCT06342037,sponsored_by,The Netherlands Cancer Institute
NCT06342037,tests,Tiragolumab
Tiragolumab,has_type,DRUG
NCT06342037,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT06342037,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT01234532,has_title,GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Neg
NCT01234532,has_status,TERMINATED
NCT01234532,has_phase,
NCT01234532,sponsored_by,"University of Maryland, Baltimore"
NCT01234532,tests,entinostat
entinostat,has_type,DRUG
NCT01234532,tests,anastrozole
anastrozole,has_type,DRUG
NCT01234532,tests,diagnostic laboratory biomarker analysis
diagnostic laboratory biomarker analysis,has_type,OTHER
NCT01234532,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT05035745,has_title,Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid T
NCT05035745,has_status,RECRUITING
NCT05035745,has_phase,
NCT05035745,sponsored_by,"National University Hospital, Singapore"
NCT05035745,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT05035745,tests,Selinexor
Selinexor,has_type,DRUG
NCT04634747,has_title,"A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembr"
NCT04634747,has_status,UNKNOWN
NCT04634747,has_phase,
NCT04634747,sponsored_by,"OncoPep, Inc."
NCT04634747,tests,PVX-410
PVX-410,has_type,DRUG
NCT02401347,has_title,A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients Wi
NCT02401347,has_status,COMPLETED
NCT02401347,has_phase,
NCT02401347,sponsored_by,Melinda Telli
NCT02401347,tests,Talazoparib Tosylate
Talazoparib Tosylate,has_type,DRUG
NCT04099277,has_title,A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
NCT04099277,has_status,TERMINATED
NCT04099277,has_phase,
NCT04099277,sponsored_by,Eli Lilly and Company
NCT04099277,tests,LY3435151
LY3435151,has_type,DRUG
NCT04099277,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02834247,has_title,A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid T
NCT02834247,has_status,TERMINATED
NCT02834247,has_phase,
NCT02834247,sponsored_by,"Calithera Biosciences, Inc"
NCT02834247,tests,TAK-659
TAK-659,has_type,DRUG
NCT02834247,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02032277,has_title,"A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the "
NCT02032277,has_status,COMPLETED
NCT02032277,has_phase,
NCT02032277,sponsored_by,AbbVie
NCT02032277,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02032277,tests,Placebo
Placebo,has_type,DRUG
NCT02032277,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02032277,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02032277,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02032277,tests,Veliparib
Veliparib,has_type,DRUG
NCT02032277,tests,Placebo
Placebo,has_type,DRUG
NCT02595905,has_title,Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Met
NCT02595905,has_status,COMPLETED
NCT02595905,has_phase,
NCT02595905,sponsored_by,National Cancer Institute (NCI)
NCT02595905,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02595905,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02595905,tests,Placebo Administration
Placebo Administration,has_type,OTHER
NCT02595905,tests,Veliparib
Veliparib,has_type,DRUG
NCT05093387,has_title,A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammator
NCT05093387,has_status,WITHDRAWN
NCT05093387,has_phase,
NCT05093387,sponsored_by,Northwestern University
NCT05093387,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05093387,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05093387,tests,Transferrin Receptor-Targeted Liposomal p53 cDNA
Transferrin Receptor-Targeted Liposomal p53 cDNA,has_type,GENETIC
NCT02641847,has_title,Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cance
NCT02641847,has_status,ACTIVE_NOT_RECRUITING
NCT02641847,has_phase,
NCT02641847,sponsored_by,Fudan University
NCT02641847,tests,docetaxel
docetaxel,has_type,DRUG
NCT02641847,tests,doxorubicin or epirubicin
doxorubicin or epirubicin,has_type,DRUG
NCT02641847,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT02641847,tests,gemcitabine
gemcitabine,has_type,DRUG
NCT02641847,tests,cisplatin
cisplatin,has_type,DRUG
NCT03225547,has_title,Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Canc
NCT03225547,has_status,ACTIVE_NOT_RECRUITING
NCT03225547,has_phase,
NCT03225547,sponsored_by,University of Chicago
NCT03225547,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03225547,tests,Mifepristone
Mifepristone,has_type,DRUG
NCT02648477,has_title,MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients Wi
NCT02648477,has_status,COMPLETED
NCT02648477,has_phase,
NCT02648477,sponsored_by,City of Hope Medical Center
NCT02648477,tests,Anastrozole
Anastrozole,has_type,DRUG
NCT02648477,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT02648477,tests,Exemestane
Exemestane,has_type,DRUG
NCT02648477,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02648477,tests,Letrozole
Letrozole,has_type,DRUG
NCT02648477,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05570253,has_title,"""A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Comb"
NCT05570253,has_status,RECRUITING
NCT05570253,has_phase,
NCT05570253,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT05570253,tests,Eribulin
Eribulin,has_type,DRUG
NCT05570253,tests,SDX-7320
SDX-7320,has_type,DRUG
NCT05570253,tests,Placebo
Placebo,has_type,OTHER
NCT04266353,has_title,Mechanisms in IGF2 Induced Chemoresistance and Mitochondrial Regulation in Triple Negative Breast Ca
NCT04266353,has_status,WITHDRAWN
NCT04266353,has_phase,
NCT04266353,sponsored_by,Loma Linda University
NCT04266353,tests,Resveratrol (RSV)
Resveratrol (RSV),has_type,DIETARY_SUPPLEMENT
NCT04251533,has_title,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy "
NCT04251533,has_status,ACTIVE_NOT_RECRUITING
NCT04251533,has_phase,
NCT04251533,sponsored_by,Novartis Pharmaceuticals
NCT04251533,tests,alpelisib
alpelisib,has_type,DRUG
NCT04251533,tests,placebo
placebo,has_type,DRUG
NCT04251533,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT06684054,has_title,Study of the Features of Senescent T Lymphocytes Induced by Chemotherapy and Its Relationship with t
NCT06684054,has_status,NOT_YET_RECRUITING
NCT06684054,has_phase,
NCT06684054,sponsored_by,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT06684054,tests,"docetaxel, anthracycline, cyclophosphamide"
"docetaxel, anthracycline, cyclophosphamide",has_type,DRUG
NCT03925233,has_title,Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Orga
NCT03925233,has_status,UNKNOWN
NCT03925233,has_phase,
NCT03925233,sponsored_by,Xijing Hospital
NCT03925233,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT03925233,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT03925233,tests,Epirubicin hydrochloride
Epirubicin hydrochloride,has_type,DRUG
NCT03925233,tests,Fluorouracil
Fluorouracil,has_type,DRUG
NCT03925233,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03925233,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03925233,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03925233,tests,Recombinant Human Endostatin
Recombinant Human Endostatin,has_type,DRUG
NCT03925233,tests,Pirarubicin hydrochloride
Pirarubicin hydrochloride,has_type,DRUG
NCT03925233,tests,Pyrrolidine
Pyrrolidine,has_type,DRUG
NCT03925233,tests,Ixabepilone
Ixabepilone,has_type,DRUG
NCT03925233,tests,Tamoxifen citrate
Tamoxifen citrate,has_type,DRUG
NCT03925233,tests,Vinorelbine tartrate
Vinorelbine tartrate,has_type,DRUG
NCT03925233,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03925233,tests,Methotrexate
Methotrexate,has_type,DRUG
NCT03925233,tests,Eribulin mesylate
Eribulin mesylate,has_type,DRUG
NCT03925233,tests,Toremifene citrate
Toremifene citrate,has_type,DRUG
NCT03925233,tests,Anastrozole
Anastrozole,has_type,DRUG
NCT03925233,tests,Letrozole
Letrozole,has_type,DRUG
NCT03925233,tests,Exemestane
Exemestane,has_type,DRUG
NCT03925233,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT03925233,tests,Olaparib
Olaparib,has_type,DRUG
NCT03925233,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT03925233,tests,Apatinib mesylate
Apatinib mesylate,has_type,DRUG
NCT03925233,tests,Pattozumab
Pattozumab,has_type,DRUG
NCT03925233,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03925233,tests,Ear particles
Ear particles,has_type,DRUG
NCT03925233,tests,Aidi Injection
Aidi Injection,has_type,DRUG
NCT03925233,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06431633,has_title,A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA
NCT06431633,has_status,RECRUITING
NCT06431633,has_phase,
NCT06431633,sponsored_by,Fundación GECP
NCT06431633,tests,Zimberelimab
Zimberelimab,has_type,DRUG
NCT06431633,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT06431633,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT06431633,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04119154,has_title,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)
NCT04119154,has_status,COMPLETED
NCT04119154,has_phase,
NCT04119154,sponsored_by,Harvard School of Public Health (HSPH)
NCT04119154,tests,Contrast Microhalography (CEM)
Contrast Microhalography (CEM),has_type,DIAGNOSTIC_TEST
NCT00576654,has_title,"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, N"
NCT00576654,has_status,COMPLETED
NCT00576654,has_phase,
NCT00576654,sponsored_by,National Cancer Institute (NCI)
NCT00576654,tests,Irinotecan Hydrochloride
Irinotecan Hydrochloride,has_type,DRUG
NCT00576654,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00576654,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT00576654,tests,Veliparib
Veliparib,has_type,DRUG
NCT03394287,has_title,"A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Tria"
NCT03394287,has_status,COMPLETED
NCT03394287,has_phase,
NCT03394287,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT03394287,tests,SHR-1210
SHR-1210,has_type,DRUG
NCT03394287,tests,Apatinib
Apatinib,has_type,DRUG
NCT02547987,has_title,"CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Can"
NCT02547987,has_status,ACTIVE_NOT_RECRUITING
NCT02547987,has_phase,
NCT02547987,sponsored_by,Mothaffar Rimawi
NCT02547987,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02547987,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06387628,has_title,A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Pa
NCT06387628,has_status,RECRUITING
NCT06387628,has_phase,
NCT06387628,sponsored_by,Fudan University
NCT06387628,tests,LM-108
LM-108,has_type,DRUG
NCT06387628,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT06387628,tests,Eribulin
Eribulin,has_type,DRUG
NCT06387628,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT06908928,has_title,"An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821"
NCT06908928,has_status,NOT_YET_RECRUITING
NCT06908928,has_phase,
NCT06908928,sponsored_by,"Mabwell (Shanghai) Bioscience Co., Ltd."
NCT06908928,tests,bulumtatug fuvedotin
bulumtatug fuvedotin,has_type,DRUG
NCT06908928,tests,bulumtatug fuvedotin
bulumtatug fuvedotin,has_type,DRUG
NCT04890028,has_title,Detection and Metabolic Characterization in DOPA PET/CT of no Treated Brain Metastases of Lung Cance
NCT04890028,has_status,UNKNOWN
NCT04890028,has_phase,
NCT04890028,sponsored_by,Institut Cancerologie de l'Ouest
NCT04890028,tests,F-DOPA PET/CT
F-DOPA PET/CT,has_type,RADIATION
NCT05746728,has_title,"A Multicenter, Open-label, Single-arm Study of Surufatinib in Combination With Tislelizumab for Seco"
NCT05746728,has_status,NOT_YET_RECRUITING
NCT05746728,has_phase,
NCT05746728,sponsored_by,Huihua Xiong
NCT05746728,tests,Surufatinib
Surufatinib,has_type,DRUG
NCT05746728,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT05111561,has_title,A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Altera
NCT05111561,has_status,RECRUITING
NCT05111561,has_phase,
NCT05111561,sponsored_by,National Cancer Institute (NCI)
NCT05111561,tests,BET Bromodomain Inhibitor ZEN-3694
BET Bromodomain Inhibitor ZEN-3694,has_type,DRUG
NCT05111561,tests,Binimetinib
Binimetinib,has_type,DRUG
NCT05111561,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT05111561,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05111561,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05111561,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03145961,has_title,c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease a
NCT03145961,has_status,UNKNOWN
NCT03145961,has_phase,
NCT03145961,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT03145961,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02934828,has_title,A Randomized Study of Preoperative Chemotherapy or Postoperative Chemotherapy for Early Triple Negat
NCT02934828,has_status,UNKNOWN
NCT02934828,has_phase,
NCT02934828,sponsored_by,Chinese Academy of Medical Sciences
NCT02934828,tests,Neoadjuvant Chemotherapy
Neoadjuvant Chemotherapy,has_type,DRUG
NCT02934828,tests,postoperative chemotherapy
postoperative chemotherapy,has_type,DRUG
NCT01936961,has_title,A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tu
NCT01936961,has_status,WITHDRAWN
NCT01936961,has_phase,
NCT01936961,sponsored_by,Western Regional Medical Center
NCT01936961,tests,CTLA-4 Antibody
CTLA-4 Antibody,has_type,DRUG
NCT01936961,tests,Hypofractionated Radiotherapy
Hypofractionated Radiotherapy,has_type,RADIATION
NCT06965361,has_title,Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Tripl
NCT06965361,has_status,COMPLETED
NCT06965361,has_phase,
NCT06965361,sponsored_by,Ziauddin University
NCT06965361,tests,carboplatin
carboplatin,has_type,DRUG
NCT06965361,tests,carboplatin
carboplatin,has_type,DEVICE
NCT03756298,has_title,"Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adj"
NCT03756298,has_status,ACTIVE_NOT_RECRUITING
NCT03756298,has_phase,
NCT03756298,sponsored_by,"National Cancer Center, Korea"
NCT03756298,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03756298,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05203445,has_title,Phase II of Neoadjuvant Olaparib in Combination with Pembrolizumab in Patients with Triple Negative 
NCT05203445,has_status,ACTIVE_NOT_RECRUITING
NCT05203445,has_phase,
NCT05203445,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT05203445,tests,Olaparib
Olaparib,has_type,DRUG
NCT05203445,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04683445,has_title,A Real-world Study: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
NCT04683445,has_status,UNKNOWN
NCT04683445,has_phase,
NCT04683445,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04683445,tests,Eribulin
Eribulin,has_type,DRUG
NCT04683445,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04683445,tests,pertuzumab
pertuzumab,has_type,DRUG
NCT04683445,tests,Pyrotinib
Pyrotinib,has_type,DRUG
NCT04683445,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04683445,tests,Camerlizumab
Camerlizumab,has_type,DRUG
NCT03396445,has_title,A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With
NCT03396445,has_status,COMPLETED
NCT03396445,has_phase,
NCT03396445,sponsored_by,Merck Sharp & Dohme LLC
NCT03396445,tests,Boserolimab
Boserolimab,has_type,DRUG
NCT03396445,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03396445,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT03396445,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03396445,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02543645,has_title,"A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezoli"
NCT02543645,has_status,TERMINATED
NCT02543645,has_phase,
NCT02543645,sponsored_by,Celldex Therapeutics
NCT02543645,tests,Combination of Varlilumab and Atezolizumab
Combination of Varlilumab and Atezolizumab,has_type,DRUG
NCT03752398,has_title,A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With
NCT03752398,has_status,COMPLETED
NCT03752398,has_phase,
NCT03752398,sponsored_by,"Xencor, Inc."
NCT03752398,tests,XmAb®23104
XmAb®23104,has_type,BIOLOGICAL
NCT03752398,tests,Yervoy® (ipilimumab)
Yervoy® (ipilimumab),has_type,BIOLOGICAL
NCT03348098,has_title,Tianjin Medical University Cancer Institute and Hospital
NCT03348098,has_status,UNKNOWN
NCT03348098,has_phase,
NCT03348098,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT03348098,tests,Apatinib
Apatinib,has_type,DRUG
NCT03348098,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03961698,has_title,"Ph 2, Multi-arm, Multicenter, Open-label Study to Evaluate Efficacy and Safety of IPI-549 Administer"
NCT03961698,has_status,ACTIVE_NOT_RECRUITING
NCT03961698,has_phase,
NCT03961698,sponsored_by,"Infinity Pharmaceuticals, Inc."
NCT03961698,tests,IPI-549 (eganelisib)
IPI-549 (eganelisib),has_type,DRUG
NCT03961698,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03961698,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03961698,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT03881605,has_title,Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with 
NCT03881605,has_status,ACTIVE_NOT_RECRUITING
NCT03881605,has_phase,
NCT03881605,sponsored_by,Sunnybrook Health Sciences Centre
NCT03881605,tests,MRI screening
MRI screening,has_type,DIAGNOSTIC_TEST
NCT05681728,has_title,A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherap
NCT05681728,has_status,UNKNOWN
NCT05681728,has_phase,
NCT05681728,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT05681728,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05681728,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05681728,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05681728,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04148911,has_title,"An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab"
NCT04148911,has_status,COMPLETED
NCT04148911,has_phase,
NCT04148911,sponsored_by,Hoffmann-La Roche
NCT04148911,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04148911,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT05692661,has_title,A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative B
NCT05692661,has_status,RECRUITING
NCT05692661,has_phase,
NCT05692661,sponsored_by,Shanghai Proton and Heavy Ion Center
NCT05692661,tests,proton plus carbon ion radiotherapy
proton plus carbon ion radiotherapy,has_type,RADIATION
NCT07045311,has_title,JS207 Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07045311,has_status,NOT_YET_RECRUITING
NCT07045311,has_phase,
NCT07045311,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT07045311,tests,JS207 in combination with 9MW2821
JS207 in combination with 9MW2821,has_type,DRUG
NCT07045311,tests,JS207 in combination with Albumin paclitaxel
JS207 in combination with Albumin paclitaxel,has_type,DRUG
NCT00897728,has_title,Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.
NCT00897728,has_status,UNKNOWN
NCT00897728,has_phase,
NCT00897728,sponsored_by,Institut Curie
NCT00897728,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT04610528,has_title,"A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breas"
NCT04610528,has_status,UNKNOWN
NCT04610528,has_phase,
NCT04610528,sponsored_by,SOLTI Breast Cancer Research Group
NCT04610528,tests,U3 1402
U3 1402,has_type,DRUG
NCT04610528,tests,U3 1402
U3 1402,has_type,DRUG
NCT02341911,has_title,"A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Ge"
NCT02341911,has_status,UNKNOWN
NCT02341911,has_phase,
NCT02341911,sponsored_by,Fudan University
NCT02341911,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
NCT02341911,tests,"Gemcitabine,carboplatin"
"Gemcitabine,carboplatin",has_type,DRUG
NCT01216111,has_title,A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF
NCT01216111,has_status,COMPLETED
NCT01216111,has_phase,
NCT01216111,sponsored_by,Fudan University
NCT01216111,tests,Paclitaxel Cisplatin
Paclitaxel Cisplatin,has_type,DRUG
NCT01216111,tests,fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T),has_type,DRUG
NCT03775928,has_title,Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for P
NCT03775928,has_status,UNKNOWN
NCT03775928,has_phase,
NCT03775928,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT03775928,tests,Apatinib
Apatinib,has_type,DRUG
NCT03775928,tests,capecitabine
capecitabine,has_type,DRUG
NCT00246571,has_title,"A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated,"
NCT00246571,has_status,COMPLETED
NCT00246571,has_phase,
NCT00246571,sponsored_by,Pfizer
NCT00246571,tests,SU011248
SU011248,has_type,DRUG
NCT00246571,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT03123211,has_title,Expanded Access to Veliparib
NCT03123211,has_status,NO_LONGER_AVAILABLE
NCT03123211,has_phase,
NCT03123211,sponsored_by,AbbVie
NCT03123211,tests,Veliparib
Veliparib,has_type,DRUG
NCT03812393,has_title,Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early
NCT03812393,has_status,ACTIVE_NOT_RECRUITING
NCT03812393,has_phase,
NCT03812393,sponsored_by,West Cancer Center
NCT03812393,tests,Neratinib
Neratinib,has_type,DRUG
NCT04486911,has_title,"Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Treatment of Stage II-III Tripl"
NCT04486911,has_status,ACTIVE_NOT_RECRUITING
NCT04486911,has_phase,
NCT04486911,sponsored_by,Shengjing Hospital
NCT04486911,tests,"Pyrotinib maleate, SHR6390, letrozole"
"Pyrotinib maleate, SHR6390, letrozole",has_type,DRUG
NCT02482311,has_title,"A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and"
NCT02482311,has_status,COMPLETED
NCT02482311,has_phase,
NCT02482311,sponsored_by,AstraZeneca
NCT02482311,tests,AZD 1775
AZD 1775,has_type,DRUG
NCT03164993,has_title,ALICE: a Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined with Immunoge
NCT03164993,has_status,COMPLETED
NCT03164993,has_phase,
NCT03164993,sponsored_by,Oslo University Hospital
NCT03164993,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03164993,tests,Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin,has_type,DRUG
NCT03164993,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03164993,tests,Placebo
Placebo,has_type,OTHER
NCT05071911,has_title,Feasability Study of a New Technique of Axillary Evaluation in Patients With Node Positive Breast Ca
NCT05071911,has_status,RECRUITING
NCT05071911,has_phase,
NCT05071911,sponsored_by,Universitair Ziekenhuis Brussel
NCT05071911,tests,TAD (Targeted Axillary Dissection)
TAD (Targeted Axillary Dissection),has_type,PROCEDURE
NCT04268693,has_title,Bisphenol and Phthalate Exposures in Women With Triple Negative Breast Cancer Receiving Doxorubicin 
NCT04268693,has_status,WITHDRAWN
NCT04268693,has_phase,
NCT04268693,sponsored_by,George Washington University
NCT04268693,tests,urine collection
urine collection,has_type,OTHER
NCT06781983,has_title,"A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a "
NCT06781983,has_status,RECRUITING
NCT06781983,has_phase,
NCT06781983,sponsored_by,Innate Pharma
NCT06781983,tests,IPH4502
IPH4502,has_type,DRUG
NCT03018405,has_title,"A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activi"
NCT03018405,has_status,UNKNOWN
NCT03018405,has_phase,
NCT03018405,sponsored_by,Celyad Oncology SA
NCT03018405,tests,NKR-2 cells
NKR-2 cells,has_type,BIOLOGICAL
NCT05660083,has_title,Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Me
NCT05660083,has_status,RECRUITING
NCT05660083,has_phase,
NCT05660083,sponsored_by,The Methodist Hospital Research Institute
NCT05660083,tests,L-NMMA
L-NMMA,has_type,DRUG
NCT06963905,has_title,Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Goviteca
NCT06963905,has_status,NOT_YET_RECRUITING
NCT06963905,has_phase,
NCT06963905,sponsored_by,Yale University
NCT06963905,tests,Relatlimab FDC + Nivolumab
Relatlimab FDC + Nivolumab,has_type,DRUG
NCT06963905,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
NCT06963905,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04790305,has_title,Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negati
NCT04790305,has_status,RECRUITING
NCT04790305,has_phase,
NCT04790305,sponsored_by,Fudan University
NCT04790305,tests,Huaier Granule
Huaier Granule,has_type,DRUG
NCT06451497,has_title,"Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combinati"
NCT06451497,has_status,RECRUITING
NCT06451497,has_phase,
NCT06451497,sponsored_by,Zumutor Biologics Inc.
NCT06451497,tests,ZM008
ZM008,has_type,BIOLOGICAL
NCT03586297,has_title,Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in
NCT03586297,has_status,ACTIVE_NOT_RECRUITING
NCT03586297,has_phase,
NCT03586297,sponsored_by,Hackensack Meridian Health
NCT03330847,has_title,"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents T"
NCT03330847,has_status,ACTIVE_NOT_RECRUITING
NCT03330847,has_phase,
NCT03330847,sponsored_by,AstraZeneca
NCT03330847,tests,Olaparib Continuous (28-Day cycle) 300 mg BD.
Olaparib Continuous (28-Day cycle) 300 mg BD.,has_type,DRUG
NCT03330847,tests,Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).,has_type,DRUG
NCT03330847,tests,Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).,has_type,DRUG
NCT02511847,has_title,"An Open Label, Phase II Trial of Afatinib With Paclitaxel for the Neoadjuvant Treatment of Triple-Ne"
NCT02511847,has_status,UNKNOWN
NCT02511847,has_phase,
NCT02511847,sponsored_by,National Taiwan University Hospital
NCT02511847,tests,Afatinib
Afatinib,has_type,DRUG
NCT04639245,has_title,ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affini
NCT04639245,has_status,TERMINATED
NCT04639245,has_phase,
NCT04639245,sponsored_by,Fred Hutchinson Cancer Center
NCT04639245,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04639245,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04639245,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT04639245,tests,MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells,has_type,BIOLOGICAL
NCT04639245,tests,PD1 Inhibitor
PD1 Inhibitor,has_type,BIOLOGICAL
NCT04348747,has_title,A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With As
NCT04348747,has_status,RECRUITING
NCT04348747,has_phase,
NCT04348747,sponsored_by,Roswell Park Cancer Institute
NCT04348747,tests,Anti-HER2/HER3 Dendritic Cell Vaccine
Anti-HER2/HER3 Dendritic Cell Vaccine,has_type,BIOLOGICAL
NCT04348747,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03654547,has_title,"A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult P"
NCT03654547,has_status,ACTIVE_NOT_RECRUITING
NCT03654547,has_phase,
NCT03654547,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT03654547,tests,TT-00420
TT-00420,has_type,DRUG
NCT04145947,has_title,Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients Via Analysis of Immun
NCT04145947,has_status,UNKNOWN
NCT04145947,has_phase,
NCT04145947,sponsored_by,Peking Union Medical College Hospital
NCT06586047,has_title,Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT
NCT06586047,has_status,RECRUITING
NCT06586047,has_phase,
NCT06586047,sponsored_by,Ahmad Shariftabrizi
NCT06586047,tests,PET imaging
PET imaging,has_type,DIAGNOSTIC_TEST
NCT05001347,has_title,A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With 
NCT05001347,has_status,COMPLETED
NCT05001347,has_phase,
NCT05001347,sponsored_by,I-Mab Biopharma US Limited
NCT05001347,tests,TJ004309
TJ004309,has_type,DRUG
NCT02983045,has_title,"A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combi"
NCT02983045,has_status,COMPLETED
NCT02983045,has_phase,
NCT02983045,sponsored_by,Nektar Therapeutics
NCT02983045,tests,Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,has_type,DRUG
NCT02983045,tests,Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,has_type,DRUG
NCT02983045,tests,Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,has_type,DRUG
NCT02983045,tests,Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,has_type,DRUG
NCT05078047,has_title,"Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced D"
NCT05078047,has_status,RECRUITING
NCT05078047,has_phase,
NCT05078047,sponsored_by,UNICANCER
NCT05078047,tests,Reduced dose intensity of IO
Reduced dose intensity of IO,has_type,DRUG
NCT05192798,has_title,"A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound"
NCT05192798,has_status,RECRUITING
NCT05192798,has_phase,
NCT05192798,sponsored_by,The First Affiliated Hospital of Bengbu Medical University
NCT05192798,tests,Albumin-Bound Paclitaxel
Albumin-Bound Paclitaxel,has_type,DRUG
NCT05192798,tests,Apatinib Mesylate
Apatinib Mesylate,has_type,DRUG
NCT05192798,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00448305,has_title,"An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1"
NCT00448305,has_status,COMPLETED
NCT00448305,has_phase,
NCT00448305,sponsored_by,MediGene
NCT00448305,tests,EndoTAG-1 + paclitaxel
EndoTAG-1 + paclitaxel,has_type,DRUG
NCT00448305,tests,EndoTAG-1
EndoTAG-1,has_type,DRUG
NCT00448305,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06492005,has_title,A Phase II Clinical Study of Efficacy and Safety of 9MW2821Monotherapy or Combined With PD-1 Inhibit
NCT06492005,has_status,RECRUITING
NCT06492005,has_phase,
NCT06492005,sponsored_by,"Mabwell (Shanghai) Bioscience Co., Ltd."
NCT06492005,tests,9MW2821
9MW2821,has_type,DRUG
NCT06492005,tests,PD-1 inhibitior
PD-1 inhibitior,has_type,DRUG
NCT06632405,has_title,Camrelizumab Plus Nab-paclitaxel and Anti-histamine Drug Levocetirizine in Metastatic or Recurrent T
NCT06632405,has_status,NOT_YET_RECRUITING
NCT06632405,has_phase,
NCT06632405,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06632405,tests,Camrelizumab
Camrelizumab,has_type,DRUG
NCT06632405,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT06632405,tests,Levocetirizine Hydrochloride
Levocetirizine Hydrochloride,has_type,DRUG
NCT03872505,has_title,A Randomized Phase II Study Evaluating Pathologic Response Rates Following Pre-operAtive Non-Anthrac
NCT03872505,has_status,WITHDRAWN
NCT03872505,has_phase,
NCT03872505,sponsored_by,Cedars-Sinai Medical Center
NCT03872505,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03872505,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT03872505,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03872505,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03623945,has_title,Autoantibodies in Breast Cancer Detection
NCT03623945,has_status,TERMINATED
NCT03623945,has_phase,
NCT03623945,sponsored_by,Sanford Health
NCT03623945,tests,Collection of blood
Collection of blood,has_type,OTHER
NCT03330405,has_title,A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE PO
NCT03330405,has_status,TERMINATED
NCT03330405,has_phase,
NCT03330405,sponsored_by,Pfizer
NCT03330405,tests,Avelumab Phase 1b
Avelumab Phase 1b,has_type,DRUG
NCT03330405,tests,Talazoparib Phase 1b
Talazoparib Phase 1b,has_type,DRUG
NCT03330405,tests,Avelumab Phase 2
Avelumab Phase 2,has_type,DRUG
NCT03330405,tests,Talazoparib Phase 2
Talazoparib Phase 2,has_type,DRUG
NCT05498597,has_title,"First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in "
NCT05498597,has_status,RECRUITING
NCT05498597,has_phase,
NCT05498597,sponsored_by,Multitude Therapeutics Inc.
NCT05498597,tests,AMT-151
AMT-151,has_type,DRUG
NCT04676997,has_title,A Phase Ⅱ Study to Evaluate Efficacy and Safety of Camrelizumab Plus Chemotherapy as Neoadjuvant The
NCT04676997,has_status,UNKNOWN
NCT04676997,has_phase,
NCT04676997,sponsored_by,Shandong Cancer Hospital and Institute
NCT04676997,tests,Camrelizumab
Camrelizumab,has_type,BIOLOGICAL
NCT04676997,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT04676997,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04676997,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05746897,has_title,"A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Anti"
NCT05746897,has_status,RECRUITING
NCT05746897,has_phase,
NCT05746897,sponsored_by,"Hefei TG ImmunoPharma Co., Ltd."
NCT05746897,tests,NM1F Injection
NM1F Injection,has_type,DRUG
NCT05746897,tests,Pembrolizumab injection
Pembrolizumab injection,has_type,DRUG
NCT06176261,has_title,DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT06176261,has_status,RECRUITING
NCT06176261,has_phase,
NCT06176261,sponsored_by,"Sarah Sammons, MD"
NCT06176261,tests,Datopotamab Deruxtecan
Datopotamab Deruxtecan,has_type,DRUG
NCT03004183,has_title,Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Vi
NCT03004183,has_status,COMPLETED
NCT03004183,has_phase,
NCT03004183,sponsored_by,The Methodist Hospital Research Institute
NCT03004183,tests,ADV/HSV-tk
ADV/HSV-tk,has_type,BIOLOGICAL
NCT03004183,tests,Valacyclovir
Valacyclovir,has_type,DRUG
NCT03004183,tests,SBRT
SBRT,has_type,RADIATION
NCT03004183,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06610097,has_title,"Impacts of Diet, Activity, and Mood on a Dynamic Gut Microbiota During Treatment for Triple-negative"
NCT06610097,has_status,RECRUITING
NCT06610097,has_phase,
NCT06610097,sponsored_by,Scripps Health
NCT06610097,tests,Nutritional Counseling
Nutritional Counseling,has_type,OTHER
NCT06710197,has_title,IL-1 Inhibition for Patients With Early Stage Triple Negative and ER-low Breast Cancer: a Window-of-
NCT06710197,has_status,RECRUITING
NCT06710197,has_phase,
NCT06710197,sponsored_by,"University Health Network, Toronto"
NCT06710197,tests,Anakinra (Kineret®)
Anakinra (Kineret®),has_type,DRUG
NCT03601897,has_title,"An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel"
NCT03601897,has_status,TERMINATED
NCT03601897,has_phase,
NCT03601897,sponsored_by,"Deciphera Pharmaceuticals, LLC"
NCT03601897,tests,Rebastinib
Rebastinib,has_type,DRUG
NCT03601897,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04574583,has_title,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activ"
NCT04574583,has_status,COMPLETED
NCT04574583,has_phase,
NCT04574583,sponsored_by,National Cancer Institute (NCI)
NCT04574583,tests,SX-682
SX-682,has_type,DRUG
NCT04574583,tests,M7824
M7824,has_type,DRUG
NCT04574583,tests,MVA-BN-CV301
MVA-BN-CV301,has_type,BIOLOGICAL
NCT04574583,tests,recombinant fowlpox viral (FPV)-CV301
recombinant fowlpox viral (FPV)-CV301,has_type,BIOLOGICAL
NCT01009983,has_title,A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Me
NCT01009983,has_status,TERMINATED
NCT01009983,has_phase,
NCT01009983,sponsored_by,Wake Forest University Health Sciences
NCT01009983,tests,panitumumab
panitumumab,has_type,BIOLOGICAL
NCT01009983,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01009983,tests,carboplatin
carboplatin,has_type,DRUG
NCT01009983,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,PROCEDURE
NCT01009983,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,PROCEDURE
NCT04835597,has_title,Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT04835597,has_status,TERMINATED
NCT04835597,has_phase,
NCT04835597,sponsored_by,M.D. Anderson Cancer Center
NCT04835597,tests,Behavioral Assessment
Behavioral Assessment,has_type,BEHAVIORAL
NCT04835597,tests,Electronic Health Record Review
Electronic Health Record Review,has_type,OTHER
NCT06318897,has_title,"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination Wit"
NCT06318897,has_status,RECRUITING
NCT06318897,has_phase,
NCT06318897,sponsored_by,M.D. Anderson Cancer Center
NCT06318897,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06318897,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06318897,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT06318897,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT06318897,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05058183,has_title,Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
NCT05058183,has_status,RECRUITING
NCT05058183,has_phase,
NCT05058183,sponsored_by,Royal Marsden NHS Foundation Trust
NCT05058183,tests,ctDNA
ctDNA,has_type,DIAGNOSTIC_TEST
NCT04158583,has_title,"An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pha"
NCT04158583,has_status,TERMINATED
NCT04158583,has_phase,
NCT04158583,sponsored_by,Hoffmann-La Roche
NCT04158583,tests,RO7296682
RO7296682,has_type,DRUG
NCT00679783,has_title,"Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA o"
NCT00679783,has_status,COMPLETED
NCT00679783,has_phase,
NCT00679783,sponsored_by,AstraZeneca
NCT00679783,tests,AZD2281
AZD2281,has_type,DRUG
NCT03101683,has_title,Partial Chest Wall Radiation Therapy After Total/Skin Sparing Mastectomy and Immediate Implant-based
NCT03101683,has_status,UNKNOWN
NCT03101683,has_phase,
NCT03101683,sponsored_by,Fondazione del Piemonte per l'Oncologia
NCT03101683,tests,Partial chest wall radiation therapy
Partial chest wall radiation therapy,has_type,RADIATION
NCT06782698,has_title,Home-Based Physical Exercise During Neoadjuvant Treatment for Improving Fatigue and Quality of Life 
NCT06782698,has_status,ACTIVE_NOT_RECRUITING
NCT06782698,has_phase,
NCT06782698,sponsored_by,Centro Hospitalar Universitário de Santo António
NCT06782698,tests,Home-based exercise program
Home-based exercise program,has_type,BEHAVIORAL
NCT06782698,tests,Promotion of Healthy Physical Activity
Promotion of Healthy Physical Activity,has_type,BEHAVIORAL
NCT02422498,has_title,A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Rec
NCT02422498,has_status,COMPLETED
NCT02422498,has_phase,
NCT02422498,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02422498,tests,external beam radiation therapy
external beam radiation therapy,has_type,RADIATION
NCT02422498,tests,cisplatin
cisplatin,has_type,DRUG
NCT02422498,tests,Biopsy of Target Tumor
Biopsy of Target Tumor,has_type,PROCEDURE
NCT04248998,has_title,Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemotherapy and a Diet Mim
NCT04248998,has_status,UNKNOWN
NCT04248998,has_phase,
NCT04248998,sponsored_by,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
NCT04248998,tests,Fasting-mimicking diet
Fasting-mimicking diet,has_type,DIETARY_SUPPLEMENT
NCT04248998,tests,Metformin
Metformin,has_type,DRUG
NCT04248998,tests,Preoperative chemotherapy
Preoperative chemotherapy,has_type,DRUG
NCT06401005,has_title,"A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuva"
NCT06401005,has_status,RECRUITING
NCT06401005,has_phase,
NCT06401005,sponsored_by,Hubei Cancer Hospital
NCT06401005,tests,Cadonilimab (AK104)
Cadonilimab (AK104),has_type,DRUG
NCT02183805,has_title,Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therap
NCT02183805,has_status,TERMINATED
NCT02183805,has_phase,
NCT02183805,sponsored_by,Sun Yat-sen University
NCT02183805,tests,"Abraxane,Cyclophosphamide,Carboplatin"
"Abraxane,Cyclophosphamide,Carboplatin",has_type,DRUG
NCT01195298,has_title,Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in E
NCT01195298,has_status,UNKNOWN
NCT01195298,has_phase,
NCT01195298,sponsored_by,South Eastern European Research Oncology Group
NCT01195298,tests,Capecitabine and Bevacizumab
Capecitabine and Bevacizumab,has_type,DRUG
NCT02129205,has_title,A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WI
NCT02129205,has_status,TERMINATED
NCT02129205,has_phase,
NCT02129205,sponsored_by,Pfizer
NCT02129205,tests,PF-06650808
PF-06650808,has_type,DRUG
NCT02129205,tests,PF-06650808
PF-06650808,has_type,DRUG
NCT03424005,has_title,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety"
NCT03424005,has_status,RECRUITING
NCT03424005,has_phase,
NCT03424005,sponsored_by,Hoffmann-La Roche
NCT03424005,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03424005,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03424005,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03424005,tests,SGN-LIV1A
SGN-LIV1A,has_type,DRUG
NCT03424005,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT03424005,tests,Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
Chemotherapy (Gemcitabine + Carboplatin or Eribulin),has_type,DRUG
NCT03424005,tests,Selicrelumab
Selicrelumab,has_type,DRUG
NCT03424005,tests,Tocilizumab
Tocilizumab,has_type,DRUG
NCT03424005,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03424005,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
NCT03424005,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT03424005,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT03424005,tests,Ribociclib (dose #1)
Ribociclib (dose #1),has_type,DRUG
NCT03424005,tests,Inavolisib (dose #2)
Inavolisib (dose #2),has_type,DRUG
NCT03424005,tests,Trastuzumab Deruxtecan
Trastuzumab Deruxtecan,has_type,DRUG
NCT03424005,tests,Ribociclib (dose #2)
Ribociclib (dose #2),has_type,DRUG
NCT03424005,tests,Letrozole
Letrozole,has_type,DRUG
NCT03424005,tests,Inavolisib (dose #1)
Inavolisib (dose #1),has_type,DRUG
NCT03424005,tests,Inavolisib
Inavolisib,has_type,DRUG
NCT04213898,has_title,SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breas
NCT04213898,has_status,UNKNOWN
NCT04213898,has_phase,
NCT04213898,sponsored_by,Henan Cancer Hospital
NCT04213898,tests,SHR-1210+Albumin-bound paclitaxel + epirubicin
SHR-1210+Albumin-bound paclitaxel + epirubicin,has_type,DRUG
NCT04405505,has_title,"A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combine"
NCT04405505,has_status,UNKNOWN
NCT04405505,has_phase,
NCT04405505,sponsored_by,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
NCT04405505,tests,TQB2450
TQB2450,has_type,DRUG
NCT04405505,tests,Anlotinib
Anlotinib,has_type,DRUG
NCT04405505,tests,Paclitaxel for Injection (albumin bound)
Paclitaxel for Injection (albumin bound),has_type,DRUG
NCT06616987,has_title,"A Multicenter, Open-label, Single-arm, Phase II Clinical Trial to Evaluate the Preventive Effect of "
NCT06616987,has_status,NOT_YET_RECRUITING
NCT06616987,has_phase,
NCT06616987,sponsored_by,Yeon Hee Park
NCT06616987,tests,Sacituzumab Govitecan with pegfilgrastim
Sacituzumab Govitecan with pegfilgrastim,has_type,DRUG
NCT03165487,has_title,Differential Comparison of the Breast Tumor Microenvironment Between Luminal A and Triple Negative B
NCT03165487,has_status,RECRUITING
NCT03165487,has_phase,
NCT03165487,sponsored_by,Columbia University
NCT03165487,tests,Breast tissue collection
Breast tissue collection,has_type,OTHER
NCT03165487,tests,Blood sample collection
Blood sample collection,has_type,OTHER
NCT02670577,has_title,Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: 
NCT02670577,has_status,COMPLETED
NCT02670577,has_phase,
NCT02670577,sponsored_by,Agendia
NCT05714553,has_title,"A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the "
NCT05714553,has_status,RECRUITING
NCT05714553,has_phase,
NCT05714553,sponsored_by,NuCana plc
NCT05714553,tests,Fosifloxuridine Nafalbenamide
Fosifloxuridine Nafalbenamide,has_type,DRUG
NCT05714553,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT05714553,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05714553,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01155453,has_title,"A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral "
NCT01155453,has_status,COMPLETED
NCT01155453,has_phase,
NCT01155453,sponsored_by,Novartis Pharmaceuticals
NCT01155453,tests,BKM120
BKM120,has_type,DRUG
NCT01155453,tests,GSK1120212
GSK1120212,has_type,DRUG
NCT02580747,has_title,Clinical Study of Chimeric Mesothelin Antigen Receptor-modified T Cells in Relapsed and/or Chemother
NCT02580747,has_status,UNKNOWN
NCT02580747,has_phase,
NCT02580747,sponsored_by,Chinese PLA General Hospital
NCT02580747,tests,anti-meso-CAR vector transduced T cells
anti-meso-CAR vector transduced T cells,has_type,BIOLOGICAL
NCT03106077,has_title,Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients 
NCT03106077,has_status,COMPLETED
NCT03106077,has_phase,
NCT03106077,sponsored_by,M.D. Anderson Cancer Center
NCT03106077,tests,Mirvetuximab Soravtansine
Mirvetuximab Soravtansine,has_type,BIOLOGICAL
NCT06833853,has_title,CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA/RNA Assessment in Metast
NCT06833853,has_status,NOT_YET_RECRUITING
NCT06833853,has_phase,
NCT06833853,sponsored_by,"Menarini Silicon Biosystems, INC"
NCT03151447,has_title,A Phase I Trial of Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients 
NCT03151447,has_status,UNKNOWN
NCT03151447,has_phase,
NCT03151447,sponsored_by,Fudan University
NCT03151447,tests,stereotactic body radiation therapy
stereotactic body radiation therapy,has_type,RADIATION
NCT01770353,has_title,"A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tum"
NCT01770353,has_status,COMPLETED
NCT01770353,has_phase,
NCT01770353,sponsored_by,Ipsen
NCT01770353,tests,Ferumoxytol
Ferumoxytol,has_type,DRUG
NCT01770353,tests,MM-398
MM-398,has_type,DRUG
NCT04133077,has_title,A Prospective Study of Xenografts Development from Samples Taken from Surgical Specimens of Patients
NCT04133077,has_status,RECRUITING
NCT04133077,has_phase,
NCT04133077,sponsored_by,Centre Jean Perrin
NCT04133077,tests,blood samples collection
blood samples collection,has_type,BIOLOGICAL
NCT03876951,has_title,Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assist
NCT03876951,has_status,ACTIVE_NOT_RECRUITING
NCT03876951,has_phase,
NCT03876951,sponsored_by,Centre Georges Francois Leclerc
NCT03876951,tests,Vacuum-assisted biopsy
Vacuum-assisted biopsy,has_type,DIAGNOSTIC_TEST
NCT04638751,has_title,"ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling th"
NCT04638751,has_status,RECRUITING
NCT04638751,has_phase,
NCT04638751,sponsored_by,Persephone Biosciences
NCT04638751,tests,Immunotherapy
Immunotherapy,has_type,DRUG
NCT04638751,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT04638751,tests,CRC surgical resection
CRC surgical resection,has_type,PROCEDURE
NCT04638751,tests,Colonoscopy
Colonoscopy,has_type,PROCEDURE
NCT06709651,has_title,Prospective Evaluation of the Breast Microbiome and Tumor Microenvironment-related Biomarkers of Res
NCT06709651,has_status,RECRUITING
NCT06709651,has_phase,
NCT06709651,sponsored_by,University College Cork
NCT05071677,has_title,Determinants of Treatment Decision Making in African American Women Diagnosed With Triple Negative B
NCT05071677,has_status,COMPLETED
NCT05071677,has_phase,
NCT05071677,sponsored_by,M.D. Anderson Cancer Center
NCT05071677,tests,Discussion
Discussion,has_type,PROCEDURE
NCT05071677,tests,Interview
Interview,has_type,OTHER
NCT05071677,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT06731153,has_title,"A Randomized, Controlled, Open-label, Phase II Clinical Study Evaluating the JAK1 Inhibitor Ivarmaci"
NCT06731153,has_status,NOT_YET_RECRUITING
NCT06731153,has_phase,
NCT06731153,sponsored_by,Fudan University
NCT06731153,tests,Ivarmacitinib
Ivarmacitinib,has_type,DRUG
NCT06731153,tests,Camrelizumab (SHR-1210)
Camrelizumab (SHR-1210),has_type,DRUG
NCT06731153,tests,Eribulin
Eribulin,has_type,DRUG
NCT02744053,has_title,Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Tri
NCT02744053,has_status,ACTIVE_NOT_RECRUITING
NCT02744053,has_phase,
NCT02744053,sponsored_by,M.D. Anderson Cancer Center
NCT02744053,tests,Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,has_type,PROCEDURE
NCT02744053,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02744053,tests,Scintimammography
Scintimammography,has_type,RADIATION
NCT02744053,tests,Technetium Tc-99m Sestamibi
Technetium Tc-99m Sestamibi,has_type,DRUG
NCT00130533,has_title,"Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Cap"
NCT00130533,has_status,COMPLETED
NCT00130533,has_phase,
NCT00130533,sponsored_by,Spanish Breast Cancer Research Group
NCT00130533,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03821454,has_title,"A Randomized, Double-blind, Placebo-controlled Study of Capecitabine in the Treatment of Early-stage"
NCT03821454,has_status,UNKNOWN
NCT03821454,has_phase,
NCT03821454,sponsored_by,Zhejiang Cancer Hospital
NCT03821454,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03821454,tests,Placebos
Placebos,has_type,DRUG
NCT03911453,has_title,Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors 
NCT03911453,has_status,COMPLETED
NCT03911453,has_phase,
NCT03911453,sponsored_by,University of Arizona
NCT03911453,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT01939054,has_title,"A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and C"
NCT01939054,has_status,UNKNOWN
NCT01939054,has_phase,
NCT01939054,sponsored_by,Chinese Academy of Medical Sciences
NCT01939054,tests,Nimotuzumab
Nimotuzumab,has_type,DRUG
NCT01939054,tests,docetaxel
docetaxel,has_type,DRUG
NCT01939054,tests,capecitabine
capecitabine,has_type,DRUG
NCT04418154,has_title,Neoadjuvant Anthracycline Followed by Toripalimab Combined With Nab-paclitaxel in Patients With Earl
NCT04418154,has_status,ACTIVE_NOT_RECRUITING
NCT04418154,has_phase,
NCT04418154,sponsored_by,Fudan University
NCT04418154,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
NCT04418154,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04418154,tests,Albumin bound paclitaxel
Albumin bound paclitaxel,has_type,DRUG
NCT04418154,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT02368951,has_title,"An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated"
NCT02368951,has_status,TERMINATED
NCT02368951,has_phase,
NCT02368951,sponsored_by,Bayer
NCT02368951,tests,BAY1187982
BAY1187982,has_type,DRUG
NCT06396754,has_title,Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatme
NCT06396754,has_status,NOT_YET_RECRUITING
NCT06396754,has_phase,
NCT06396754,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT06396754,tests,AI-analysis on diagnostic and surgical specimens
AI-analysis on diagnostic and surgical specimens,has_type,OTHER
NCT06162351,has_title,"A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advance"
NCT06162351,has_status,RECRUITING
NCT06162351,has_phase,
NCT06162351,sponsored_by,Institut Curie
NCT06162351,tests,PLX038
PLX038,has_type,DRUG
NCT00717951,has_title,"A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretrea"
NCT00717951,has_status,UNKNOWN
NCT00717951,has_phase,
NCT00717951,sponsored_by,"Academy Military Medical Science, China"
NCT00717951,tests,"docetaxol, cisplatin, capecitabine"
"docetaxol, cisplatin, capecitabine",has_type,DRUG
NCT04975451,has_title,Neoadjuvant Treatment Anlotinib Combined With Docetaxel and Carboplatin in Triple-negative Early-sta
NCT04975451,has_status,UNKNOWN
NCT04975451,has_phase,
NCT04975451,sponsored_by,Anqin Zhang
NCT04975451,tests,Anlotinib
Anlotinib,has_type,DRUG
NCT01596751,has_title,Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macropha
NCT01596751,has_status,COMPLETED
NCT01596751,has_phase,
NCT01596751,sponsored_by,"Hope Rugo, MD"
NCT01596751,tests,PLX3397
PLX3397,has_type,DRUG
NCT01596751,tests,Eribulin
Eribulin,has_type,DRUG
NCT05867251,has_title,"A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodyna"
NCT05867251,has_status,RECRUITING
NCT05867251,has_phase,
NCT05867251,sponsored_by,"Avenzo Therapeutics, Inc."
NCT05867251,tests,AVZO-021
AVZO-021,has_type,DRUG
NCT05867251,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT05867251,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT05867251,tests,Letrozole
Letrozole,has_type,DRUG
NCT05867251,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT05867251,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT05867251,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05867251,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT01876251,has_title,Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negativ
NCT01876251,has_status,TERMINATED
NCT01876251,has_phase,
NCT01876251,sponsored_by,Pfizer
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01876251,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01876251,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05253053,has_title,"A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the S"
NCT05253053,has_status,COMPLETED
NCT05253053,has_phase,
NCT05253053,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT05253053,tests,TT-00420
TT-00420,has_type,DRUG
NCT05253053,tests,Combination Product: Atezolizumab
Combination Product: Atezolizumab,has_type,DRUG
NCT05253053,tests,Combination Product: Nab-Paclitaxel
Combination Product: Nab-Paclitaxel,has_type,DRUG
NCT06435351,has_title,Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negati
NCT06435351,has_status,RECRUITING
NCT06435351,has_phase,
NCT06435351,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT06435351,tests,Leukapheresis
Leukapheresis,has_type,PROCEDURE
NCT06435351,tests,Dendritic Cell (DC) Vaccine
Dendritic Cell (DC) Vaccine,has_type,BIOLOGICAL
NCT05274451,has_title,"A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults W"
NCT05274451,has_status,TERMINATED
NCT05274451,has_phase,
NCT05274451,sponsored_by,"Lyell Immunopharma, Inc."
NCT05274451,tests,LYL797
LYL797,has_type,BIOLOGICAL
NCT02839954,has_title,Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Pos
NCT02839954,has_status,UNKNOWN
NCT02839954,has_phase,
NCT02839954,sponsored_by,"PersonGen BioTherapeutics (Suzhou) Co., Ltd."
NCT02839954,tests,anti-MUC1 CAR-pNK cells
anti-MUC1 CAR-pNK cells,has_type,BIOLOGICAL
NCT07011654,has_title,Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative 
NCT07011654,has_status,NOT_YET_RECRUITING
NCT07011654,has_phase,
NCT07011654,sponsored_by,M.D. Anderson Cancer Center
NCT07011654,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT07011654,tests,Naxitamab
Naxitamab,has_type,DRUG
NCT06841354,has_title,"A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sa"
NCT06841354,has_status,RECRUITING
NCT06841354,has_phase,
NCT06841354,sponsored_by,Merck Sharp & Dohme LLC
NCT06841354,tests,Sacituzumab tirumotecan
Sacituzumab tirumotecan,has_type,BIOLOGICAL
NCT06841354,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06841354,tests,Rescue Medication
Rescue Medication,has_type,DRUG
NCT06841354,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06841354,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06841354,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06841354,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02089854,has_title,"Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 "
NCT02089854,has_status,UNKNOWN
NCT02089854,has_phase,
NCT02089854,sponsored_by,Peking Union Medical College Hospital
NCT02089854,tests,Toremifene
Toremifene,has_type,DRUG
NCT03915951,has_title,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small "
NCT03915951,has_status,ACTIVE_NOT_RECRUITING
NCT03915951,has_phase,
NCT03915951,sponsored_by,Pfizer
NCT03915951,tests,encorafenib
encorafenib,has_type,DRUG
NCT03915951,tests,binimetinib
binimetinib,has_type,DRUG
NCT05633654,has_title,"A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus T"
NCT05633654,has_status,RECRUITING
NCT05633654,has_phase,
NCT05633654,sponsored_by,Gilead Sciences
NCT05633654,tests,Sacituzumab govitecan-hziy (SG)
Sacituzumab govitecan-hziy (SG),has_type,DRUG
NCT05633654,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05633654,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03096054,has_title,A Cancer Research UK (CR-UK) Phase I Trial of LY3143921 a Cdc7 Inhibitor in Adult Patients with Adva
NCT03096054,has_status,ACTIVE_NOT_RECRUITING
NCT03096054,has_phase,
NCT03096054,sponsored_by,Cancer Research UK
NCT03096054,tests,LY3143921 hydrate
LY3143921 hydrate,has_type,DRUG
NCT04909554,has_title,MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to N
NCT04909554,has_status,COMPLETED
NCT04909554,has_phase,
NCT04909554,sponsored_by,Guangdong Provincial People's Hospital
NCT06793553,has_title,Randomized Phase II Trial Evaluating the Efficacy of Paclitaxel+Bevacizumab INDUCtion Followed by at
NCT06793553,has_status,RECRUITING
NCT06793553,has_phase,
NCT06793553,sponsored_by,Japan Breast Cancer Research Group
NCT06793553,tests,Induction therapy
Induction therapy,has_type,DRUG
NCT06143553,has_title,"A Randomized, Controlled Phase Ⅲ Study of Paclitaxel Polymeric Micelles for Injection Versus Physici"
NCT06143553,has_status,RECRUITING
NCT06143553,has_phase,
NCT06143553,sponsored_by,"Shanghai Yizhong Pharmaceutical Co., Ltd."
NCT06143553,tests,Paclitaxel Polymeric Micelles for Injection
Paclitaxel Polymeric Micelles for Injection,has_type,DRUG
NCT06143553,tests,Eribulin Mesilate injection
Eribulin Mesilate injection,has_type,DRUG
NCT06143553,tests,Capecitabine Tablets
Capecitabine Tablets,has_type,DRUG
NCT06143553,tests,Gemcitabine Hydrochloride for Injection
Gemcitabine Hydrochloride for Injection,has_type,DRUG
NCT06143553,tests,Vinorelbine Tartrate Injection
Vinorelbine Tartrate Injection,has_type,DRUG
NCT06143553,tests,Paclitaxel (albumin-bound)
Paclitaxel (albumin-bound),has_type,DRUG
NCT03254654,has_title,"A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Secon"
NCT03254654,has_status,COMPLETED
NCT03254654,has_phase,
NCT03254654,sponsored_by,Fudan University
NCT03254654,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT03254654,tests,Apatinib
Apatinib,has_type,DRUG
NCT00951054,has_title,A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients W
NCT00951054,has_status,COMPLETED
NCT00951054,has_phase,
NCT00951054,sponsored_by,"Nippon Kayaku Co., Ltd."
NCT00951054,tests,NK012
NK012,has_type,DRUG
NCT05420454,has_title,"A Prospective, Open-label Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for"
NCT05420454,has_status,RECRUITING
NCT05420454,has_phase,
NCT05420454,sponsored_by,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
NCT05420454,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05420454,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05420454,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT05420454,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT05420454,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT05420454,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05420454,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05420454,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05420454,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT05420454,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05420454,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
NCT04101851,has_title,Omission of Sentinel Lymph Node Biopsy in Triple-negative and HER2-positive Breast Cancer Patients w
NCT04101851,has_status,ACTIVE_NOT_RECRUITING
NCT04101851,has_phase,
NCT04101851,sponsored_by,"Toralf Reimer, MD PhD"
NCT04101851,tests,omission of SLNB
omission of SLNB,has_type,PROCEDURE
NCT07015853,has_title,IIT2024-02-SHIAO-ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combinati
NCT07015853,has_status,NOT_YET_RECRUITING
NCT07015853,has_phase,
NCT07015853,sponsored_by,Stephen Shiao
NCT07015853,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT07015853,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT07015853,tests,Axatilimab
Axatilimab,has_type,DRUG
NCT03193853,has_title,Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (H
NCT03193853,has_status,COMPLETED
NCT03193853,has_phase,
NCT03193853,sponsored_by,Joyce O'Shaughnessy
NCT03193853,tests,Tak-228 & Tak-117
Tak-228 & Tak-117,has_type,DRUG
NCT03193853,tests,Cisplatin & Nab Paclitaxel
Cisplatin & Nab Paclitaxel,has_type,DRUG
NCT03454451,has_title,"A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AG"
NCT03454451,has_status,COMPLETED
NCT03454451,has_phase,
NCT03454451,sponsored_by,"Corvus Pharmaceuticals, Inc."
NCT03454451,tests,CPI-006
CPI-006,has_type,DRUG
NCT03454451,tests,CPI-006 + ciforadenant
CPI-006 + ciforadenant,has_type,DRUG
NCT03454451,tests,CPI-006 + pembrolizumab
CPI-006 + pembrolizumab,has_type,DRUG
NCT03454451,tests,CPI-006
CPI-006,has_type,DRUG
NCT03454451,tests,CPI-006 + ciforadenant
CPI-006 + ciforadenant,has_type,DRUG
NCT03454451,tests,CPI-006 + pembrolizumab
CPI-006 + pembrolizumab,has_type,DRUG
NCT03789851,has_title,Minimally Invasive Biopsy Technique Predicting Breast Pathological Complete Respons After Neoadjuvan
NCT03789851,has_status,UNKNOWN
NCT03789851,has_phase,
NCT03789851,sponsored_by,Shandong Cancer Hospital and Institute
NCT03789851,tests,core needle biopsy
core needle biopsy,has_type,DEVICE
NCT04142554,has_title,Window of Opportunity Study of Parsaclisib in Subjects With Newly Diagnosed Stage I-IIIC Triple-Nega
NCT04142554,has_status,WITHDRAWN
NCT04142554,has_phase,
NCT04142554,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT04142554,tests,Parsaclisib
Parsaclisib,has_type,DRUG
NCT06498154,has_title,Eliminating Breast Surgery for Triple Negative or HR-/HER2+ Breast Cancer Patients With Clinical Com
NCT06498154,has_status,NOT_YET_RECRUITING
NCT06498154,has_phase,
NCT06498154,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT06498154,tests,Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy,has_type,RADIATION
NCT05212454,has_title,Efficacy and Safety of Supplement Adjuvant Capecitabine in Postoperative Hormone Receptor (HR)-Posit
NCT05212454,has_status,RECRUITING
NCT05212454,has_phase,
NCT05212454,sponsored_by,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
NCT05212454,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03983954,has_title,"Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, AB"
NCT03983954,has_status,RECRUITING
NCT03983954,has_phase,
NCT03983954,sponsored_by,NeoTX Therapeutics Ltd.
NCT03983954,tests,"Obinutuzumab, naptumomab estafenatox and durvalumab"
"Obinutuzumab, naptumomab estafenatox and durvalumab",has_type,COMBINATION_PRODUCT
NCT03983954,tests,Naptumomab estafenatox and durvalumab
Naptumomab estafenatox and durvalumab,has_type,COMBINATION_PRODUCT
NCT01091454,has_title,Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Canc
NCT01091454,has_status,COMPLETED
NCT01091454,has_phase,
NCT01091454,sponsored_by,Alliance for Clinical Trials in Oncology
NCT01091454,tests,brostallicin
brostallicin,has_type,DRUG
NCT01091454,tests,cisplatin
cisplatin,has_type,DRUG
NCT05403554,has_title,"A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibo"
NCT05403554,has_status,RECRUITING
NCT05403554,has_phase,
NCT05403554,sponsored_by,Light Chain Bioscience - Novimmune SA
NCT05403554,tests,Biological NI-1801
Biological NI-1801,has_type,DRUG
NCT05403554,tests,NI-1801 in combination with anti-PD1 (Pembrolizumab)
NI-1801 in combination with anti-PD1 (Pembrolizumab),has_type,DRUG
NCT05403554,tests,NI-1801 in combination with paclitaxel
NI-1801 in combination with paclitaxel,has_type,DRUG
NCT05403554,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03719833,has_title,"Sentinel Lymph Node Biopsy After Neoadjuvant Oncological Treatment in Luminal B, HER-2 Positive and "
NCT03719833,has_status,ACTIVE_NOT_RECRUITING
NCT03719833,has_phase,
NCT03719833,sponsored_by,Clinical Hospital Center Rijeka
Pembrolizumab,targets_gene,PD-1
Nivolumab,targets_gene,PD-1
Atezolizumab,targets_gene,PD-L1
Olaparib,targets_gene,BRCA1
Olaparib,targets_gene,BRCA2
NCT06245889,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT01930292,has_trial_type,CHEMO
NCT02157792,has_trial_type,CHEMO
NCT06418594,has_trial_type,TARGETED
NCT02883062,has_trial_type,"IMMUNO, CHEMO"
NCT06636591,has_trial_type,CHEMO
NCT05522491,has_trial_type,TARGETED
NCT01186991,has_trial_type,"TARGETED, CHEMO"
NCT03872791,has_trial_type,CHEMO
NCT05636644,has_trial_type,CHEMO
NCT06976944,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT06229067,has_trial_type,IMMUNO
NCT06371989,has_trial_type,TARGETED
NCT01167192,has_trial_type,CHEMO
NCT04081389,has_trial_type,CHEMO
NCT02445391,has_trial_type,CHEMO
NCT02187991,has_trial_type,CHEMO
NCT03473691,has_trial_type,CHEMO
NCT05064280,has_trial_type,IMMUNO
NCT04561362,has_trial_type,IMMUNO
NCT05076760,has_trial_type,IMMUNO
NCT04434560,has_trial_type,IMMUNO
NCT05806060,has_trial_type,CHEMO
NCT06324240,has_trial_type,IMMUNO
NCT03435640,has_trial_type,IMMUNO
NCT04464967,has_trial_type,TARGETED
NCT06690840,has_trial_type,IMMUNO
NCT04907344,has_trial_type,CHEMO
NCT00528567,has_trial_type,TARGETED
NCT03168880,has_trial_type,CHEMO
NCT05629429,has_trial_type,TARGETED
NCT03109080,has_trial_type,TARGETED
NCT02620280,has_trial_type,CHEMO
NCT05209529,has_trial_type,TARGETED
NCT02041429,has_trial_type,CHEMO
NCT06081244,has_trial_type,IMMUNO
NCT03366844,has_trial_type,IMMUNO
NCT03256344,has_trial_type,IMMUNO
NCT05852691,has_trial_type,"CHEMO, IMMUNO"
NCT01928394,has_trial_type,IMMUNO
NCT00542191,has_trial_type,CHEMO
NCT05208762,has_trial_type,IMMUNO
NCT02425891,has_trial_type,"CHEMO, IMMUNO"
NCT05491694,has_trial_type,CHEMO
NCT02393794,has_trial_type,"CHEMO, IMMUNO"
NCT05181462,has_trial_type,CHEMO
NCT03289962,has_trial_type,IMMUNO
NCT03849469,has_trial_type,IMMUNO
NCT06448169,has_trial_type,IMMUNO
NCT06246968,has_trial_type,IMMUNO
NCT05318469,has_trial_type,IMMUNO
NCT05537740,has_trial_type,IMMUNO
NCT04434040,has_trial_type,IMMUNO
NCT05420467,has_trial_type,"TARGETED, CHEMO"
NCT03606967,has_trial_type,CHEMO
NCT01745367,has_trial_type,CHEMO
NCT06975644,has_trial_type,CHEMO
NCT06849492,has_trial_type,CHEMO
NCT05438329,has_trial_type,IMMUNO
NCT03292172,has_trial_type,IMMUNO
NCT04770272,has_trial_type,"CHEMO, IMMUNO"
NCT05194072,has_trial_type,IMMUNO
NCT04664972,has_trial_type,CHEMO
NCT06910072,has_trial_type,CHEMO
NCT04216472,has_trial_type,CHEMO
NCT02499367,has_trial_type,"CHEMO, IMMUNO"
NCT03945604,has_trial_type,IMMUNO
NCT04249167,has_trial_type,"CHEMO, IMMUNO"
NCT03644589,has_trial_type,"CHEMO, IMMUNO"
NCT02530489,has_trial_type,"IMMUNO, CHEMO"
NCT02125344,has_trial_type,"TARGETED, CHEMO"
NCT03197389,has_trial_type,IMMUNO
NCT04395989,has_trial_type,"IMMUNO, CHEMO"
NCT03367689,has_trial_type,TARGETED
NCT04095689,has_trial_type,IMMUNO
NCT02657889,has_trial_type,IMMUNO
NCT05544929,has_trial_type,IMMUNO
NCT06125080,has_trial_type,TARGETED
NCT05645380,has_trial_type,"IMMUNO, CHEMO"
NCT02488967,has_trial_type,CHEMO
NCT06926868,has_trial_type,CHEMO
NCT05953168,has_trial_type,TARGETED
NCT05893368,has_trial_type,TARGETED
NCT00912444,has_trial_type,CHEMO
NCT01910844,has_trial_type,CHEMO
NCT07040644,has_trial_type,CHEMO
NCT05081492,has_trial_type,IMMUNO
NCT04517292,has_trial_type,CHEMO
NCT01434420,has_trial_type,TARGETED
NCT04734262,has_trial_type,CHEMO
NCT01307891,has_trial_type,CHEMO
NCT02624973,has_trial_type,TARGETED
NCT07017673,has_trial_type,CHEMO
NCT04373031,has_trial_type,IMMUNO
NCT02260531,has_trial_type,TARGETED
NCT01750073,has_trial_type,"TARGETED, CHEMO"
NCT04725331,has_trial_type,IMMUNO
NCT02365831,has_trial_type,TARGETED
NCT02993094,has_trial_type,CHEMO
NCT06691594,has_trial_type,IMMUNO
NCT03564691,has_trial_type,"CHEMO, IMMUNO"
NCT05000294,has_trial_type,IMMUNO
NCT05422794,has_trial_type,"CHEMO, IMMUNO"
NCT03328494,has_trial_type,CHEMO
NCT05983094,has_trial_type,"TARGETED, CHEMO"
NCT04750382,has_trial_type,"CHEMO, IMMUNO"
NCT05492682,has_trial_type,IMMUNO
NCT03621982,has_trial_type,IMMUNO
NCT05076682,has_trial_type,IMMUNO
NCT03970382,has_trial_type,IMMUNO
NCT02227082,has_trial_type,TARGETED
NCT02929576,has_trial_type,CHEMO
NCT03241173,has_trial_type,IMMUNO
NCT04556773,has_trial_type,"TARGETED, CHEMO"
NCT03170960,has_trial_type,IMMUNO
NCT05020860,has_trial_type,"IMMUNO, TARGETED, CHEMO"
NCT03356860,has_trial_type,CHEMO
NCT03362060,has_trial_type,IMMUNO
NCT02681562,has_trial_type,TARGETED
NCT02708680,has_trial_type,IMMUNO
NCT06880029,has_trial_type,IMMUNO
NCT03101280,has_trial_type,IMMUNO
NCT02435680,has_trial_type,CHEMO
NCT01426880,has_trial_type,CHEMO
NCT06369831,has_trial_type,TARGETED
NCT05809895,has_trial_type,"IMMUNO, CHEMO"
NCT00789581,has_trial_type,CHEMO
NCT03580395,has_trial_type,CHEMO
NCT04331067,has_trial_type,"CHEMO, IMMUNO"
NCT03752723,has_trial_type,IMMUNO
NCT05303038,has_trial_type,TARGETED
NCT02041338,has_trial_type,CHEMO
NCT05582538,has_trial_type,CHEMO
NCT03775850,has_trial_type,IMMUNO
NCT02419495,has_trial_type,"IMMUNO, TARGETED, CHEMO"
NCT06405295,has_trial_type,TARGETED
NCT02788981,has_trial_type,CHEMO
NCT06027268,has_trial_type,"CHEMO, IMMUNO"
NCT04585750,has_trial_type,IMMUNO
NCT05973864,has_trial_type,IMMUNO
NCT01208480,has_trial_type,"TARGETED, CHEMO"
NCT01928680,has_trial_type,CHEMO
NCT06268327,has_trial_type,CHEMO
NCT06774027,has_trial_type,TARGETED
NCT00777673,has_trial_type,"TARGETED, CHEMO"
NCT00532727,has_trial_type,CHEMO
NCT03838367,has_trial_type,CHEMO
NCT02689427,has_trial_type,CHEMO
NCT03205176,has_trial_type,TARGETED
NCT03010176,has_trial_type,IMMUNO
NCT05086692,has_trial_type,IMMUNO
NCT05843292,has_trial_type,CHEMO
NCT06140576,has_trial_type,CHEMO
NCT04085276,has_trial_type,CHEMO
NCT03150576,has_trial_type,"TARGETED, CHEMO"
NCT01127763,has_trial_type,CHEMO
NCT03197935,has_trial_type,"CHEMO, IMMUNO"
NCT02207335,has_trial_type,CHEMO
NCT02432963,has_trial_type,IMMUNO
NCT06817525,has_trial_type,TARGETED
NCT05402722,has_trial_type,IMMUNO
NCT06692725,has_trial_type,CHEMO
NCT03544125,has_trial_type,TARGETED
NCT05453825,has_trial_type,CHEMO
NCT05238922,has_trial_type,"TARGETED, CHEMO"
NCT06449222,has_trial_type,CHEMO
NCT01560663,has_trial_type,CHEMO
NCT03280563,has_trial_type,"TARGETED, IMMUNO"
NCT01377363,has_trial_type,TARGETED
NCT01287624,has_trial_type,CHEMO
NCT07064018,has_trial_type,CHEMO
NCT05340413,has_trial_type,TARGETED
NCT06261918,has_trial_type,TARGETED
NCT01445418,has_trial_type,CHEMO
NCT04159818,has_trial_type,"CHEMO, IMMUNO"
NCT02162719,has_trial_type,CHEMO
NCT04408118,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT01939418,has_trial_type,CHEMO
NCT04418219,has_trial_type,IMMUNO
NCT05750719,has_trial_type,TARGETED
NCT03289819,has_trial_type,"CHEMO, IMMUNO"
NCT01372579,has_trial_type,CHEMO
NCT01094184,has_trial_type,"TARGETED, CHEMO"
NCT06078384,has_trial_type,"CHEMO, IMMUNO"
NCT05969184,has_trial_type,TARGETED
NCT03777579,has_trial_type,"CHEMO, IMMUNO"
NCT04514484,has_trial_type,IMMUNO
NCT02981303,has_trial_type,IMMUNO
NCT05741164,has_trial_type,IMMUNO
NCT04877821,has_trial_type,CHEMO
NCT05227664,has_trial_type,CHEMO
NCT03815890,has_trial_type,IMMUNO
NCT05019690,has_trial_type,CHEMO
NCT06175390,has_trial_type,IMMUNO
NCT00203502,has_trial_type,TARGETED
NCT01207102,has_trial_type,CHEMO
NCT06419621,has_trial_type,CHEMO
NCT05949021,has_trial_type,CHEMO
NCT02124902,has_trial_type,CHEMO
NCT02876302,has_trial_type,CHEMO
NCT06533384,has_trial_type,"TARGETED, IMMUNO"
NCT04067102,has_trial_type,CHEMO
NCT05770102,has_trial_type,IMMUNO
NCT04521621,has_trial_type,IMMUNO
NCT02950064,has_trial_type,TARGETED
NCT06976021,has_trial_type,IMMUNO
NCT06279364,has_trial_type,CHEMO
NCT03742102,has_trial_type,"TARGETED, CHEMO"
NCT03414684,has_trial_type,"CHEMO, IMMUNO"
NCT05447702,has_trial_type,CHEMO
NCT03125902,has_trial_type,"CHEMO, IMMUNO"
NCT04927884,has_trial_type,IMMUNO
NCT05675579,has_trial_type,IMMUNO
NCT00691379,has_trial_type,"TARGETED, CHEMO"
NCT06112379,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT03799679,has_trial_type,CHEMO
NCT01042379,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT02161679,has_trial_type,CHEMO
NCT04683679,has_trial_type,"TARGETED, IMMUNO"
NCT05252390,has_trial_type,TARGETED
NCT02734290,has_trial_type,"CHEMO, IMMUNO"
NCT04925284,has_trial_type,"TARGETED, IMMUNO"
NCT06103864,has_trial_type,"IMMUNO, CHEMO"
NCT06291064,has_trial_type,CHEMO
NCT04809779,has_trial_type,"CHEMO, IMMUNO"
NCT01250379,has_trial_type,TARGETED
NCT06434064,has_trial_type,CHEMO
NCT01779479,has_trial_type,CHEMO
NCT02658214,has_trial_type,CHEMO
NCT02263495,has_trial_type,CHEMO
NCT06618014,has_trial_type,CHEMO
NCT03761914,has_trial_type,IMMUNO
NCT03893955,has_trial_type,CHEMO
NCT04690855,has_trial_type,IMMUNO
NCT02838823,has_trial_type,IMMUNO
NCT01969643,has_trial_type,TARGETED
NCT02779855,has_trial_type,CHEMO
NCT05916755,has_trial_type,IMMUNO
NCT02978495,has_trial_type,CHEMO
NCT02322814,has_trial_type,"IMMUNO, CHEMO"
NCT00483223,has_trial_type,CHEMO
NCT01281150,has_trial_type,CHEMO
NCT03756090,has_trial_type,CHEMO
NCT00499603,has_trial_type,CHEMO
NCT03206203,has_trial_type,"CHEMO, IMMUNO"
NCT04031703,has_trial_type,CHEMO
NCT05889390,has_trial_type,CHEMO
NCT02644369,has_trial_type,IMMUNO
NCT01617668,has_trial_type,CHEMO
NCT05742269,has_trial_type,IMMUNO
NCT01194869,has_trial_type,CHEMO
NCT02977468,has_trial_type,IMMUNO
NCT01057069,has_trial_type,CHEMO
NCT05929768,has_trial_type,"IMMUNO, CHEMO"
NCT02957968,has_trial_type,"IMMUNO, TARGETED, CHEMO"
NCT02768701,has_trial_type,IMMUNO
NCT02755272,has_trial_type,"CHEMO, IMMUNO"
NCT02513472,has_trial_type,IMMUNO
NCT00608972,has_trial_type,"TARGETED, CHEMO"
NCT01421472,has_trial_type,"TARGETED, CHEMO"
NCT01045304,has_trial_type,CHEMO
NCT00894504,has_trial_type,CHEMO
NCT06433804,has_trial_type,TARGETED
NCT03829501,has_trial_type,IMMUNO
NCT04762901,has_trial_type,CHEMO
NCT05581004,has_trial_type,IMMUNO
NCT04297267,has_trial_type,CHEMO
NCT04335669,has_trial_type,"CHEMO, IMMUNO"
NCT01276769,has_trial_type,CHEMO
NCT04001569,has_trial_type,CHEMO
NCT02484404,has_trial_type,TARGETED
NCT06400472,has_trial_type,"TARGETED, CHEMO"
NCT04722718,has_trial_type,CHEMO
NCT02637531,has_trial_type,IMMUNO
NCT03720431,has_trial_type,IMMUNO
NCT06545331,has_trial_type,IMMUNO
NCT04243616,has_trial_type,CHEMO
NCT04102618,has_trial_type,"TARGETED, IMMUNO"
NCT06845319,has_trial_type,"IMMUNO, CHEMO"
NCT02819518,has_trial_type,"CHEMO, IMMUNO"
NCT03002103,has_trial_type,CHEMO
NCT02447003,has_trial_type,IMMUNO
NCT03098550,has_trial_type,IMMUNO
NCT03301350,has_trial_type,CHEMO
NCT02476955,has_trial_type,CHEMO
NCT04508803,has_trial_type,TARGETED
NCT04192903,has_trial_type,CHEMO
NCT02423603,has_trial_type,CHEMO
NCT05609903,has_trial_type,"CHEMO, IMMUNO"
NCT05005403,has_trial_type,TARGETED
NCT06795503,has_trial_type,CHEMO
NCT04849364,has_trial_type,IMMUNO
NCT05862064,has_trial_type,"CHEMO, IMMUNO"
NCT03997123,has_trial_type,CHEMO
NCT03650738,has_trial_type,CHEMO
NCT03449108,has_trial_type,IMMUNO
NCT06210438,has_trial_type,TARGETED
NCT00603408,has_trial_type,CHEMO
NCT03390608,has_trial_type,TARGETED
NCT00733408,has_trial_type,"TARGETED, CHEMO"
NCT03369223,has_trial_type,IMMUNO
NCT01333423,has_trial_type,CHEMO
NCT02370238,has_trial_type,CHEMO
NCT04177108,has_trial_type,"CHEMO, IMMUNO"
NCT03577743,has_trial_type,TARGETED
NCT02762981,has_trial_type,CHEMO
NCT06532812,has_trial_type,IMMUNO
NCT03483012,has_trial_type,IMMUNO
NCT05314114,has_trial_type,TARGETED
NCT06407310,has_trial_type,"CHEMO, IMMUNO"
NCT03126110,has_trial_type,IMMUNO
NCT05269381,has_trial_type,IMMUNO
NCT03917381,has_trial_type,IMMUNO
NCT04584112,has_trial_type,"CHEMO, IMMUNO"
NCT01031446,has_trial_type,CHEMO
NCT03801369,has_trial_type,TARGETED
NCT06700369,has_trial_type,CHEMO
NCT05082610,has_trial_type,IMMUNO
NCT05872412,has_trial_type,CHEMO
NCT06627712,has_trial_type,IMMUNO
NCT05390710,has_trial_type,CHEMO
NCT05374512,has_trial_type,CHEMO
NCT05918133,has_trial_type,CHEMO
NCT01953536,has_trial_type,CHEMO
NCT06637306,has_trial_type,"CHEMO, IMMUNO"
NCT05555706,has_trial_type,CHEMO
NCT05180006,has_trial_type,"TARGETED, IMMUNO"
NCT04799249,has_trial_type,CHEMO
NCT04879849,has_trial_type,IMMUNO
NCT01618136,has_trial_type,CHEMO
NCT02366949,has_trial_type,CHEMO
NCT06404736,has_trial_type,"CHEMO, IMMUNO"
NCT06247449,has_trial_type,TARGETED
NCT01674842,has_trial_type,CHEMO
NCT04060342,has_trial_type,"IMMUNO, CHEMO"
NCT03464942,has_trial_type,IMMUNO
NCT05383170,has_trial_type,IMMUNO
NCT05097599,has_trial_type,TARGETED
NCT02938442,has_trial_type,CHEMO
NCT01910870,has_trial_type,CHEMO
NCT05810870,has_trial_type,TARGETED
NCT04159142,has_trial_type,CHEMO
NCT07054242,has_trial_type,IMMUNO
NCT03499899,has_trial_type,CHEMO
NCT04296942,has_trial_type,TARGETED
NCT01074970,has_trial_type,CHEMO
NCT06224673,has_trial_type,TARGETED
NCT03911973,has_trial_type,TARGETED
NCT05888831,has_trial_type,IMMUNO
NCT01525966,has_trial_type,CHEMO
NCT04140526,has_trial_type,IMMUNO
NCT05255666,has_trial_type,IMMUNO
NCT03797326,has_trial_type,IMMUNO
NCT01986426,has_trial_type,IMMUNO
NCT04443348,has_trial_type,"CHEMO, IMMUNO"
NCT03639948,has_trial_type,"CHEMO, IMMUNO"
NCT01982448,has_trial_type,CHEMO
NCT05097248,has_trial_type,CHEMO
NCT03487666,has_trial_type,IMMUNO
NCT05579366,has_trial_type,"IMMUNO, TARGETED, CHEMO"
NCT03952325,has_trial_type,IMMUNO
NCT04224922,has_trial_type,CHEMO
NCT01111825,has_trial_type,TARGETED
NCT01204125,has_trial_type,CHEMO
NCT04432857,has_trial_type,IMMUNO
NCT04301739,has_trial_type,CHEMO
NCT05358639,has_trial_type,TARGETED
NCT00618657,has_trial_type,"TARGETED, CHEMO"
NCT02456857,has_trial_type,"TARGETED, CHEMO"
NCT05088057,has_trial_type,CHEMO
NCT02555657,has_trial_type,IMMUNO
NCT05978648,has_trial_type,"TARGETED, CHEMO"
NCT04152057,has_trial_type,"TARGETED, CHEMO"
NCT02685657,has_trial_type,CHEMO
NCT06802757,has_trial_type,"CHEMO, IMMUNO"
NCT02489448,has_trial_type,IMMUNO
NCT03616886,has_trial_type,CHEMO
NCT05957939,has_trial_type,TARGETED
NCT03546686,has_trial_type,IMMUNO
NCT03310957,has_trial_type,IMMUNO
NCT02730130,has_trial_type,IMMUNO
NCT01975831,has_trial_type,IMMUNO
NCT03589339,has_trial_type,IMMUNO
NCT05382286,has_trial_type,"CHEMO, IMMUNO"
NCT03295552,has_trial_type,CHEMO
NCT01238952,has_trial_type,CHEMO
NCT01251900,has_trial_type,TARGETED
NCT02358200,has_trial_type,CHEMO
NCT05174832,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT04148937,has_trial_type,IMMUNO
NCT03106415,has_trial_type,IMMUNO
NCT02509507,has_trial_type,IMMUNO
NCT05953909,has_trial_type,CHEMO
NCT02670109,has_trial_type,CHEMO
NCT06371807,has_trial_type,"IMMUNO, CHEMO"
NCT02876107,has_trial_type,CHEMO
NCT05504707,has_trial_type,TARGETED
NCT03818685,has_trial_type,IMMUNO
NCT00546156,has_trial_type,"TARGETED, CHEMO"
NCT01165385,has_trial_type,CHEMO
NCT05266937,has_trial_type,"CHEMO, IMMUNO"
NCT03717415,has_trial_type,CHEMO
NCT02752685,has_trial_type,"CHEMO, IMMUNO"
NCT02379585,has_trial_type,"TARGETED, CHEMO"
NCT02628132,has_trial_type,"CHEMO, IMMUNO"
NCT04024800,has_trial_type,IMMUNO
NCT03277352,has_trial_type,IMMUNO
NCT04244552,has_trial_type,"CHEMO, IMMUNO"
NCT02789332,has_trial_type,"TARGETED, CHEMO"
NCT05329532,has_trial_type,IMMUNO
NCT04460456,has_trial_type,IMMUNO
NCT03554109,has_trial_type,CHEMO
NCT04837209,has_trial_type,IMMUNO
NCT03853707,has_trial_type,"IMMUNO, CHEMO"
NCT03971409,has_trial_type,CHEMO
NCT02898207,has_trial_type,TARGETED
NCT04895709,has_trial_type,IMMUNO
NCT04230109,has_trial_type,IMMUNO
NCT06771609,has_trial_type,IMMUNO
NCT02971761,has_trial_type,IMMUNO
NCT03411161,has_trial_type,CHEMO
NCT04137653,has_trial_type,CHEMO
NCT03599453,has_trial_type,IMMUNO
NCT03012477,has_trial_type,CHEMO
NCT01676753,has_trial_type,IMMUNO
NCT07005583,has_trial_type,TARGETED
NCT05491083,has_trial_type,IMMUNO
NCT00861705,has_trial_type,"TARGETED, CHEMO"
NCT02365805,has_trial_type,CHEMO
NCT06355037,has_trial_type,CHEMO
NCT01333137,has_trial_type,CHEMO
NCT01969032,has_trial_type,CHEMO
NCT01116648,has_trial_type,TARGETED
NCT01881230,has_trial_type,CHEMO
NCT06353997,has_trial_type,IMMUNO
NCT06471205,has_trial_type,IMMUNO
NCT04332653,has_trial_type,IMMUNO
NCT02309177,has_trial_type,"CHEMO, IMMUNO"
NCT01289353,has_trial_type,CHEMO
NCT03674242,has_trial_type,CHEMO
NCT00887575,has_trial_type,CHEMO
NCT04296175,has_trial_type,CHEMO
NCT01401959,has_trial_type,TARGETED
NCT06746870,has_trial_type,CHEMO
NCT06134375,has_trial_type,IMMUNO
NCT02208375,has_trial_type,TARGETED
NCT02672475,has_trial_type,CHEMO
NCT05749575,has_trial_type,"CHEMO, IMMUNO"
NCT06492759,has_trial_type,"CHEMO, IMMUNO"
NCT05082259,has_trial_type,IMMUNO
NCT02737475,has_trial_type,IMMUNO
NCT00601159,has_trial_type,CHEMO
NCT04691375,has_trial_type,IMMUNO
NCT02685059,has_trial_type,"CHEMO, IMMUNO"
NCT01130259,has_trial_type,CHEMO
NCT02637375,has_trial_type,CHEMO
NCT01104259,has_trial_type,CHEMO
NCT03281954,has_trial_type,IMMUNO
NCT01238133,has_trial_type,CHEMO
NCT02441933,has_trial_type,CHEMO
NCT01378533,has_trial_type,CHEMO
NCT03044730,has_trial_type,IMMUNO
NCT02474173,has_trial_type,CHEMO
NCT06767527,has_trial_type,CHEMO
NCT05498896,has_trial_type,"CHEMO, IMMUNO"
NCT04348916,has_trial_type,IMMUNO
NCT01752686,has_trial_type,CHEMO
NCT04602117,has_trial_type,"TARGETED, CHEMO"
NCT03213041,has_trial_type,"IMMUNO, CHEMO"
NCT04711824,has_trial_type,TARGETED
NCT06355024,has_trial_type,CHEMO
NCT05128734,has_trial_type,TARGETED
NCT03337724,has_trial_type,CHEMO
NCT05386524,has_trial_type,"TARGETED, CHEMO"
NCT00868634,has_trial_type,TARGETED
NCT03686124,has_trial_type,IMMUNO
NCT02546934,has_trial_type,CHEMO
NCT05585034,has_trial_type,IMMUNO
NCT03371017,has_trial_type,"CHEMO, IMMUNO"
NCT01929941,has_trial_type,CHEMO
NCT06190600,has_trial_type,"TARGETED, CHEMO"
NCT04742959,has_trial_type,CHEMO
NCT05673200,has_trial_type,"IMMUNO, CHEMO"
NCT06165900,has_trial_type,CHEMO
NCT03057600,has_trial_type,CHEMO
NCT01641406,has_trial_type,TARGETED
NCT04335006,has_trial_type,CHEMO
NCT05234606,has_trial_type,IMMUNO
NCT04954599,has_trial_type,CHEMO
NCT05582499,has_trial_type,"TARGETED, CHEMO"
NCT07016399,has_trial_type,"IMMUNO, CHEMO"
NCT02001519,has_trial_type,CHEMO
NCT04225117,has_trial_type,IMMUNO
NCT04303741,has_trial_type,IMMUNO
NCT02455141,has_trial_type,CHEMO
NCT01898117,has_trial_type,"IMMUNO, CHEMO"
NCT05068141,has_trial_type,CHEMO
NCT01931163,has_trial_type,CHEMO
NCT04191135,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT02018458,has_trial_type,TARGETED
NCT04626635,has_trial_type,TARGETED
NCT03326258,has_trial_type,IMMUNO
NCT06797635,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT06604858,has_trial_type,"CHEMO, IMMUNO"
NCT01069796,has_trial_type,"TARGETED, CHEMO"
NCT02315196,has_trial_type,"TARGETED, CHEMO"
NCT02985658,has_trial_type,"TARGETED, CHEMO"
NCT01276496,has_trial_type,CHEMO
NCT01848834,has_trial_type,IMMUNO
NCT06938724,has_trial_type,TARGETED
NCT00540358,has_trial_type,CHEMO
NCT02926196,has_trial_type,IMMUNO
NCT03184558,has_trial_type,IMMUNO
NCT00516724,has_trial_type,CHEMO
NCT03267316,has_trial_type,CHEMO
NCT03667716,has_trial_type,IMMUNO
NCT01147016,has_trial_type,"TARGETED, CHEMO"
NCT02694224,has_trial_type,CHEMO
NCT05620134,has_trial_type,IMMUNO
NCT02978716,has_trial_type,CHEMO
NCT03498716,has_trial_type,"CHEMO, IMMUNO"
NCT01818063,has_trial_type,CHEMO
NCT04083963,has_trial_type,CHEMO
NCT01431196,has_trial_type,TARGETED
NCT06685796,has_trial_type,CHEMO
NCT05383196,has_trial_type,CHEMO
NCT06538896,has_trial_type,CHEMO
NCT03594396,has_trial_type,TARGETED
NCT04129996,has_trial_type,CHEMO
NCT03876886,has_trial_type,CHEMO
NCT03316586,has_trial_type,IMMUNO
NCT04537286,has_trial_type,"IMMUNO, CHEMO"
NCT05670925,has_trial_type,CHEMO
NCT06606730,has_trial_type,IMMUNO
NCT01145430,has_trial_type,CHEMO
NCT04136782,has_trial_type,CHEMO
NCT03735082,has_trial_type,CHEMO
NCT02000882,has_trial_type,TARGETED
NCT05333874,has_trial_type,TARGETED
NCT05834582,has_trial_type,"TARGETED, CHEMO"
NCT02413320,has_trial_type,CHEMO
NCT05868226,has_trial_type,TARGETED
NCT02833766,has_trial_type,CHEMO
NCT03719326,has_trial_type,CHEMO
NCT02535026,has_trial_type,TARGETED
NCT00479674,has_trial_type,"TARGETED, CHEMO"
NCT02954874,has_trial_type,IMMUNO
NCT04595565,has_trial_type,CHEMO
NCT02622074,has_trial_type,"CHEMO, IMMUNO"
NCT05107674,has_trial_type,CHEMO
NCT05933265,has_trial_type,TARGETED
NCT01251874,has_trial_type,"TARGETED, CHEMO"
NCT05062174,has_trial_type,TARGETED
NCT03102320,has_trial_type,CHEMO
NCT04464174,has_trial_type,CHEMO
NCT03567720,has_trial_type,"CHEMO, IMMUNO"
NCT01201265,has_trial_type,"TARGETED, CHEMO"
NCT06393374,has_trial_type,IMMUNO
NCT03175666,has_trial_type,"TARGETED, CHEMO"
NCT05491226,has_trial_type,IMMUNO
NCT05485766,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT06786026,has_trial_type,"TARGETED, CHEMO"
NCT05756166,has_trial_type,IMMUNO
NCT05539365,has_trial_type,IMMUNO
NCT04739670,has_trial_type,"IMMUNO, TARGETED, CHEMO"
NCT05776875,has_trial_type,"TARGETED, IMMUNO"
NCT04491942,has_trial_type,CHEMO
NCT01815242,has_trial_type,CHEMO
NCT04787042,has_trial_type,IMMUNO
NCT06829199,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT04745975,has_trial_type,CHEMO
NCT06270706,has_trial_type,IMMUNO
NCT02593175,has_trial_type,CHEMO
NCT00930930,has_trial_type,CHEMO
NCT05067530,has_trial_type,CHEMO
NCT03012230,has_trial_type,IMMUNO
NCT05233696,has_trial_type,"IMMUNO, CHEMO"
NCT05177796,has_trial_type,"IMMUNO, CHEMO"
NCT02203513,has_trial_type,TARGETED
NCT04234113,has_trial_type,IMMUNO
NCT03829436,has_trial_type,IMMUNO
NCT05112536,has_trial_type,"IMMUNO, CHEMO"
NCT03154749,has_trial_type,CHEMO
NCT01623349,has_trial_type,TARGETED
NCT00674206,has_trial_type,TARGETED
NCT04333706,has_trial_type,TARGETED
NCT05438706,has_trial_type,CHEMO
NCT01918306,has_trial_type,CHEMO
NCT05007106,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT03167619,has_trial_type,TARGETED
NCT00892736,has_trial_type,TARGETED
NCT00998036,has_trial_type,CHEMO
NCT03251313,has_trial_type,"CHEMO, IMMUNO"
NCT03800836,has_trial_type,"IMMUNO, CHEMO"
NCT02035813,has_trial_type,TARGETED
NCT04485013,has_trial_type,IMMUNO
NCT01150513,has_trial_type,CHEMO
NCT02498613,has_trial_type,TARGETED
NCT06351332,has_trial_type,"CHEMO, IMMUNO"
NCT02531932,has_trial_type,CHEMO
NCT05629585,has_trial_type,IMMUNO
NCT03121352,has_trial_type,"CHEMO, IMMUNO"
NCT04958785,has_trial_type,CHEMO
NCT03387085,has_trial_type,"TARGETED, CHEMO"
NCT02661100,has_trial_type,IMMUNO
NCT05556200,has_trial_type,IMMUNO
NCT03907800,has_trial_type,"TARGETED, CHEMO"
NCT03095352,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT04193059,has_trial_type,"TARGETED, CHEMO"
NCT06966700,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT02783300,has_trial_type,IMMUNO
NCT01075100,has_trial_type,CHEMO
NCT00938652,has_trial_type,CHEMO
NCT04986852,has_trial_type,IMMUNO
NCT03918278,has_trial_type,"CHEMO, IMMUNO"
NCT04303988,has_trial_type,"TARGETED, CHEMO"
NCT04711109,has_trial_type,TARGETED
NCT00707707,has_trial_type,CHEMO
NCT05760378,has_trial_type,CHEMO
NCT02264678,has_trial_type,"TARGETED, CHEMO"
NCT01672671,has_trial_type,"TARGETED, CHEMO"
NCT03036488,has_trial_type,"CHEMO, IMMUNO"
NCT03504488,has_trial_type,IMMUNO
NCT02301988,has_trial_type,CHEMO
NCT00463788,has_trial_type,CHEMO
NCT05145907,has_trial_type,IMMUNO
NCT05812807,has_trial_type,IMMUNO
NCT03232593,has_trial_type,IMMUNO
NCT03915678,has_trial_type,IMMUNO
NCT04722978,has_trial_type,CHEMO
NCT04771871,has_trial_type,CHEMO
NCT04180371,has_trial_type,IMMUNO
NCT04498793,has_trial_type,CHEMO
NCT05244993,has_trial_type,CHEMO
NCT03740893,has_trial_type,"TARGETED, IMMUNO"
NCT06110793,has_trial_type,"TARGETED, IMMUNO"
NCT00472693,has_trial_type,TARGETED
NCT04185311,has_trial_type,IMMUNO
NCT04427293,has_trial_type,IMMUNO
NCT06231693,has_trial_type,TARGETED
NCT02682693,has_trial_type,"TARGETED, CHEMO"
NCT05131893,has_trial_type,"TARGETED, CHEMO"
NCT06894771,has_trial_type,IMMUNO
NCT06955156,has_trial_type,IMMUNO
NCT03205761,has_trial_type,TARGETED
NCT06067061,has_trial_type,IMMUNO
NCT03201861,has_trial_type,CHEMO
NCT04468061,has_trial_type,IMMUNO
NCT01920061,has_trial_type,CHEMO
NCT02411656,has_trial_type,IMMUNO
NCT05382299,has_trial_type,CHEMO
NCT02221999,has_trial_type,CHEMO
NCT04138719,has_trial_type,CHEMO
NCT03805399,has_trial_type,"CHEMO, IMMUNO"
NCT01777932,has_trial_type,TARGETED
NCT00813956,has_trial_type,CHEMO
NCT05768932,has_trial_type,CHEMO
NCT06342037,has_trial_type,IMMUNO
NCT02401347,has_trial_type,TARGETED
NCT04099277,has_trial_type,IMMUNO
NCT02834247,has_trial_type,IMMUNO
NCT02032277,has_trial_type,CHEMO
NCT02595905,has_trial_type,CHEMO
NCT05093387,has_trial_type,"CHEMO, IMMUNO"
NCT02641847,has_trial_type,CHEMO
NCT03225547,has_trial_type,"TARGETED, IMMUNO"
NCT02648477,has_trial_type,"CHEMO, IMMUNO"
NCT04251533,has_trial_type,CHEMO
NCT03925233,has_trial_type,"TARGETED, CHEMO"
NCT06431633,has_trial_type,CHEMO
NCT02547987,has_trial_type,"TARGETED, CHEMO"
NCT06387628,has_trial_type,"CHEMO, IMMUNO"
NCT03145961,has_trial_type,IMMUNO
NCT06965361,has_trial_type,CHEMO
NCT03756298,has_trial_type,IMMUNO
NCT05203445,has_trial_type,"TARGETED, IMMUNO"
NCT04683445,has_trial_type,"TARGETED, IMMUNO"
NCT03396445,has_trial_type,"CHEMO, IMMUNO"
NCT02543645,has_trial_type,IMMUNO
NCT03348098,has_trial_type,CHEMO
NCT03961698,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT05681728,has_trial_type,"CHEMO, IMMUNO"
NCT04148911,has_trial_type,"CHEMO, IMMUNO"
NCT05692661,has_trial_type,TARGETED
NCT07045311,has_trial_type,CHEMO
NCT02341911,has_trial_type,CHEMO
NCT01216111,has_trial_type,CHEMO
NCT03164993,has_trial_type,"CHEMO, IMMUNO"
NCT04268693,has_trial_type,CHEMO
NCT05660083,has_trial_type,"TARGETED, CHEMO"
NCT06963905,has_trial_type,IMMUNO
NCT03330847,has_trial_type,TARGETED
NCT02511847,has_trial_type,CHEMO
NCT04639245,has_trial_type,IMMUNO
NCT04348747,has_trial_type,"TARGETED, IMMUNO"
NCT05001347,has_trial_type,IMMUNO
NCT02983045,has_trial_type,IMMUNO
NCT05192798,has_trial_type,"TARGETED, CHEMO"
NCT00448305,has_trial_type,CHEMO
NCT06492005,has_trial_type,IMMUNO
NCT06632405,has_trial_type,CHEMO
NCT03872505,has_trial_type,CHEMO
NCT04676997,has_trial_type,CHEMO
NCT05746897,has_trial_type,IMMUNO
NCT03004183,has_trial_type,IMMUNO
NCT03601897,has_trial_type,CHEMO
NCT01009983,has_trial_type,CHEMO
NCT06318897,has_trial_type,"CHEMO, IMMUNO"
NCT00679783,has_trial_type,TARGETED
NCT02422498,has_trial_type,CHEMO
NCT02183805,has_trial_type,CHEMO
NCT01195298,has_trial_type,TARGETED
NCT03424005,has_trial_type,"CHEMO, TARGETED, IMMUNO"
NCT04213898,has_trial_type,CHEMO
NCT04405505,has_trial_type,CHEMO
NCT05714553,has_trial_type,IMMUNO
NCT03151447,has_trial_type,IMMUNO
NCT03911453,has_trial_type,IMMUNO
NCT04418154,has_trial_type,CHEMO
NCT00717951,has_trial_type,CHEMO
NCT04975451,has_trial_type,CHEMO
NCT05867251,has_trial_type,CHEMO
NCT05253053,has_trial_type,"CHEMO, IMMUNO"
NCT06841354,has_trial_type,"CHEMO, IMMUNO"
NCT05633654,has_trial_type,IMMUNO
NCT06793553,has_trial_type,"TARGETED, CHEMO"
NCT06143553,has_trial_type,CHEMO
NCT05420454,has_trial_type,"TARGETED, CHEMO"
NCT04101851,has_trial_type,TARGETED
NCT07015853,has_trial_type,IMMUNO
NCT03193853,has_trial_type,CHEMO
NCT03454451,has_trial_type,IMMUNO
NCT06498154,has_trial_type,TARGETED
NCT01091454,has_trial_type,CHEMO
NCT05403554,has_trial_type,"CHEMO, IMMUNO"
Pembrolizumab,has_trial_type,IMMUNO
Nivolumab,has_trial_type,IMMUNO
Atezolizumab,has_trial_type,IMMUNO
Olaparib,has_trial_type,TARGETED
